WorldWideScience

Sample records for baclofen

  1. Baclofen overdose.

    OpenAIRE

    Lipscomb, D J; Meredith, T. J.

    1980-01-01

    A 57-year-old woman suffering from multiple sclerosis took an estimated 1500 mg of baclofen. She became deeply unconscious with generalized flaccid muscle paralysis and absent tendon reflexes. Toxicological analysis confirmed the presence of baclofen together with small amounts of paracetamol and glutethimide. Supportive therapy, including assisted ventilation for 3 days, led to complete recovery; anticonvulsant drugs were necessary for the treatment of grand mal fits. The clinical features a...

  2. Baclofen in Spastic Cerebral Palsy

    OpenAIRE

    J Akhundian

    2002-01-01

    To evaluate the effect of oral baclofen in spastic cerebral palsy (cp), we studied 40 children with different clinical types of spastic cp. Half of these children served as control group and the others received oral baclofen. All of them were treated with physiotherapy under equal conditions for 6 weeks. We used two methods, modified Ashworth scale and range of motion for evaluation. At the end of therapy we found a significant improvement in the baclofen group compared to control group. As a...

  3. Correlates of Baclofen Effectiveness in Alcohol Dependence

    OpenAIRE

    Lekhansh Shukla; Tulika Shukla; Spandana Bokka; Arun Kandasamy; Vivek Benegal; Pratima Murthy; Prabhat Chand

    2015-01-01

    Alcohol dependence is a global concern. Baclofen has shown promise as an anti-craving agent but its efficiency remains to be settled. We reviewed 549 male cases diagnosed with alcohol dependence who received Acamprosate (201) or Baclofen (348). ′Time to first drink′ was compared between two groups and multiple regression analysis was done in baclofen group to identify correlates of effectiveness. There was a significant difference in outcome measure between Baclofen (M = 4.44, SD = 3.75) and ...

  4. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: A case report

    OpenAIRE

    Mohammed, Imran; Hussain, Asif

    2004-01-01

    Background Intrathecal baclofen pump has been used effectively with increasing frequency in patients with severe spasticity, particularly for those patients who are unresponsive to conservative pharmacotherapy or develop intolerable side effects at therapeutic doses of oral baclofen. Drowsiness, nausea, headache, muscle weakness, light-headedness and return of pretreatment spasticity can be caused by intrathecal pump delivering an incorrect dose of baclofen. Intrathecal baclofen withdrawal sy...

  5. Treatment of recalcitrant cough with baclofen

    Directory of Open Access Journals (Sweden)

    Paolo Agostinis

    2013-04-01

    Full Text Available Background: Chronic dry cough is a debilitating symptom often refractory to standard antitussive therapy. It may result from increased sensitivity of the cough reflex. Baclofen, an agonist of gamma-aminobutyric acid (GABA, has been shown, in animals, to have antitussive activity via a central mechanism. In normal subjects baclofen has been revealed ability to inhibit capsaicininduced cough and cough due to angiotensin-converting enzyme (ACE inhibitors. In addition, chronic therapy with baclofen has been shown to reduce cough reflex sensitivity in subjects with cervical spinal cord injury. Clinical cases: We describe two patients with chronic refractory cough who obtained symptomatic improvement after oral baclofen administration. The antitussive effect of baclofen, usually used for treatment of spasticity associated with multiple sclerosis and spinal cord lesions, can be explained by central inhibition, but may also involve peripheral inhibitory mechanisms.

  6. R(+)-Baclofen, but Not S(−)-Baclofen, Alters Alcohol Self-Administration in Alcohol-Preferring Rats

    OpenAIRE

    Lorrai, Irene; Maccioni, Paola; Gessa, Gian Luigi; Colombo, Giancarlo

    2016-01-01

    Racemic baclofen [(±)-baclofen] has repeatedly been reported to suppress several ­alcohol-motivated behaviors, including alcohol drinking and alcohol ­self-administration, in rats and mice. Recent data suggested that baclofen may have bidirectional, stereospecific effects, with the more active enantiomer, R(+)-baclofen, suppressing alcohol intake and the less active enantiomer, S(−)-baclofen, stimulating alcohol intake in mice. The present study was designed to investigate whether this enanti...

  7. Correlates of baclofen effectiveness in alcohol dependence

    Directory of Open Access Journals (Sweden)

    Lekhansh Shukla

    2015-01-01

    Full Text Available Alcohol dependence is a global concern. Baclofen has shown promise as an anti-craving agent but its efficiency remains to be settled. We reviewed 549 male cases diagnosed with alcohol dependence who received Acamprosate (201 or Baclofen (348. ′Time to first drink′ was compared between two groups and multiple regression analysis was done in baclofen group to identify correlates of effectiveness. There was a significant difference in outcome measure between Baclofen (M = 4.44, SD = 3.75 and Acamprosate group (M = 3.73, SD = 2.19; t (547 = 2.45, P = 0.01. Initial regression analysis with six predictor variables (average daily alcohol units, current age, age at onset of dependence, family history, duration of dependence and dose of baclofen in mg/day showed significant correlation of outcome variable with only two predictor variables - dose of baclofen and average daily intake. Using the hierarchical method it was found that ′dose of baclofen′ and ′average alcohol intake′ explain a significant amount of variance in ′time to first drink′. [F (1, 345 = 182.8, P < 0.001, R2 = 0.52, R2 adjusted = 0.51]. This information can be used to select patients in long term longitudinal studies and may explain variable results seen in clinical trials of baclofen done earlier.

  8. R(+)-Baclofen, but Not S(−)-Baclofen, Alters Alcohol Self-Administration in Alcohol-Preferring Rats

    Science.gov (United States)

    Lorrai, Irene; Maccioni, Paola; Gessa, Gian Luigi; Colombo, Giancarlo

    2016-01-01

    Racemic baclofen [(±)-baclofen] has repeatedly been reported to suppress several ­alcohol-motivated behaviors, including alcohol drinking and alcohol ­self-administration, in rats and mice. Recent data suggested that baclofen may have bidirectional, stereospecific effects, with the more active enantiomer, R(+)-baclofen, suppressing alcohol intake and the less active enantiomer, S(−)-baclofen, stimulating alcohol intake in mice. The present study was designed to investigate whether this enantioselectivity of baclofen effects may also extend to the reinforcing properties of alcohol in rats. To this end, selectively bred Sardinian alcohol-preferring (sP) rats were initially trained to lever respond on a fixed ratio 4 (FR4) schedule of reinforcement for alcohol (15%, v/v) in daily 30-min sessions. Once responding had stabilized, rats were tested with vehicle, (±)-baclofen (3 mg/kg), R(+)-baclofen (0.75, 1.5, and 3 mg/kg), and S(−)-baclofen (6, 12, and 24 mg/kg) under the FR4 schedule of reinforcement. Treatment with 3 mg/kg (±)-baclofen reduced the number of lever responses for alcohol and estimated amount of self-administered alcohol by approximately 60% in comparison to vehicle treatment. R(+)-baclofen was approximately twice as active as (±)-baclofen: treatment with 1.5 mg/kg R(+)-baclofen decreased both variables to an extent similar to that of the decreasing effect of 3 mg/kg (±)-baclofen. Conversely, treatment with all doses of S(−)-baclofen failed to affect alcohol self administration. These results (a) confirm that non-sedative doses of (±)-baclofen effectively suppressed the reinforcing properties of alcohol in sP rats and (b) apparently do not extend to operant alcohol self-administration in sP rats the capability of S(−)-baclofen to stimulate alcohol drinking in mice. PMID:27148096

  9. R(+-baclofen, but not S(--baclofen, alters alcohol self-administration in alcohol-preferring rats

    Directory of Open Access Journals (Sweden)

    Irene eLorrai

    2016-04-01

    Full Text Available Racemic baclofen [(±-baclofen] has repeatedly been reported to suppress several alcohol-motivated behaviors, including alcohol drinking and alcohol self-administration, in rats and mice. Recent data suggested that baclofen may have bidirectional, stereospecific effects, with the more active enantiomer, R(+-baclofen, suppressing alcohol intake and the less active enantiomer, S(--baclofen, stimulating alcohol intake in mice. The present study was designed to investigate whether this enantioselectivity of baclofen effects may extend also to the reinforcing properties of alcohol in rats. To this end, selectively bred Sardinian alcohol-preferring (sP rats were initially trained to lever-respond on a Fixed Ratio (FR 4 (FR4 schedule of reinforcement for alcohol (15%, v/v in daily 30-min sessions. Once responding had stabilized, rats were tested with vehicle, (±-baclofen (3 mg/kg, R(+-baclofen (0.75, 1.5, and 3 mg/kg, and S(--baclofen (6, 12, and 24 mg/kg under the FR4 schedule of reinforcement. Treatment with 3 mg/kg (±-baclofen reduced the number of lever-responses for alcohol and estimated amount of self-administered alcohol by approximately 60% in comparison to vehicle treatment. R(+-baclofen was approximately twice as active as (±-baclofen: treatment with 1.5 mg/kg R(+-baclofen decreased both variables to an extent similar to that of the decreasing effect of 3 mg/kg (±-baclofen. Conversely, treatment with all doses of S(--baclofen failed to affect alcohol self-administration. These results (a confirm that non-sedative doses of (±-baclofen effectively suppressed the reinforcing properties of alcohol in sP rats and (b apparently do not extend to operant alcohol self-administration in sP rats the capability of S(--baclofen to stimulate alcohol drinking in mice.

  10. Reversible cardiomyopathy complicating intrathecal baclofen withdrawal: A case report

    OpenAIRE

    Pizon, Anthony F.; LoVecchio, Frank

    2007-01-01

    This case report is about reversible cardiomyopathy associated with intrathecal baclofen withdrawal. Previous literature has reported that enteral baclofen does not adequately control intrathecal baclofen withdrawal. In our case, coronary atherosclerosis did not play a role in the development of the cardiomyopathy. However, reinstitution of intrathecal baclofen promptly resulted in improvement. One could hypothesize that myocardial stunning from sympathetic hyperactivity led to a similar card...

  11. Role of hemodialysis in baclofen overdose with normal renal function

    OpenAIRE

    Dias, Lorraine S.; Vivek, G; M Manthappa; Acharya, Raviraja V

    2011-01-01

    The treatment of baclofen overdose is primarily supportive. There have been case reports of hemodialysis being used in patients with chronic kidney disease with baclofen overdose. A case report of hemodialysis in a baclofen-overdose patient with normal renal function is presented. Review of literature has also been provided.

  12. Role of hemodialysis in baclofen overdose with normal renal function

    Directory of Open Access Journals (Sweden)

    Lorraine S Dias

    2011-01-01

    Full Text Available The treatment of baclofen overdose is primarily supportive. There have been case reports of hemodialysis being used in patients with chronic kidney disease with baclofen overdose. A case report of hemodialysis in a baclofen-overdose patient with normal renal function is presented. Review of literature has also been provided.

  13. Intrathecal Baclofen Therapy: Benefits and Complications

    Science.gov (United States)

    Zdolsek, Helena Aniansson; Olesch, Christine; Antolovich, Giuliana; Reddihough, Dinah

    2011-01-01

    Background: Spasticity and dystonia in children with cerebral palsy has been treated with intrathecal baclofen therapy (ITB) at the Royal Children's Hospital, Melbourne, Australia (RCH) since 1999. Methods: The records of children having received or still receiving ITB during the period September 1999 until August 2005 were studied to evaluate…

  14. Baclofen-Induced Encephalopathy in End Stage Renal Disease

    Directory of Open Access Journals (Sweden)

    Andrew Meillier

    2015-01-01

    Full Text Available Baclofen is a highly used centrally acting GABA agonist that continues to be an effective therapy for spasticity and chronic hiccups. The renally dependent excretion determines the circulating concentrations and guides effective dosing to decrease adverse reactions. Caution should be considered in administering baclofen to patients with decreased renal function. We present a patient with end stage renal disease on hemodialysis with recent baclofen ingestion who presented with toxic encephalopathy that was resolved with additional dialysis sessions.

  15. Baclofen-Induced Encephalopathy in End Stage Renal Disease

    OpenAIRE

    Andrew Meillier; Cara Heller; Shyam Patel

    2015-01-01

    Baclofen is a highly used centrally acting GABA agonist that continues to be an effective therapy for spasticity and chronic hiccups. The renally dependent excretion determines the circulating concentrations and guides effective dosing to decrease adverse reactions. Caution should be considered in administering baclofen to patients with decreased renal function. We present a patient with end stage renal disease on hemodialysis with recent baclofen ingestion who presented with toxic encephalop...

  16. A human laboratory pilot study with baclofen in alcoholic individuals

    OpenAIRE

    Leggio, Lorenzo; Zywiak, William H.; McGeary, John E.; Edwards, Steven; Fricchione, Samuel R.; Shoaff, Jessica R.; Addolorato, Giovanni; Swift, Robert M; Kenna, George A.

    2012-01-01

    Preclinical and clinical studies show that the GABAB receptor agonist baclofen may represent a pharmacotherapy for alcohol dependence (AD). However, the mechanisms by which baclofen affects drinking are not well characterized; thus this pilot study investigated possible baclofen’s biobehavioral mechanisms. The design was a double-blind controlled randomized human laboratory pilot study. Fourteen non-treatment seeking alcohol-dependent heavy drinking subjects received either baclofen 10 mg t.i...

  17. Baclofen in the management of cannabis dependence syndrome

    OpenAIRE

    Imbert, Bruce; Labrune, Nathalie; Lancon, Christophe; Simon, Nicolas

    2014-01-01

    Cannabis is the most commonly used illicit drug in the world. However, only few studies have shown the efficacy of pharmacologic agents in targeting cannabis withdrawal symptoms or reducing the reinforcing effects of cannabis. Baclofen has been shown to reduce cannabis withdrawal symptoms and the subjective effects of cannabis. We think that the clinical utility of baclofen for cannabis dependence is a reasonable approach. A case report using baclofen is presented and provides preliminary sup...

  18. Intestinal pseudo-obstruction following oral baclofen: An unusual complication

    OpenAIRE

    Vilvapathy Senguttuvan Karthikeyan; Kuppusamy Senthilkumaran; Bettaiyagowder Easwaran; Rajamariappan Rajbhaskar

    2015-01-01

    Baclofen is a gamma- aminobutyric acid B (GABA B) agonist used for the management of spasticity associated with spinal cord injury. Oral baclofen might cause constipation, but intestinal pseudo-obstruction is very rare. We report a 50-year-old male with spasticity following cervical discectomy (C3-4) on oral baclofen for 6 months with intestinal pseudo-obstruction. He had undergone open suprapubic cystostomy for traumatic urethral injury, 45 days prior to the presentation and adhesive intesti...

  19. Complications of Intrathecal Baclofen Pump: Prevention and Cure

    OpenAIRE

    G. Michael Waines; Norbert Roosen; Kelly Mcintosh; Iram Siddiqui; Tamer Rizk; Yasser Awaad

    2012-01-01

    Increasingly, spasticity is managed with surgically implanted Intrathecal Baclofen pumps. Intrathecal Baclofen pump revision surgery unrelated to programmable pump end-of-life is not uncommon, requiring special attention during pre-, intra-, and postoperative management. We aimed to identify and describe complications of Intrathecal Baclofen pump as well as to report avoidance and management of complications. Methods and Materials. Through 2002–2006, at the department of neurosurgery, Henry F...

  20. Baclofen for narcolepsy with cataplexy: two cases

    Directory of Open Access Journals (Sweden)

    Lee EK

    2015-07-01

    Full Text Available Elliott Kyung Lee,1,2 Alan Bruce Douglass1,2 1Department of Psychiatry, Faculty of Medicine, Institute of Mental Health Research, University of Ottawa, 2Royal Ottawa Mental Health Center, Ottawa, ON, Canada Abstract: Narcolepsy is a disabling sleep disorder characterized by daytime hypersomnolence. Those with cataplexy have spells of muscle weakness precipitated by strong emotions, especially laughter or surprise. Cataplexy treatments include antidepressants or a GABA-B agonist, gamma hydroxybutyrate (GHB. GHB is the most effective treatment for cataplexy, but is expensive and can have significant side effects. A recent report of a murine model of narcolepsy-cataplexy suggests R-baclofen has potential efficacy against cataplexy. We report on two narcolepsy patients with multiple daily cataplexy episodes, one of whom had been effectively treated with GHB, but had to discontinue it for unrelated medical reasons. Both subsequently tried baclofen and experienced almost complete resolution of cataplexy. This report suggests baclofen can be an effective treatment for cataplexy in humans and warrants further study. Keywords: hypersomnolence, gamma hydroxybutyrate, excessive daytime sleepiness

  1. Increase of baclofen intoxications : risks involved and management

    OpenAIRE

    Arbouw, M.E.L.; Hoge, H L; Meulenbelt, J.; Jansman, F.G.A.

    2014-01-01

    Baclofen has been increasingly used in the treatment of alcohol withdrawal syndrome (AWS). We present a patient with AWS and psychiatric comorbidity who ingested 700 mg of baclofen. ICU admission was necessary for ventilatory support and symptomatic treatment. The patient was dismissed without sequelae.

  2. A Nationwide Register-Based Survey of Baclofen Toxicity

    DEFF Research Database (Denmark)

    Kiel, Louise Bendix; Hoegberg, Lotte Christine Groth; Jansen, Tejs;

    2015-01-01

    was conducted with ICD-10 codes for poisoning, self-harm and suicide, and coupled with the baclofen ATC code. All enquiries about baclofen to the Danish Poison Information Centre (DPIC) in the same period were evaluated. Demographic and clinical data were extracted, and the poisonings were classified...

  3. Intestinal pseudo-obstruction following oral baclofen: An unusual complication

    Directory of Open Access Journals (Sweden)

    Vilvapathy Senguttuvan Karthikeyan

    2015-01-01

    Full Text Available Baclofen is a gamma- aminobutyric acid B (GABA B agonist used for the management of spasticity associated with spinal cord injury. Oral baclofen might cause constipation, but intestinal pseudo-obstruction is very rare. We report a 50-year-old male with spasticity following cervical discectomy (C3-4 on oral baclofen for 6 months with intestinal pseudo-obstruction. He had undergone open suprapubic cystostomy for traumatic urethral injury, 45 days prior to the presentation and adhesive intestinal obstruction was also considered a possibility. However, there were no air fluid levels on abdominal radiographs and ultrasound abdomen was non-contributory. Withdrawal of baclofen was therapeutic in this patient. This case is being reported to highlight the rare possibility of oral baclofen induced intestinal pseudo-obstruction.

  4. Baclofen reduces fat intake under binge-type conditions

    OpenAIRE

    Buda-Levin, Ariel; Wojnicki, Francis H. E.; Corwin, Rebecca L.

    2005-01-01

    The GABA-B agonist baclofen reduces drug self-administration in rats and has shown promise clinically in the treatment of substance abuse. Baclofen generally does not reduce food intake in non-binge feeding protocols. In this study, baclofen was tested in a fat-binge protocol. Thirty male rats were divided into three groups (B: binge; FM: fat-matched; C: chow). B received a bowl of vegetable shortening for 2 h on Monday, Wednesday, and Friday (MWF) and continuous access to powdered chow (regu...

  5. Theophylline-induced potentiation of the antinociceptive action of baclofen.

    OpenAIRE

    Sawynok, J

    1983-01-01

    1--Theophylline (35, 50 mg/kg) potentiated the antinociceptive action of intraperitoneally administered baclofen in the tail flick and hot plate tests. Potentiation was most marked when the pretreatment time was 1 h, but some potentiation was still apparent following a 2 h pretreatment. 2--Theophylline alone (50 mg/kg) produced only slight alterations in reaction latency in the two tests. 3--When baclofen was applied directly into the spinal subarachnoid space, a 1 h pretreatment with theophy...

  6. Zdravljenje spastičnosti z intratekalnim baklofenom: Intrathecal baclofen therapy of spasticity: Intrathecal baclofen therapy of spasticity:

    OpenAIRE

    Bošnjak, Roman; Grabljevec, Klemen; Gregorič, Milan

    2009-01-01

    In some patients, severe spasticity of cerebral or spinal origin cannot be treated succesfully with conventional oral medication or physical modalities. Intrathecal baclofen therapy with implanted pump represents an effective treatment since mid 80's. Baclofen (Lioresal) is a muscle relaxant and potent GABA agonist that acts via GABAb receptors at the posterior coloumns of spinal cord level to inhibit the release of excitatory neurotransmiters by inhibiting calcium ions influx into presynapti...

  7. Permeation and Systemic Absorption of R- and S-Baclofen across the Nasal Mucosa

    OpenAIRE

    Zhang, Hefei; Schmidt, Mark; Murry, Daryl J.; Donovan, Maureen D.

    2011-01-01

    Baclofen, an antispasmodic agent that acts as a GABAB agonist, resembles phenylalanine in structure and has been reported to be a substrate of the large amino acid transporter, LAT-1. The objective of this study was to investigate the absorption of baclofen across the nasal mucosa both in vitro and in vivo. Baclofen transport was measured across excised bovine olfactory and respiratory mucosae to investigate site-specific uptake of baclofen, and the intranasal bioavailability of R- and S- bac...

  8. Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen.

    OpenAIRE

    Dressnandt, J; Conrad, B

    1996-01-01

    OBJECTIVE--To investigate whether the dose of intrathecal baclofen necessary for a sufficient reduction of muscle tone and spasms changes during treatment of severe spasticity. METHODS--A group of 27 patients received intrathecal baclofen for 61 (SD 18) months. RESULTS--Spasticity remained absent or strongly reduced after stopping the intrathecal baclofen infusion in seven patients. The dose of baclofen could be reduced to 40% of that dose which was originally necessary in 10 patients. The do...

  9. Retraction of an intrathecal baclofen infusion catheter following suprapubic cystotomy: a case report.

    NARCIS (Netherlands)

    Martens, F.M.J.; Somford, D.M.; Kuppevelt, D.H. van; Burg, M.J. van den; Heesakkers, J.P.F.A.

    2009-01-01

    INTRODUCTION: Intrathecal baclofen, administered via a Baclofen pump, is used for patients with spasticity. We report here a case of intrathecal catheter retraction following surgery. CASE REPORT: A male patient with adrenoleukodystrophy and a baclofen pump implant was admitted to the urology depart

  10. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial.

    Science.gov (United States)

    Gilmartin, R; Bruce, D; Storrs, B B; Abbott, R; Krach, L; Ward, J; Bloom, K; Brooks, W H; Johnson, D L; Madsen, J R; McLaughlin, J F; Nadell, J

    2000-02-01

    Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower-extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable. PMID:10695888

  11. Baclofen for stroke patients with persistent hiccups: a randomized, double-blind, placebo-controlled trial

    OpenAIRE

    Zhang, Cuie; Zhang, Ruifen; Zhang, Shuangyan; Xu, Meiling; Zhang, Shuyan

    2014-01-01

    Background The results of preclinical studies suggest that baclofen may be useful in the treatment of stroke patients with persistent hiccups. This study was aimed to assess the possible efficacy of baclofen for the treatment of persistent hiccups after stroke. Methods In total, 30 stroke patients with persistent hiccups were randomly assigned to receive baclofen (n = 15) or a placebo (n = 15) in a double-blind, parallel-group trial. Participants in the baclofen group received 10 mg baclofen ...

  12. Baclofen reduces fat intake under binge-type conditions.

    Science.gov (United States)

    Buda-Levin, Ariel; Wojnicki, Francis H E; Corwin, Rebecca L

    2005-09-15

    The GABA-B agonist baclofen reduces drug self-administration in rats and has shown promise clinically in the treatment of substance abuse. Baclofen generally does not reduce food intake in non-binge feeding protocols. In this study, baclofen was tested in a fat-binge protocol. Thirty male rats were divided into three groups (B: binge; FM: fat-matched; C: chow). B received a bowl of vegetable shortening for 2 h on Monday, Wednesday, and Friday (MWF) and continuous access to powdered chow (regular chow) in all phases. FM had continuous access to a regular chow+shortening mixture (FM chow) that provided the same proportion of shortening and regular chow that the B rats consumed in all phases. In addition, FM had the following: phase 1: no separate bowl of shortening; phase 2: 2-h MWF access to a separate bowl of shortening; phase 3, daily 2-h access to a separate bowl of shortening; C rats had continuous access to the regular chow in all phases. In addition, C had the following: phase 1: no separate bowl of shortening; phase 2: 2-h MWF access to a separate bowl of shortening; in phase 3, daily 2-h access to a separate bowl of shortening. Baclofen (1.0, 1.8 mg/kg, i.p.) reduced shortening intake regardless of access condition. Baclofen had no effect on, or stimulated, FM and regular chow intake. These results demonstrate that baclofen can reduce fat intake in rats under binge-type conditions. Furthermore, these results indicate that bingeing, as modeled in our protocol, is different from other forms of food intake and may share similarities with substance abuse. PMID:16140347

  13. FAT EMULSION COMPOSITION ALTERS INTAKE AND THE EFFECTS OF BACLOFEN

    OpenAIRE

    Y Wang; Wilt, DC; Wojnicki, FHE; Babbs, RK; Coupland, JN; Corwin, RLC

    2011-01-01

    Thickened oil-in-water emulsions are useful model foods in rat studies due to their high acceptance and similarity to foods consumed by humans. Previous work from this laboratory used oil-in-water emulsions thickened with a biopolymer blend containing starch. Intake and effects of baclofen, a GABA-B agonist that decreases fat intake and drug self-administration, were reported, but the contribution of starch was not assessed. In the present study, intake and effects of baclofen were assessed i...

  14. Synthesis and pharmacological characterization of certain baclofen analogues

    DEFF Research Database (Denmark)

    Attia, M.I.; Herdeis, C.; Bräuner-Osborne, Hans

    2013-01-01

    (RS)-4-Amino-3-(4-chlorophenyl)butanoic acid (baclofen, 2) is the prototypic selective GABAR agonist and is used clinically for the treatment of spasticity associated with brain and spinal cord injuries. Synthesis and GABA receptor agonist activity of certain amino acids structurally related to...... baclofen (2) are reported. (RS)-4-amino-3-(4- ethynylphenyl)butanoic acid hydrochloride (1b) showed GABA receptor agonist activity with EC = 240 µM whereas (RS)-4-amino-3-(4-iodophenyl)butanoic acid hydrochloride (1c) emerged as the best GABAB receptor agonist congener in the synthesized compounds with ED...

  15. Scoliosis, spinal fusion, and intrathecal baclofen pump implantation.

    Science.gov (United States)

    Scannell, Brian; Yaszay, Burt

    2015-02-01

    This article reviews the incidence, management, and complications of scoliosis in patients with cerebral palsy. Treatment of scoliosis in patients with cerebral palsy includes both nonoperative and operative management and often the decision to proceed with surgery is a multidisciplinary decision. Because of severe spasticity, many of these patients undergo intrathecal baclofen pump placement before, during, or after posterior spinal fusion. The complication rates can be high with intrathecal baclofen pump placement, but many patients can have significant benefit with this therapy. PMID:25479781

  16. Review of Intrathecal Baclofen Therapy for Spastic and Rigidity Disorders

    Science.gov (United States)

    Obringer, S. John; Coffey, Kenneth M.

    2002-01-01

    Intrathecal baclofen therapy, a treatment for cerebral palsy and other spastic and rigidity disorders, is showing promise as an effective intervention. This article synthesizes both the medical and rehabilitation conceptual literature to update educators and related service providers as to the efficacy of this intervention. Implications for…

  17. The use of very high-doses of baclofen for the treatment of alcohol-dependence: a case series.

    Directory of Open Access Journals (Sweden)

    Renaud ede Beaurepaire

    2014-10-01

    Full Text Available Baclofen, particularly high-dose baclofen, has recently emerged as a treatment of major interest for alcohol-dependence. However, baclofen has many potentially dangerous side effects, and the maximal dose of baclofen that may be used is a matter of discussion. Here, the author analyses the medical charts of the last 100 patients seen in his clinic, 17 of whom have been taking a very high dose of baclofen, that is to say, more than 300mg per day. The analysis of the charts shows that the very high doses baclofen were justified in almost all the cases. Side effects are analyzed.

  18. Resolution of the stereoisomers of baclofen by high performance liquid chromatography

    International Nuclear Information System (INIS)

    The GABA analogue baclofen [3-(p-chlorophenyl)-4-aminobutanoic acid] has stereospecific actions on the peripheral and central nervous systems. This paper describes the resolution of tritium-labelled baclofen by high performance liquid chromatography on a reverse-phase C18 column using a chiral mobile phase. The method, which may have general application to certain other GABA analogues, affords optically pure (+)- and (-)-baclofen labelled with tritium to high specific activity suitable for ligand binding and other neurochemical studies. (Auth.)

  19. Individualised Treatment of Alcohol Dependent Patients with Baclofen: A Clinical Observation

    OpenAIRE

    Becker, Martin; Boesch, Lukas; Baumgartner, Markus R.; Johnson, David; Stohler, Rudolf

    2014-01-01

    Objective: The objective of this observational study was to investigate the effectiveness, safety and tolerability of baclofen in individualised doses for the treatment of alcohol dependence in a sample of patients suffering from additional co-occurring mental disorders. Methods: Fifteen subjects requesting baclofen treatment to achieve abstinence from, or reduction of, alcohol consumption, were included in the study. Baclofen was titrated individually responding to the participants' reports ...

  20. Baclofen intoxication after accidental ingestion in a 3-year-old child

    OpenAIRE

    Dasarwar Nagesh; Shanbag Preeti; Kumbhare Nilesh

    2009-01-01

    Baclofen is a skeletal muscle relaxant, used to control spasticity in both adults and children with neuromuscular disorders. Several cases of baclofen overdose have been reported, but only a small number have involved children. We report a 3-year-old girl with accidental ingestion of baclofen, who presented with coma, bradycardia and hypotension. She recovered within 24 hours with supportive treatment. The case emphasizes the importance of warning parents about the potential toxicity of baclo...

  1. Resolution of the stereoisomers of baclofen by high performance liquid chromatography

    Energy Technology Data Exchange (ETDEWEB)

    Weatherby, R.P.; Allan, R.D.; Johnston, G.A.R. (Sydney Univ. (Australia))

    1984-01-01

    The GABA analogue baclofen (3-(p-chlorophenyl)-4-aminobutanoic acid) has stereospecific actions on the peripheral and central nervous systems. This paper describes the resolution of tritium-labelled baclofen by high performance liquid chromatography on a reverse-phase C18 column using a chiral mobile phase. The method, which may have general application to certain other GABA analogues, affords optically pure (+)- and (-)-baclofen labelled with tritium to high specific activity suitable for ligand binding and other neurochemical studies.

  2. Selective depression of synaptic excitation in cat spinal neurones by baclofen: an iontophoretic study.

    OpenAIRE

    Davies, J

    1981-01-01

    1 The effects of baclofen have been examined on responses of neurones in the spinal cord of the anaesthetized cat to stimulation of appropriate synaptic pathways, acetylcholine and a range of amino acid excitants. Baclofen and excitant substances were administered by standard microiontophoretic techniques. 2 Small ejecting currents of baclofen (less than 10 nA) depressed non-cholinergic, excitatory, synaptic responses evoked by stimulation of dorsal roots or muscle or cutaneous afferents. Exc...

  3. Differential development of tolerance to the functional and behavioral effects of repeated baclofen treatment in rats

    OpenAIRE

    Beveridge, T.J.R.; Smith, H. R.; Porrino, L.J.

    2013-01-01

    Baclofen, a gamma-aminobutyric acid (GABA)B receptor agonist, has been used clinically to treat muscle spasticity, rigidity and pain. More recently, interest in the use of baclofen as an addiction medicine has grown, with promising preclinical cocaine and amphetamine data and demonstrated clinical benefit from alcohol and nicotine studies. Few preclinical investigations, however, have utilized chronic dosing of baclofen, which is important given that tolerance can occur to many of its effects...

  4. Baclofen blocks postsynaptic inhibition but not the effect of muscimol in the olfactory cortex.

    OpenAIRE

    Scholfield, C. N.

    1983-01-01

    1 The olfactory cortex slice preparation from the guinea-pig brain was used to study the effects of baclofen on inhibition using intracellular recording. Stimulation of the lateral olfactory tract activities sequentially excitatory and inhibitory pathways. Inhibition is manifest as a period of increased membrane conductance (termed postsynaptic inhibitory conductance, IPSC). 2 Bath application of baclofen (0.2-500 muM) reversibly blocked the IPSC. Baclofen also produced a secondary increase i...

  5. Two Cases of Baclofen-Induced Encephalopathy in Hemodialysis and Peritoneal Dialysis Patients

    OpenAIRE

    Lee, Junseop; Shin, Ho Sik; Jung, Yeon Soon; Rim, Hark

    2012-01-01

    Hiccups are a spasmodic contraction of the diaphragm and usually transient phenomenon that affects nearly everyone. When hiccups develop, the patients are administrated antispastic agent, such as balcofen. Baclofen is widely used for the treatment of this spastic movement disorders. Also, baclofen is a gamma-aminobutyric acid (GABA) derivative that induces presynaptic motor neuron inhibition and produces a central antispastic response. Baclofen toxicity is rare and has been reported with intr...

  6. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats

    OpenAIRE

    Le Foll, Bernard; Wertheim, Carrie E.; Goldberg, Steven R.

    2008-01-01

    Neurochemical studies suggest that baclofen, an agonist at GABAB receptors, may be useful for treatment of nicotine dependence. However, its ability to selectively reduce nicotine’s abuse-related behavioral effects remains in question. We assessed effects of baclofen doses ranging from 0.1 to 3 mg/kg on nicotine-induced conditioned place preferences (CPP), nicotine discrimination, locomotor activity and food-reinforced behavior in male Sprague Dawley rats. The high dose of baclofen (3 mg/kg) ...

  7. Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

    OpenAIRE

    Raymundo Sanchez-Ponce; Li-Quan Wang; Wei Lu; Jana von Hehn; Maryann Cherubini; Roger Rush

    2012-01-01

    STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric...

  8. Characterization of pre- and postsynaptic actions of (-)-baclofen in the guinea-pig hippocampus in vitro.

    OpenAIRE

    M. Inoue; T. Matsuo; Ogata, N.

    1985-01-01

    The effects of (-)-baclofen on evoked potentials in the hippocampus were examined through intracellular recordings from guinea-pig brain slices. The evoked responses were recorded in two fibre connections within the hippocampus: the Schaffer collateral/commissural-CA1 pyramidal cell, and the mossy fibre-CA3 pyramidal cell. The Schaffer collateral/commissural-CA1 response was suppressed by (-)-baclofen in concentrations over 2 X 10(-5)M, whereas (+)-baclofen, an inactive isomer, in a concentra...

  9. Suppression of Alcohol Dependence Using Baclofen: A 2-Year Observational Study of 100 Patients

    OpenAIRE

    de Beaurepaire, Renaud

    2012-01-01

    Aims: The purpose of this study was to examine the long-term effects of baclofen in a large cohort of alcohol-dependent patients compliant to baclofen treatment. Methods: A hundred patients with alcohol dependence, resistant to usual treatments, were treated with escalating doses of baclofen (no superior limit). Alcohol consumption (in grams) and craving for alcohol were assessed before treatment and at 3, 6, 12, and 24 months. Assessments were simply based on patients’ statements. The outcom...

  10. Encephalopathy and Hypotonia due to Baclofen Toxicity in a Patient with End-Stage Renal Disease

    OpenAIRE

    Ijaz, Mohsin; Tariq, Hassan; Kashif, Muhammad; Marquez, Jose Gomez

    2015-01-01

    Patient: Female, 57 Final Diagnosis: Baclofen toxicity Symptoms: Encephalopathy • hypotonia Medication: Baclofen Clinical Procedure: Hemodialysis Specialty: Critical Care Objective: Unusual or unexpected effect of treatment Background: Baclofen is a centrally acting gamma-aminobutyric acid agonist used for the symptomatic relief of skeletal muscle spasm and spasticity in traumatic spinal cord lesions, multiple sclerosis, cerebral palsy, and stroke. It is also used in the treatment of chronic ...

  11. Severe Central Sleep Apnea Associated With Chronic Baclofen Therapy: A Case Series.

    Science.gov (United States)

    Olivier, Pierre-Yves; Joyeux-Faure, Marie; Gentina, Thibaut; Launois, Sandrine H; d'Ortho, Marie Pia; Pépin, Jean-Louis; Gagnadoux, Frédéric

    2016-05-01

    Baclofen, a gamma-aminobutyric acid-B agonist with muscle-relaxant properties, is widely used in patients with severe spasticity. In animals, baclofen has been shown to decrease respiratory drive. In humans, however, use of baclofen at the standard dose did not significantly impair sleep-disordered breathing in a susceptible population of snorers. Recently, there has been increasing interest in the role of baclofen for the treatment of alcohol dependence. We describe severe central sleep apnea (CSA) in four patients with none of the conditions commonly associated with CSA who were receiving chronic baclofen therapy for alcohol withdrawal. In one patient, baclofen withdrawal was associated with a complete resolution of CSA. Three patients were treated by adaptive servo-ventilation while continuing their treatment with baclofen. Given the increasing number of patients receiving baclofen for alcohol withdrawal treatment, physicians should be aware that these patients might be affected by severe CSA. Future studies are required to determine the mechanisms, prevalence, and treatment modalities of sleep-disordered breathing associated with baclofen usage. PMID:27157226

  12. Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

    Directory of Open Access Journals (Sweden)

    Raymundo Sanchez-Ponce

    2012-09-01

    Full Text Available STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS and autism spectrum disorders (ASD. New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric configuration. This metabolite undergoes some further metabolism by glucuronide conjugation. Consequences of this metabolic difference are a lower Cmax and lower early plasma exposure of S-baclofen compared to R-baclofen and marginally lower urinary excretion of S-baclofen after racemic baclofen administration. These differences introduce compound-related exposure variances in humans in which subjects dosed with racemic baclofen are exposed to a prominent metabolite of baclofen whilst subjects dosed with STX209 are not. For potential clinical use, our findings suggest that STX209 has the advantage of being a biologically defined and active enantiomer.

  13. Development, evaluation and optimization of baclofen oral floating tablet

    OpenAIRE

    Singh, Akhilesh V.; Pandey, Rishabh D.; Nath, Lila K.; Das, Anudwipa

    2010-01-01

    The present investigation concerns the development of a floating matrix tablet, which after oral administration prolong the gastric residence time and increases bioavailability of drugs, which are predominantly absorbed from gastric region .With this aim, floating dosage form containing baclofen as drug, and different grades of HPMC as release retarding polymer was prepared. Sodium bicarbonate and citric acid were used as gas generating agents. Some factors were investigated concerning the ef...

  14. Baclofen Withdrawal Presenting as Irritability in a Developmentally Delayed Child

    Directory of Open Access Journals (Sweden)

    C. Anthoney Lim

    2012-09-01

    Full Text Available Irritability in children has a broad differential diagnosis, ranging from benign processes to lifethreatening emergencies. In children with comorbid conditions and developmental delay, the diagnostic process becomes more challenging. This case report describes a developmentally delayed 14-year-old boy who presented with pain and crying caused by a malfunction of a surgically implanted baclofen pump. We describe recommendations concerning the diagnostic evaluation, medical management, and surgical repair.

  15. DEVELOPMENT OF SUSTAINED RELEASE TABLETS CONTAINING SOLID DISPERSIONS OF BACLOFEN

    Directory of Open Access Journals (Sweden)

    K. H. Janardhana

    2015-07-01

    Full Text Available Sustained release tablets containing solid dispersions granules of a poorly water soluble drug were prepared to investigate the controlled release of the drug. Baclofen was chosen because of its poor water solubility and short elimination half-life. Poloxamer 188 and PEG 6000 were used as solid dispersion carrier. Free flowing solid dispersion granules were prepared by adsorbing the melt of the drug and carriers onto the surface of an adsorbent, Carbopol 934P followed by direct compression with HPMC K4M and HPMC K100 to obtain an solid dispersion loaded sustained release tablets. FTIR studies confirmed that the compatibility of drug and carriers. Differential scanning calorimetry (DSC and X-ray diffraction (XRD revealed partially amorphous structures of the drug in solid dispersion granules. The solid dispersion granules dissolved completely within 30 min, which was much faster than that of pure drug baclofen. The sustained release of baclofen from the solid dispersion containing tablet was achieved for 2 h in gastric fluid (pH 1.2 and for up to 10 h in intestinal fluid (pH 6.8. A combination of solid dispersion techniques using adsorption and sustained release concepts is a promising approach to control the release rate of poorly water-soluble drugs.

  16. Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption

    OpenAIRE

    Kasten, Chelsea R.; Blasingame, Shelby N.; Boehm, Stephen L.

    2014-01-01

    The GABAB receptor agonist baclofen has been studied extensively in preclinical models of alcohol use disorders, yet results on its efficacy have been uncertain. Racemic baclofen, which is used clinically, can be broken down into separate enantiomers of the drug. Baclofen has been shown to produce enantioselective effects in behavioral assays including those modeling reflexive and sexual behavior. The current studies sought to characterize the enantioselective effects of baclofen in two separ...

  17. Hypothermia induced by baclofen, a possible index of GABAB receptor function in mice, is enhanced by antidepressant drugs and ECS.

    OpenAIRE

    Gray, J. A.; Goodwin, G. M.; Heal, D. J.; Green, A R

    1987-01-01

    1 Intraperitoneal injection to mice of the gamma-aminobutyric acidB (GABAB) receptor agonist (+/-)-baclofen induces a dose-dependent decrease in rectal temperature. 2 Injection of (-)-baclofen intracerebroventricularly at doses that had no effect when given peripherally induced a marked hypothermia. (+)-Baclofen was without effect. 3 The decrease in rectal temperature induced by (-)-baclofen when injected intraperitoneally was highly correlated with an increase in sedation. 4 Repeated adminis...

  18. Reduction of chronic non-specific low back pain: A randomised controlled clinical trial on acupuncture and baclofen

    Directory of Open Access Journals (Sweden)

    Rastqar Ali

    2010-04-01

    Full Text Available Abstract Background Chronic non-specific low back pain (LBP is a prevalent (80% and multi-dimensional illness. This study aims to test whether acupuncture, baclofen, or combined treatment with acupuncture and baclofen alleviates symptoms of non-specific chronic LBP in men. Methods Eight-four (84 men aged 50-60 years with non-specific chronic LBP were randomly assigned to four groups: the baclofen group received only baclofen (30 mg/day; the acupuncture group received only acupuncture at selected acupoints; the acupuncture + baclofen group received combined treatment with acupuncture and baclofen treatments; and the control group received no pain reduction treatment. After five weeks of treatment, visual analogue scale (VAS and self-reported pain disability with the Roland-Morris Disability Questionnaire (RDQ were conducted for outcome measures. Results After treatment, the baclofen, acupuncture and acupuncture + baclofen groups all had lower VAS and RDQ scores. Significantly higher reduction and improvement in VAS and RDQ scores were found in the acupuncture and acupuncture + baclofen groups compared to the baclofen group. Conclusion The present study indicates that the combined treatment of acupuncture and baclofen is more effective than baclofen treatment alone to reduce pain in patients with non-specific chronic LBP. Trial registration number ACTRN12609000698279

  19. Baclofen overdose from possible intrinsic malfunction of SynchroMed II pump.

    Science.gov (United States)

    Davanzo, Justin R; Rizk, Elias

    2015-08-01

    This is a case report illustrating an overdose of baclofen in a 10-year-old boy due to a likely malfunction of a SynchroMed II pump. This ultimately necessitated a pump replacement. One-year follow-up showed no further incidents of baclofen overdose, with multiple pump refills. PMID:25978532

  20. Baclofen-induced neurotoxicity in a patient with end-stage renal disease.

    Science.gov (United States)

    Radhakrishnan, Hemachandar

    2016-05-01

    Baclofen, predominantly excreted by the kidneys is accumulated in patients with renal insufficiency leading to the central nervous system toxicity. Here the author reports a patient with end-stage renal disease on maintenance hemodialysis (HD) who developed drowsiness and became unresponsive within a day after taking single 10 mg dose of baclofen. Patient improved completely after two sessions of HD. PMID:27215257

  1. Baclofen-induced neurotoxicity in a patient with end-stage renal disease

    OpenAIRE

    Hemachandar Radhakrishnan

    2016-01-01

    Baclofen, predominantly excreted by the kidneys is accumulated in patients with renal insufficiency leading to the central nervous system toxicity. Here the author reports a patient with end-stage renal disease on maintenance hemodialysis (HD) who developed drowsiness and became unresponsive within a day after taking single 10 mg dose of baclofen. Patient improved completely after two sessions of HD.

  2. Pharmacokinetic Alteration of Baclofen by Multiple Oral Administration of Herbal Medicines in Rats

    Directory of Open Access Journals (Sweden)

    Tae Hwan Kim

    2014-01-01

    Full Text Available The potential pharmacokinetic (PK interaction of conventional western drug, baclofen, and oriental medications Oyaksungisan (OY and Achyranthes bidentata radix (AB extract for the treatment of spasticity has been evaluated. Rats were pretreated with distilled water (DW, OY, or AB extract by oral administration every day for 7 days. After 10 min of the final dose of DW or each herbal medication, baclofen (1 mg/kg was given by oral administration and plasma concentrations of baclofen were determined by LC/MS/MS. The plasma baclofen concentration-time profiles were then analyzed by noncompartmental analysis and a population PK model was developed. Baclofen was rapidly absorbed, showed biexponential decline with elimination half-life of 3.42–4.10 hr, and mostly excreted into urine. The PK of baclofen was not affected by AB extract pretreatment. However, significantly lower maximum plasma concentration (Cmax and longer time to reach Cmax (Tmax were observed in OY pretreated rats without changes in the area under the curve (AUC and the fraction excreted into urine (Furine. The absorption rate (Ka of baclofen was significantly decreased in OY pretreated rats. These data suggested that repeated doses of OY might delay the absorption of baclofen without changes in extent of absorption, which needs further evaluation for clinical significance.

  3. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis.

    Science.gov (United States)

    Dalton, Catherine M; Keenan, Elizabeth; Jarrett, Louise; Buckley, Lisa; Stevenson, Valerie L

    2008-05-01

    Intrathecal baclofen is a GABA-receptor agonist and one of the mainstay treatments of severe spasticity due to multiple sclerosis (MS). The authors report a case on the use of intrathecal baclofen administered using a Medtronic Synchromed II infusion pump. A healthy male infant (2.68 kg, Apgars 9 and 10) was born at 36 weeks gestation by cesarean section, under general anesthetic. This is the fifth reported case of intrathecal baclofen administered during pregnancy and adds to the knowledge that thus far it is relatively safe in pregnancy and may in fact be safer for the infant than oral baclofen. This is the first case report of the use of intrathecal baclofen in pregnancy and MS. PMID:18562512

  4. The Use of Very High-Doses of Baclofen for the Treatment of Alcohol-Dependence: A Case Series

    OpenAIRE

    de Beaurepaire, Renaud

    2014-01-01

    Baclofen, particularly high-dose baclofen, has recently emerged as a treatment of major interest for alcohol-dependence. However, baclofen has many potentially dangerous side effects, and the maximal dose of baclofen that may be used is a matter of discussion. Here, the author analyses the medical charts of the last 100 patients seen in his clinic, 17 of whom have been taking a very high dose of baclofen, which is to say, more than 300 mg/day. The analysis of the charts shows that the very hi...

  5. GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators

    Directory of Open Access Journals (Sweden)

    Roberta Agabio

    2015-04-01

    Full Text Available The present paper summarizes experimental and clinical data indicating the therapeutic potential of the GABAB receptor agonist, baclofen, in the treatment of alcohol use disorder (AUD and substance use disorder (SUD. Multiple preclinical studies have demonstrated the ability of baclofen to suppress alcohol drinking (including binge- and relapse-like drinking, oral alcohol self-administration, and intravenous self-administration of cocaine, nicotine, amphetamine, methamphetamine, morphine, and heroin in rodents. Some randomized, controlled trials (RCTs and case reports support the efficacy of baclofen in suppressing alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. Data from RCTs and open studies investigating baclofen efficacy on SUD are currently less conclusive. Interest in testing high doses of baclofen in AUD and SUD treatment has recently emerged. Preclinical research has extended the anti-addictive properties of baclofen to positive allosteric modulators of the GABAB receptor (GABAB PAMs. In light of their more favourable side effect profile (compared to baclofen, GABAB PAMs may represent a major step forward in a GABAB receptor-based pharmacotherapy of AUD and SUD.

  6. Status dystonicus resembling the intrathecal baclofen withdrawal syndrome: a case report and review of the literature

    Directory of Open Access Journals (Sweden)

    Muirhead William

    2010-08-01

    Full Text Available Abstract Introduction Status dystonicus is a rare but life-threatening disorder characterized by increasingly frequent and severe episodes of generalized dystonia that may occur in patients with primary or secondary dystonia. Painful and repetitive spasms interfere with respiration and may cause metabolic disturbances such as hyperpyrexia, dehydration, respiratory insufficiency, and acute renal failure secondary to rhabdomyolysis. Intrathecally administered baclofen, delivered by an implantable pump system, is widely used for the treatment of refractory spasticity. Abrupt cessation of intrathecal baclofen infusion has been associated with a severe withdrawal syndrome comprised of dystonia, autonomic dysfunction, hyperthermia, end-organ failure and sometimes death. The aetiology of this syndrome is not well understood. Status dystonicus describes the episodes of acute and life-threatening generalized dystonia, which occasionally manifest themselves in patients with dystonic syndromes. Case presentation We present the case of a nine-year-old Caucasian boy who experienced a severe episode of status dystonicus with no known cause and clinical features resembling those described in intrathecal baclofen withdrawal. Our patient subsequently underwent the placement of an intrathecal baclofen pump without incident. Conclusion The similarity between the clinical features of the case we present and those reported in connection to abrupt withdrawal of intrathecal baclofen is emphasized. Several drugs, although not intrathecal baclofen withdrawal, have previously been associated with status dystonicus. The similarity between the life-threatening dystonic episode experienced by our patient, and those reported in intrathecal baclofen withdrawal, highlights the possibility that, rather than representing a true physiological withdrawal syndrome, abrupt withdrawal of intrathecal baclofen may simply precipitate an episode of status dystonicus in susceptible

  7. Asymmetric Transfer Hydrogenation to Synthesize R-(-)-Baclofen%不对称氢转移合成R-(-)-Baclofen

    Institute of Scientific and Technical Information of China (English)

    许波洪; 张跃

    2010-01-01

    以外消旋的β-羟基酮酸酯为原料,通过不对称氢转移的方法,高效的合成了光学活性的手性中间体β-羟基酮酸酯,光学纯度达到98%,然后通过亲核取代反应生成了光学活性的β-氰基丙酮酸酯,最后还原生成R-(-)-Baclofen.

  8. CGP 35348, a new GABAB antagonist, prevents antinociception and muscle-relaxant effect induced by baclofen.

    OpenAIRE

    Malcangio, M.; Ghelardini, C.; Giotti, A.; Malmberg-Aiello, P.; Bartolini, A.

    1991-01-01

    1. CGP 35348, a new GABAB antagonist, was examined on antinociception induced by (+/-)-baclofen by use of the hot plate and writhing tests in mice and the paw pressure test in rats. CGP 35348 was also studied in mice on (+/-)-baclofen-induced impairment of rota-rod performance. 2. CGP 35348, injected either i.p. (60-100 mg kg-1 in mouse) or intracerebroventricularly (i.c.v.) (0.5-2.5 micrograms per mouse; 25 micrograms per rat) prevented (+/-)-baclofen-induced antinociception. 3. CGP 35348 di...

  9. L-baclofen-sensitive GABAB binding sites in the medial vestibular nucleus localized by immunocytochemistry

    Science.gov (United States)

    Holstein, G. R.; Martinelli, G. P.; Cohen, B.

    1992-01-01

    L-Baclofen-sensitive GABAB binding sites in the medial vestibular nucleus (MVN) were identified immunocytochemically and visualized ultrastructurally in L-baclofen-preinjected rats and monkeys, using a mouse monoclonal antibody with specificity for the p-chlorophenyl moiety of baclofen. Saline-preinjected animals showed no immunostain. In drug-injected animals, there was evidence for both pre- and postsynaptic GABAergic inhibition in MVN mediated by GABAB receptors. These neural elements could be utilized in control of velocity storage in the vestibulo-ocular reflex.

  10. Inhibition of calcium currents in cultured rat dorsal root ganglion neurones by (-)-baclofen.

    OpenAIRE

    Dolphin, A.C.; Scott, R. H.

    1986-01-01

    Voltage-dependent inward calcium currents (ICa) activated in cultured rat dorsal root ganglion neurones were reversibly reduced in a dose-dependent manner by (-)-baclofen (10 microM to 100 microM). Baclofen (100 microM) reduced the calcium-dependent slow outward potassium current (IK(Ca)). This current was abolished in calcium-free medium and by 300 microM cadmium chloride. The action of baclofen on IK(Ca) was reduced when the calcium concentration in the medium was increased from 5 mM to 30 ...

  11. [Anesthetic Management of an Adrenoleukodystrophy Patient for Intrathecal Baclofen Therapy].

    Science.gov (United States)

    Hashimoto, Yuichi; Takahashi, Kei; Yamamoto, Yuko; Ogata, Tokiko; Arai, Takero; Okuda, Yasuhisa

    2016-04-01

    A 34-year-old man with adrenoleukodystrophy (ALD) was scheduled for pump system insertion of intrathecal baclofen therapy under general anesthesia. ALD, a rare genetic disorder, is associated with a total body increase in long chain fatty acids caused by defective degradation, and includes various nervous system abnormalities, muscular weakness, in addition to adrenal insufficiency. He had contracture of the both legs, and muscular weakness of the left hand, and Mallampati class III, but no respiratory disability. In the operating room, we administered hydrocortisone 100 mg for steroid coverage, and low-dose midazolam, and fentanyl. As spontaneous breathing remained, we could easily see epiglottis and arytenoid cartilage by McGRATH. Therefore we selected rapid-induction of anesthesia with thiamylal, and rocuronium 40 mg, under cricoid pressure. We avoided propofol. Anesthsia was maintained with sevoflurane and remifentanil, monitoring BIS and train of four. No more rocuronium was administered, and anesthesia was uneventful. Intrathecal baclofen therapy is given to patients who have severe contracture. When we selected general anesthesia, we should be aware of the possibility of muscular weakness, and cannot intubate cannot ventilate scenario. PMID:27188115

  12. FORMULATION AND EVALUATION OF BACLOFEN CONTROLLED POROSITY OSMOTIC PUMP TABLETS

    Directory of Open Access Journals (Sweden)

    Indarapu Rajendra Prasad

    2013-06-01

    Full Text Available In the present study, attempts were made to develop and evaluate the controlled porosity osmotic pump (CPOP based drug delivery system of sparingly water soluble drug Baclofen. Formulation variables, such as, levels of solubility enhancer, ratio of drug to osmogents, coat thickness of semi permeable membrane (SPM and level of pore former were found to affect the drug release from the developed formulations. Cellulose acetate was used as the semi permeable membrane. Drug release was directly proportional to the level of the solubility enhancer, osmotic pressure generated by osmotic agent and level of pore former; however, was inversely proportional to the coat thickness of SPM. Drug release from developed formulations was independent of pH and agitation intensities of release media. Burst strength of the exhausted shells decreased with increase in the level of pore former. This system was found to deliver Baclofen at a zero-order rate. The optimized formulations were subjected to stability studies as per ICH guidelines, and formulations were found to be stable after 45days study.

  13. PREPARATION AND IN-VITRO EVALUATION OF BACLOFEN LOADED MICROSPHERES

    Directory of Open Access Journals (Sweden)

    Polepalle Madhulatha

    2012-09-01

    Full Text Available The present study was aimed to prepare Baclofen microspheres for sustained release using various polymers such as ethyl cellulose (hydrophobic, hydroxy propyl methyl cellulose (hydrophilic by employing solvent evaporation technique. Drug and excipients compatibility was studied by Fourier Transform Infrared Spectroscopy and no incompatibility was observed. The obtained microspheres were evaluated for the percent drug content, entrapment efficiency and in-vitro dissolution studies. The entrapment efficiency of the obtained formulations was in between 66-88% and in-vitro release of F7 formulation showed 93% in 24 hrs. Scanning Electron Microscopy, Differential Scanning Calorimetry and X-Ray Diffraction studies were performed for F7 formulation. From the results Scanning Electron Microscopy of reveals that microspheres was found in spherical and porous nature. X-Ray Diffraction studies results showed baclofen was in amorphous form which was further confirmed by Differential Scanning Calorimetry. The curve fitting data revealed that the release of obtained formulations follows mixed order kinetics with non‐fickian type of drug release (anomalous.

  14. Ga BaB pharmacophoric pattern based on conformational analysis of 3-hetero aromatic baclofen analogues

    International Nuclear Information System (INIS)

    Substituting a furan, a thiophen, a benzo (b) furan or a benzo (b) thiophen ring for the p-chlorophenyl moiety of baclofen has led to GABAB (GABA = γ-aminobutyric acid) ligands with different affinities according to the nature of the hetero-aromatic ring, and the nature and position of its substituent. In order to determine the structural requirements that are important for GABAB affinity, we have aligned the 3D structures of several 3-hetero-aromatic baclofen analogues with that of baclofen. As a result, we have suggested a pharmacophoric pattern for 3-hetero-aromatic baclofen analogues. The 3D structures have been studied by X-ray diffraction and by ab initio molecular orbital calculations. (authors). 29 refs., 6 figs., 5 tabs

  15. Effect of intrathecal baclofen on the monosynaptic reflex in humans: evidence for a postsynaptic action.

    OpenAIRE

    Azouvi, P; Roby-Brami, A.; Biraben, A; Thiebaut, J B; Thurel, C; Bussel, B

    1993-01-01

    Intrathecal baclofen is a very powerful antispastic agent. Its mechanism of action on the monosynaptic H-reflex in spinal patients was investigated. It could inhibit rapidly and profoundly monosynaptic reflexes in lower limbs, but did not modify Ia vibratory inhibition of the soleus H-reflex. To assess more precisely its effect on Ia afferents, an experimental paradigm using Ia heteronymous facilitation of the soleus H-reflex was used. Intrathecal baclofen did not modify the amount of monosyn...

  16. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review

    Directory of Open Access Journals (Sweden)

    Brennan JL

    2013-07-01

    Full Text Available Jessica L Brennan,2 Jonathan G Leung,1 Jane P Gagliardi,3 Sarah K Rivelli,3 Andrew J Muzyk4 1Department of Hospital Pharmacy Services, Mayo Clinic, Rochester, MN, 2Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 4Department of Pharmacy Practice, Campbell University School of Pharmacy and Health Sciences, Buies Creek, NC, USA Abstract: Baclofen, an agonist at the B subunit of gaba-aminobutyric acid receptor, possesses pharmacologic properties that may confer utility for the treatment of alcohol dependence. Research suggests that not only can it be useful in promoting maintenance of alcohol abstinence but also it may play a key role in decreasing alcohol cravings and anxiety often associated with alcohol dependence. To assess the benefit of baclofen for alcohol dependence, a review of the literature was conducted to identify published data investigating this off-label treatment. Four randomized controlled trials to date have been published and were included in this review. Although primary outcomes differ between studies, patients randomized to baclofen experience higher rates of abstinence from alcohol than those taking placebo in two of the trials. Secondary analyses indicate that baclofen is safe in patients with alcohol dependence, including those with moderate to severe liver cirrhosis, and may provide beneficial anxiolytic effects. Despite some positive data, the largest available randomized controlled trial failed to find any differences between baclofen and placebo. In all studies, individuals with severe medical comorbidities, seizure disorders, and psychiatric disorders were excluded from trials, which may limit external validity. In summary, there may be beneficial effects from using baclofen for the treatment of alcohol dependence; however, limited conclusions can be drawn from the small number of studies

  17. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome

    OpenAIRE

    Reddy, Vikram K.; Girish, K.; Pandit Lakshmi; R Vijendra; Ajay Kumar; Harsha, R.

    2014-01-01

    Objectives: Benzodiazepines (BZDs) are the first-line drugs in alcohol-withdrawal syndrome (AWS). Baclofen, a gamma-aminobutyric acid B (GABA B ) agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of baclofen and chlordiazepoxide in the management of uncomplicated AWS. Materials and Methods : This was a randomized, open label, standard controlled, parallel group study of cost-effectiveness an...

  18. GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators

    OpenAIRE

    Roberta Agabio; Giancarlo Colombo

    2015-01-01

    The present paper summarizes experimental and clinical data indicating the therapeutic potential of the GABAB receptor agonist, baclofen, in the treatment of alcohol use disorder (AUD) and substance use disorder (SUD). Multiple preclinical studies have demonstrated the ability of baclofen to suppress alcohol drinking (including binge- and relapse-like drinking), oral alcohol self-administration, and intravenous self-administration of cocaine, nicotine, amphetamine, methamphetamine, morphine, ...

  19. Baclofen in the short-term maintenance treatment of benzodiazepine dependence

    OpenAIRE

    Lekhansh Shukla; Arun Kandasamy; Muralidharan Kesavan; Vivek Benegal

    2014-01-01

    Benzodiazepine (BZD) dependence is a significant public health problem. Apart from the long-term tapering doses of BZD, no others drugs are available for the maintenance treatment of BZD dependence. Baclofen has been used in alcohol and other drug dependence as long-term anti-craving agent. Since alcohol and BZD act through the GABA receptor, we attempted to study the effect of Baclofen as maintenance treatment in a series of five cases with BZD dependence.

  20. Anticonvulsant-like actions of baclofen in the rat hippocampal slice.

    OpenAIRE

    Ault, B.; Nadler, J V

    1983-01-01

    1 The effects of baclofen were tested on epileptiform discharge in the rat hippocampal slice. Slices were superfused with bicuculline methiodide (100 microM) and maximal periods of afterdischarge were evoked by stimulating the Schaffer collateral-commissural pathway in area CA1, mossy fibres in area CA3 or perforant path fibres in the fascia dentata or by antidromic stimulation of CA1 pyramidal cells. 2 (-)-Baclofen attenuated the afterdischarge evoked by stimulating all three sets of fibres ...

  1. Effect of intrathecal baclofen on gait control in human hereditary spastic paraparesis.

    OpenAIRE

    Dan, Bernard; Bouillot, Ethel; Bengoetxea, Ana; Chéron, Guy

    2000-01-01

    The covariation between thigh, shank and foot elevation angles during locomotion was analysed by means of orthogonal planar regression in a patient with pure hereditary spastic paraparesis before and after an intrathecal bolus of baclofen and in seven healthy subjects. The size, shape and spatial orientation of the loop defining patient's planar covariation (thigh angle vs. shank angle vs. foot angle) significantly differed from the controls' before baclofen, whereas these features resumed no...

  2. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome

    Directory of Open Access Journals (Sweden)

    Vikram K Reddy

    2014-01-01

    Full Text Available Objectives: Benzodiazepines (BZDs are the first-line drugs in alcohol-withdrawal syndrome (AWS. Baclofen, a gamma-aminobutyric acid B (GABA B agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of baclofen and chlordiazepoxide in the management of uncomplicated AWS. Materials and Methods : This was a randomized, open label, standard controlled, parallel group study of cost-effectiveness analysis (CEA of baclofen and chlordiazepoxide in 60 participants with uncomplicated AWS. Clinical efficacy was measured by the Clinical Institute Withdrawal Assessment for alcohol (CIWA-Ar scores. Lorazepam was used as supplement medication if withdrawal symptoms could not be controlled effectively by the study drugs alone. Both direct and indirect medical costs were considered and the CEA was analyzed in both patient′s perspective and third-party perspective. Results : The average cost-effectiveness ratio (ACER in patient′s perspective of baclofen and chlordiazepoxide was Rs. 5,308.61 and Rs. 2,951.95 per symptom-free day, respectively. The ACER in third-party perspective of baclofen and chlordiazepoxide was Rs. 895.01 and Rs. 476.29 per symptom-free day, respectively. Participants on chlordiazepoxide had more number of symptom-free days when compared with the baclofen group on analysis by Mann-Whitney test (U = 253.50, P = 0.03. Conclusion : Both study drugs provided relief of withdrawal symptoms. Chlordiazepoxide was more cost-effective than baclofen. Baclofen was relatively less effective and more expensive than chlordiazepoxide.

  3. Baclofen in the short-term maintenance treatment of benzodiazepine dependence

    Directory of Open Access Journals (Sweden)

    Lekhansh Shukla

    2014-01-01

    Full Text Available Benzodiazepine (BZD dependence is a significant public health problem. Apart from the long-term tapering doses of BZD, no others drugs are available for the maintenance treatment of BZD dependence. Baclofen has been used in alcohol and other drug dependence as long-term anti-craving agent. Since alcohol and BZD act through the GABA receptor, we attempted to study the effect of Baclofen as maintenance treatment in a series of five cases with BZD dependence.

  4. Successful resolution of refractory chronic cough induced by gastroesophageal reflux with treatment of baclofen

    OpenAIRE

    Xu, Xianghuai; Chen, Qiang; Liang, Siwei; LÜ, Hanjing; Qiu, Zhongmin

    2012-01-01

    Gastroesophageal reflux induced cough is a common cause of chronic cough, and proton pump inhibitors are a standard therapy. However, the patients unresponsive to the standard therapy are difficult to treat and remain a challenge to doctors. Here, we summarized the experience of successful resolution of refractory chronic cough due to gastroesophageal reflux with baclofen in three patients. It is concluded that baclofen may be a viable option for gastroesophageal reflux induced cough unrespon...

  5. BACLOFEN-INDUCED REDUCTIONS IN OPTIONAL FOOD INTAKE DEPEND UPON FOOD COMPOSITION

    OpenAIRE

    Wojnicki, F.H.E.; Charny, G.; Corwin, R.L.W.

    2013-01-01

    Baclofen reduces intake of some foods but stimulates intake or has no effect on others. The reasons for these differences are not known. The present study examined effects of baclofen when composition, energy density, preference, presentation and intake of optional foods varied. Semi-solid fat emulsions and sucrose products were presented for brief periods to non-food-deprived rats. In Experiment 1, fat and sucrose composition were varied while controlling energy density. In Experiment 2A, sc...

  6. Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump.

    OpenAIRE

    Patterson, V; Watt, M.; Byrnes, D; Crowe, D; Lee, A.

    1994-01-01

    Intrathecal baclofen abolishes spasticity in many patients with neurological diseases but there are few studies on its long-term effectiveness. Since 1986 a manually operated subcutaneous pump has been used to deliver baclofen intrathecally in 21 patients with a follow up of at least one year. Most patients had multiple sclerosis and all were wheelchair-bound. Sixteen patients had a complete and sustained benefit. In four other patients the treatment was effective in the short term but not in...

  7. The Effect of Ginkgo on Baclofen Induced Amnesia using Passive Avoidance Learning and Memory in Rats

    OpenAIRE

    Elaheh Nooshinfar; Mostafa Rezaei Tavirani; Akram Safaei; Yara Tambrchi

    2015-01-01

    Background & Objective: Ginkgo biloba is an herbal medicine that has a positive effect on improving memory. It prevents oxidative damage in mitochondria and cell death in a variety of Neuropathies. Besides, baclofen is prescribed for its analgesic and anti-inflammatory effects but has negative impact on memory. The objective of this study is to investigate the interaction of ginkgo with GABA b receptor agonist (baclofen) by passive avoidance behavior in mice. Materials & Methods: Passive ...

  8. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome

    OpenAIRE

    Reddy, Vikram K.; Girish, K.; Lakshmi, Pandit; R Vijendra; Kumar, Ajay; Harsha, R.

    2014-01-01

    Objectives: Benzodiazepines (BZDs) are the first-line drugs in alcohol-withdrawal syndrome (AWS). Baclofen, a gamma-aminobutyric acidB (GABAB) agonist, controls withdrawal symptoms without causing significant adverse effects. The objective of this study was to compare the cost-effectiveness of baclofen and chlordiazepoxide in the management of uncomplicated AWS. Materials and Methods: This was a randomized, open label, standard controlled, parallel group study of cost-effectiveness analysis (...

  9. Effects of baclofen on synaptically-induced cell firing in the rat hippocampal slice.

    OpenAIRE

    Ault, B.; Nadler, J V

    1983-01-01

    The effects of baclofen on the synaptically-induced firing of pyramidal and granule cell populations were tested in the rat hippocampal slice. Population spikes were evoked by stimulating excitatory pathways in the presence and absence of bath-applied drug. (+/-)-Baclofen (20 microM) completely blocked the firing of CA1 or CA3 hippocampal pyramidal cells subsequent to stimulation of projections that originate in area CA3. In contrast, the firing of dentate granule cells evoked by stimulation ...

  10. The synthesis and biodistribution of 3-(4'-[125I]-iodophenyl)-4-aminobutyric acid, a radioiodinated analogue of baclofen

    International Nuclear Information System (INIS)

    Baclofen has been found to bind to receptors in the central nervous system that are specific for γ-aminobutyric acid (GABA), a well known inhibitory neurotransmitter. This paper describes the synthesis of a radioiodinated analog of baclofen as part of an effort to develop receptor probes useful in single photon emission computed tomography. Preliminary biodistribution studies showed the radioiodinationed analog to be essentially stable to in vivo deiodination and have a distribution profile similar to that of baclofen. (Author)

  11. Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581

    OpenAIRE

    Ahmadi-Abhari Seyed Ali; Radgoodarzi Reza; Assadi Seyed Mohammad

    2003-01-01

    Abstract Background Results of preclinical studies suggest that the GABAB receptor agonist baclofen may be useful in treatment of opioid dependence. This study was aimed at assessing the possible efficacy of baclofen for maintenance treatment of opioid dependence. Methods A total of 40 opioid-dependent patients were detoxified and randomly assigned to receive baclofen (60 mg/day) or placebo in a 12-week, double blind, parallel-group trial. Primary outcome measure was retention in treatment. S...

  12. Bruxism Associated with Anoxic Encephalopathy: Successful Treatment with Baclofen

    Directory of Open Access Journals (Sweden)

    A. Bruce Janati

    2013-01-01

    Full Text Available Introduction. Bruxism is a movement disorder characterized by grinding and clenching of the teeth. Etiology of bruxism can be divided into three groups: psychosocial factors, peripheral factors, and pathophysiological factors. Methods. The clinical investigation was conducted at King Khaled Hospital in Hail, Saudi Arabia, in 2012. Results. A 16-year-old Saudi female was brought to the hospital in a comatose state and with generalized convulsive seizures secondary to acute anoxic encephalopathy. In the third week of hospitalization, while still in a state of akinetic mutism, she developed incessant bruxism which responded favorably to a GABA receptor agonist (baclofen. Conclusion. Our data support the hypothesis that bruxism emanates from imbalance or dysregulation of the neurotransmitter system. Larger scale studies will be needed to confirm this hypothesis.

  13. Unusual placement of intrathecal baclofen pumps: report of two cases.

    Science.gov (United States)

    Devine, Oliver; Harborne, Andrew; Lo, William B; Weinberg, Daniel; Ciras, Mahesh; Price, Rupert

    2016-01-01

    Intrathecal baclofen delivery via implantable pump represents an important modality for symptomatic relief in patients with chronic spasticity. Pumps are routinely implanted subcutaneously in the anterior abdominal wall. We describe two unusual cases where skin-related complications necessitated revision surgery in order to relocate the pump to alternative sites. The first patient was an international power canoeist, whose strenuous exercise programme interfered with his pump's original siting. The second patient was a cachectic university student with a history of cerebral palsy, who maintained low body mass despite attempted weight gain. The relocation of these two intrathecal devices to the medial compartment of the right thigh and right iliac fossa, respectively, is described. PMID:26592253

  14. Enantioseparation of baclofen with highly sulfated β-cyclodextrin by capillary electrophoresis with laser-induced fluorescence detection

    OpenAIRE

    Kavran-Belin, Gamze; Rudaz, Serge; Veuthey, Jean-Luc

    2005-01-01

    The enantioseparation of baclofen (4-amino-3-p-chlorophenylbutyric acid) was achieved by CE-LIF with highly sulfated -CD (HS--CD) as chiral selector. Naphthalene-2,3-dicarboxaldehyde was used for the derivatization of nonfluorescent baclofen. HS--CD (2%) containing 50 mM borate buffer at pH 9.5 was chosen as the optimal running electrolyte and applied to the analysis of baclofen enantiomers in human plasma. The linearity of calibration curves (R 2 0.998) for R-(-) and S-(+)-baclofen was in th...

  15. Reduction of chronic non-specific low back pain: A randomised controlled clinical trial on acupuncture and baclofen

    OpenAIRE

    Rastqar Ali; Manaheji Homa; Zaringhalam Jalal; Zaringhalam Maryam

    2010-01-01

    Abstract Background Chronic non-specific low back pain (LBP) is a prevalent (80%) and multi-dimensional illness. This study aims to test whether acupuncture, baclofen, or combined treatment with acupuncture and baclofen alleviates symptoms of non-specific chronic LBP in men. Methods Eight-four (84) men aged 50-60 years with non-specific chronic LBP were randomly assigned to four groups: the baclofen group received only baclofen (30 mg/day); the acupuncture group received only acupuncture at s...

  16. Once daily baclofen sustained release or gastro-retentive system are acceptable alternatives to thrice daily baclofen immediate release at same daily dosage in patients

    Directory of Open Access Journals (Sweden)

    Sampat Nitin

    2009-01-01

    Full Text Available Background: Baclofen, a GABA-agonist, is currently available as an immediate release (IR formulation for relieving neurogenic spasticity in a variety of disorders. Baclofen IR requires to be administered three times a day which inadvertently increases the chances of medication noncompliance among patients and is also associated with side effects such as drowsiness and muscle weakness. Aim: To overcome the shortcomings of baclofen IR, two modified formulations, baclofen sustained release (SR and gastric retentive system (GRS, have been proposed to be equivalent in efficacy to baclofen IR with the administration of a single daily dose. Materials and Methods: Ninety patients with chronic neurogenic muscular spasticity were enrolled requiring 10-20 mg of baclofen IR every eight hours. The patients were randomized to two treatment arms: SR (n = 46 or GRS (n = 44 at the same once-daily dose for four weeks. Efficacy was measured by Ashworth score for muscle tone, spasm score, reflex score, 30-item functional independence score, and patient′s diary score for three most affected activities of daily life. Results: The mean Ashworth score changed significantly (P = 0.00 for patients in the SR group from 3.03-2.69 (-0.35 and 3.07-2.70 (-0.37 for patients in the GRS group. There was no significant difference (P = 0.87 between baseline-adjusted Ashworth score reductions on SR (-0.35 and GRS (-0.37. Similar results were obtained for spasm, reflex, and functional independence scores. The mean baseline-adjusted patient-diary scores did not differ significantly between 8 am, 12 pm, 4 pm, and 8 pm (P = 0.96, either on SR (-5.3 to -6.1 or GRS (-7.3 to -8.1, indicating a uniform effect round-the-day on both. Further, sedation scores (mean ± SEM decreased significantly (P < 0.05 on both SR (10.36 ± 1.37 to 6.18 ± 0.92 and GRS (8.14 ± 1.57 to 5.33 ± 1.11, suggesting better toleration. Conclusion: Once-daily baclofen SR and GRS are efficacious, convenient, and

  17. Baclofen and severe alcohol dependence: an uncertain harm-benefit balance as of early 2013.

    Science.gov (United States)

    2013-09-01

    Alcohol dependence is a severe, chronic illness. Even the best-assessed drugs used to maintain abstinence are poorly effective. Some patients remain dependent after several treatment attempts. Baclofen has been tested for its capacity to reduce craving for alcohol. We reviewed the data available as of early 2013, using the standard Prescrire methodology, in order to assess the harm-benefit balance of baclofen in maintaining abstinence or moderation in alcohol-dependent patients. Two double-blind, randomised, placebo-controlled trials conducted by the same team tested baclofen 30 mg/day in 123 alcohol-dependent patients referred to alcohol treatment centres. After 1 or 3 months of followup, more patients remained abstinent in the baclofen group than in the placebo group. In another double-blind, randomised trial, baclofen 30 mg/day was not more effective than placebo in 80 alcohol-dependent patients recruited through advertisements, many of whom were seeking treatment for the first time. Three uncontrolled retrospective series reported the results obtained in 300 alcohol-dependent patients, most of whom were in treatment failure. They were treated with high, escalating doses of baclofen (on average about 150 mg per day, up to 400 mg per day) with the intention of reducing their craving for alcohol. After 3 to 24 months of follow-up, about half of the patients reported moderate or zero alcohol consumption. At moderate doses, baclofen has been used since the 1970s in the treatment of certain forms of muscle spasticity. The main adverse effects reported in this setting were drowsiness (especially early during treatment) and various neuropsychiatric disorders such as dizziness, euphoria, depression, headache, paraesthesias, speech disorders, ataxia and insomnia. The adverse effects of high-dose baclofen are mainly based on monitoring of hundreds of alcohol-dependent patients, 69 reports to French pharmacovigilance centres in 2011, and cases of overdose or accidental

  18. Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption

    Science.gov (United States)

    Kasten, Chelsea R.; Blasingame, Shelby N.; Boehm, Stephen L.

    2014-01-01

    The GABAB receptor agonist baclofen has been studied extensively in preclinical models of alcohol use disorders, yet results on its efficacy have been uncertain. Racemic baclofen, which is used clinically, can be broken down into separate enantiomers of the drug. Baclofen has been shown to produce enantioselective effects in behavioral assays including those modeling reflexive and sexual behavior. The current studies sought to characterize the enantioselective effects of baclofen in two separate models of ethanol consumption. The first was a Drinking-in-the-Dark procedure that provides “binge-like” ethanol access to mice by restricting access to a two hour period, three hours into the dark cycle. The second was a two-bottle choice procedure that utilized selectively bred High Alcohol Preferring 1 (HAP1) mice to model chronic ethanol access. HAP1 mice are selectively bred to consume pharmacologically relevant amounts of ethanol in a 24-hour two-bottle choice paradigm. The results showed that baclofen yields enantioselective effects on ethanol intake in both models, and that these effects are bidirectional. Total ethanol intake was decreased by R(+)- baclofen, while total intake was increased by S(-)-baclofen in the binge-like and chronic drinking models. Whereas overall binge-like saccharin intake was significantly reduced by R(+)- baclofen, chronic intake was not significantly altered. S(-)- baclofen did not significantly alter saccharin intake. Neither enantiomer significantly affected locomotion during binge-like reinforcer consumption. Collectively, these results demonstrate that baclofen produces enantioselective effects on ethanol consumption. More importantly, the modulation of consumption is bidirectional. The opposing enantioselective effects may explain some of the variance seen in published baclofen literature. PMID:25557834

  19. Baclofen blocks yohimbine-induced increases in ethanol-reinforced responding in rats.

    Science.gov (United States)

    Williams, Keith L; Nickel, Melissa M; Bielak, Justin T

    2016-05-01

    Chronic or repeated stress increases alcohol consumption. The GABA-B agonist baclofen decreases alcohol consumption and may be most effective for individuals with comorbid anxiety/stress disorders. The present study sought to determine if baclofen blocks stress-induced increases in ethanol self-administration as modeled by repeated yohimbine injections in rats. Rats were trained to respond for 15% w/v ethanol in operant chambers using a method that applies neither water deprivation nor saccharin/sucrose fading. Following training, the rats received 6 injections of 1.25mg/kg yohimbine were given immediately prior to the operant sessions during a 2-week time period. Subsequently, some rats were pair-matched to receive either 1.25mg/kg yohimbine or saline in the presence of 0.3, 1, and 3mg/kg baclofen prior to sessions. Acquisition of ethanol self-administration was poor. Pretreatment with yohimbine consistently increased responding across repeated injections. Yohimbine's effect on ethanol intake unexpectedly diverged from the effect on responding as the rats failed to consume all reinforcers earned. Smaller doses of baclofen paired with saline injections had no effect on ethanol responding; only 3mg/kg baclofen reduced ethanol self-administration. The smallest baclofen dose of 0.3mg/kg failed to block the yohimbine-induced increase in self-administration. The large baclofen dose of 3mg/kg continued to suppress ethanol self-administration when given with yohimbine. Baclofen 1mg/kg blocked the effect of yohimbine even though it had no effect when given in the absence of yohimbine. Exposure to high ethanol concentrations may induce self-administration only in certain conditions. The dissociation between responding and intake suggests that repeated yohimbine injections may initiate other behavioral or physiological mechanisms that confound its effects as a pharmacological stressor. Furthermore, an optimal baclofen dose range may specifically protect against stress

  20. Baclofen influences lipopolysaccharide-mediated interleukin-6 release from murine pituicytes

    DEFF Research Database (Denmark)

    Kjeldsen, Tine H; Hansen, Erik W; Christensen, Jens D;

    2002-01-01

    ) butanoic acid (R-baclofen; 10, 100 or 500 microM). However, R-baclofen itself (10, 100 or 500 microM) did not stimulate the interleukin-6 secretion. Furthermore, the potent GABA(B) receptor antagonists 3-[[(3,4-Dichlorophenyl)methyl]amino]propyl]diethoxymethyl) phosphinic acid (CGP52432; 30 or 300 micro......M) and (RS)-3-Amino-2-(4-chlorophenyl)-2-hydroxypropyl-sulphonic acid (2-OH-saclofen; 10 or 100 microM) did not remove the effect of R-baclofen (100 microM). Gamma-amino butyric acid (GABA; 30 or 300 microM) did not alter the lipopolysaccharide-mediated interleukin-6 response. After 30 min, intracellular...... cyclic AMP (cAMP) was higher in cells stimulated with lipopolysaccharide compared to control, and R-baclofen significantly inhibited this increase in cAMP. Nevertheless, neither lipopolysaccharide nor R-baclofen had any effect on intracellular cAMP after 24 h of stimulation. The results suggest that the...

  1. Baclofen Induced Encephalopathy in a 6-Year-Old Boy with Advanced Renal Failure

    Directory of Open Access Journals (Sweden)

    Majid MALAK

    2015-06-01

    Full Text Available How to Cite This Article: Malak M, Barzgar M. Baclofen Induced Encephalopathy in a 6-Year-Old boy with Advanced Renal Failure. Iran J Child Neurol. Spring 2015;9(2:61-63. AbstractBaclofen is a drug for many diseases for all ages, but it is hazardous in patients with renal failure. This article talks about a case of baclofen overdose in a child with renal failure.A 6-year-old boy admitted to the emergency department with a loss of consciousness, hypotonia, and areflexia following administration of 20 mg baclofen (1mg/kg/daily in total dose for his voiding dysfunction. His laboratory tests showed advanced renal failure. After withholding the medication andsupportive therapy, he recovered completely after two days. After arousal, he complained of insomnia, strange sensations on the skin, intentional tremors, and ataxia. He left the hospital in good condition in three days.Renal function control before baclofen administration is mandatory especially in high-risk groups. A total dose of 1mg/kg lead to encephalopathy in children with advanced renal failure, with subtle persistent complaints persist are often overlooked for a while.

  2. Effect of Gabapentin and Baclofen on Histology Study in Neuropathic Pain

    Directory of Open Access Journals (Sweden)

    Fifteen A. Fajrin

    2015-12-01

    Full Text Available Neuropathic pain resulted from injury to nerves is often resistant to current treatments and can seriously cause chronic pain if no appropriate treatment is given. This study was designed to prove the effectiveness of gabapentin and baclofen in increasing latency time toward thermal stimulus and recovering the morphology of dorsal horn of spinal cord in neuropathic-induced chronic pain. Forty mice were divided into 8 groups i.e sham, negative control, gabapentin at three different doses (10, 30, 100 nmol and baclofen at three different doses (1, 10, 30 nmol. Neuropathic condition was induced by ligation of sciatic nerve with Partial Sciatic Nerve Ligation (PSNL method. Gabapentin and baclofen were administrated intrathecally once a day for seven days, a week after neuropathic induction. Latency time toward thermal stimulus was measured on days 0, 1, 3, 5, 7, 8, 10, 12 and 14 after induction. Histology of the dorsal horn of spinal cord tissue was examined by haematoxylline-eosin staining. The results showed that intrathecal injection of gabapentin and baclofen significantly increased latency time of mice toward thermal stimulus compared with negative control. Gabapentin and baclofen are effective as treatment for neuropathic pain. They can also help the recovery process of the histology in dorsal horn in neuropathic pain.

  3. Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study.

    Science.gov (United States)

    Corwin, Rebecca L; Boan, Jarol; Peters, Kathryn F; Ulbrecht, Jan S

    2012-09-01

    Baclofen has shown promise in treating substance use disorders and also reduced binge frequency in an open-label trial. This placebo-controlled, double-blind, crossover study further assessed the effects of baclofen on binge eating. Twelve individuals who self-reported binge eating completed the study. Data were collected during a run-in period (no drug or placebo), placebo phase (48 days), and baclofen phase (titrated up to 60 mg daily or the maximum tolerated dose, 48 days). All the participants were exposed to all conditions. Participants completed a binge diary daily, and the Binge Eating Scale (BES), Food Craving Inventory-II (FCI-II), and Hospital Anxiety and Depression Scale (HADS) at regular intervals throughout the study. Baclofen significantly reduced binge frequency relative to placebo and run-in (Peffects. Tiredness, fatigue, and upset stomach were the most commonly reported side-effects. These results indicate that baclofen may be a useful treatment for binge eating in some patients. PMID:22854310

  4. The absorption, distribution, metabolism and elimination of β-(p-chlorophenyl)-GABA (Baclofen), 4

    International Nuclear Information System (INIS)

    Distribution of 14C-baclofen was studied according to the autoradiography of a whole body in SD-JCL male rats after oral administration of 14C-baclofen (100 μCi/kg). Distribution of radioactivity in kidney and liver was already apparent 15 min after administration. Radioactivity in kidney and liver was increased distribution of radioactivity in skeletal muscle was apparent 1 hr after administration. Radio and activity in various tissues decreased 3 hrs after administration. Distribution of radioactivity in brain and spinal cord remained low at any time after administration. Distribution of radioactivity of 14C-baclofen in autoradiography was consistent with that in tracer study (Yamamoto et al 1977). (auth.)

  5. Phaclofen-insensitive presynaptic inhibitory action of (+/-)-baclofen in neonatal rat motoneurones in vitro.

    OpenAIRE

    Wang, M. Y.; Dun, N. J.

    1990-01-01

    1. Intracellular recordings were made from antidromically identified motoneurones in transverse spinal cord slices from neonatal (12-16 day) rats. 2. Superfusion of (+/-)-baclofen (0.5-50 microM) reduced the excitatory postsynaptic potentials (e.p.s.ps) and inhibitory postsynaptic potentials (i.p.s.ps) evoked by dorsal root or dorsal root entry zone stimulation in a concentration-dependent manner; the calculated EC50 was 2.4 microM. Baclofen in comparable concentrations also reversibly elimin...

  6. Baclofen for maintenance treatment of opioid dependence: A randomized double-blind placebo-controlled clinical trial [ISRCTN32121581

    Directory of Open Access Journals (Sweden)

    Ahmadi-Abhari Seyed Ali

    2003-11-01

    Full Text Available Abstract Background Results of preclinical studies suggest that the GABAB receptor agonist baclofen may be useful in treatment of opioid dependence. This study was aimed at assessing the possible efficacy of baclofen for maintenance treatment of opioid dependence. Methods A total of 40 opioid-dependent patients were detoxified and randomly assigned to receive baclofen (60 mg/day or placebo in a 12-week, double blind, parallel-group trial. Primary outcome measure was retention in treatment. Secondary outcome measures included opioids and alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with a visual analogue scale, opioid withdrawal symptoms as measured by the Short Opiate Withdrawal Scale and depression scores on the Hamilton inventory. Results Treatment retention was significantly higher in the baclofen group. Baclofen also showed a significant superiority over placebo in terms of opiate withdrawal syndrome and depressive symptoms. Non-significant, but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and self-reported opioid and alcohol use. However, no significant difference was seen in the rates of opioid-positive urine tests. Additionally, the drug side effects of the two groups were not significantly different. Conclusion The results support further study of baclofen in the maintenance treatment of opioid dependence.

  7. Hat intrathekal appliziertes Baclofen (Lioresal) einen neuroprotektiven Effekt im 4-Gefäßverschlussmodell der Ratte?

    OpenAIRE

    Stubenvoll, Florian Michael

    2015-01-01

    Einleitung: Im 4-Gefäßverschlussmodell der Ratte wird überprüft, ob intrathekal appliziertes Baclofen einen neuroprotektiven Effekt hat. Material und Methoden: Hierzu werden zunächst 1µg/5µl Baclofen über 5 Minuten beginnend 30 Minuten vor einer 10-minütigen zerebralen Ischämie bei männlichen Wistar-Ratten intrazerebroventrikulär appliziert und gegen eine Kontrollgruppe verglichen, dann werden 2µg/5µl Baclofen über 5 Minu...

  8. Effect of intracerebroventricular administration of the GABAB-receptor agonist baclofen on operant feeding in satiated pigs.

    OpenAIRE

    Ebenezer, I. S.; Baldwin, B. A.

    1990-01-01

    1. The present study investigated the effects of intracerebroventricular (i.c.v.) administration of the GABAB-receptor agonist baclofen on food and water intake in satiated pigs previously trained to make operant responses for food and water, which were available ad libitum. 2. Baclofen (25-100 nmol) i.c.v. produced a dose-related increase in food intake. Baclofen (50 nmol) increased feeding during the first 15 min after administration (P less than 0.01), while the 100 nmol dose increased fee...

  9. Actions of the GABAB agonist, (-)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro.

    OpenAIRE

    Allerton, C. A.; Boden, P. R.; Hill, R G

    1989-01-01

    1. The electrophysiological actions of the GABAB agonist, (-)-baclofen, on deep dorsal horn neurones were studied using an in vitro preparation of the spinal cord of 9-16 day old rat. 2. On all neurones tested, (-)-baclofen (100 nM-30 microM) had a hyperpolarizing action which was associated with a reduction in apparent membrane input resistance. The increase in membrane conductance was dose-dependent and had a Hill coefficient of 1.0. 3. The (-)-baclofen-activated hyperpolarization persisted...

  10. [Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity].

    Science.gov (United States)

    Berg-Johnsen, J; Røste, G K; Solgaard, T; Lundar, T

    1998-09-10

    Intrathecal administration of baclofen is now generally accepted as a powerful treatment of spasticity caused by spinal lesions. 35 patients with severe spasticity, 29 of spinal origin and six of supraspinal origin resistant to conservative treatment, had a programmable pump (Synchromed, Medtronic) for continuous intrathecal baclofen infusion implanted. The patients were followed-up for an average of 29 months (0-68). The initial effect of the treatment was positive for all patients; spasms were less frequent, there was remission of pain caused by cramps, and in some cases improved ambulation. In five patients, however, the pump was later removed: in two patients the pump ceased to be effective, two patients became infected, and one experienced multiple catheter problems. Problems with the catheter was the most common complication experienced, and this was seen in nine patients. Three patients died of the underlying disease. The majority of patients became accommodated to intrathecal baclofen and it was necessary to administer increasingly larger doses to maintain the clinical effect. Long-term control of spinal spasticity by intrathecal baclofen can be achieved in most patients, but close follow-up is necessary for assessing efficacy and refilling the pump. PMID:9772811

  11. Baclofen reversed thermal place preference in rats with chronic constriction injury.

    Science.gov (United States)

    Salte, K; Lea, G; Franek, M; Vaculin, S

    2016-06-20

    Chronic constriction injury to the sciatic nerve was used as an animal model of neuropathic pain. Instead of frequently used reflex-based tests we used an operant thermal place preference test to evaluate signs of neuropathic pain and the effect of baclofen administration in rats with neuropathy. Chronic constriction injury was induced by four loose ligations of the sciatic nerve. Thermal place preference (45 °C vs. 22 °C and 45 °C vs. 11 °C) was measured after the ligation and after the administration of baclofen in sham and experimental rats. Rats with the chronic constriction injury spent significantly less time on the colder plate compared to sham operated animals at the combination 45 °C vs. 11 °C. After administration of baclofen (10 mg/kg s.c.), the aversion to the colder plate in rats with chronic constriction injury disappeared. At the combination 45 °C vs. 22 °C, no difference in time spent on colder and/or warmer plate was found between sham and experimental animals. These findings show the importance of cold allodynia evaluation in rats with chronic constriction injury and the effectiveness of baclofen in this neuropathic pain model. PMID:26447518

  12. Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy

    DEFF Research Database (Denmark)

    Overgård, Tinett Martesen; Kjærsgaard-Hansen, Lars; Søe, Morten;

    2015-01-01

    INTRODUCTION: Treatment of severe spasticity and dystonia with intrathecal baclofen (ITB) in children has been shown to be effective and has therefore been employed in the Region of Southern Denmark. The aim of this retrospective study was to analyse the efficacy and adverse events since ITB was...... introduced in 2003. METHODS: A total of 46 children who had a baclofen pump from April 2003 to January 2013 were included. The children's medical records were reviewed and clinical characteristics, efficacy and adverse events were registered. The efficacy of treatment experienced by parents was ascertained....... Baclofen infusion was 105.1-2,000 micrograms/day (mean 494.9 micrograms/day). Oral baclofen was reduced from 27.3 to 17.7 mg/day after ITB (p < 0.01). The parents' assessment of improvement in well-being, function and ease of care of their child had a mean score of 3.7, 2.2 and 3.4, respectively. 87.1% of...

  13. Baclofen-responsive hiccups after esophageal stenting for malignancy-related dysphagia.

    Science.gov (United States)

    Sharma, Vishal; De, Arka; Lamoria, Sandeep; Lamba, Brinder Mohan Singh

    2016-04-01

    Hiccups can have multiple causes, including esophageal lesions. Hiccups after insertion of self-expanding metallic stents have been reported occasionally following stenting for lesions of the gastroesophageal junction. We report a patient who developed hiccups after insertion of a stent for squamous cell carcinoma of the proximal esophagus. The hiccups responded only to the initiation of baclofen therapy. PMID:27034549

  14. Effects of GABA-B receptor agonist baclofen on cortical epileptic afterdischarges in rats

    Czech Academy of Sciences Publication Activity Database

    Mareš, Pavel; Lindovský, Jiří; Šlamberová, Romana; Kubová, Hana

    2007-01-01

    Roč. 10, Suppl.1 (2007), s. 45-52. ISSN 1294-9361 R&D Projects: GA ČR(CZ) GA305/05/2581 Institutional research plan: CEZ:AV0Z50110509 Keywords : epileptic afterdischarges * evoked potentials * baclofen Subject RIV: ED - Physiology Impact factor: 0.919, year: 2007

  15. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system

    NARCIS (Netherlands)

    Postma, TJBM; Oenema, D; Terpstra, S; Bouma, J; Kuipers-Upmeijer, H; Staal, MJ; Middel, BJ

    1999-01-01

    Objective: The purpose of our study was to analyse and evaluate the costs of continuous intrathecal baclofen administration as a modality in the treatment of severe spasticity in the Netherlands. Design: A cost analysis was conducted as part of a prospective, multicentre, multidisciplinary, randomis

  16. Tolerance to continuous intrathecal baclofen infusion can be reversed by pulsatile bolus infusion

    NARCIS (Netherlands)

    Heetla, H. W.; Staal, M. J.; van Laar, T.

    2010-01-01

    Study design: Pilot study. Objective: To study the effect of pulsatile bolus infusion of intrathecal baclofen (ITB) on daily ITB dose, in patients showing dose increases, probably due to tolerance. Setting: Department of neurology and neurosurgery, University Medical Center Groningen, the Netherland

  17. Effects of baclofen and raclopride on reinstatement of cocaine self-administration in the rat.

    Science.gov (United States)

    Froger-Colléaux, Christelle; Castagné, Vincent

    2016-04-15

    At present there is no satisfactory treatment against relapse of drug-seeking behavior. Relapse can be modeled in laboratory animals using reinstatement procedures, whereby previously extinguished self-administration for a drug is reinstated by different factors, such as exposure to cues or drug priming. It is thought that activation of gamma-aminobutyric acid (GABA) B receptor complexes could represent a promising approach to pharmacotherapy for diminishing relapse potential with drugs possessing reinforcing properties. The effects of baclofen (a prototypic GABAB receptor agonist) on cue-induced cocaine reinstatement were evaluated in the rat with or without a priming injection of cocaine. The effects of raclopride (an antagonist of dopamine D2 receptors) were also evaluated. Cue-induced reinstatement under vehicle resulted in a significant increase in the number of presses on the active lever, as compared with extinction lever responding. This effect was accentuated in rats receiving a priming injection of cocaine (cocaine-plus-cue-induced reinstatement). Baclofen, at doses without effects on food-motivated operant behavior (2.5 and 5mg/kg i.p.), dose-dependently decreased the number of active lever presses during cue-induced reinstatement. Baclofen had slightly weaker effects on cocaine-plus-cue-induced reinstatement. Raclopride (0.08 and 0.15 mg/kg s.c.) had similar effects against cue-induced reinstatement although it failed to inhibit cocaine-plus-cue-induced reinstatement at the lower dose. Baclofen dose-dependently and selectively decreased reinstatement of cocaine self-administration. The data obtained provide support for the potential anti-craving efficacy of baclofen in the treatment of cocaine drug-seeking. PMID:26948316

  18. Effect of the GABA B agonist baclofen on dipyrone-induced delayed gastric emptying in rats

    Directory of Open Access Journals (Sweden)

    E.F. Collares

    2005-01-01

    Full Text Available Dipyrone administered intravenously (iv or intracerebroventricularly (icv delays gastric emptying (GE in rats. Gamma-aminobutyric acid (GABA is the most potent inhibitory neurotransmitter of the central nervous system. The objective of the present study was to determine the effect of icv baclofen, a GABA B receptor agonist, on delayed GE induced by dipyrone. Adult male Wistar rats received a saline test meal containing phenol red as a marker. GE was indirectly evaluated by determining the percent of gastric retention (%GR of the meal 10 min after orogastric administration. In the first experiment, the animals were injected iv with vehicle (Civ or 80 mg/kg (240 µmol/kg dipyrone (Dp iv, followed by icv injection of 10 µl vehicle (bac0, or 0.5 (bac0.5, 1 (bac1 or 2 µg (bac2 baclofen. In the second experiment, the animals were injected icv with 5 µl vehicle (Cicv or an equal volume of a solution containing 4 µmol (1333.2 µg dipyrone (Dp icv, followed by 5 µl vehicle (bac0 or 1 µg baclofen (bac1. GE was determined 10 min after icv injection. There was no significant difference between control animals from one experiment to another concerning GR values. Baclofen at the doses of 1 and 2 µg significantly reduced mean %GR induced by iv dipyrone (Dp iv bac1 = 35.9% and Dp iv bac2 = 26.9% vs Dp iv bac0 = 51.8%. Similarly, baclofen significantly reduced the effect of dipyrone injected icv (mean %GR: Dp icv bac1 = 30.4% vs Dp icv bac0 = 54.2%. The present results suggest that dipyrone induces delayed GE through a route in the central nervous system that is blocked by the activation of GABA B receptors.

  19. Ga Ba{sub B} pharmacophoric pattern based on conformational analysis of 3-hetero aromatic baclofen analogues

    Energy Technology Data Exchange (ETDEWEB)

    Pirard, B.; Paquet, B.; Evrard, G.; Durant, F. [Facultes Universitaires Notre-Dame de la Paix, Namur (Belgium); Berthelot, P.; Vaccher, C.; Ansard, M.H.; Debaert, M. [UFR de Pharmacie, 59 - Lille (France)

    1995-12-31

    Substituting a furan, a thiophen, a benzo (b) furan or a benzo (b) thiophen ring for the p-chlorophenyl moiety of baclofen has led to GABA{sub B} (GABA = {gamma}-aminobutyric acid) ligands with different affinities according to the nature of the hetero-aromatic ring, and the nature and position of its substituent. In order to determine the structural requirements that are important for GABA{sub B} affinity, we have aligned the 3D structures of several 3-hetero-aromatic baclofen analogues with that of baclofen. As a result, we have suggested a pharmacophoric pattern for 3-hetero-aromatic baclofen analogues. The 3D structures have been studied by X-ray diffraction and by ab initio molecular orbital calculations. (authors). 29 refs., 6 figs., 5 tabs.

  20. The Effects of Baclofen for the Treatment of Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Trials

    OpenAIRE

    Shujie Li; Shengying Shi; Feng Chen; Jingming Lin

    2014-01-01

    Objectives. Baclofen can relieve gastroesophageal reflux-related symptoms in healthy subjects and gastroesophageal reflux disease (GERD) patients by reducing the incidence of transient lower esophageal sphincter relaxation. This meta-analysis aimed to evaluate the efficacy and safety of baclofen for the treatment of GERD. Methods. We systematically searched randomized controlled trials published prior to November 2013 from PubMed, Medline, Embase, ScienceDirect, ClinicalTrials.gov, and the Co...

  1. Influence of intraventricular application of baclofen on arterial blood pressure and neurotransmitter concentrations in the hypothalamic paraventricular nucleus of rats.

    Science.gov (United States)

    Czell, David; Efe, Turgay; Preuss, Matthias; Schofer, Markus D; Becker, Ralf

    2012-02-01

    The hypothalamic paraventricular nucleus (PVN) is a key site for regulating neuroendocrine functions in the magnocellular part and autonomic activities in the parvocellular part. Its anatomical proximity to the third ventricle could be a good target for intrathecal injection of baclofen. We investigated the correlation of intrathecal application of baclofen (a specific GABAB receptor agonist) and the release of epinephrine, norepinephrine, dopac, homovanillinic acid (HVA), glutamate and aspartate from the PVN. The decomposition products HVA, dopa and dopac of norepinephrine, epinephrine and dopamine, respectively, were used as parameters for the secretion of dopamine. We implanted a microdialysis probe in the PVN of 25 Wistar rats. In 13 rats, 1.5 μg baclofen was injected in the lateral ventricle and the equivalent quantity of Ringer's lactate solution injected in the remaining 12 rats as a control group. Neurotransmitters and amino acids were quantified by high-performance liquid chromatography. There was a conspicuous but not significant effect of baclofen concerning the secretion of epinephrine, norepinephrine, dopac, glutamate and aspartate from the PVN. A significant increase in HVA concentration was observed only in rats treated with baclofen compared with the control group. These findings suggest that baclofen influences the secretion of neurotransmitters and amino acids involved in autonomic activities mediated by GABAB receptors. PMID:21984200

  2. Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen.

    Science.gov (United States)

    Geisel, Olga; Hellweg, Rainer; Müller, Christian A

    2016-06-30

    The neurotrophin brain-derived neurotrophic factor (BDNF) has been suggested to be involved in the development and maintenance of addictive and other psychiatric disorders. Also, interactions of γ-aminobutyric acid (GABA)-ergic compounds and BDNF have been reported. The objective of this study was to investigate serum levels of BDNF over time in alcohol-dependent patients receiving individually titrated high-dose treatment (30-270mg/d) with the GABA-B receptor agonist baclofen or placebo for up to 20 weeks. Serum levels of BDNF were measured in patients of the baclofen/placebo group at baseline (t0), 2 weeks after reaching individual high-dose of baclofen/placebo treatment (t1) and after termination of study medication (t2) in comparison to carefully matched healthy controls. No significant differences in serum levels of BDNF between the baclofen and the placebo group or healthy controls were found at t0, t1, or at t2. Based on these findings, it seems unlikely that baclofen exerts a direct effect on serum levels of BDNF in alcohol-dependent patients. Future studies are needed to further explore the mechanism of action of baclofen and its possible relationship to BDNF in alcohol use disorders. PMID:27107672

  3. The Effects of Baclofen for the Treatment of Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Trials

    Directory of Open Access Journals (Sweden)

    Shujie Li

    2014-01-01

    Full Text Available Objectives. Baclofen can relieve gastroesophageal reflux-related symptoms in healthy subjects and gastroesophageal reflux disease (GERD patients by reducing the incidence of transient lower esophageal sphincter relaxation. This meta-analysis aimed to evaluate the efficacy and safety of baclofen for the treatment of GERD. Methods. We systematically searched randomized controlled trials published prior to November 2013 from PubMed, Medline, Embase, ScienceDirect, ClinicalTrials.gov, and the Cochrane Central Register of Randomized Controlled Trials. We performed a meta-analysis of all eligible trials. Results. Nine studies were identified with a total of 283 GERD patients and healthy subjects. Comparative analysis provided high quality data supporting the ability of baclofen to promote a short-term decrease in the number of reflux episodes per patient, the average length of reflux episodes, and the incidence of transient lower esophageal sphincter relaxation. No serious adverse events or death events were reported, and there were no significant differences in the overall adverse events between baclofen and placebo. All reported side effects of baclofen were of mild-to-moderate intensity, and the drug was well tolerated. Conclusion. Abundant evidence suggests that baclofen may be a useful approach for the treatment of GERD patients; however, a larger well-designed research study would further confirm this recommendation.

  4. Baclofen activates voltage-dependent and 4-aminopyridine sensitive K+ conductance in guinea-pig hippocampal pyramidal cells maintained in vitro.

    OpenAIRE

    M. Inoue; T. Matsuo; Ogata, N.

    1985-01-01

    The ionic mechanism underlying the effect of (-)-baclofen in the hippocampus was investigated using guinea-pig brain slices. (-)-Baclofen either perfused or applied directly by microiontophoresis hyperpolarized the membrane and decreased the membrane input resistance of pyramidal cells in a dose-dependent manner. The value of the reversal potential for the baclofen-induced hyperpolarization, as estimated from the current-voltage relationships, was about -95mV. The reversal potential of the ba...

  5. The synthesis and biodistribution of 3-(4'-[[sup 125]I]-iodophenyl)-4-aminobutyric acid, a radioiodinated analogue of baclofen

    Energy Technology Data Exchange (ETDEWEB)

    Wakita, Y.; Kojima, M. (Kyushu Univ., Fukuoka (Japan). Div. of Radiopharmaceutical Chemistry); Schwendner, S.W.; McConnell, D.; Counsell, R.E. (Michigan Univ., Ann Arbor, MI (United States). School of Medicine)

    1990-02-01

    Baclofen has been found to bind to receptors in the central nervous system that are specific for [gamma]-aminobutyric acid (GABA), a well known inhibitory neurotransmitter. This paper describes the synthesis of a radioiodinated analog of baclofen as part of an effort to develop receptor probes useful in single photon emission computed tomography. Preliminary biodistribution studies showed the radioiodinationed analog to be essentially stable to in vivo deiodination and have a distribution profile similar to that of baclofen. (Author).

  6. Chronic Intrathecal Baclofen Administration for the Treatment of Severe Generalized Tetanus via a Synchromed Infusion Pump.

    Science.gov (United States)

    Deibert, E; Bhardwaj, A; Staats, P S; Ulatowski, J A

    1998-01-01

    Centers for Disease Control (CDC) data indicate that the incidence of tetanus in the United States is highest among the elderly. Conventional therapies for the control of accompanying generalized muscle spasms include large doses of oral or intravenous GABA agonists as antispasticity agents. We describe a case of an elderly patient with severe symptoms of tetanus who developed a prolonged encephalopathy and ventilatory insufficiency with oral baclofen and benzodiazepine therapy. Intrathecal baclofen adequately controlled her severe extensor spasms, facilitated her ventilatory management, and did not compromise her mental status during her extended convalescence. Accordingly, we report the first placement of a permanent implanted infusion pump for this disease. This modality offers advantage for continuous long-term titration of medication for spasms or rigidity control without the systemic sedative effects of conventional therapy. PMID:22150880

  7. Detection of compatibility between baclofen and excipients with aid of infrared spectroscopy and chemometry

    Science.gov (United States)

    Rojek, Barbara; Wesolowski, Marek; Suchacz, Bogdan

    2013-12-01

    In the paper infrared (IR) spectroscopy and multivariate exploration techniques: principal component analysis (PCA) and cluster analysis (CA) were applied as supportive methods for the detection of physicochemical incompatibilities between baclofen and excipients. In the course of research, the most useful rotational strategy in PCA proved to be varimax normalized, while in CA Ward's hierarchical agglomeration with Euclidean distance measure enabled to yield the most interpretable results. Chemometrical calculations confirmed the suitability of PCA and CA as the auxiliary methods for interpretation of infrared spectra in order to recognize whether compatibilities or incompatibilities between active substance and excipients occur. On the basis of IR spectra and the results of PCA and CA it was possible to demonstrate that the presence of lactose, β-cyclodextrin and meglumine in binary mixtures produce interactions with baclofen. The results were verified using differential scanning calorimetry, differential thermal analysis, thermogravimetry/differential thermogravimetry and X-ray powder diffraction analyses.

  8. Pain treatment with ziconotide and baclofen in a case of spasticity associated with neuropathic pain

    OpenAIRE

    Danilo G. Quarta; Allegra Cionini Ciardi; Daniela Clerici; Patrizia Spina; Luigi Parigi

    2009-01-01

    This study presents the clinical case of a patient with paraparesis, subjected for a long period of time to treatment with intrathecal baclofen and morphine to control spasticity and neuropathic pain, resulting from spinal cord injury due to road trauma. After several years of treatment the pain was not controlled with high doses of intrathecal morphine combined with transmucosal fentanyl that were given when needed. It was therefore decided to switch to intrathecal ziconotide. Starting with ...

  9. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system

    OpenAIRE

    Postma, TJBM; Oenema, D.; Terpstra, S.; Bouma, J; Kuipers-Upmeijer, H; Staal, MJ; Middel, BJ

    1999-01-01

    Objective: The purpose of our study was to analyse and evaluate the costs of continuous intrathecal baclofen administration as a modality in the treatment of severe spasticity in the Netherlands. Design: A cost analysis was conducted as part of a prospective, multicentre, multidisciplinary, randomised and placebo-controlled clinical trial. The study covered the period from December 1991 to September 1995. The data on medical consumption and costs were collected over a 3-year period from diffe...

  10. Bi-Directional Effect of Increasing Doses of Baclofen on Reinforcement Learning

    OpenAIRE

    Andres Ort

    2011-01-01

    In rodents as well as in humans, efficient reinforcement learning depends on dopamine (DA) released from ventral tegmental area (VTA) neurons. It has been shown that in brain slices of mice, GABA(B)-receptor agonists at low concentrations increase the firing frequency of VTA-DA neurons, while high concentrations reduce the firing frequency. It remains however elusive whether baclofen can modulate reinforcement learning in humans. Here, in a double-blind study in 34 healthy human volunteers, w...

  11. Clinical effectiveness of baclofen for the treatment of alcohol dependence: a review

    OpenAIRE

    Brennan JL; Leung JG; Gagliardi JP; Rivelli SK; Muzyk AJ

    2013-01-01

    Jessica L Brennan,2 Jonathan G Leung,1 Jane P Gagliardi,3 Sarah K Rivelli,3 Andrew J Muzyk4 1Department of Hospital Pharmacy Services, Mayo Clinic, Rochester, MN, 2Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 4Department of Pharmacy Practice, Campbell University School of Pharmacy and Health Sciences, Buies Creek, NC, USA Abstract: Baclofen, an agonist at the ...

  12. Pain treatment with ziconotide and baclofen in a case of spasticity associated with neuropathic pain

    Directory of Open Access Journals (Sweden)

    Danilo G. Quarta

    2009-03-01

    Full Text Available This study presents the clinical case of a patient with paraparesis, subjected for a long period of time to treatment with intrathecal baclofen and morphine to control spasticity and neuropathic pain, resulting from spinal cord injury due to road trauma. After several years of treatment the pain was not controlled with high doses of intrathecal morphine combined with transmucosal fentanyl that were given when needed. It was therefore decided to switch to intrathecal ziconotide. Starting with high levels of intrathecal morphine, the patient was referred first to weaning from morphine to a gradual titration of ziconotide doses of up to 7.4 mcg/die associated with 680 mcg/die of baclofen. A technical problem related to the infusion pump has led to the abrupt interruption of the administration of ziconotide and baclofen, which did not cause side effects, except for a poorly controlled pain. The spasticity, however, did not recur. After replacing the intrathecal pump and restarting the gradual titration of ziconotide alone, the patient has once again regained a good pain control with no recurrence to date of spasticity.

  13. Indwelling intrathecal catheter with subcutaneous abdominal reservoir: a viable baclofen delivery system in severely cachectic patients.

    Science.gov (United States)

    Waqar, Mueez; Ellenbogen, Jonathan R; Kumar, Ram; Sneade, Christine; Zebian, Bassel; Williams, Dawn; Pettorini, Benedetta L

    2014-10-01

    Intrathecal baclofen (ITB) is a reversible treatment that reduces muscle tone to ameliorate spasticity and dystonia in patients with cerebral palsy (CP). The resulting decrease in energy expenditure allows patients to gain much-needed weight, albeit temporarily. Modern techniques require sufficient abdominal musculature and subcutaneous fat to permit the implantation of an indwelling pump. In patients with extremely low muscle bulk, visceral pumps may be impractical or impossible, with increased risks of dehiscence and infection. The authors describe a variation of the classical procedure in a young patient with severe cachexia. A 10-year-old boy with spastic-dystonic quadriplegic CP was admitted to the neuromedical unit. Numerous drug trials had failed, and surgical intervention was deemed necessary but was complicated by his cachectic body habitus. The authors inserted a lumbar intrathecal catheter and subcutaneously tunneled it to the anterolateral abdomen, where it was connected to a subcutaneous injection port. Baclofen was continuously infused into the subcutaneous port using a noncoring needle connected to an external pump. The needle and line were changed every 5 days to minimize the risk of sepsis. Although other techniques, such as intraventricular baclofen delivery, have been described, these are largely dependent upon sufficient musculature to support a visceral pump. A subcutaneous injection port system represents an alternative approach that reduces the risk of sepsis and may be better tolerated in cachectic patients. PMID:25084089

  14. Baclofen (β-p-chlorophenyl-γ-aminobutyric acid) enhances [3H]γ-aminobutyric acid (3H-GABA) release from rat globus pallidus in vitro

    International Nuclear Information System (INIS)

    The rat globus pallidus has been investigated as a possible model in which to study pre-synaptic GABA mechanisms in vitro. (+ -)-Baclofen (300μM-1 mM) significantly enhanced the release of radioactivity from superfused slices of rat globus pallidus prelabelled with 3H-GABA in vitro. This releasing action was specific to the (+)-isomer of baclofen. Neither the (-)-isomer nor another neuronal depressant DL-α-upsilon-diaminopimelic acid had any significant effect. The releasing effect of baclofen appeared unrelated to the phenethylamine moiety of its structure as neither β-phenethylamine nor dopamine evoked release of 3H-GABA from pallidal slices. Baclofen increased the efflux of radioactivity from pallidal slices prelabelled with either [3H]β-alanine or 3H diaminobutric acid in vitro. The use of specific glial and neuronal GABA uptake blocking compounds (β-alanine and (+ -)-cis-1,3-aminocyclohexanecarboxylic acid) did not permit resolution of the elements from which baclofen was evoking [3H]GABA release. Baclofen also inhibited uptake of [3H]GABA into pallidal slices with an IC50 value of 6 x 10-4m. The GABA-like properties of baclofen may be related to the (+)-isomer while non-specific neuronal depressant actions are an effect of the (-)-isomer. The potential of the (+)-isomer as an antipyschotic agent while (-)-baclofen remains the effective antispastic drug free from unwanted side-effects is discussed. (author)

  15. One-Pot Synthesis of (S)-Baclofen via Aldol Condensation of Acetaldehyde with Diphenylprolinol Silyl Ether Mediated Asymmetric Michael Reaction as a Key Step.

    Science.gov (United States)

    Hayashi, Yujiro; Sakamoto, Daisuke; Okamura, Daichi

    2016-01-01

    An efficient asymmetric total synthesis of (S)-baclofen was accomplished via a one-pot operation from commercially available materials using sequential reactions, such as aldol condensation of acetaldehyde, diphenylprolinol silyl ether mediated asymmetric Michael reaction of nitromethane, Kraus-Pinnick oxidation, and Raney Ni reduction. Highly enantioenriched baclofen was obtained in one pot with a good yield over four reactions. PMID:26636719

  16. Baclofen prevents the elevated plus maze behavior and BDNF expression during naloxone precipitated morphine withdrawal in male and female mice.

    Science.gov (United States)

    Pedrón, Valeria T; Varani, André P; Balerio, Graciela N

    2016-05-01

    In previous studies we have shown that baclofen, a selective GABAB receptor agonist, prevents the somatic expression and reestablishes the dopamine and μ-opioid receptors levels, modified during naloxone-precipitated morphine withdrawal syndrome in male and female mice. There are no previous reports regarding sex differences in the elevated plus maze (EPM) and the expression of BDNF in morphine-withdrawn mice. The present study analyses the behavioral and biochemical variations during morphine withdrawal in mice of both sexes, and whether these variations are prevented with baclofen. Swiss-Webster albino prepubertal mice received morphine (2 mg/kg, i.p.) twice daily, for 9 consecutive days. On the 10th day, one group of morphine-treated mice received naloxone (opioid receptor antagonist; 6 mg/kg, i.p.) 1 h after the last dose of morphine to precipitate withdrawal. A second group received baclofen (2 mg/kg, i.p.) before naloxone administration. The EPM behavior was measured during 15 min after naloxone injection. The expression of BDNF-positive cells was determined by immunohistochemistry. Withdrawn male mice showed a higher percentage of time spent and number of entries to the open arms compared to withdrawn female mice. Baclofen prevented this behavior in both sexes. BDNF expression decreased in the AcbC, BNST, CeC, and CA3 of the hippocampus while increased in the BLA of morphine withdrawn male. Baclofen pretreatment prevented the BDNF expression observed in morphine withdrawn male mice in all the brain areas studied except in the CeC. Baclofen prevention of the EPM behavior associated to morphine withdrawal could be partially related to changes in BDNF expression. PMID:26789010

  17. Intra-accumbens baclofen, but not muscimol, increases second order instrumental responding for food reward in rats.

    Directory of Open Access Journals (Sweden)

    Kim G T Pulman

    Full Text Available Stimulation of either GABA(A or GABA(B receptors within the nucleus accumbens shell strongly enhances food intake in rats. However the effects of subtype-selective stimulation of GABA receptors on instrumental responses for food reward are less well characterized. Here we contrast the effects of the GABA(A receptor agonist muscimol and GABA(B receptor agonist baclofen on instrumental responding for food using a second order reinforcement schedule. Bilateral intra-accumbens administration of baclofen (220-440 pmol stimulated responding but a higher dose (660 pmol induced stereotyped oral behaviour that interfered with responding. Baclofen (220-660 pmol also stimulated intake of freely available chow. Muscimol (220-660 pmol was without effect on responding for food on this schedule but did stimulate intake of freely available chow. Unilateral administration of either baclofen or muscimol (220 pmol induced similar patterns of c-fos immunoreactivity in several hypothalamic sites but differed in its induction in the central nucleus of the amygdala. We conclude that stimulation of GABA(A or GABA(B receptors in the nucleus accumbens shell of rats produces clearly distinguishable effects on operant responding for food.

  18. Controlled Study of the Effects of Continuous Intrathecal Baclofen Infusion in Non-Ambulant Children with Cerebral Palsy

    Science.gov (United States)

    Morton, Richard E.; Gray, Natalie; Vloeberghs, Michael

    2011-01-01

    Aim: To measure changes in children with severe spastic cerebral palsy (CP) after continuous intrathecal baclofen (ITB) infusion over 18 months and to compare the results with those of a comparison group awaiting treatment. Method: Thirty-eight children with severe spastic CP considered suitable for ITB were assessed when first seen, just before…

  19. Intrathecal Baclofen in Children with Spastic Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study

    Science.gov (United States)

    Hoving, Marjanke A.; van Raak, Elisabeth P. M.; Spincemaille, Geert H. J. J.; Palmans, Liesbeth J.; Sleypen, Frans A. M.; Vles, Johan S. H.

    2007-01-01

    Intrathecal baclofen (ITB) therapy can be very effective in the treatment of intractable spasticity, but its effectiveness and safety have not yet been thoroughly studied in children with cerebral palsy (CP). The aims of this double-blind, randomized, placebo-controlled, dose-finding study were to select children eligible for continuous ITB…

  20. Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators.

    Directory of Open Access Journals (Sweden)

    Shunying Jin

    Full Text Available Immune-complexes play an important role in the inflammatory diseases of the lung. Neutrophil activation mediates immune-complex (IC deposition-induced acute lung injury (ALI. Components of gamma amino butyric acid (GABA signaling, including GABA B receptor 2 (GABABR2, GAD65/67 and the GABA transporter, are present in the lungs and in the neutrophils. However, the role of pulmonary GABABR activation in the context of neutrophil-mediated ALI has not been determined. Thus, the objective of the current study was to determine whether administration of a GABABR agonist, baclofen would ameliorate or exacerbate ALI. We hypothesized that baclofen would regulate IC-induced ALI by preserving pulmonary GABABR expression. Rats were subjected to sham injury or IC-induced ALI and two hours later rats were treated intratracheally with saline or 1 mg/kg baclofen for 2 additional hours and sacrificed. ALI was assessed by vascular leakage, histology, TUNEL, and lung caspase-3 cleavage. ALI increased total protein, tumor necrosis factor α (TNF-α and interleukin-1 receptor associated protein (IL-1R AcP, in the bronchoalveolar lavage fluid (BALF. Moreover, ALI decreased lung GABABR2 expression, increased phospho-p38 MAPK, promoted IκB degradation and increased neutrophil influx in the lung. Administration of baclofen, after initiation of ALI, restored GABABR expression, which was inhibited in the presence of a GABABR antagonist, CGP52432. Baclofen administration activated pulmonary phospho-ERK and inhibited p38 MAPK phosphorylation and IκB degradation. Additionally, baclofen significantly inhibited pro-inflammatory TNF-α and IL-1βAcP release and promoted BAL neutrophil apoptosis. Protective effects of baclofen treatment on ALI were possibly mediated by inhibition of TNF-α- and IL-1β-mediated inflammatory signaling. Interestingly, GABABR2 expression was regulated in the type II pneumocytes in lung tissue sections from lung injured patients, further suggesting

  1. Assessment of Feasibility of Maillard Reaction between Baclofen and Lactose by Liquid Chromatography and Tandem Mass Spectrometry, Application to Pre Formulation Studies

    OpenAIRE

    Monajjemzadeh, Farnaz; Hassanzadeh, Davoud; Valizadeh, Hadi; Siahi-Shadbad, Mohammad R.; Mojarrad, Javid Shahbazi; Robertson, Thomas; Roberts, Michael S

    2009-01-01

    The aim of this study was to determine any possible, baclofen–lactose Maillard reaction products. Granules and tablets of baclofen and lactose were prepared and maintained in heat ovens for a certain time period. The effects of lactose type, addition of magnesium stearate, and water were monitored. Heated lactose and baclofen were analyzed using reverse-phase HPLC. Liquid chromatography tandem mass spectroscopy revealed nominal mass values consistent with baclofen–lactose, early-stage Maillar...

  2. The effect of baclofen and diazepam on motor skill acquisition in healthy subjects

    DEFF Research Database (Denmark)

    Willerslev-Olsen, Maria; Lundbye-Jensen, Jesper; Petersen, Tue Hvass;

    2011-01-01

    investigated the influence of baclofen and diazepam on acquisition of a visuomotor skill. The study was designed as a semi-randomized, double-blinded, placebo-controlled, crossover study in 16 healthy human subjects. The motor skill task required the subjects to match a given force trajectory by increasing or...... decreasing ankle dorsiflexor torque. Subjects trained for a total of 30 min. Transcranial magnetic stimulation of the primary motor cortex leg area was applied to elicit motor evoked potentials in the anterior tibial muscle (TA). Coupling between populations of TA motor units was calculated in the frequency...... progression in motor performance (P > 0.05), and the training was not accompanied by a decrease in intramuscular coherence. TA motor evoked potentials had significantly lower threshold following the training in the placebo group, whereas this was not the case in the treatment groups. These data indicate that...

  3. Risk factors for baclofen pump infection in children: a multivariate analysis.

    Science.gov (United States)

    Spader, Heather S; Bollo, Robert J; Bowers, Christian A; Riva-Cambrin, Jay

    2016-06-01

    OBJECTIVE Intrathecal baclofen infusion systems to manage severe spasticity and dystonia are associated with higher infection rates in children than in adults. Factors unique to this population, such as poor nutrition and physical limitations for pump placement, have been hypothesized as the reasons for this disparity. The authors assessed potential risk factors for infection in a multivariate analysis. METHODS Patients who underwent implantation of a programmable pump and intrathecal catheter for baclofen infusion at a single center between January 1, 2000, and March 1, 2012, were identified in this retrospective cohort study. The primary end point was infection. Potential risk factors investigated included preoperative (i.e., demographics, body mass index [BMI], gastrostomy tube, tracheostomy, previous spinal fusion), intraoperative (i.e., surgeon, antibiotics, pump size, catheter location), and postoperative (i.e., wound dehiscence, CSF leak, and number of revisions) factors. Univariate analysis was performed, and a multivariate logistic regression model was created to identify independent risk factors for infection. RESULTS A total of 254 patients were evaluated. The overall infection rate was 9.8%. Univariate analysis identified young age, shorter height, lower weight, dehiscence, CSF leak, and number of revisions within 6 months of pump placement as significantly associated with infection. Multivariate analysis identified young age, dehiscence, and number of revisions as independent risk factors for infection. CONCLUSIONS Young age, wound dehiscence, and number of revisions were independent risk factors for infection in this pediatric cohort. A low BMI and the presence of either a gastrostomy or tracheostomy were not associated with infection and may not be contraindications for this procedure. PMID:26919315

  4. Baclofen Oral

    Science.gov (United States)

    ... is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. ... on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. ...

  5. Kainate-enhanced release of D-(3H)aspartate from cerebral cortex and striatum: reversal by baclofen and pentobarbital

    Energy Technology Data Exchange (ETDEWEB)

    Potashner, S.J.; Gerard, D.

    1983-06-01

    A study was made of the actions of the excitant neurotoxin, kainic acid, on the uptake and the release of D-(2,3-3H)aspartate (D-ASP) in slices of guinea pig cerebral neocortex and striatum. The slices took up D-ASP, reaching concentrations of the amino acid in the tissue which were 14-23 times that in the medium. Subsequently, electrical stimulation of the slices evoked a Ca2+-dependent release of a portion of the D-ASP. Kainic acid (10(-5)-10(-3) M) produced a dose-dependent inhibition of D-ASP uptake. The electrically evoked release of D-ASP was increased 1.6-2.0 fold by 10(-5) and 10(-4)M kainic acid. The kainate-enlarged release was Ca2+-dependent. Dihydrokainic acid, an analogue of kainic acid with little excitatory or toxic action, did not increase D-ASP release but depressed D-ASP uptake. Attempts were made to block the action of kainic acid with baclofen and pentobarbital, compounds which depress the electrically evoked release of L-glutamate (L-GLU) and L-aspartate (L-ASP). Baclofen (4 X 10(-6)M), an antispastic drug, and pentobarbital (10(-4)M), an anesthetic agent, each inhibited the electrically evoked release of D-ASP and prevented the enhancement of the release above control levels usually produced by 10(-4)M kainic acid. It is proposed that 10(-5) and 10(-4)M kainic acid may enhance the synaptic release of L-GLU and L-ASP from neurons which use these amino acids as transmitters. This action is prevented by baclofen and pentobarbital. In view of the possibility that cell death in Huntington's disease could involve excessive depolarization of striatal and other cells by glutamate, baclofen might be effective in delaying the loss of neurons associated with this condition.

  6. Effect of baclofen on morphine-induced conditioned place preference, extinction, and stress-induced reinstatement in chronically stressed mice

    OpenAIRE

    Meng, Shanshan; Quan, Wuxing; Xu QI; Su, Zhiqiang; Yang, Shanshan

    2013-01-01

    Rationale and Objective A stress-induced increase in excitability can result from a reduction in inhibitory neurotransmission. Modulation of gamma-aminobutyric acid (GABA)ergic transmission is an effective treatment for drug seeking and relapse. This study investigated whether baclofen, a GABAB receptor agonist, had an impact on morphine-induced conditioned place preference (CPP), extinction, and stress-induced relapse in chronically stressed mice. Methods Chronic stress was induced by restra...

  7. ACAMPROSATE AND BACLOFEN WERE NOT EFFECTIVE IN THE TREATMENT OF PATHOLOGICAL GAMBLING: PRELIMINARY BLIND RATER COMPARISON STUDY

    Directory of Open Access Journals (Sweden)

    Pinhas N Dannon

    2011-06-01

    Full Text Available Objectives: Pathological gambling (PG is a highly prevalent and disabling impulse control disorder. A range of psychopharmacological options are available for the treatment of PG, including selective serotonin reuptake inhibitors (SSRI, opioid receptor antagonists, anti-addiction drugs and mood stabilizers. In our preliminary study, we examined the efficacy of two anti-addiction drugs, Baclofen and Acamprosate, in the treatment of PG. Materials & Methods: 17 male gamblers were randomly divided into two groups. Each group received one of the two drugs without being blind to treatment. All patients underwent a comprehensive psychiatric diagnostic evaluation and completed a series of semi-structured interviews. During the six months of study, monthly evaluations were carried out to assess improvement and relapses. Relapse was defined as recurrent gambling behavior. Results: None of the 17 patients reached the six months abstinence. One patient receiving Baclofen sustained abstinence for 4 months. 14 patients succeeded in sustaining abstinence for 1-3 months. 2 patients stopped attending monthly evaluations. Conclusion: Baclofen and Acamprosate did not prove efficient in treating pathological gamblers.

  8. Modulation of TLR3/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis

    Directory of Open Access Journals (Sweden)

    Tadhg eCrowley

    2015-07-01

    Full Text Available The GABAB receptor agonist, baclofen, is used to treat muscle tightness and cramping caused by spasticity in a number of disorders including Multiple Sclerosis (MS, but its precise mechanism of action is unknown. Neuroinflammation drives the central pathology in MS and is mediated by both immunoreactive glial cells and invading lymphocytes. Furthermore, a body of data indicates that the Toll-like receptor (TLR family of innate immune receptors is implicated in MS progression. In the present study we investigated whether modulation of GABAB receptors using baclofen can exert anti-inflammatory effects by targeting TLR3 and(or TLR4-induced inflammatory signaling in murine glial cells and human peripheral blood mononuclear cells (PBMCs isolated from healthy control individuals and patients with the relapse-remitting (RR form of MS. TLR3 and TLR4 stimulation promoted the nuclear sequestration of NF-κB and pro-inflammatory cytokine expression in murine glia, while TLR4, but not TLR3, promoted pro-inflammatory cytokine expression in PBMCs isolated from both healthy donors and RR-MS patients. Importantly, this effect was exacerbated in RR-MS patient immune cells. We present further evidence that baclofen dose-dependently attenuated TLR3- and TLR4-induced inflammatory signaling in primary glial cells. Pre-exposure of PBMCs isolated from healthy donors to baclofen attenuated TLR4-induced TNF-α expression, but did not affect TLR4-induced TNF-α expression in RR-MS patient PBMCs. Interestingly, mRNA expression of the GABAB receptor was reduced in PBMCs from RR-MS donors when compared to healthy controls, an effect that might contribute to the differential sensitivity to baclofen seen in healthy and RR-MS patient cells. Overall these findings indicate that baclofen differentially regulates TLR3 and TLR4 signaling in glia and immune cells, and offers insight on the role of baclofen in the treatment of neuroinflammatory disease states including MS.

  9. How should an infected perinephric haematoma be drained in a tetraplegic patient with baclofen pump implanted in the abdominal wall? – A case report

    Directory of Open Access Journals (Sweden)

    Watt John WH

    2002-09-01

    Full Text Available Abstract Background We present a case to illustrate controversies in percutaneous drainage of infected, perinephric haematoma in a tetraplegic patient, who had implantation of baclofen pump in anterior abdominal wall on the same side as perinephric haematoma. Case presentation A 56-year-old male with C-4 tetraplegia had undergone implantation of programmable pump in the anterior abdominal wall for intrathecal infusion of baclofen to control spasticity. He developed perinephric haematoma while he was taking warfarin as prophylactic for deep vein thrombosis. Perinephric haematoma became infected with a resistant strain of Pseudomonas aeruginosa, and required percutaneous drainage. Positioning this patient on his abdomen without anaesthesia, for insertion of a catheter from behind, was not a realistic option. Administration of general anaesthesia in this patient in the radiology department would have been hazardous. Results and Conclusion Percutaneous drainage was carried out by anterior approach under propofol sedation. The site of entry of percutaneous catheter was close to cephalic end of baclofen pump. By carrying out drainage from anterior approach, and by keeping this catheter for ten weeks, we took a risk of causing infection of the baclofen pump site, and baclofen pump with a resistant strain of Pseudomonas aeruginosa. The alternative method would have been to anaesthetise the patient and position him prone for percutaneous drainage of perinephric collection from behind. This would have ensured that the drainage track was far away from the baclofen pump with minimal risk of infection of baclofen pump, but at the cost of incurring respiratory complications in a tetraplegic subject.

  10. Effect of baclofen on liquid and solid gastric emptying in rats Efeito do baclofen no esvaziamento gástrico de líquido e de sólidos em rato

    Directory of Open Access Journals (Sweden)

    Edgard Ferro Collares

    2010-09-01

    Full Text Available CONTEXT: Gamma-aminobutyric acid (GABA is a potent inhibitory neurotransmitter. There is evidence that GABA B receptors located in the dorsal complex and in afferent fibers of the vagus nerve participate in the control of gastrointestinal motility. OBJECTIVE: To assess the intracerebroventricularly (ICV and intravenously (IV effect of baclofen, a GABA B receptor agonist, on liquid and solid gastric emptying in rats. METHODS: Adult male Wistar rats weighing 250-300 g (n = 6-8 animals were used. Gastric emptying of liquid test meals labeled with phenol red was evaluated by the determination of percent gastric retention (%GR 10 and 15 min after orogastric administration of saline and 10% glucose meals, respectively. Baclofen was injected ICV (1 and 2 µg/animal through a tube implanted into the lateral ventricle of the brain and was injected IV (1 and 2 mg/kg into a tail vein. The gastric emptying of liquid was determined 10 or 30 min after ICV and IV baclofen administration, respectively. The gastric emptying of the solid meal was assessed by the determination of percent gastric retention 2 h after the beginning of the ingestion of the habitual ratio by the animal, consumed over a period of 30 min. Baclofen was administered ICV (1 and 2 µg/animal or IV (1 and 2 mg/kg immediately after the end of the ingestion of the solid meal. The control groups received vehicle (sterile saline solution ICV or IV. RESULTS: The group of animals receiving baclofen ICV (2 mg/animal presented a significantly lower (PCONTEXTO: O ácido gama-aminobutírico (GABA é um potente neurotransmissor inibitório. Há evidências que receptores GABA>B localizados no complexo dorsal do vago e em fibras aferentes do nervo vago participam no controle da motricidade gastrointestinal. OBJETIVO: Avaliar o efeito intracerebroventricular (ICV e intravenoso (IV do baclofen, um agonista para receptores GABA B, sobre o esvaziamento gástrico de líquidos e de sólidos em ratos. M

  11. Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen

    Directory of Open Access Journals (Sweden)

    Perić Predrag

    2006-01-01

    Full Text Available Background. Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a longterm cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity. Continuous intrathecal administration of baclofen (ITB, using a subcutaneously implanted programmable infusion pump, is a minimally invasive, reversible method for the treatment of severe diffuse spasticity of the spinal origin. Case report. The first two cases in our country, treated by ITB due to severe spasticity caused by MS, were reported. Despite the local complications of surgical wound healing above the implanted components of the ITB-system in one patient, the optimal reduction of spasticity the with complete elimination of spastic pain was obtained in both patients. Conclusion. Our initial experiences confirmed ITB as a safe and effective therapeutical option for the treatment of intractable spasticity in patients with MS. Major prerequisites for this were adequate patient selection and good control of the basic disease. The use of the minimal invasive implantation technique and the experience in choosing of the adequate ITB-system components, could successfully prevent the occurrence of local complications related to the impaired healing of the ITB-system implantation site.

  12. Enantiodifferentiation of chiral baclofen by β-cyclodextrin using capillary electrophoresis: A molecular modeling approach

    Science.gov (United States)

    Suliman, FakhrEldin O.; Elbashir, Abdalla A.

    2012-07-01

    Using capillary electrophoresis baclofen (BF) enantiomers were separated only in the presence of β-cyclodextrin (βCD) as a chiral selector when added to the background electrolyte. Proton nuclear magnetic resonance and electrospray ionization mass spectrometry (ESI-MS) techniques were used to determine the structure of the BF-βCD inclusion complexes. From the MS data BF was found to form a 1:1 complex with α- and βCD, while the NMR data suggest location of the aromatic ring of BF into the cyclodextrin cavity. A molecular modeling study, using the semiempirical PM6 calculations was used to investigate the mechanism of enantiodifferentiation of BF with cyclodextrins. Optimization of the structures of the complexes by PM6 method indicated that separation is obtained in the presence of β-CD due to a large binding energy difference (ΔΔE) of 46.8 kJ mol-1 between S-BF-βCD and R-BF-βCD complexes. In the case of αCD complexes ΔΔE was 1.3 kJ mol-1 indicating poor resolution between the two enantiomers. Furthermore, molecular dynamic simulations show that the formation of more stable S-BF-βCD complex compared to R-BF-β-CD complex is primarily due to differences in intermolecular hydrogen bonding.

  13. Resolution of Enantiomers of (RS)-Baclofen by Ligand-Exchange Thin-Layer Chromatography.

    Science.gov (United States)

    Singh, Manisha; Malik, Poonam; Bhushan, Ravi

    2016-05-01

    A new chromatographic method has been developed for direct enantioresolution of (RS)-baclofen by ligand-exchange thin-layer chromatography (TLC) adopting two different approaches; (A) TLC plates were prepared by mixing the ligand exchange reagents (LER) with silica gel slurry and the chromatograms were developed with different achiral solvents or solvents having no chiral additive, and (B) the LER consisting of Cu(II)-l-amino acid complex was used as chiral mobile phase additive and the plain plates of silica gel having no chiral selector were used. Cu(II) acetate and fourl-amino acids (namely,l-tryptophan,l-histidine,l-proline andl-phenylalanine) were used for the preparation of LERs. Spots were located by the use of iodine vapor. Effect of temperature and the mole ratio of Cu(II)-to-amino acid on enantioresolution were also studied. The results for the two methods have been compared, and the issue of involvement of the Cu(II) cation for the best performance of the two methods has been discussed with respect to the same mobile phase.l-Trp proved to be a good ligand using a common mobile phase in each case. PMID:26896346

  14. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal.

    Science.gov (United States)

    Diaz, Silvina L; Kemmling, Alma K; Balerio, Graciela N

    2003-03-01

    The present study analyzes the effects of baclofen (BAC) on mice brain neurochemical alterations during the morphine (MOR) withdrawal syndrome. Male Swiss-Webster albino mice (27-33 g) were rendered dependent by intraperitoneal (i.p.) injection of MOR (2mg/kg), twice daily for 9 days. On day 10, the dependent animals were divided into two groups: one receiving naloxone (NAL; 6 mg/kg i.p.) to precipitate the withdrawal syndrome 60 min after the last dose of MOR and the other received BAC (2mg/kg, i.p.) followed by NAL (6 mg/kg, i.p.), injected 30 and 60 min after the last dose of MOR, respectively. Ten minutes after these treatments, mice were killed by decapitation and the striatum, cortex and hippocampus were dissected to determine endogenous concentrations of dopamine (DA), 5-hydroxytryptamine (5-HT) and their metabolites using HPLC with electrochemical detection. Striatal DA, dihydroxyphenyl acetic acid (DOPAC) and homovanillic acid (HVA) concentrations as well as cortical DA concentrations of the withdrawal groups decreased significantly with respect to the control groups. BAC attenuated the decrease in DA and DOPAC concentrations observed during the withdrawal, without modifying per se the control DA concentrations. No changes on 5-HT and its metabolite 5-hydroxyindolacetic acid (5-HIAA) concentrations were observed during the MOR abstinence syndrome. The prevention caused by BAC on the decreased concentrations of DA induced by MOR withdrawal could have a therapeutic interest for the management of withdrawal syndrome. PMID:12470702

  15. Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry.

    Science.gov (United States)

    Nahar, Limon Khatun; Cordero, Rosa Elena; Nutt, David; Lingford-Hughes, Anne; Turton, Samuel; Durant, Claire; Wilson, Sue; Paterson, Sue

    2016-03-01

    A highly sensitive and fully validated method was developed for the quantification of baclofen in human plasma. After adjusting the pH of the plasma samples using a phosphate buffer solution (pH 4), baclofen was purified using mixed mode (C8/cation exchange) solid-phase extraction (SPE) cartridges. Endogenous water-soluble compounds and lipids were removed from the cartridges before the samples were eluted and concentrated. The samples were analyzed using triple-quadrupole liquid chromatography-tandem mass spectrometry (LC-MS-MS) with triggered dynamic multiple reaction monitoring mode for simultaneous quantification and confirmation. The assay was linear from 25 to 1,000 ng/mL (r(2) > 0.999; n = 6). Intraday (n = 6) and interday (n = 15) imprecisions (% relative standard deviation) were baclofen (10 and 60 mg) on nonconsecutive days were analyzed to demonstrate method applicability. PMID:26538544

  16. Baclofen and adenosine inhibition of synaptic transmission at CA3-CA1 synapses display differential sensitivity to K+ channel blockade.

    Science.gov (United States)

    Skov, Jane; Andreasen, Mogens; Hablitz, John J; Nedergaard, Steen

    2011-05-01

    The metabotropic GABA(B) and adenosine A(1) receptors mediate presynaptic inhibition through regulation of voltage-dependent Ca(2+) channels, whereas K(+) channel regulation is believed to have no role at the CA3-CA1 synapse. We show here that the inhibitory effect of baclofen (20 μM) and adenosine (300 μM) on field EPSPs are differentially sensitive to Cs(+) (3.5 mM) and Ba(2+) (200 μM), but not 4-aminopyridine (100 μM). Barium had no effect on paired-pulse facilitation (PPF) in itself, but gave significant reduction (14 ± 5%) when applied in the presence of baclofen, but not adenosine, suggesting that the effect is presynaptic and selective on the GABA(B) receptor-mediated response. The effect of Ba(2+) on PPF was not mimicked by tertiapin (30 nM), indicating that the underlying mechanism does not involve GIRK channels. Barium did not affect PPF in slices from young rats (P7-P8), suggesting developmental regulation. The above effects of Ba(2+) on adult tissue were reproduced when measuring evoked whole-cell EPSCs from CA1 pyramidal neurons: PPF was reduced by 22 ± 3% in the presence of baclofen and unaltered in adenosine. In contrast, Ba(2+) caused no significant change in frequency or amplitude of miniature EPSCs. The Ba(2+)-induced reduction of PPF was antagonized by LY341495, suggesting metabotropic glutamate receptor involvement. We propose that these novel effects of Ba(2+) and Cs(+) are exerted through blockade of inwardly rectifying K(+) channels in glial cells, which are functionally interacting with the GABA(B) receptor-dependent glutamate release that generates heterosynaptic depression. PMID:21274618

  17. The positive allosteric GABAB receptor modulator rac-BHFF enhances baclofen-mediated analgesia in neuropathic mice.

    Science.gov (United States)

    Zemoura, Khaled; Ralvenius, William T; Malherbe, Pari; Benke, Dietmar

    2016-09-01

    Neuropathic pain is associated with impaired inhibitory control of spinal dorsal horn neurons, which are involved in processing pain signals. The metabotropic GABAB receptor is an important component of the inhibitory system and is highly expressed in primary nociceptors and intrinsic dorsal horn neurons to control their excitability. Activation of GABAB receptors with the orthosteric agonist baclofen effectively reliefs neuropathic pain but is associated with severe side effects that prevent its widespread application. The recently developed positive allosteric GABAB receptor modulators lack most of these side effects and are therefore promising drugs for the treatment of pain. Here we tested the high affinity positive allosteric modulator rac-BHFF for its ability to relief neuropathic pain induced by chronic constriction of the sciatic nerve in mice. rac-BHFF significantly increased the paw withdrawal threshold to mechanical stimulation in healthy mice, indicating an endogenous GABABergic tone regulating the sensitivity to mechanical stimuli. Surprisingly, rac-BHFF displayed no analgesic activity in neuropathic mice although GABAB receptor expression was not affected in the dorsal horn as shown by quantitative receptor autoradiography. However, activation of spinal GABAB receptors by intrathecal injection of baclofen reduced hyperalgesia and its analgesic effect was considerably potentiated by co-application of rac-BHFF. These results indicate that under conditions of neuropathic pain the GABAergic tone is too low to provide a basis for allosteric modulation of GABAB receptors. However, allosteric modulators would be well suited as an add-on to reduce the dose of baclofen required to achieve analgesia. PMID:27108932

  18. Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. Case report.

    Science.gov (United States)

    Delhaas, E M; Verhagen, J

    1992-07-01

    A report on pregnancy in a quadriplegic patient treated with a high dose of 1000 mcg/24 h continuous intrathecal baclofen infusion using an implanted drug delivery system (Synchromed, Medtronic, USA). Spasticity could be managed up to the 35th week of gestation. However, uterine contractions evoke enormous spastic symptoms which we, even with maximum values of the spasticity scales, could not classify. The recurrence of spasticity was associated with autonomic dysregulation. With continuous epidurally infused bupivacaine (11.25 mg/h) adequate relaxation could be reached and gestation was terminated by a primary caesarean section. A healthy girl was born (2040 g, Apgar 9 and 10). PMID:1508570

  19. Baclofen differentially mediates fructose-conditioned flavor preference and quinine-conditioned flavor avoidance in rats.

    Science.gov (United States)

    Rotella, Francis M; Vig, Vishal; Olsson, Kerstin; Pagirsky, Jeremy; Aminov, Alon; Kohen, Ilanna; Bodnar, Richard J

    2016-03-15

    Rats display both fructose-conditioned flavor preference (CFP) and quinine conditioned flavor avoidance (CFA). Dopamine (D1 and D2), muscarinic and nicotinic, but not NMDA or opioid receptor antagonists reduced fructose-CFP expression. Dopamine D1, dopamine D2, muscarinic or NMDA, but not opioid or nicotinic receptor antagonists reduced fructose-CFP acquisition. Dopamine D1, NMDA, nicotinic or opioid, but not dopamine D2 or muscarinic receptor antagonists enhanced quinine-CFA acquisition. Baclofen (BAC), a GABAB receptor agonist, alternately enhances or reduces feeding under specific conditions. The present study examined whether systemic BAC administration mediated fructose-CFP expression and acquisition or quinine-CFA acquisition. Fructose-CFP expression studies trained rats with one flavor (CS+) in 8% fructose and 0.2% saccharin and a second (CS-) flavor in 0.2% saccharin, followed by vehicle (VEH) and BAC (0.5-5 mg/kg) preceding 2-bottle (CS+, CS-) 0.2% saccharin choice tests. Fructose-CFP acquisition studies administered VEH or BAC (3 or 5 mg/kg) prior to CS+ and CS- training sessions followed by six 2-bottle (CS+, CS-) 0.2% saccharin choice tests. Quinine-CFA acquisition studies administered VEH or BAC (3 or 5 mg/kg) prior to CS- (8% fructose+0.2% saccharin) and CS+ (fructose+saccharin+0.030% quinine) training sessions followed by six 2-bottle (CS-, CS+) fructose+saccharin choice tests. BAC (3 mg/kg) minimally (66%) reduced fructose-CFP expression. BAC failed to alter fructose-CFP acquisition. Quinine-CFA acquisition was enhanced by the 5 mg/kg BAC dose (15-25%) relative to VEH (34-48%). These data implicate GABAB receptor signaling in acquisition of quinine avoidance with minimal or no effects upon fructose preferences. PMID:26852956

  20. The gamma-aminobutyric acid type B (GABAB receptor agonist baclofen inhibits morphine sensitization by decreasing the dopamine level in rat nucleus accumbens

    Directory of Open Access Journals (Sweden)

    Fu Zhenyu

    2012-07-01

    Full Text Available Abstract Background Repeated morphine exposure can induce behavioral sensitization. There are evidences have shown that central gamma-aminobutyric acid (GABA system is involved in morphine dependence. However, the effect of a GABAB receptor agonist baclofen on morphine-induced behavioral sensitization in rats is unclear. Methods We used morphine-induced behavioral sensitization model in rat to investigate the effects of baclofen on behavioral sensitization. Moreover, dopamine release in the shell of the nucleus accumbens was evaluated using microdialysis assay in vivo. Results The present study demonstrated that morphine challenge (3 mg/kg, s.c. obviously enhanced the locomotor activity following 4-day consecutive morphine administration and 3-day withdrawal period, which indicated the expression of morphine sensitization. In addition, chronic treatment with baclofen (2.5, 5 mg/kg significantly inhibited the development of morphine sensitization. It was also found that morphine challenge 3 days after repeated morphine administration produced a significant increase of extracellular dopamine release in nucleus accumbens. Furthermore, chronic treatment with baclofen decreased the dopamine release induced by morphine challenge. Conclusions Our results indicated that gamma-aminobutyric acid system plays an important role in the morphine sensitization in rat and suggested that behavioral sensitization is a promising model to study the mechanism underlying drug abuse.

  1. Effect of baclofen combined with neural facilitation technique on the reduction of muscular spasm in patients with spinal cord injury

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    BACKGROUND: Recent researches have demonstrated that baclofen is a commonly central anti-spasm drug. In addition, neural facilitation technique based on nerve development and neurophysiology is widely used for rehabilitation training of motor disorder after central nerve injury. However, whether baclofen combining with neural facilitation technique can relieve muscular spasm after spinal cord injury needs further studies.OBJECTIVE: To observe the effect of baclofen combining with neural facilitation technique on decreasing muscular tension in two lower extremities after spinal cord injury.DESIGN: Randomized controlled study.SETTING: Departments of Rehabilitation and Orthopaedics, the Third Affiliated Hospital of Guangzhou Medical College.PARTICIPANTS: A total of 28 patients with spinal cord injury, including 17 males and 11 females, whose age ranged from 31 to 71 years, were selected from Departments of Rehabilitation and Orthopaedics, the Third Affiliated Hospital of Guangzhou Medical College from March 2005 to September 2006. The illness course ranged from 22 to 54 days and the mean course was (38 ± 8) days. All patients were diagnosed as the first onset and the increase of extensor muscular tension in two lower extremities after thoracic vertebra injury by using spine MR or CT examination. Informed consents were obtained from all the patients.METHODS: All 28 patients who had upper motor neuronal paralysis in two lower extremities after spinal cord injury in thoracic vertebra region were randomly divided into treatment group and control group with 14 cases in each group. Patients in both groups received routine therapy, while those in the treatment group were treated with oral baclofen (the beginning dosage: 5 mg/time; three times per day, 5 mg was increased every three days; the maximal dosage was 60 mg/day; 6 weeks in total) (made in Weicai Pharmaceutical Co., Ltd.;tablet; batch number: HC20040029) combining with neural facilitation technique, which accorded

  2. Baclofen alters gustatory discrimination capabilities and induces a conditioned taste aversion (CTA

    Directory of Open Access Journals (Sweden)

    Wilson Gina N

    2011-12-01

    Full Text Available Abstract Background Studies intending to measure drug-induced changes in learning and memory are challenged to parse out the effects of drugs on sensory, motor, and associative systems in the brain. In the context of conditioned taste aversion (CTA, drugs that alter the sensorium of subjects and affect their ability to taste and/or feel malaise may limit the ability of investigators to make conclusions about associative effects of these substances. Since the GABAergic system is implicated in inhibition, the authors were hopeful to use the GABA agonist, baclofen (BAC, to enhance extinction of a CTA, but first a preliminary evaluation of BAC's peripheral effects on animals' sensorium had to be completed due to a lack of published literature in this area. Findings Our first experiment aimed to evaluate the extent to which the GABAB agonist, BAC, altered the ability of rats to differentiate between 0.3% and 0.6% saccharin (SAC in a two bottle preference test. Here we report that 2 or 3 mg/kg (i.p. BAC, but not 1 mg/kg BAC, impaired animals' gustatory discrimination abilities in this task. Furthermore, when SAC consumption was preceded by 2 or 3 mg/kg (i.p. BAC, rats depressed their subsequent SAC drinking. A second experiment evaluated if the suppression of SAC and water drinking (revealed in Experiment 1 was mediated by amnesiac effects of BAC or whether BAC possessed US properties in the context of the CTA paradigm. The time necessary to reach an asymptotic level of CTA extinction was not significantly different in those animals that received the 3 mg/kg dose of BAC compared to more conventionally SAC + lithium chloride (LiCl, 81 mg/kg conditioned animals. Conclusions Our findings were not consistent with a simple amnesia-of-neophobia explanation. Instead, results indicated that 2 and 3 mg/kg (i.p. BAC were capable of inducing a CTA, which was extinguishable via repeated presentations of SAC only. Our data indicate that, depending on the dose, BAC

  3. Regulation by divalent cations of 3H-baclofen binding to GABA/sub B/ sites in rat cerebellar membranes

    International Nuclear Information System (INIS)

    When investigating the effects of divalent cations (Mg2+, Ca2+, Sr2+, Ba2+, Mn2+ and Ni2+) on 3H-baclofen binding to rat cerebellar synaptic membranes, we found that the specific binding of 3H-baclofen was not only dependent on divalent cations, but was increased dose-dependently in the presence of these cations. The effects were in the following order of potency: Mn2+ approx. = Ni2+ > Mg2+ > Ca2+ > Sr2+ > Ba2+. Scatchard analysis of the binding data revealed a single component of the binding sites in the presence of 2.5 mM MgCl2, 2.5 mM CaCl2 or 0.3 mM MnCl2 whereas two components appeared in the presence of 2.5 mM MnCl2 or 1 mM NiCl2. In the former, divalent cations altered the apparent affinity (K/sub d/) without affecting density of the binding sites (B/sub max/). In the latter, the high-affinity sites showed a higher affinity and lower density of the binding sites than did the single component of the former. As the maximal effects of four cations (Mg2+, Ca2+, Mn2+, and Ni2+) were not additive, there are probably common sites of action of these divalent cations. Among the ligands for GABA/sub B/ sites, the affinity for (-), (+) and (+/-)baclofen, GABA and β-phenyl GABA increased 2 - 6 fold in the presence of 2.5 mM MnCl2, in comparison with that in HEPES-buffered Krebs solution (containing 2.5 mM CaCl2 and 1.2 mM MgSO4), whereas that for muscimol was decreased to one-fifth. Thus, the affinity of GABA/sub B/ sites for its ligands is probably regulated by divalent cations, through common sites of action

  4. Intra-nucleus accumbens shell injections of R(+)- and S(-)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice

    OpenAIRE

    Kasten, Chelsea R.; Boehm, Stephen L.

    2014-01-01

    The GABAB agonist baclofen has been widely researched clinically and preclinically as a treatment of alcohol use disorders (AUDs). However, the efficacy of baclofen remains uncertain. The clinically used racemic compound can be separated into separate enantiomers. These enantiomers have produced different profiles in behavioral assays, with the S- compound often being ineffective compared to the R- compound, or the S- compound antagonizing the effects of the R- compound. We have previously de...

  5. Baclofen ameliorates spatial working memory impairments induced by chronic cerebral hypoperfusion via up-regulation of HCN2 expression in the PFC in rats.

    Science.gov (United States)

    Luo, Pan; Chen, Cheng; Lu, Yun; Fu, TianLi; Lu, Qing; Xu, Xulin; Li, Changjun; He, Zhi; Guo, Lianjun

    2016-07-15

    Chronic cerebral hypoperfusion (CCH) causes memory deficits and increases the risk of vascular dementia (VD) through several biologically plausible pathways. However, whether CCH causes prefrontal cortex (PFC)-dependent spatial working memory impairments and Baclofen, a GABAB receptor agonist, could ameliorate the impairments is still not clear especially the mechanisms underlying the process. In this study, rats were subjected to permanent bilateral occlusion of the common carotid arteries (two-vessel occlusion, 2VO) to induce CCH. Two weeks later, rats were treated with 25mg/kg Baclofen (intraperitioneal injection, i.p.) for 3 weeks. Spatial working memory was evaluated in a Morris water maze using a modified delayed matching-to-place (DMP) procedure. Western blotting and immunohistochemistry were used to quantify the protein levels and protein localization. Our results showed that 2VO caused striking spatial working memory impairments, accompanied with a decreased HCN2 expression in PFC, but the protein levels of protein gene product 9.5 (PGP9.5, a neuron specific protein), glial fibrillary acidic protein (GFAP), synaptophysin (SYP), brain-derived neurotrophic factor (BDNF), parvalbumin (PV) and HCN1 were not distinguishably changed as compared with sham-operated rats. Baclofen treatment significantly improved the spatial working memory impairments caused by 2VO, accompanied with a reversion of 2VO-induced down-regulation of HCN2. Furthermore, there was a co-localization of HCN2 subunits and parvalbumin-positive neurons in PFC. Therefore, HCN2 may target inhibitory interneurons that is implicated in working memory processes, which may be a possible mechanism of the up-regulation of HCN2 by Baclofen treatment that reliefs spatial working memory deficits in rats with CCH. PMID:27085590

  6. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation

    OpenAIRE

    Abdelkader, Hamdy; Abdalla, Ossama Youssef; Salem, Hesham

    2007-01-01

    This work aims at investigating different types and levels of hydrophilic matrixing agents, including methylcellulose (MC), sodium alginate (Alg), and sodium carboxymethylcellulose (CMC), in an attempt to formulate controlled-release matrix tablets containing 25 mg baclofen. The tablets were prepared by wet granulation. Prior to compression, the prepared granules were evaluated for flow and compression characteristics. In vitro, newly formulated controlled-release tablets were compared with s...

  7. Attenuation of cocaine-seeking by GABAB receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons

    OpenAIRE

    Weerts, Elise M.; Froestl, Wolfgang; Kaminski, Barbara J.; Griffiths, Roland R.

    2007-01-01

    The current study evaluated the effects of drugs that increase GABA levels by activation of GABAB receptors (baclofen and CGP44532) or by inhibition of GABA reuptake (tiagabine) on the reinstatement of extinguished lever responding produced by priming doses of cocaine in baboons (i.e., cocaine-seeking). Cocaine self-injection was established and maintained under a fixed ratio (FR10) schedule of reinforcement during daily 2-h sessions. Lever responding was extinguished by substituting vehicle ...

  8. Intrathecal baclofen withdrawal syndrome caused by low residual volume in the pump reservoir: a report of 2 cases.

    Science.gov (United States)

    Rigoli, Gianfranco; Terrini, Giovanni; Cordioli, Zeno

    2004-12-01

    Intrathecal baclofen (ITB) is an effective treatment for spasticity caused by spinal or cerebral pathologies. Severe withdrawal symptoms can result, however, if ITB is abruptly withdrawn as a result of equipment malfunctions or human error. We describe 2 cases of severe ITB withdrawal syndrome. In the first case, the symptoms appeared 5 months after pump placement, when residual volume was 2.0 mL; in the second case, symptoms appeared 2 months after the replacement of a new pump, when residual volume was 0.9 mL. In both cases, there was no evidence of system malfunction or human error. The syndrome occurred from up to 72 hours before the scheduled refilling procedure, and the residual volume in the Medtronic SynchroMed EL pump reservoir was either at, or significantly lower than, the recommended 2 mL. These cases suggest that the SynchroMed EL pump reservoir should be refilled, to avoid potentially serious consequences, when the residual volume is not lower than 3 mL by programming the alarm to sound at a volume larger than the recommended 2 mL. PMID:15605349

  9. Efficient Synthesis of β-Aryl-γ-lactams and Their Resolution with (S-Naproxen: Preparation of (R- and (S-Baclofen

    Directory of Open Access Journals (Sweden)

    Iris J. Montoya-Balbás

    2015-12-01

    Full Text Available An efficient synthesis of enantiomerically-pure β-aryl-γ-lactams is described. The principal feature of this synthesis is the practical resolution of β-aryl-γ-lactams with (S-Naproxen. The procedure is based on the Michael addition of nitromethane to benzylidenemalonates, which was easily obtained, followed by the reduction of the γ-nitroester in the presence of Raney nickel and the subsequent saponification/decarboxylation reaction. The utility of this methodology was highlighted by the preparation of enantiomerically-pure (R- and (S-Baclofen hydrochloride.

  10. Long-term follow-up for lumbar intrathecal baclofen catheters placed using the paraspinal subfascial technique.

    Science.gov (United States)

    Thakur, Saumitra K; Rubin, Benjamin A; Harter, David H

    2016-03-01

    OBJECT Intrathecal baclofen (ITB) is a valuable therapeutic option for patients with spasticity and dystonia. The techniques that place an ITB pump catheter into the subcutaneous fat of a lumbar incision are well described. Because patients who require ITB often have low body fat content, they may be predisposed to catheter-related complications. The senior author used a novel technique to place the catheter in a paraspinal subfascial fashion, and the short-term results were previously published. That study demonstrated no development of hardware erosions, catheter migrations, or CSF leaks within an average follow-up of 5 months. This study followed up on those initial findings by looking at the long-term outcomes since this technique was introduced. METHODS Using the institutional review board-approved protocol, the electronic medical records were reviewed retrospectively for all patients who underwent paraspinal subfascial catheter placement by the senior author. Patients received follow-up with the surgeon at 2 weeks postoperatively and were followed routinely by their physiatrist thereafter. RESULTS Of the 43 patients identified as having undergone surgery by the senior author using the paraspinal subfascial technique between July 2010 and February 2014, 12 patients (27.9%) required reoperation. There were 5 patients (11.6%) who had complications related to the catheter or lumbar incision. No hardware erosions or CSF leaks were identified. These patients received a median follow-up of 3.0 years, with 30 of 43 patients receiving follow-up over 2.0 years. CONCLUSION This follow-up study suggests that the technique of paraspinal subfascial catheter placement translates to long-term decreases in CSF leakage and complications from erosion, infection, and also catheter malfunctions. It does not seem to affect the overall rate of complications. PMID:26588457

  11. Bladder stones – red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen – a case report

    Science.gov (United States)

    Vaidyanathan, Subramanian; Soni, Bakul M; Oo, Tun; Hughes, Peter L; Singh, Gurpreet; Watt, John WH; Sett, Pradipkumar

    2003-01-01

    Background Increased spasms in spinal cord injury (SCI) patients, whose spasticity was previously well controlled with intrathecal baclofen therapy, are due to (in order of frequency) drug tolerance, increased stimulus, low reservoir volume, catheter malfunction, disease progression, human error, and pump mechanical failure. We present a SCI patient, in whom bladder calculi acted as red herring for increased spasticity whereas the real cause was spontaneous extrusion of catheter from intrathecal space. Case Presentation A 44-year-old male sustained a fracture of C5/6 and incomplete tetraplegia at C-8 level. Medtronic Synchromed pump for intrathecal baclofen therapy was implanted 13 months later to control severe spasticity. The tip of catheter was placed at T-10 level. The initial dose of baclofen was 300 micrograms/day of baclofen, administered by a simple continuous infusion. During a nine-month period, he required increasing doses of baclofen (875 micrograms/day) to control spasticity. X-ray of abdomen showed multiple radio opaque shadows in the region of urinary bladder. No malfunction of the pump was detected. Therefore, increased spasticity was attributed to bladder stones. Electrohydraulic lithotripsy of bladder stones was carried out successfully. Even after removal of bladder stones, this patient required further increases in the dose of intrathecal baclofen (950, 1050, 1200 and then 1300 micrograms/day). Careful evaluation of pump-catheter system revealed that the catheter had extruded spontaneously and was lying in the paraspinal space at L-4, where the catheter had been anchored before it entered the subarachnoid space. A new catheter was passed into the subarachnoid space and the tip of catheter was located at T-8 level. The dose of intrathecal baclofen was decreased to 300 micrograms/day. Conclusion Vesical calculi acted as red herring for resurgence of spasticity. The real cause for increased spasms was spontaneous extrusion of whole length of

  12. Bladder stones – red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen – a case report

    Directory of Open Access Journals (Sweden)

    Singh Gurpreet

    2003-03-01

    Full Text Available Abstract Background Increased spasms in spinal cord injury (SCI patients, whose spasticity was previously well controlled with intrathecal baclofen therapy, are due to (in order of frequency drug tolerance, increased stimulus, low reservoir volume, catheter malfunction, disease progression, human error, and pump mechanical failure. We present a SCI patient, in whom bladder calculi acted as red herring for increased spasticity whereas the real cause was spontaneous extrusion of catheter from intrathecal space. Case Presentation A 44-year-old male sustained a fracture of C5/6 and incomplete tetraplegia at C-8 level. Medtronic Synchromed pump for intrathecal baclofen therapy was implanted 13 months later to control severe spasticity. The tip of catheter was placed at T-10 level. The initial dose of baclofen was 300 micrograms/day of baclofen, administered by a simple continuous infusion. During a nine-month period, he required increasing doses of baclofen (875 micrograms/day to control spasticity. X-ray of abdomen showed multiple radio opaque shadows in the region of urinary bladder. No malfunction of the pump was detected. Therefore, increased spasticity was attributed to bladder stones. Electrohydraulic lithotripsy of bladder stones was carried out successfully. Even after removal of bladder stones, this patient required further increases in the dose of intrathecal baclofen (950, 1050, 1200 and then 1300 micrograms/day. Careful evaluation of pump-catheter system revealed that the catheter had extruded spontaneously and was lying in the paraspinal space at L-4, where the catheter had been anchored before it entered the subarachnoid space. A new catheter was passed into the subarachnoid space and the tip of catheter was located at T-8 level. The dose of intrathecal baclofen was decreased to 300 micrograms/day. Conclusion Vesical calculi acted as red herring for resurgence of spasticity. The real cause for increased spasms was spontaneous extrusion

  13. Regulation by divalent cations of /sup 3/H-baclofen binding to GABA/sub B/ sites in rat cerebellar membranes

    Energy Technology Data Exchange (ETDEWEB)

    Kato, K.; Goto, M.; Fukuda, H.

    1983-02-21

    When investigating the effects of divalent cations (Mg/sup 2 +/, Ca/sup 2 +/, Sr/sup 2 +/, Ba/sup 2 +/, Mn/sup 2 +/ and Ni/sup 2 +/) on /sup 3/H-baclofen binding to rat cerebellar synaptic membranes, we found that the specific binding of /sup 3/H-baclofen was not only dependent on divalent cations, but was increased dose-dependently in the presence of these cations. The effects were in the following order of potency: Mn/sup 2 +/ approx. = Ni/sup 2 +/ > Mg/sup 2 +/ > Ca/sup 2 +/ > Sr/sup 2 +/ > Ba/sup 2 +/. Scatchard analysis of the binding data revealed a single component of the binding sites in the presence of 2.5 mM MgCl/sub 2/, 2.5 mM CaCl/sub 2/ or 0.3 mM MnCl/sub 2/ whereas two components appeared in the presence of 2.5 mM MnCl/sub 2/ or 1 mM NiCl/sub 2/. In the former, divalent cations altered the apparent affinity (K/sub d/) without affecting density of the binding sites (B/sub max/). In the latter, the high-affinity sites showed a higher affinity and lower density of the binding sites than did the single component of the former. As the maximal effects of four cations (Mg/sup 2 +/, Ca/sup 2 +/, Mn/sup 2 +/, and Ni/sup 2 +/) were not additive, there are probably common sites of action of these divalent cations. Among the ligands for GABA/sub B/ sites, the affinity for (-), (+) and (+/-)baclofen, GABA and ..beta..-phenyl GABA increased 2 - 6 fold in the presence of 2.5 mM MnCl/sub 2/, in comparison with that in HEPES-buffered Krebs solution (containing 2.5 mM CaCl/sub 2/ and 1.2 mM MgSO/sub 4/), whereas that for muscimol was decreased to one-fifth. Thus, the affinity of GABA/sub B/ sites for its ligands is probably regulated by divalent cations, through common sites of action.

  14. Clinical Use of Baclofen at the late stage of stroke%巴氯芬在中风后期的临床应用研究

    Institute of Scientific and Technical Information of China (English)

    秦绍森; 张晓燕; 罗盛; 王作为; 刘明; 陈海波

    2001-01-01

    目的:观察国产巴氯芬对中风后期伴肌张力增高患者的治疗效果及不良反应。方法:门诊就诊病程3月以上的中风伴肌张力增高的患者30例予以巴氯芬口服治疗。起始剂量为5mg,每日1次, 3天后增加5mg,最大剂量每日小于80mg,维持治疗8周。服药前、后4周、 8周检查血尿常规及肝肾功能。肌张力测定按国际通用的Ashworth评分,与治疗前相比肌张力恢复正常为痊愈。肌张力减低2级以上为显效,减低1级为有效。结果:除1例脱落外,余29例患者中显效9例,有效16例,总有效率为86.2%,而且未见明显毒副作用。结论:巴氯芬对脑血管病患者的偏瘫痉挛有较好效果,有利于偏瘫肢体的功能锻炼及康复。%Objective:To assess the efficacy and side effect of Baclofen in treating patients with hypertonia at the late stage of stroke. Methods: Thorty patients with hypertonia at the late stage of strole were treated with Baclofen (initial dosage:15mg/d, plus 5mg/d every 3 days, maximal dose: <80mg/d) for 8 weeks. Blood and Urine routine test, and hepatic and renal function were monitored before and 4 , 8 weeks after the treatment. Muscle tone was assessed according to Ashworth score. Complete recovery was considered if muscle tone ncrmdized, excellent efficacy if muscle tone decreased by two degrees, and good efficacy if muscle tone decreased by one degree. Results:Nine patients were found to have the decrease of muscle tone for more than 2 degrees, 16 patients for one degree. The total efficacy rate was 86.2%. The results indicate than Baclofen is effective in relieving suffered-limb spasm sfter cerebral vascular disorders. No side effect was observed. Conclusion: Baclofen is effective to patients with hypertonia at the late stage of stroke. It is beneficial to the rehabilitation and suffered-limb exercise.

  15. Bladder stones – red herring for resurgence of spasticity in a spinal cord injury patient with implantation of Medtronic Synchromed pump for intrathecal delivery of baclofen – a case report

    OpenAIRE

    Singh Gurpreet; Hughes Peter L; Oo Tun; Soni Bakul M; Vaidyanathan Subramanian; Watt John WH; Sett Pradipkumar

    2003-01-01

    Abstract Background Increased spasms in spinal cord injury (SCI) patients, whose spasticity was previously well controlled with intrathecal baclofen therapy, are due to (in order of frequency) drug tolerance, increased stimulus, low reservoir volume, catheter malfunction, disease progression, human error, and pump mechanical failure. We present a SCI patient, in whom bladder calculi acted as red herring for increased spasticity whereas the real cause was spontaneous extrusion of catheter from...

  16. 毛细管电泳分离-激光诱导荧光检测巴氯芬和加巴喷丁%Determination of baclofen and gabapentin by capillary electrophoresis-laser-induced fluorescence method

    Institute of Scientific and Technical Information of China (English)

    曹丽伟; 李聪; 任东

    2011-01-01

    采用新合成的6-氧-(N-琥珀酰亚胺乙酸酯)-9-(2’-甲氧羰基)荧光素(SAMF)作为柱前衍生试剂,用甘氨酸做内标,毛细管电泳分离-激光诱导荧光检测血清中的巴氯芬(baclofen)和加巴喷丁(gabapentin).研究表明,在磷酸盐缓冲溶液(pH=8)介质中,25℃下15 min即可完成衍生反应.以pH =5的30 mmol/L的磷酸盐缓冲溶液作为电泳介质,衍生产物在16 min内达到电泳基线分离,检出限为4×10-10 mol/L.将新建立的方法用于血清中巴氯芬、加巴喷丁的分析测定,回收率为95.5% ~ 102.01%,结果令人满意.%A sensitive and efficient analysis method for determination of baclofen and gabapentin in human serum based on capillary electrophoresis with laser-induced fluorescence (LIF) has been established. 6-Oxy-( N-succinimidylacetate)- 9-(2'-Meth-oxycarbonyl) fluorescein (SAMF), a new synthesized fluorescence reagent, was used for pre-column derivatization of the "non-fluorescent drug in serum. Glycin was used as an internal standard. The best derivation condition was obtained in phosphate buffer (pH =8) at 25℃ for 15 min. Optimal separation and detection were obtained with an background electrolyte of 30 mmol/L phosphate buffer ( pH = 5 ) and LJF was excited at 473 nm. The detection limit of baclofen was 4 x 10-10 mol/L. This sensitive method was effectively used to determine baclofen and gabapentin in human serum with recoveries ranging from 95.5% to 102.01%.

  17. The therapeutic effect comparative study of botulinum toxin A and baclofen in hemifacial spasm%A型肉毒毒素与巴氯芬治疗偏侧面肌痉挛的疗效对比

    Institute of Scientific and Technical Information of China (English)

    辛晋敏

    2012-01-01

    Objective To compare the therapeutic effect of local injection of botulinum toxin A (BTXA) and oral baclofen in hemifacial spasm (HFS).Methods Sixty-six patients with HFS were divided into BTXA treatment group (33 patients) and baclofen treatment group (33 patients) by random digits table.The patients in BTXA treatment group was given local multipoint target muscle injection of BTXA,and the patients in baclofen treatment group was given oral baclofen.The therapeutic effect was assessed after treatment of 2 weeks and 4 weeks.Results The scores of spasticity before treatment had no significant difference between two groups (P > 0.05).After treatment of 2 weeks and 4 weeks,the scores of spasticity in BTXA treatment group and baclofen treatment group were significantly decreased [BTXA treatment group:(1.80 ±0.70),(1.57 ± 0.17) scores vs.(3.15 ±0.43) scores;baclofen treatment group:(2.14 ±0.60),(1.14 ± 0.70) scores vs.(3.00 ± 0.48) scores] (P < 0.01).The scores of spasticity in BTXA treatment group after treatment of 2 weeks and 4 weeks were significantly lower than those in baclofen treatment group (P <0.05 or <0.01).After treatment of 4 weeks,the grades of spasticity between two groups had significant difference (P <0.05).The rate of adverse reaction in BTXA treatment group [15.15% (5/33)] was significantly lower than that in baclofen treatment group [51.52% (17/33)] (P < 0.01).Conclusions Local injection of BTXA and low dose oral baclofen in treatment of HFS can reach the obvious relief.But BTXA treatment has rapid onset,Iess adverse reaction and high compliance of the patients,and also symptoms improve more completely after BTXA treatment.BTXA can be used as preferred method of treating HFS.%目的 比较局部注射A型肉毒毒素(BTXA)与口服巴氯芬治疗偏侧面肌痉挛(HFS)的效果.方法 将2010年7月至2012年6月确诊HFS患者66例按随机数字表法分为BTXA治疗组和巴氯芬治疗组,对BTXA治疗组33例患者进行

  18. Effect of baclofen on analgesia in the rat with chronic neuropathic pain%Baclofen对慢性神经痛大鼠镇痛效果的影响

    Institute of Scientific and Technical Information of China (English)

    杜冬萍; 陈志峰; 徐惠芳

    2003-01-01

    目的研究GABAB受体激动剂baclofen对慢性神经痛大鼠痛阈的影响以及对脊髓c-fos表达的影响,探讨脊髓GABA能系统在神经痛调节中的可能机制.方法结扎大鼠左侧L5脊神经根建立慢性神经痛模型.SD大鼠24只随机等分成(1)假手术+baclofen组:大鼠背部假手术而未行神经根结扎,术后28至34 d每天腹腔注射baclofen 10 mg/kg两次;(2)假手术组:背部假手术后28至34 d每天腹腔注射0.9% NaCl 2 ml两次;(3)L5结扎+baclofen组:实施L5神经根结扎,术后28至34 d每天腹腔注射baclofen 10 mg/kg两次;(4)L5结扎组:实施L5神经根结扎,术后28至34 d每天腹腔注射0.9% NaCl 2 ml两次.术后1、3、7、10、14、21、28、35 d测大鼠双后肢光热刺激性痛阈.术后35 d处死大鼠取出腰段脊髓,冰冻切片,免疫组化法检测c-fos免疫阳性细胞.结果 (1)术后7~28d,左L5脊神经结扎大鼠较假手术大鼠痛阈明显降低(P0.05),双侧脊髓深层(Ⅲ-Ⅹ层)FLI细胞无显著差异(P>0.05);(2)术后35 d,使用baclofen的L5结扎大鼠的左后肢痛觉显著低于未使用baclofen的L5结扎大鼠(P<0.01),前者脊髓深层(Ⅲ-Ⅹ层)FLI细胞显著减少(P<0.01).结论大鼠慢性疼痛引起的FLI细胞在脊髓深层Ⅲ-Ⅹ层表达增多.baclofen可减轻慢性神经痛大鼠痛觉过敏,使神经损伤后双侧脊髓深层FLI细胞表达减少.

  19. The lesion of dorsolateral funiculus changes the antiallodynic effect of the intrathecal muscimol and baclofen in distinct phases of neuropathic pain induced by spinal nerve ligation in rats.

    Science.gov (United States)

    Dias, Quintino Moura; Prado, Wiliam A

    2016-06-01

    The abnormal firing of damaged primary afferents and the changes in the central nervous system (CNS) play important role in the initiation and maintenance phases of neuropathic pain. These phases of neuropathic pain involve changes in the GABAergic control of descending pathways that travel through the dorsolateral funiculus (DLF). The present study shows that unilateral DLF lesion increased the antiallodynic effect of muscimol (0.2μg/5μL) (a GABAA receptor agonist) in the initiation, but not maintenance phase of the mechanical allodynia induced by a spinal nerve ligation (SNL) of the ipsilateral hindpaw of rats. The unilateral DLF lesion increased the antiallodynic effect of baclofen (0.8μg/5μL) (a GABAB receptor agonist) in the initiation phase and reduced your effect in the maintenance phase of the mechanical allodynia induced by a spinal nerve ligation (SNL) of the ipsilateral paw of rats. The unilateral DLF lesion significantly reduced the proallodynic effect of an intrathecal injection of phaclofen (30μg/5μL) (a GABAB receptor antagonist), but not bicuculline (0.3μg/5μL) (a GABAA receptor antagonist). The effect of DLF lesion on the proallodynic effect of phaclofen was observed in the maintenance, but not in the initiation phase of the mechanical allodynia induced by SNL. We than conclude that the spinal GABAergic neurotransmission is negatively modulated by DLF using GABAA and GABAB receptors, in the initiation phase of mechanical allodynia induced by SNL. In addition, the integrity of DLF is necessary for the effectiveness of GABAergic transmission that occurs via spinal GABAB, but not GABAA receptors, in the maintenance phase of mechanical allodynia induced by SNL. PMID:27063286

  20. Leucocytopenia and remitten fever induced by baclofen in one patient%巴氯芬致驰张热合并白细胞减少1例

    Institute of Scientific and Technical Information of China (English)

    姜从玉; 胡永善; 李放

    2003-01-01

    @@ 巴氯芬(baclofen),其化学名:4-氨基-3-(4-氯苯基)-丁酸,商品名:力奥来素(Lioresal),是一类肌松药物,γ-氨基丁酸(GABA)受体激动剂[1,2].巴氯芬作用于脊髓后,由于其对GABA受体有较高的亲和力,能与之结合,从而产生抑制兴奋性氨基酸释放的作用,如天门冬氨酸、谷氨酸;抑制脊髓的单突触反射和多突触反射,从而缓解骨骼肌痉挛状态,使肌张力降低,改善肌肉的功能状态等作用[3,4].治疗开始时常出现日间镇静、嗜睡和恶心等中枢神经系统的不良反应,偶尔出现欣快、抑郁、感觉异常、肌痛、肌无力、共济失调、震颤、眼球震颤、调节紊乱、幻觉和恶梦等神经精神病学症状;偶有轻度的胃肠功能紊乱(便秘、腹泻);低血压、心功能降低;偶有或罕见排尿困难、尿频、遗尿;个别病例有视力障碍、味觉障碍、多汗、皮疹、肝功能损害[5,6].巴氯芬引起驰张热合并白细胞降低作者未见国内外文献报道.现遇见1例报道如下.

  1. 左归丸和巴氯芬联用对脑瘫鼠运动认知的影响%Effect of combined application of Zuoguiwan and Baclofen on motor and cognition of rats with cerebral palsy

    Institute of Scientific and Technical Information of China (English)

    李玲; 焦银香; 张菡; 李静; 李红霞

    2015-01-01

    Objective To investigate the effect of the combined application of Zuoguiwan and Baclofen on motor coordination ability and cognitive function of newborn rats with cerebral palsy ( CP) and to study its possible mechanism.Methods SD rats were randomly divided into sham-operated group, CP model without treatment group, CP model with Zuoguiwan group, CP model with Baclofen group, and CP model with Zuoguiwan combined with Baclofen group.Neurobehavioral indexes were detected in each group before treatment, 7, 14, 21 and 28 day treatment, and 7 day after treatment, respectively.TNF-αand NOS in serum, and MDA and SOD in brain tissue of rats were measured in each group 7 day after treatment.Results Compared with CP model without treatment group, muscle tension reduced significantly and the time of going through the balance reduced in Baclofen group and Zuoguiwan combined with Baclofen group after having taken the drugs for 14 days (t value was 4.603, 5.590, 6.337 and 5.575, respectively, all P0.05).Conclusion Compared with single drug therapy, combined application of Zuoguiwan and Baclofen can improve motor more obviously, and it may improve the cognition function of rats by protecting neurocyte and repairing neuron.%目的:探讨左归丸和巴氯芬联用对新生脑瘫大鼠运动协调能力和认知能力的影响,并研究其可能的机制。方法随机将SD大鼠分为假手术组、脑瘫( CP)模型未给药组、CP模型左归丸组、CP模型巴氯芬组以及CP模型左归丸+巴氯芬联用组。分别于药物处理前,处理7、14、21、28天及治疗结束后7天时分别测定各组大鼠神经行为学指标,治疗结束后7天后测定血清中肿瘤坏死因子( TNF-α),一氧化氮合酶( NOS)和脑组织中丙二醛( MDA)、超氧化物歧化酶( SOD)的变化。结果巴氯芬治疗组和联用组在服药14天后与同期CP模型未给药组比较肌张力显著降低(t值分别为4.603、5.590,均P<0

  2. 巴氯芬及β-环糊精的包结物与牛血清白蛋白的相互作用研究%Interaction of baclofen or its complex of β-cyclodextrin with bovine serum albumin

    Institute of Scientific and Technical Information of China (English)

    刘宇飞; 孙小梅; 王献; 李步海

    2011-01-01

    Objective : The inclusion interaction of β - cyclodextrin and baclofen, and the interactions of bovine ser um albumin and baclofen or complex were investigated. Methods : The inclusion interaction of β - cyclodextrin and baclofen was studied by UV spectra and H1NMR. The stoichiometry ratio for the formation of the inclusion comple xes was determined by molar ratio method. The constants of baclofen and β - cyclodextrin at different temperatures were estimated according to the formula. The interactions of bovine serum albumin and baclofen or complex have been studied by fluorescence spectroscopy. Results :The result showed that the inclusion process was spontaneous, the hydrophobic force was main binding force of β - cyclodextrin inclusion complex; Both baclofen and complex could quench the fluorescence of bovine serum albumin. Conclusion : The stoichiometry ratio for the formation of the inclusion complexes is 1∶1. The hydrophobic force of baclofen alone and bovine serum albumin is mainly interaction force, and the electrostatic force of inclusion compond and bovine serum albumin is mainly interaction force , for the reason that baclofen is included by the β - cyclodextrin.%目的:研究巴氯芬及β-环糊精的包结作用和巴氯芬及β-环糊精包结物与牛血清白蛋白的相互作用.方法:用紫外可见分光光度法与核磁共振法研究了β-环糊精对巴氯芬的包结行为;用摩尔比法确定了包结物的化学计量比;用公式计算了不同温度下巴氯芬与β-环糊精的包结常数;用荧光光谱法研究了巴氯芬与包结物对牛血清白蛋白牛血清白蛋白的相互作用.结果:巴氯芬与β-环糊精的包结过程是自发的,主要驱动力为疏水作用力;巴氯芬及包结物都会对牛血清白蛋白产生静态猝灭.结论:巴氯芬与β-环糊精的包结比为1:1;巴氯芬与牛血清白蛋白的主要作用为疏水作用,而包结物与牛血清白蛋白主要为静电作用,这是由于β-

  3. 卡马西平联合巴氯芬治疗三叉神经痛的临床分析%Clinical analysis of carbamazepine combined with baclofen treating trigeminal neuralgia

    Institute of Scientific and Technical Information of China (English)

    程福璋

    2015-01-01

    Objective To explore the clinical effect of carbamazepine combined with baclofen treating trigeminal neu-ralgia. Methods 82 patients with trigeminal neuralgia meeting clinical diagnostic criteria and received in our hospital from February 2013 to February 2015 were selected as study object.Patients were divided into control group and treat-ment group by random number table method,and each group was 41 cases.Patients in control group were treated simply with carbamazepine,while patients in treatment group were given carbamazepine combined with baclofen.Disappear time of trigeminal neuralgia symptom,the total time of medicine treatment plan implement,treatment effect and incidence rate of adverse reaction and so on in patients between two groups was compared respectively. Results The disappear time of trigeminal neuralgia symptom and the total time of medicine treatment plan implement in treatment group [(7.32±1.08) d and (10.75±1.68) d] was obviously shorter than that of control group [(10.68±2.15) d and (14.79±2.53) d] respectively (P<0.05).The total effective rate in treatment group (90.3%) was obviously higher than that of control group (68.3%) (P<0.05).The incidence rate of adverse reaction in treatment group (2.4%) obviously lower than that of control group (17.1%) (P<0.05). Conclusion The clinical effect is very obvious by using carbamazepine combined with baclofen treat-ing trigeminal neuralgia.%目的:探讨卡马西平联合巴氯芬治疗三叉神经痛的临床效果。方法选择2013年2月~2015年2月我院收治的符合临床诊断标准的三叉神经痛患者82例作为研究对象,采取随机数字表法将其分成对照组和治疗组,每组41例。对照组患者给予单纯卡马西平治疗;治疗组患者给予卡马西平联合巴氯芬治疗。比较两组患者的三叉神经痛症状消失时间和用药治疗计划实施总时间、治疗效果、不良反应发生率等。结果治疗组患者的三

  4. 胶束电动色谱-激光诱导荧光检测法测定肌松弛药巴氯芬%Determination of baclofen using micellar electrokinetic chromatography with laser induced fluorescence detection

    Institute of Scientific and Technical Information of China (English)

    王宇飞; 杨甲甲; 蔡元丽; 林夏; 李晖

    2011-01-01

    A novel micellar electrokinetic chromatographic method with laser induced fluorescence detection after derivatization with 4-chloro-7-nitrobenzo-2-oxa-l ,3-diazole( NBD-C1) was developed for the determination of muscle relaxant drug baclofen ( BAL). After optimization, baseline separation of the derivatives of BAL and gabapentin (internal standard) was obtained within 7 min in a running buffer (pH 9. 75) composed of 15 mmol/L sodium borate, 20 mmol/L sodium dodecyl sulfate and 10% (v/v) acetonitrile. The separation voltage was 17. 5 kV. The column temperature was 25 ℃. The samples were injected by a pressure of 3. 45 kPa(0. 5 psi) for 3 s. The method has a linear range of 0. 025 - 25 mg/L for BAL with the correlation coefficient of 0. 999 9. The limit of detection ( LOD, S/N = 3) and the limit of quantification (LOQ, S/Af = 10) were 0.90 |xg/L and 6.25 μg/L, respectively. The developed method was used for the analysis of BAL pharmaceutical preparation and urine samples spiked with BAL standard. The ranges of recovery were 101. 6% - 107. 9% for BAL preparation and 107. 0% - 109. 6% for urine samples. This method can be applied to the quality assessment of baclofen drug products, and provide supplementary means for the drug metabolism research of baclofen.%以4-氯-7-硝基苯并-2-氧杂-1,3-二唑(NBD-CIl)为柱前衍生试剂,建立了胶束电动色谱-激光诱导荧光检测法测定肌松弛药巴氯芬( BAL)的新方法.经过实验条件的优化,采用15 mmol/L硼砂、20 mmol/L十二烷基硫酸钠、10%(v/v)乙腈、pH 9.75的缓冲体系,在分离电压为17.5 kV、柱温为25℃的条件下,压力进样3.45 kPa(0.5 psi)×3s,巴氯芬及其内标物的衍生产物在7 min内实现较好的基线分离,线性范围为0.025 ~25 mg/L,相关系数为0 999 9,检出限(S/N=3)和定量限(S/N=10)分别为0.90 μg/L和6.25 μg/L.该方法被应用于巴氯芬制剂及加入巴氯芬对照品的尿液样品分析,回收率范围分别为101.6%~107.9

  5. 毛细管电泳分离-激光诱导荧光检测血清中的巴氯芬%Detection of Baclofen in Serum by Capillary Electrophoresis-Laser Induced Fluorescence Method

    Institute of Scientific and Technical Information of China (English)

    曹丽伟; 胡杨

    2011-01-01

    首次将新合成的柱前衍生试剂6-氧-(N-琥珀酰亚胺乙酸酯)-9-(2′-甲氧羰基)荧光素(SAMF)用于巴氯芬(Baclofen)的衍生标记,并采用毛细管电泳分离-激光诱导荧光(CE-LIF)法分离检测衍生物.研究表明,在磷酸盐缓冲溶液(pH=7.5)介质中,30℃下10min即可完成衍生反应.反应物在pH 5.6,35mmol·L-1的磷酸盐缓冲溶液中12min内达到分离,检出限为6×10-10mol·L-1.本法用于血清中巴氯芬的分析测定,回收率为95.8%-101.0%.

  6. The influence of GABAB receptor expression in the spinal dorsal horn of rats by using baclofen in combination with morphine%巴氯芬与吗啡联合应用对脊髓背角GABAB受体表达的影响

    Institute of Scientific and Technical Information of China (English)

    单文燕; 陈艳平; 曹德权

    2012-01-01

    目的 探讨巴氯芬与吗啡联合应用对脊髓背角GABAB受体表达的影响.方法 成年雄性SD大鼠48只鞘内置管成功后,随机均分为四组,分别鞘内注射生理盐水10μl(NS组),吗啡10μg(M组),巴氯芬0.5μg(B组)和巴氯芬0.5μg+吗啡10 μg(BM组).每天9:00和16:00鞘内注射,在9:30行热水浴甩尾潜伏期(TFL)测定,连测3次,间隔5 min,取其均值,将第1天注药后的TFL均值作为基础值,以TFL恢复到基础值作为出现吗啡耐受的标准.第11天晨,取大鼠腰段脊髓行免疫组织化学染色观察脊髓背角GABAB受体的表达.结果 注药后第10天M组大鼠TFL恢复至基础值,出现吗啡耐受现象,B组和BM组未出现吗啡耐受现象(P<0.01).M组GABABR1及GABABR2表达明显低于其它三组(P<0.01).结论 巴氯芬与吗啡联合应用可以减轻吗啡对脊髓背角GABAB受体表达的下调作用.%Objective To investigate the effects of GABAB receptor expression in the spinal dorsal horn of rats by using baclofen in combination with morphine. Methods Healthy male SD rats were randomly divided into four groups after the success of intrathecal cathetemation (n=12). They included saline group(group NS): 0. 9% saline 10 /μ∣, morphine group(group M). morphine 10 figs baclofen group(group B): baclofen 0. 5 μg, baclofen-morphine group (group BM): baclofen 0. 5 μg +morphine 10 μg. Drugs were given by intrathecal injection on 9:00 am and 16:00 pm for 10 consecutive days. At 9:30 the tail-flick latency (TFL) in rats were measured continued 3 limes with an interval of 5 mm. The mean value of TFL measured on the first day were considered as the baseline, and the return to baseline level of TFL were regarded as the morphine tolerance standard. In the morning of the eleventh day, spinal lumbar enlargement of rats were removed and cut into frozen sections to test GABAB receptors expression by immunohistochemical staining. Results TFL of rats returned to baseline in group M after 10 days

  7. The effect of baclofen on spontaneous and evoked behavioural expression of experimental neuropathic chronic pain Efeito do baclofeno sobre a expressão comportamental espontânea e evocada da dor crônica neuropática experimental

    Directory of Open Access Journals (Sweden)

    TEREZINHA DE JESUS T. SANTOS

    1999-09-01

    Full Text Available Baclofen (beta-p-chlorophenyl-GABA has been used in humans to treat spasticity, as well as trigeminal neuralgia. Since GABA (gamma-aminobutyric acid has been implicated in inhibitory and analgesic effects in the nervous system, it was of interest to study the effect of baclofen in experimental neuropathic pain. With this purpose, experiments were carried out in 17 neuropathic rats with constrictive sciatic injury, as described by Bennet and Xie (1988, taking as pain parameters scratching behaviour and the latency to the thermal nociceptive stimulus. The results showed that baclofen induces, in a dose-dependent manner, significant decrease (p O baclofeno (beta-p-clorofenil-GABA é usado em seres humanos para tratar espasticidade, assim como neuralgia do trigêmeo. Como o GABA (ácido amino-gama-butírico tem sido implicado em efeitos inibitórios e analgésicos no sistema nervoso, tornou-se de interesse estudar o efeito do baclofeno em dor neuropática experimental. Com esse objetivo, foram realizados experimentos em 17 ratos neuropáticos com lesão constritiva do nervo ciático, como descrito por Bennet e Xie (1988, tomando como parâmetros de dor o comportamento de coçar-se (scratching e a latência ao estímulo térmico nociceptivo. Os resultados mostraram que o baclofeno induziu, de forma dose-dependente, diminuição significativa (p < 0,05 do comportamento de coçar-se e aumento significativo (p < 0,05 da latência ao estímulo térmico nociceptivo. A ausência de antagonismo pela naloxona sugere a não participação de mecanismo opióide-mediado nesse efeito analgésico do baclofeno em dor neuropática experimental.

  8. 巴氯酚并康复训练对脑卒中患者痉挛性偏瘫的治疗效应%Efficacy of baclofen combined with rehabilitation training in stroke patients with spastic hemiplegia

    Institute of Scientific and Technical Information of China (English)

    姚金荣; 王东生; 倪新宝; 戎黛敏; 郑惠民

    2004-01-01

    目的:观察巴氯酚(Baclofen)结合康复治疗对脑卒中痉挛性偏瘫患者关节活动度、运动功能和ADL等方面的影响.方法:对144.例脑卒中痉挛性偏瘫患者,随机分为治疗组和对照组.治疗组84例,服用巴氯酚结合康复治疗;对照组60例,只接受康复治疗.在治疗前和治疗后12周分别进行Ashworth,FMA和MBI量表评定以观察疗效.结果:治疗后Ashworth评定治疗组显效率为67.86%(上肢),63.60%(下肢),有效率为86.90%(上肢),89.29%(下肢);对照组显效率为41.60%(上肢),45.00%(下肢),有效率为76.67%(上肢),78.33%(下肢).两组患者关节活动度、运动功能和生活能力均有明显改善(P<0.01),但治疗组明显优于对照组(P<0.05).结论:巴氯酚结合康复治疗能明显改善脑卒中偏瘫肢体的痉挛状态,提高患者的关节活动度、运动功能和生活能力.

  9. 氯苯氨丁酸抑制脊髓背角神经元谷氨酸量子释放的机制%Mechanism for baclofen inhibition on quantal glutamate release in spinal dorsal horn neurons

    Institute of Scientific and Technical Information of China (English)

    马红雨; 杨鲲

    2004-01-01

    目的研究GABAB受体特异性激动剂氯苯氨丁酸(baclofen)在脊髓背角神经元抑制谷氨酸量子释放的机制.方法在脊髓薄片标本上,采用全细胞电压钳法记录脊髓背角神经元谷氨酸能的微兴奋性突触后电流(miniature excitatory postsynaptic currents;mEPSCs),通过分析这些电流的变化来研究baclofen影响谷氨酸量子释放的机制.结果 baclofen抑制mEPSCs的发放频率,但对平均幅度无明显影响,表明baclofen抑制谷氨酸释放的作用部位在突触前.在无钙溶液或者K+通道阻滞剂4-AP存在的条件下,baclofen对mEPSCs发放频率的抑制作用不受影响,但腺苷酸环化酶激动剂foskolin (可使cAMP保持在较高水平)能降低其抑制作用.而蛋白激酶C (PKC)激动剂PDBu对baclofen的抑制作用无影响.用NEM破坏G蛋白,则可取消baclofen的抑制效果.结论 baclofen不是通过影响突触前Ca2+通道或K+通道,或PKC途径,而是通过作用于G蛋白和(或)cAMP途径抑制谷氨酸的释放;这种抑制作用可能参与baclofen在脊髓水平的镇痛.

  10. 巴氯芬治疗儿童难治性胃食管反流性咳嗽40例临床评价%Baclofen for Treating Children with Refractory Gastroesophageal Reflux Induced Cough in 40 Cases

    Institute of Scientific and Technical Information of China (English)

    黄静; 吴绍英

    2015-01-01

    Objective To observe the clinical effect and safety of baclofen for treating children with refractory gastroesoPhageal reflux in-duced cough. Methods 80 cases of refractory gastroesoPhageal reflux induced cough in the hosPital were randomly selected and divided into the observation grouP and the control grouP,40 cases in each grouP. Both grouPs were guided to adjust the way of life. The control grouP was treated with DomPeridone Tablets [ 0. 3 mg/ ( kg · time ) ,3 times/d ] ,OmePrazole Magnesium Enteric-Coated Tablets (20 mg/time,1 time/d). The observation grouP received baclofen tablets[0. 25 mg/ (kg·time),4 times/d] on the basis of the control grouP. The two grouPs were treated for 8 weeks. Observe and record the changes of cough,acid regurgitation,retrosternal burning sen-sation,and belching and other clinical symPtoms in the Patients during the treatment,and evaluate the scores of the clinical symPtom severity and symPtom frequency before treatment and after treatment. Observe the Patients before and after treatment. The changes of blood routine,liver and kidney function and adverse reaction were recorded before and after treatment. Results After treatment,the clin-ical efficacy of the observation grouP was 92. 50%,which was significantly higher than 67. 50% of the control grouP,the difference was statistically significant ( P < 0. 05 ) . ComPared with before treatment,the symPtom score and total score of symPtoms in the two grouPs were decreased,the difference is statistically significant ( P < 0. 05 ) and the observation grouP decreased more significantly,with signifi-cant difference ( P < 0. 05 ) . The incidence rate of adverse reactions in the observation grouP was 22. 50% which was obviously higher than 7. 50% in the control grouP ( P < 0. 05 ) ,and the adverse reactions were tolerable. The two grouPs before and after medication in children,the changes of blood routine,liver and kidney function changes were not found in the two grouPs. Conclusion

  11. Inhibitory Effect of Baclofen on GABA-and NMDA-Activated Currents in Neurons Freshly Dissociated from Rat Dorsal Root Ganglion%Baclofen对大鼠新鲜分离DRG神经元GABA和NMDA激活电流的抑制作用

    Institute of Scientific and Technical Information of China (English)

    赵义梅; 木拉提; 王英姿; 呼海燕; 司军强

    2002-01-01

    用全细胞膜片箝技术在大鼠新鲜分离的背根神经节(DRG)细胞上观察到baclofen对GABA和NMDA激活电流有调制作用.单独给予DRG细胞baclofen (1~100 μmol/L)未记录到可测的电流改变,但预加baclofen 对GABA和NMDA激活电流具有明显的抑制作用,且呈剂量依赖性.100 μmol/L baclofen对GABA和NMDA激活电流分别抑制(51.2±10.9)%(X±SE,n=8,P<0.01)和(64.1±21.1)%(X±SE,n=6,P<0.01),此抑制作用是可逆的,可被GABAB受体拮抗剂saclofen(100 μmol/L )所取消(n=4).

  12. 鞘内注射巴氯酚对神经病理性痛大鼠的镇痛作用及其对脊髓GABA转运体-1的影响%Effects of intrathecal injection of GABAB receptor agonist baclofen on hyperalgesia and spinal GAT-1 of neuropathic rats

    Institute of Scientific and Technical Information of China (English)

    朱珊珊; 谭珊珊; 曾因明

    2011-01-01

    目的 研究鞘内注射GABAB受体激动剂巴氯酚(baclofen,Bac)对神经病理性痛大鼠的镇痛作用及其对脊髓GABA转运体-1的影响.方法 建立坐骨神经结扎致神经病理性痛大鼠模型.在行为学实验部分,将32只大鼠随机分为NS组、Bac1组、Bac2组、Bac3组(n=8),分别鞘内注射生理盐水、0.1、0.3、1.0 μg巴氯酚10 μl,并分别于给药前、给药后0.5、1、2、4、8、12、24 h测定大鼠机械缩足反射阈值(mechanical withdrawl threshold,MWT)和热缩足反射潜伏期(thermal withdrawl latency,TWL)以及运动功能.在第2部分,将大鼠分为 NS组与Bac组,鞘内分别给予0.3 μg巴氯酚或生理盐水,分别于给药前、给药后1、4、8 h取大鼠脊髓腰段,免疫组织化学检测脊髓节段GAT-1免疫阳性神经元(n=6);分别于给药前、给药后30 min、1、2、4、8、12和24 h取大鼠脊髓腰段,用Western blot方法测定脊髓节段GAT-1蛋白含量(n=4).结果 鞘内注射巴氯酚后0.5~2 h,Bac1组、Bac2组与Bac3组大鼠MWT和TWL均较NS组明显升高(P0.05).结论 鞘内注射GABAB受体激动剂巴氯酚可减轻坐骨神经结扎致神经病理性痛大鼠的痛觉过敏,其镇痛作用可能与抑制脊髓水平GAT-1的表达有关.%Aim To explore the effects of intrathecal injection of GABAB receptor agonist baclofen on hyperalgesia and spinal GAT-I of neuropathic rats induced by chronic constriction of sciatic nerve. Methods The left common sciatic nerve of anesthetized rats was tied loosely to establish the chronic constriction injury CCI ) model. For the behavioral experiments, 32 rats exhibiting neuropathic pain after nerve ligation were divided into 4 groups ( n =8 ): NS group, Bacl group,Bac2 group and Bac3 group, which were intrathecally injected with normal saline, 0. 1 . 0. 3 and 1. 0 μg baclofen respectively. MWT ( mechanical withdrawl threshold )and TWL( thermal withdrawl latency ) were recorded before drug administration, 0. 5 . 1, 2. 4, 8,12 h

  13. Baclofen for narcolepsy with cataplexy: two cases

    OpenAIRE

    Lee EK; Douglass AB

    2015-01-01

    Elliott Kyung Lee,1,2 Alan Bruce Douglass1,2 1Department of Psychiatry, Faculty of Medicine, Institute of Mental Health Research, University of Ottawa, 2Royal Ottawa Mental Health Center, Ottawa, ON, Canada Abstract: Narcolepsy is a disabling sleep disorder characterized by daytime hypersomnolence. Those with cataplexy have spells of muscle weakness precipitated by strong emotions, especially laughter or surprise. Cataplexy treatments include antidepressants or a GABA-B agonist, gamma hydrox...

  14. 联合应用巴氯芬、埃索美拉唑和莫沙必利治疗难治性胃食管反流病的疗效%Efficacy of Baclofen Combined with Esomeprazole and Mosapride on Refractory Gastroesophageal Reflux Disease

    Institute of Scientific and Technical Information of China (English)

    吴登峰; 黄中华; 陈思杰

    2014-01-01

    背景:对常规剂量质子泵抑制剂治疗无反应的胃食管反流病( GERD)称为难治性胃食管反流病( rGERD),国内主要联合多种药物治疗rGERD患者,但巴氯芬的报道较少见。目的:探讨巴氯芬联合埃索美拉唑和莫沙必利治疗rGERD的疗效。方法:纳入2013年3月-2014年4月福建省莆田市第一医院72例rGERD患者,随机分为两组。A组患者口服埃索美拉唑20 mg bid +莫沙必利5 mg tid +巴氯芬5 mg tid;B组口服埃索美拉唑20 mg bid +莫沙必利5 mg tid,疗程均为8周。比较两组症状、内镜下食管炎改善情况和不良反应。结果:治疗8周后,两组烧心、反酸、胸骨后疼痛、吞咽困难、症状总计分均较治疗前显著降低( P﹤0.05),A组症状改善总有效率显著高于 B组(90.6%对70.0%;χ2=4.585,P=0.032)。两组内镜下食管炎分级情况明显改善,A组内镜下治疗有效率显著高于B组(93.8%对75.0%;χ2=4.500,P=0.034)。巴氯芬的主要不良反应为嗜睡、头晕和乏力,患者均能耐受。结论:巴氯芬联合埃索美拉唑和莫沙必利是一种有效治疗rGERD的方法。%Background:Gastroesophageal reflux disease( GERD)that does not respond satisfactorily to standard proton pump inhibitor is defined as refractory gastroesophageal reflux disease( rGERD). Combined therapy is used to treat rGERD, however,the addition of baclofen is rarely studied. Aims:To investigate the efficacy of baclofen combined with esomeprazole and mosapride on rGERD. Methods:Seventy-two patients with rGERD from March 2013 to April 2014 at the First Hospital of Putian City were enrolled and randomly divided into group A and group B. Patients in group A were orally administrated with esomeprazole 20 mg bid + mosapride 5 mg tid + baclofen 5 mg tid. Patients in group B were treated with esomeprazole 20 mg bid + mosapride 5 mg tid. The treatment course was 8 weeks. The efficacy on symptoms, esophagitis

  15. Biocatalytic desymmetric hydrolysis of 3-(4-chlorophenyl)-glutaronitrile to the key precursor of optically pure baclofen%生物催化3-(4-氯苯基)-戊二腈去对称性水解合成光学纯巴氯芬的关键前体

    Institute of Scientific and Technical Information of China (English)

    徐美珍; 任杰; 龚劲松; 董文玥; 吴洽庆; 许正宏; 朱敦明

    2013-01-01

    研究了利用生物催化剂制备(S)-4-氰基-3-(4-氯苯基)-丁酸.以3-(4-氯苯基)-戊二腈为底物,采用苯酚-次氯酸钠法对实验室保藏的菌株进行筛选,得到一株产物立体选择性较高的菌株赤霉菌Gibberella intermedia WX12,并对其催化特性和发酵条件进行了初步研究.以30 g/L的乳糖和20 g/L的蛋白胨分别为碳、氮源,发酵培养96 h,收集的菌体在50 mmol/L磷酸缓冲液(pH 8.0)中30℃催化反应24 h,将3-(4-氯苯基)-戊二腈转化为4-氰基-3-(4-氯苯基)-丁酸,产率为90%.将产物化学转化为巴氯芬,手性HPLC分析表明水解产物构型是(S),其对映异构体过量值ee> 99%.该产物可以用来合成光学纯的(R)-和(S)-巴氯芬.%We produced (S)-4-cyano-3-(4-chlorophenyl)-butyrate by highly stereoselective biocatalyst in this study. A nitrilase-producing strain, named Gibberella intermedia WX12, was isolated by 3-(4-chlorophenyl)-glutaronitrile as substrate in the screening with phenol-sodium hypochlorite method. The fermentation conditions and catalytic properties of this strain were investigated. The preferred carbon and nitrogen sources for nitrilase production were lactose (30 g/L) and peptone (20 g/L). After being cultivated for 96 h, the cells were collected for use in biotransformation. The hydrolysis of 3-(4-chlorophenyl)-glutaronitrile was performed at 30 ℃ in phosphate buffer (pH 8.0, 50 mmol/L) for 24 h to give (S)-4-cyano-3-(4-chlorophenyl)-butyric acid with 90% yield and >99% of ee, which can be used for the synthesis of (R)-and (S)-baclofen. The configuration of product was determined by chemically converting it to baclofen and comparison with the authentic sample by chiral HPLC analysis.

  16. Effect of diabetes on baclofen-induced inhibition of mEPSCs in spinal glutamatergic neurons in rats with neuropathic pain%糖尿病因素对巴氯芬抑制神经痛大鼠脊髓谷氨酸能神经元突触后电流的影响

    Institute of Scientific and Technical Information of China (English)

    白惠萍; 彭云水; 王倩; 吴川; 刘飞飞; 刘朋; 郭跃先; 王秀丽

    2014-01-01

    Objective To evaluate the effect of diabetes on baclofen-induced inhibition of miniature excitatory postsynaptic currents (mEPSCs) in spinal glutamatergic neurons in rats with neuropathic pain.Methods Thirty male Sprague-Dawley rats,aged 4 weeks,weighing 150-170 g,were randomly divided into 2 groups (n=15 each group):control group (C group) and diabetic neuropathic pain group (D group).Diabetic neuropathic pain was induced by intraperitoneal injection of streptozotocin 50 mg/kg and confirmed 28 days later by blood glucose > 16.7 mmol/L and pain threshold < 4 g in group D,while the rats received the equal volume of normal saline in C group.The animals were anesthetized with intraperitoneal 10% chloral hydrate 50 mg/kg.The rats were then sacrificed and lumbar segments (L1.5) of the spinal cord were removed for slice preparations.Glutamatergic mEPSCs in lamina Ⅱ neurons were recorded by using whole-cell patch-clamp technique and 20 neurons located in lamina Ⅱ of the spinal cord were recorded in each group.The cells stabilized for 30 min after sealing,and then baclofen with the final concentrations of 1,10,20,50 μmol/L was added to the perfusion solution at 5 min intervals followed by washout.The frequency and intensity of glutamatergic mEPSCs were recorded immediately before and after administration and at 5 min after washout.The inhibitory effect of baclofen on glutamatergic mEPSCs was measured and the inhibitory rate was calculated.Results Compared with group C,the frequency of glutamatergic mEPSCs was significantly increased and the inhibitory rate was decreased under each concentration (P < 0.05),and no significant change was found in the intensity of mEPSCs under each concentration in D group (P > 0.05).Conclusion Diabetes decreases baclofen-induced analgesic effect in rats with neuropathic pain,which is related to inhibition of mEPSCs in spinal glutamatergic neurons.%目的 评价糖尿病因素对巴氯芬抑制神经痛大鼠脊髓谷氨酸

  17. The intervention effect of rectal administration of Baclofen combined with comprehensive rehabilitation on the spastic state in the recovery period of stroke%巴氯酚直肠给药配合综合康复对脑卒中恢复期偏瘫痉挛状态的干预效应

    Institute of Scientific and Technical Information of China (English)

    杨贵青

    2012-01-01

    Objective To explore more effective ways to improve hemiplegia spasticity of stroke in the recovery period. Methods 100 subjects were given Baclofen rectal administration (retention enema) + comprehensive rehabilitation measures in the treatment of muscle spasticity on the basis of the implementation of the conventional treatment of neurology and stable conditions and physical signs. The dose was once 15 mg in the first day, then with an increase of 5-10 mg per day, the enema of 14 d was a course of treatment, for three courses. The comprehensive rehabilitation measures included good limb placed to maintain joint mobility, ease of body movement to control the static stretch around the cramps, muscle spasms, passive movement and massage. The effects were evaluated before treatment and after treatment of 32 d. Results 32 d after treatment compared with before treatment, the patient's muscle tone to improve the situation had a significant difference (P < 0.01). Muscle tone after treatment showed significant improvement, and gradually returned to normal; the results of the ADL score also had a significant difference (P < 0.01), and prompt patients after treatment of 32 d, the activities of daily living improved significantly. Conclusion Rectal administration of Baclofen with comprehensive rehabilitation training is helpful for the neurological rehabilitation of stroke patients and can improve the prognosis of stroke patients with hemiplegia spasm.%目的 探讨改善脑卒中恢复期偏瘫痉挛状态更为有效的方法.方法 100例研究对象在实施神经内科常规治疗以及病情和生命体征稳定的情况下,采用巴氯酚直肠给药(即保留灌肠)+综合康复措施治疗肌痉挛状态.用药第1天剂量为15 mg/次,然后每天增加5~10 mg,灌肠14 d为1个疗程,连续治疗3个疗程.综合康复措施具体内容包括良肢位的摆放、保持关节的活动度、缓解身体运动控制点周围痉挛、肌肉痉挛的静态牵拉、

  18. INHIBITORY EFFECT OF BACLOFEN ON GABA-ACTIVATED CURRENT IN MECHANICALLY ISOLATED PYRAMIDAL CELLS OF RAT HIPPOCAMPUS%Baclofen对机械分离的大鼠海马锥体细胞GABA-激活电流的抑制作用

    Institute of Scientific and Technical Information of China (English)

    甘志强; 罗加烈; 郑少萍; 李之望

    2004-01-01

    在机械分离的海马锥体细胞上,应用全细胞膜片钳技术.证明大多数细胞(88.5%,46/52)对GABA敏感.10-5~10-3mol/L的GABA引起一剂量依赖性、有明显去敏感作用的内向电流.预加3×10-5 mol/L baclofen(GABAB受体的特异性激动剂)30 s后再加GABA,84.8%(39/46)的细胞GABA-激活电流被抑制,其中仅有一个细胞(2.2%,1/46)GABA-激活电流幅值增强,13%(6/46)的细胞GABA-激活电流幅值无变化.预加baclofen后,GABA-激活电流量-效曲线明显下移.预加baclofen前后IGABA量效曲线的Kd值非常接近(1.0X10-4 vs1.4×10-4mol/L).经saclofen预处理可消除baclofen对GABA-激活电流的抑制.这与我室以往在外周神经元上的研究结果一致.本文结果不仅证明了GABAA和GABAB受体在海马锥体细胞上的共存,而且也证明了GABAB受体激活后对GABAA受体功能抑制这一现象无论在外周或中枢神经系统均具有普遍性.

  19. Effect of intrathecal baclofen on excitatory amino acids in spinal cords of acute pain rat model%鞘内注射巴氯芬对急性切口痛大鼠脊髓兴奋性氨基酸含量的影响

    Institute of Scientific and Technical Information of China (English)

    杜冬萍; 徐永明; 江伟

    2007-01-01

    目的 研究急性疼痛时脊髓内兴奋性氨基酸含量的变化、γ-氨基丁酸B受体(GABAB受体)激动剂巴氯芬(baclofen)的镇痛作用及其与脊髓兴奋性氨基酸含量变化的关系.方法 SD大鼠鞘内置管后行左后爪足底切口建立急性切口痛大鼠模型,随即分为假手术组、0.9%氯化钠溶液组、1μ巴氯芬组(鞘内注射巴氯芬1μg)和5μg巴氯芬组(鞘内注射巴氯芬5μg),每组25只.观察大鼠左后爪机械痛阈,并于术后1、2、6、12、24 h分离大鼠腰膨大部脊髓节段,检测其中兴奋性氨基酸的含量.结果 所有手术组的痛阈均明显低于假手术组(P值均<0.05),脊髓兴奋性氨基酸含量明显增加(P值均<0.05).鞘内注射巴氯芬后3 h内可以部分提高大鼠的痛阈(P值均<0.05),且鞘内注射5μg巴氯芬较1μg后3 h内大鼠的痛阈明显提高(P值均<0.05).鞘内注射1或5μg巴氯芬大鼠脊髓兴奋性氨基酸含量较使用0.9%氯化钠溶液大鼠明显下降(P值均<0.05).结论 大鼠脚爪切口痛模型可以引起大鼠局部痛阈降低,脊髓兴奋性氨基酸含量提高.鞘内注射巴氯芬可以提高切口痛大鼠的局部痛阈,并且抑制脊髓兴奋性氨基酸的升高.

  20. Bruxism Associated with Anoxic Encephalopathy: Successful Treatment with Baclofen

    OpenAIRE

    Bruce Janati, A; Naif Saad ALGhasab; Fahad Saad ALGhassab

    2013-01-01

    Introduction. Bruxism is a movement disorder characterized by grinding and clenching of the teeth. Etiology of bruxism can be divided into three groups: psychosocial factors, peripheral factors, and pathophysiological factors. Methods. The clinical investigation was conducted at King Khaled Hospital in Hail, Saudi Arabia, in 2012. Results. A 16-year-old Saudi female was brought to the hospital in a comatose state and with generalized convulsive seizures secondary to acute anoxic encephalopath...

  1. New Technical Synthesis of(R)-Baclofen%(R)-巴氯芬的合成研究

    Institute of Scientific and Technical Information of China (English)

    陈云华; 毛侦军; 杨伟强; 林旭锋

    2008-01-01

    从对氯苯乙酮出发,经过Wittig-Homer、溴代、酞酰亚胺化、不对称还原和酸解反应五步合成了(R)-巴氯芬,总收率达到了62%.目标产物的结构经过核磁和质谱的确证.

  2. Baclofen for intractable hiccup%巴氯芬治疗顽固性呃逆

    Institute of Scientific and Technical Information of China (English)

    陈协辉; 吴贤仁

    2001-01-01

    目的:观察巴氯芬对顽固性呃逆的疗效.方法:80例顽固性呃逆病人分为2组,其中治疗组42例(男性28例,女性14例,年龄48 a±s 8 a)采用巴氯芬治疗.最小剂量是10 mg,bid.最大剂量为15 mg,tid.小剂量开始,逐步递增.疗程4 d.38例对照组(男性24例,女性14例,年龄44 a±11 a)采用氯丙嗪、苯妥英、硝苯地平、东莨菪碱等常规治疗.结果:治疗组总有效率98 %,对照组总有效率58 %(P<0.05),治疗组服药d 1起效率86 %,对照组服药d 1起效率21 %(P<0.01),治疗组疗程明显缩短(P<0.01),不良反应少.结论:巴氯芬是治疗顽固性呃逆较为有效的药物.

  3. 不对称氢转移合成R-(-)-Baclofen

    Institute of Scientific and Technical Information of China (English)

    许波洪; 张跃

    2010-01-01

    以外消旋的β-羟基酮酸酯为原料,通过不对称氢转移的方法,高效的合成了光学活性的手性中间体β-羟基酮酸酯,光学纯度达到98%,然后通过亲核取代反应生成了光学活性的β-氰基丙酮酸酯,最后还原生成R-(-)-Baclofen。

  4. 盐酸巴氯芬的合成%Synthesis of Baclofen Hydrochloride

    Institute of Scientific and Technical Information of China (English)

    江淼; 谌志华; 邹志芹; 马红梅; 虞心红

    2010-01-01

    对氯苯甲醛和丙二酸经Knoevenagel-Doebner反应、硫酸氢钾催化下酯化得到3-(4-氯苯基)丙烯酸甲酯,再经Michael加成、水解、催化氢化及成盐制得解痉药盐酸巴氯芬,总收率约52%.

  5. Anticonvulsant action of GABA-B receptor agonist SKF97541 Differs from that of Baclofen

    Czech Academy of Sciences Publication Activity Database

    Mareš, Pavel

    2008-01-01

    Roč. 57, č. 5 (2008), s. 789-792. ISSN 0862-8408 R&D Projects: GA ČR(CZ) GA305/05/2581 Institutional research plan: CEZ:AV0Z50110509 Keywords : PTZ seizures * GABA -B * ontogeny Subject RIV: FH - Neurology Impact factor: 1.653, year: 2008

  6. Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

    Science.gov (United States)

    2015-07-03

    Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neurotoxicity; Pain; Unspecified Adult Solid Tumor, Protocol Specific

  7. 脊舒治疗顽固性呃逆40例%Baclofen Treating 40 Cases of Refractory Hiccup

    Institute of Scientific and Technical Information of China (English)

    毛志光

    2002-01-01

    脊舒治疗顽固性呃逆病人62例,治疗组40例,用脊舒10mg,bid,po.对照组22例,用苯妥英钠0.1,tid,po,胃复安10mg,tid,po,加两侧足三里穴位封闭.结果治疗组总有效率97.5%,对照组总有效率59.1%(P<0.01),两组疗效有非常显著差异.

  8. Analysis of Baclofen by HPLC%巴氯酚的高效液相色谱分析方法

    Institute of Scientific and Technical Information of China (English)

    黄朋勉; 陈巨涛; 吴莹; 徐果果; 唐文娟

    2014-01-01

    建立了简便、快捷巴氯酚[4-氨基-3-(4-氯苯基)-丁酸]的高效液相色谱定量分析方法;色谱柱Diamonsil C18 column (250 mm×4.6 mm),流动相v(0.30 mol/L冰醋酸水溶液)∶v(甲醇)∶v(0.36 mol/L乙酸钠水溶液)=55∶44∶20,流速1.0 mL/min,检测波长226 nm.方法精密度良好,RSD值为0.11%(n=5),平均加标回收率为100.54%,RSD为1.76%(n=5).

  9. Conformational distribution of baclofen analogues by 1H and 13C NMR analysis and ab initio HF MO STO-3G or STO-3G* calculations

    Science.gov (United States)

    Vaccher, Claude; Berthelot, Pascal; Debaert, Michel; Vermeersch, Gaston; Guyon, René; Pirard, Bernard; Vercauteren, Daniel P.; Dory, Magdalena; Evrard, Guy; Durant, François

    1993-12-01

    The conformations of 3-(substituted furan-2-yl) and 3-(substituted thien-2-yl)-γ-aminobutyric acid 1-9 in solution (D 2O) are estimated from high-resolution (300 MHz) 1H NMR coupling data. Conformations and populations of conformers are calculated by means of a modified Karplus-like relationship for the vicinal coupling constants. The results are compared with X-ray crystallographic investigations (torsion angles) and ab initio HF MO ST-3G or STO-3G* calculations. 1H NMR spectral analysis shows how 1-9 in solution retain the preferred g- conformation around the C3C4 bond, as found in the solid state, while a partial rotation is set up around the C2C3 bond: the conformations about C2C3 are all highly populated in solution. The 13C spin-lattice relaxation times are also discussed.

  10. Preparation of (+)- and (-)- β-phenyl- and β-(4-chlorophenyl)-γ- butyro lactones: Key intermediates in the synthesis of β-phenyl-Gaba and baclofene

    Energy Technology Data Exchange (ETDEWEB)

    Gomez G, J.; Melendez R, M.; Suarez C, O. R.; Castelan D, L. E.; Fragoso V, M. J.; Lopez V, E.; Sanchez Z, M., E-mail: melendez@uaeh.edu.mx [Universidad Autonoma del Estado de Hidalgo, Area Academica de Quimica, Carretera Pachuca-Tulancingo Km. 4.5, Mineral de la Reforma 42184, Hidalgo (Mexico)

    2014-07-01

    the preparation of β-phenyl- and β-(4-chlorophenyl)-γ-butyro lactones (±)-4 and their resolution to the corresponding (+)-(S)-3, (-)-(R)-3 and (+)-(S)-4, (-)-(R)-4 through formation, flash column chromatography separation and subsequent hydrolysis of dia stereoisomeric 4-hydroxybutyramide s (2'R,3S)-5, (2'R,3R)-5, (2'R,3S)-6 and (2'R,3R)-6 is described. The absolute configuration assignment of enantiopure 3 and 4 was supported by X-ray crystallographic structures of (2'R,3R)-5, (2'R,3S)-6 and (2'R,3R)-6. (Author)

  11. Effect of Baclofen on Spasticity in Spinal Cord Injury: 136 Cases Report%Baclofen治疗脊髓损伤后痉挛的疗效观察

    Institute of Scientific and Technical Information of China (English)

    刘根林; 李建军; 周红俊; 郑樱; 郝春霞; 汪家琮

    2008-01-01

    目的 观察脊髓损伤性痉挛患者口服Baclofen的解痉效果.方法 136例患者连续服药2个月.采用改良Ashworth评分进行评定.结果 改良Ashworth评分降低超过1级的131例(96.3%).结论 该药对不同年龄、性别、损伤部位、损伤程度和损伤时间的患者均有明显的解痉效果,长期服药对肝肾功能无影响.

  12. Effects of the GABAB Receptor-Positive Modulators CGP7930 and rac-BHFF in Baclofen- and γ-Hydroxybutyrate-Discriminating Pigeons

    OpenAIRE

    Koek, Wouter; France, Charles P; Cheng, Kejun; Rice, Kenner C.

    2012-01-01

    In vivo effects of GABAB receptor-positive modulators suggest them to have therapeutic potential to treat central nervous system disorders such as anxiety and drug abuse. Although these effects are thought to be mediated by positive modulation of GABAB receptors, such modulation has been examined primarily in vitro. This study further examined the in vivo properties of the GABAB receptor-positive modulators 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl) phenol (CGP7930) and (R,S)-5,7-di-t...

  13. 过量巴氯芬导致的酷似脑死亡的昏迷%Coma mimicking brain death following baclofen overdose

    Institute of Scientific and Technical Information of China (English)

    李志军; 张苏明

    2001-01-01

    巴氯芬中毒可能是引起脑干功能失调,产生酷似脑死亡的深昏迷的一种原因.这种情况是一种临床诊断,有时血清浓度测不到而且结果也可能产生误导.影像结果往往正常.脑电图显示一种发放抑制模式.目前尚没有特效的治疗方法.然而,正如在我们病例中显示的,即使是很严重的病例,如果能尽早识别并给予恰当的支持治疗,预后较好.

  14. Preparation of (+)- and (-)- β-phenyl- and β-(4-chlorophenyl)-γ- butyro lactones: Key intermediates in the synthesis of β-phenyl-Gaba and baclofene

    International Nuclear Information System (INIS)

    the preparation of β-phenyl- and β-(4-chlorophenyl)-γ-butyro lactones (±)-4 and their resolution to the corresponding (+)-(S)-3, (-)-(R)-3 and (+)-(S)-4, (-)-(R)-4 through formation, flash column chromatography separation and subsequent hydrolysis of dia stereoisomeric 4-hydroxybutyramide s (2'R,3S)-5, (2'R,3R)-5, (2'R,3S)-6 and (2'R,3R)-6 is described. The absolute configuration assignment of enantiopure 3 and 4 was supported by X-ray crystallographic structures of (2'R,3R)-5, (2'R,3S)-6 and (2'R,3R)-6. (Author)

  15. GABA-B receptor activation and conflict behavior

    Energy Technology Data Exchange (ETDEWEB)

    Ketelaars, C.E.J.; Bollen, E.L.; Rigter, H.; Bruinvels, J.

    1988-01-01

    Baclofen and oxazepam enhance extinction of conflict behavior in the Geller-Seifter test while baclofen and diazepam release punished behavior in Vogel's conflict test. In order to investigate the possibility that the effect of the selective GABA-B receptor agonist baclofen is mediated indirectly via the GABA-A/benzodiazepine receptor complex, the effect of pretreatment of rats with baclofen on (/sup 3/H)-diazepam binding to washed and unwashed cortical and cerebellar membranes of rats has been studied. Baclofen pretreatment increase Bmax in washed cerebellar membranes when bicuculline was present in the incubation mixture. No effect was seen in cortical membranes. The present results render it unlikely that the effect of baclofen on extinction of conflict behavior and punished drinking is mediated via the GABA-A/benzodiazepine receptor complex. 50 references, 1 figure, 4 tables.

  16. GABA-B receptor activation and conflict behavior

    International Nuclear Information System (INIS)

    Baclofen and oxazepam enhance extinction of conflict behavior in the Geller-Seifter test while baclofen and diazepam release punished behavior in Vogel's conflict test. In order to investigate the possibility that the effect of the selective GABA-B receptor agonist baclofen is mediated indirectly via the GABA-A/benzodiazepine receptor complex, the effect of pretreatment of rats with baclofen on [3H]-diazepam binding to washed and unwashed cortical and cerebellar membranes of rats has been studied. Baclofen pretreatment increase Bmax in washed cerebellar membranes when bicuculline was present in the incubation mixture. No effect was seen in cortical membranes. The present results render it unlikely that the effect of baclofen on extinction of conflict behavior and punished drinking is mediated via the GABA-A/benzodiazepine receptor complex. 50 references, 1 figure, 4 tables

  17. HPLC手性流动相添加剂法拆分巴氯芬对映体%Chiral separation of baclofen enantiomers by HPLC withchiral mobile phase additives

    Institute of Scientific and Technical Information of China (English)

    卢建国; 王立艳; 苏立强

    2011-01-01

    建立了以羧甲基-β-环糊精为手性流动相添加剂,在反相液谱条件下拆分巴氯芬对映体的方法.研究了手性添加剂的种类及浓度、流动相组成、pH值及流速等因素对拆分的影响.流动相为甲醇、乙腈、水,体积比为90∶5∶5,其中含2.00g/L CM-β-CD,pH值5.95,流速0.60mL/min,检测波长231 nm,分离度为1.31.该方法简便、快速、相对偏差小.

  18. Electroacupuncture Enached Analgesic Effects of Muscimol and Baclofen Microinjected in Hippocampus%电针加强海马微量注射蝇蕈碱与氯苯氨丁酸的镇痛作用

    Institute of Scientific and Technical Information of China (English)

    胡宗礼; 黄晓萍

    2001-01-01

    目的 观察电针对大鼠海马微量注射GABA受体激动剂蝇蕈碱(Mus)和氯苯氨丁酸(Bac)镇痛作用的影响。方法 实验分生理盐水对照组、药物组和电针+药物组,在2分钟内将1μl Mus或Bac(1×10-3mol.L-1)注射入海马,取双侧足三里进行电针,用甩尾法测定大鼠的痛阈。结果 从给药后5min至60min,Mus或Bac均能明显提高大鼠的痛阈(P<0.01),20min时作用最显著,痛阈分别提高0.386±0.062mA和0.549±0.116mA。电针能加强Mus和Bac的镇痛作用(P<0.05或P<0.01),痛阈最大提高值分别为0.603±0.117mA和0.704±0.099mA。结论 海马微量注射Mus或Bac能产生镇痛作用,并且电针能加强其镇痛作用。

  19. RP-HPLC separation of Baclofen enantiomer by pre-column derivatization%柱前衍生化RP-HPLC分离巴氯芬的对映异构体

    Institute of Scientific and Technical Information of China (English)

    张春艳; 袁牧; 黄碧云; 季红; 朱柳

    2008-01-01

    目的 建立巴氯芬对映异构体的拆分方法.方法 采用柱前衍生化RP-HPLC法,以2,3,4,6-乙酰基-β-D-吡喃葡萄糖基异硫氰酸酯为柱前手性衍生化试剂,察衍生化时间、试剂用量、流动相组成及其Ph等因素对手性分离的影响.结果采用ZORBAX-C8(150 mm×4.6 mm,5 靘)色谱柱,在流动相为甲醇-0.05 mol·L-1磷酸二氢钾溶液(40:60,Ph6.0)、紫外检测波长为254 nm、流速为1.5 ml·min-1、柱温35%的色谱条件下,巴氯芬对映体衍生物获得了基线分离,分离度为1.93,并确认了R(+)-衍生物的色谱峰.结论所建方法简便、快速,为巴氯芬的光学异构体的测定提供了参考.

  20. A preliminary study on Baclofen in treatment of spastic cerebral palsy%巴氯芬治疗痉挛型小儿脑性瘫痪的初步探讨

    Institute of Scientific and Technical Information of China (English)

    李林; 林萍; 姜志梅

    2000-01-01

    目的探讨巴氯芬治疗痉挛型小儿脑性瘫痪的效果.方法对确诊的50例患儿按年龄给药,剂量为每日40~75 mg,逐渐增量,10~15 d为1疗程,分级标准采用改良的Ashuorth评分法.结果显效3例,有效12例,好转20例,总有效为35例,总有效率70%.并且1~3岁与4~6岁两年龄组间存在显著性差异(P<0.001).结论巴氯芬是目前降低痉挛型脑瘫患儿肌张力最有效的方法之一,且年龄越小,效果越好,同时应严密观察其副作用.

  1. Badofen对大鼠脊髓薄片胶状质神经元的抑制作用%Inhibitory effects of baclofen upon substantia gelatinosa neurons in rat spinal cord slice

    Institute of Scientific and Technical Information of China (English)

    闫励; 杨鲲; 冯宇鹏; 赵华; 李云庆

    2001-01-01

    用脊髓薄片全细胞电压钳法观察激活γ-氨基丁酸B亚型受体(GABABR)对大鼠脊髓背角胶状质(SG)神经元活动的影响.选择性GABABR激动剂baclofen减少所有被记录SG神经元(n=15)的微小兴奋性突触后电流(mEPSCs)的发放频率,同时引起一缓慢的抑制性(外向)膜电流并伴有膜电导增加.细胞内电泳G蛋白偶联受体抑制剂(GDP-β-S)抑制被钳制神经元的G蛋白偶联受体后,baclofen引起的缓慢外向电流被抑制,但对mEPSC频率的减低作用依然存在.结果提示脊髓内baclofen敏感的GABAB受体被激活后直接引起SG神经元超极化并能减少突触前递质的释放.

  2. 巴氯芬缓减大鼠胫骨癌痛及可能机制%Baclofen attenuates pain in rat tibia bone cancer and its possible mechanism

    Institute of Scientific and Technical Information of China (English)

    李伟; 杨建平; 王丽娜; 周静; 任春光

    2010-01-01

    目的 探讨巴氯芬对大鼠胫骨癌痛的作用及可能机制.方法 使用Walker 256乳腺癌细胞建立SD大鼠胫骨癌痛模型,第9天64只模型大鼠随机分8组(n=8):N1、N2组(生理盐水 10μ1),B1、B2组(巴氯芬0.1旭),C1、C2组[γ-氨基丁酸B型受体(GABAB)特异性拮抗剂(CGP3534:8)60 μg],D1、D2组(CGP35348 60 μg+巴氯芬0.1 μg).NI、B1、C1、D1组单次鞘内给药前0.5 h、给药后0.5、1、2、4、8、24 h使用Von Frey纤维测定患肢机械缩足阈值(MWT).N2、B2、C2、192组鞘内连续给药4 d,每天给药1次,最后一次给药后6 h处死,用免疫组织化学方法检测磷酸化细胞外信号调节激酶(p-ERKl/2)表达.结果 与N1组比较,B1组大鼠MWT明显增加(P<0.05),持续时间为4 h;与N2组比较,B2组大鼠脊髓背角p-ERK1/2阳性细胞数明显减少(P<0.05).结论 巴氯芬可能通过GABAB受体调控下游p-ERK1/2变化减缓胫骨癌痛,其作用可被CGP35348阻断.

  3. 液相色谱串联质谱法测定猪肉和猪尿中巴氯芬%Determination of Baclofen in Pork and Swine Urine by Liquid Chromatograpy Tandem Mass Spectrometry

    Institute of Scientific and Technical Information of China (English)

    许秀琴; 吴银良; 杨挺; 朱勇; 赵健; 叶宇飞

    2013-01-01

    样品中的巴氯芬用0.01 mol/L HCl溶液提取,提取液经WCX柱净化、富集后,进行液相色谱串联质谱(LC/MS-MS)分析.分析时采用BEH C18色谱柱(100mm×2.1mm,1.7μm),以0.10%甲酸水/甲醇作为流动相进行梯度洗脱,电喷雾正电子(ESI+)模式电离,多反应监测(MRM)模式检测,内标法进行定量.结果表明:巴氯芬标准溶液在1.0~100.0μg/L范围内,峰面积与含量呈线性相关.猪肉和猪尿中巴氯芬检出限分别为0.30μg/kg和0.10μg/L,两种样品中添加回收率在85%~110%之间,相对标准偏差(RSD)小于10%.

  4. Clinical observation of baclofen for treatment of postherpetic neuralgia%巴氯芬治疗带状疱疹感染后神经痛的临床观察

    Institute of Scientific and Technical Information of China (English)

    范红杰; 于维东

    2005-01-01

    目的观察巴氯芬治疗带状疱疹感染后神经痛的疗效.方法69例带状疱疹感染后神经痛的患者随机分为治疗组(37例)、对照纽(32例).治疗组服用巴氯芬,对照组服用卡马西平,其他治疗两组相同,治疗1个月后疗效评价.结果治疗前两组患者年龄、性别、病程、神经痛分布区域无显著性差异,具有可比性.治疗后治疗组总有效率86.49%,明显高于对照组65.63%,且副作用少.结论巴氯芬可作为治疗带状疱疹感染后神经痛的首选药物.

  5. 鞘内注射巴氯酚在治疗脑性瘫痪儿童痉挛中的应用%Application of intrathecal baclofen in the treatment of spasticity in children with cerebral palsy

    Institute of Scientific and Technical Information of China (English)

    蔡斌; 陈博昌

    2004-01-01

    鞘内注射巴氯酚由于作用持久,全身副作用轻等优点被应用于治疗脑瘫儿童痉挛.介绍了鞘内注射巴氯酚的原理及其实施方法.综述了鞘内注射巴氯酚治疗脑瘫儿童上肢或下肢痉挛的有效性和安全性的文献(含非对照性研究和对照性研究) , 鞘内注射巴氯酚是一种有效的缓解脑瘫痉挛的疗法.

  6. GABAB受体激动剂巴氯酚重复注射对大鼠血压的影响%Effects of repeated injection of GABAB receptor agonist baclofen on mean blood pressure in rats

    Institute of Scientific and Technical Information of China (English)

    刘翠清; 林国华

    2006-01-01

    目的 观察GABAB受体激动剂-巴氯酚二次重复注射对大鼠血压的影响.方法 对氨基甲酸乙酯麻醉的大鼠行巴氯酚二次重复腹腔注射,通过股动脉插管记录血压,比较两次注射后血压的变化.结果 首次注入后血压由(113.2±8.3)mmHg显著升至(139.2±11.2)mmHg(P<0.05)并维持;60min后行第二次巴氯酚注射,血压却显著降至(120.3±20.4)mmHg,与首次注射前血压无显著性差异(P>0.05).结论 巴氯酚重复注射翻转了首次注射的升压效应,原因可能与受体内化有关.

  7. Baclofen与异搏停治疗脊髓损伤后痉挛性膀胱的对比研究%Comparative study on Baclofen and Verapamil in the treatment of spastic bladder after spinal cord injury

    Institute of Scientific and Technical Information of China (English)

    刘明轩; 侯春林; 邱实

    2000-01-01

    目的:观察Baclofen与异搏停治疗脊髓完全性损伤后痉挛性膀胱的疗效并进行比较分析.方法:将32例脊髓损伤后痉挛性膀胱患者按随机抽样法分为Baclofen组和异搏停组,分别于用药后2、4、8周观察膀胱功能变化,并进行尿流动力学检测.结果:两组患者用药后排尿间隔延长、排尿量增加、尿道压力降低,膀胱贮尿及排尿功能均较用药前明显提高,Baclofen组优于异搏停组.结论:Baclofen与异搏停治疗脊髓损伤后痉挛性膀胱疗效显著,Baclofen可做为首选用药.

  8. Effect of Herbal Fumigation with Baclofen on Spasm Hemiplegia after Stroke%中药熏蒸结合巴氯芬治疗脑卒中偏瘫痉挛临床观察

    Institute of Scientific and Technical Information of China (English)

    陈佳; 张国庆; 周湘明; 杨春桥

    2010-01-01

    目的 观察中药熏蒸结合巴氯芬治疗脑卒中偏瘫痉挛的临床疗效.方法 50例患者随机分为观察组(巴氯芬)和治疗组(中药熏蒸结合巴氯芬),每组各25例,并给予相应治疗,疗程30 d.观察痉挛临床疗效、经修改的Ashworth量表痉挛程度评定变化.结果 治疗组患肢肌张力改善总有效率高于对照组(P<0.05).结论 中药熏蒸结合巴氯芬治疗法能有效减轻脑卒中偏瘫肢体痉挛.

  9. Rhizotomibehandling af børn med svaer spastisk cerebral parese

    DEFF Research Database (Denmark)

    Illum, Niels Ove; Torp-Pedersen, Lisbeth; Midholm, Steen;

    2006-01-01

    INTRODUCTION: Severe spasticity is a limiting factor for motor development in children with spastic cerebral palsy. Botulinum toxin, intrathecal baclofen and peroral baclofen all reduce spasticity but might also limit improvements in functional development over time. In the selective dorsal or...

  10. Intratekal baclofenbehandling ved svaer spastisk tetraplegi og dystoni hos børn og unge

    DEFF Research Database (Denmark)

    Illum, Niels Ove; Hansen, Flemming Juul; Fischer, Claudia;

    2003-01-01

    INTRODUCTION: Continuous intrathecal baclofen has been used over the past years especially in adult patients with spasticity of spinal origin. Children and young adults with severe spasticity and dystonia of cerebral origin are difficult to treat in spite of optimal systemic antispasmotic therapy...... with baclofen, tizanidine, dantrolene and/or diazepam. Intrathecal baclofen has therefore been applied in a group of young patients. MATERIAL AND METHODS: Eight children and young adults from East Denmark with spasticity and 12 with dystonia aged 3-18 years (median 10.9 years) were tested, operated and...... treated with continuous intrathecal baclofen for a period of 2-64 months (median 22.2 months). Registration of efficacy, fillings, adjustments of baclofen and other therapies were performed in an out patient setting since 1995. RESULTS: Spasticity in lower extremities was reduced from Ashworth score 3...

  11. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action

    DEFF Research Database (Denmark)

    Lehmann, Anders; Antonsson, Madeleine; Holmberg, Ann Aurell;

    2009-01-01

    mice, AZD3355 produced considerably less central side effects than the prototypical GABA(B) receptor agonist baclofen but evoked hypothermia at very high doses (blocked by a GABA(B) receptor antagonist and absent in GABA(B)-/- mice). AZD3355 and baclofen differed markedly in their distribution in rat...... brain; AZD3355, but not baclofen, was concentrated in circumventricular organs as a result of active uptake (shown by avid intracellular sequestration) and related to binding of AZD3355 to native GABA transporters in rat cerebrocortical membranes. AZD3355 was also shown to be transported by all four...

  12. GABAB antagonists

    DEFF Research Database (Denmark)

    Frydenvang, Karla Andrea; Hansen, J J; Krogsgaard-Larsen, P;

    1994-01-01

    Phaclofen, which is the phosphonic acid analogue of the GABAB agonist (RS)-3-(4-chlorophenyl)-4-aminobutyric acid (baclofen), is a GABAB antagonist. As part of our studies on the structural requirements for activation and blockade of GABAB receptors, we have resolved phaclofen using chiral...... chromatographic techniques. The absolute stereochemistry of (-)-(R)-phaclofen was established by X-ray crystallographic analysis. (-)-(R)-Phaclofen was shown to inhibit the binding of [3H]-(R)-baclofen to GABAB receptor sites on rat cerebellar membranes (IC50 = 76 +/- 13 microM), whereas (+)-(S)-phaclofen was...... inactive in this binding assay (IC50 > 1000 microM). (-)-(R)-Phaclofen (200 microM) was equipotent with (RS)-phaclofen (400 microM) in antagonizing the action of baclofen in rat cerebral cortical slices, while (+)-(S)-phaclofen (200 microM) was inactive. The structural similarity of the agonist (R)-baclofen...

  13. Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis

    OpenAIRE

    Hilliard, A.; Stott, C.; Wright, S; Guy, G.; Pryce, G.; Al-Izki, S.; Bolton, C; Giovannoni, G.

    2012-01-01

    This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the “stiffness” of limbs assessed by the resistance force against hind limb flexion. Vehicle alone caused no significant change in spasticity. Baclofen (5 mg/kg) induced approximately a 40% peak reducti...

  14. Reduserer snittføringen ved implantasjon av bakflofenpumpe sensibiliteten over påfyllingsporten?

    OpenAIRE

    2010-01-01

    Abstract Bakground Knowledge: Baclofen pump treatment is used with patients with spasms and spasticity. The pump is implanted subcutaneous on the abdomen, and a spinal catheter continuously delivers the medication to the cerebrospinal fluid. Current practice is to implant the pump with an angular incision. Hypothesis: In this project we have examined patients with a baclofen pump with a view to the impact of the incision to the sensibility over the pump. Our hypothesis was that the a...

  15. 3-Aminopropylphosphinic acid--a potent, selective GABAB receptor agonist in the guinea-pig ileum and rat anococcygeus muscle.

    OpenAIRE

    Hills, J. M.; Dingsdale, R. A.; Parsons, M.E.; Dolle, R. E.; Howson, W.

    1989-01-01

    1. 3-Aminopropylphosphinic acid, a gamma-aminobutyric acid (GABA) analogue, was tested for activity on guinea-pig isolated ileum and rat isolated anococcygeus muscle preparations. The effects of 3-aminopropylphosphinic acid were compared with those of GABA and baclofen. 2. In the electrically stimulated ileum, 3-aminopropylphosphinic acid, like GABA and baclofen, caused a concentration-dependent inhibition of the cholinergic twitch contraction, the IC50 value being 1.84 +/- 0.23 microM (n = 1...

  16. GABAB receptor modulation of adenylate cyclase activity in rat brain slices.

    OpenAIRE

    Hill, D R

    1985-01-01

    An investigation of the effects of gamma-aminobutyric acid (GABA) and the selective GABAB receptor agonist, baclofen, on basal and stimulated adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels in slices of rat cerebral cortex has been carried out. Neither GABA nor baclofen produced any significant change in basal cyclic AMP levels. By contrast noradrenaline and forskolin both produced dose-dependent increases in cellular cyclic AMP accumulation. GABA (in the presence of nipecotic acid) ...

  17. GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.

    Science.gov (United States)

    Huang, Dongyang; Huang, Sha; Peers, Chris; Du, Xiaona; Zhang, Hailin; Gamper, Nikita

    2015-09-18

    Growing evidence suggests that mammalian peripheral somatosensory neurons express functional receptors for gamma-aminobutyric acid, GABAA and GABAB. Moreover, local release of GABA by pain-sensing (nociceptive) nerve fibres has also been suggested. Yet, the functional significance of GABA receptor triggering in nociceptive neurons is not fully understood. Here we used patch-clamp recordings from small-diameter cultured DRG neurons to investigate effects of GABAB receptor agonist baclofen on voltage-gated Ca(2+) currents. We found that baclofen inhibited both low-voltage activated (LVA, T-type) and high-voltage activated (HVA) Ca(2+) currents in a proportion of DRG neurons by 22% and 32% respectively; both effects were sensitive to Gi/o inhibitor pertussis toxin. Inhibitory effect of baclofen on both current types was about twice less efficacious as compared to that of the μ-opioid receptor agonist DAMGO. Surprisingly, only HVA but not LVA current modulation by baclofen was partially prevented by G protein inhibitor GDP-β-S. In contrast, only LVA but not HVA current modulation was reversed by the application of a reducing agent dithiothreitol (DTT). Inhibition of T-type Ca(2+) current by baclofen and the recovery of such inhibition by DTT were successfully reconstituted in the expression system. Our data suggest that inhibition of LVA current in DRG neurons by baclofen is partially mediated by an unconventional signaling pathway that involves a redox mechanism. These findings reinforce the idea of targeting peripheral GABA receptors for pain relief. PMID:26239659

  18. The clinical observation of "baclofen" on the anti-spastic effect of acute paroxysm of lumbar intervertebral disc herniation%巴氯芬对腰椎间盘突出症急性发作期抗痉挛作用的临床观察

    Institute of Scientific and Technical Information of China (English)

    施问民

    2005-01-01

    目的探讨巴氯芬对改善腰突症急性发作期的肌痉挛症状的效果.方法观察组采用理疗加药物:(1)理疗:腰椎牵引+电脑中频,每天一次,每次各20min.(2)药物:选用国产巴氯芬(枢芬),起始剂量每次5mg,每天三次,酌情每三天增加5mg/d,可加至30mg/d.对照组为腰椎牵引加电脑中频.以上二组均10d为一疗程,共观察二个疗程.结果经过二个疗程的治疗后,二组患者整体水平均有提高,但观察组各项指标均优于对照组.结论在腰突症急性期有肌痉挛症状者,不失时机地介入巴氯芬治疗,对缓解肌痉挛,提高康复疗效是有价值的.

  19. Severe Seizures During Propofol Induction in a Patient with Syringomyelia Receiving Baclofen%服用巴氯芬的脊髓空洞症患者丙泊酚诱导时癫痫大发作一例报道

    Institute of Scientific and Technical Information of China (English)

    Sethuraman Manikandan; Prabhat K.Sinha; Praveen K.Neema; Ramesh C.Rathod; 任飞

    2006-01-01

    我们报道一例服用巴氯芬治疗曲肌痉挛的脊髓空洞症患者在神经外科手术前使用丙泊酚麻醉诱导时反复出现癫痫全身性大发作,并对丙泊酚和巴氯芬在该病例癫痫发作中可能的相互作用进行了讨论.

  20. Inhibitory actions of GABA on rabbit urinary bladder muscle strips: mediation by potassium channels.

    Science.gov (United States)

    Ferguson, D R; Marchant, J S

    1995-05-01

    1. The actions of gamma-aminobutyric acid (GABA) upon rabbit urinary bladder muscle were investigated to determine whether they were mediated through potassium channels. 2. In vitro experiments were undertaken in which bladder muscle strips were caused to contract with carbachol. Addition of GABA or baclofen reduced the size of such evoked contractions in the case of GABA by 20.7 +/- 3.2%, in the case of baclofen by 22.4 +/- 2.2%. 3. Electrical stimulation of autonomic nerves in bladder wall strips also evoked contractions which were significantly smaller in potassium-free Krebs solution. The size of contractions produced by carbachol on the other hand were unaffected by the absence of potassium in the Krebs solution. 4. The inhibitory actions of GABA and baclofen on carbachol-induced contractions of bladder muscle were detected at much lower concentrations in potassium-free compared with potassium containing solutions. 5. The inhibitory effects of baclofen were completely reversed by tetraethyl ammonium chloride between 1 and 5 mM, caesium chloride between 0.5 and 3 mM and barium chloride between 0.5 and 2.5 mM. The actions of baclofen were only partially reversed by 4-amino-pyridine between 1 and 5 mM. 6. It was concluded that the GABAB receptor-mediated inhibitory actions on rabbit urinary bladder smooth muscle cells were produced by activation of potassium channels. PMID:7647988

  1. GABA/sub B/ receptor activation inhibits Ca2+-activated potassium channels in synaptosomes: involvement of G-proteins

    International Nuclear Information System (INIS)

    86Rb-efflux assay from preloaded synaptosomes of rat cerebral cortex was developed to study the effect of GABA/sub B/ receptor agonist baclofen on Ca2+-activated K+-channels. Depolarization of 86Rb-loaded synaptosomes in physiological buffer increased Ca2+-activated 86Rb-efflux by 400%. The 86Rb-efflux was blocked by quinine sulfate, tetraethylammonium, and La3+ indicating the involvement of Ca2+-activated K+-channels. (-)Baclofen inhibited Ca2+-activated 86Rb-efflux in a stereospecific manner. The inhibitory effect of (-)baclofen was mediated by GABA/sub B/ receptor activation, since it was blocked by GABA/sub B/ antagonist phaclofen, but not by bicuculline. Further, pertussis toxin also blocked the ability of baclofen or depolarizing action to affect Ca2+-activated K+-channels. These results suggest that baclofen inhibits Ca2+-activated K+-channels in synaptosomes and these channels are regulated by G-proteins. This assay may provide an ideal in vitro model to study GABA/sub B/ receptor pharmacology

  2. GABA/sub B/ receptor activation inhibits Ca/sup 2 +/-activated potassium channels in synaptosomes: involvement of G-proteins

    Energy Technology Data Exchange (ETDEWEB)

    Ticku, M.K.; Delgado, A.

    1989-01-01

    /sup 86/Rb-efflux assay from preloaded synaptosomes of rat cerebral cortex was developed to study the effect of GABA/sub B/ receptor agonist baclofen on Ca/sup 2 +/-activated K/sup +/-channels. Depolarization of /sup 86/Rb-loaded synaptosomes in physiological buffer increased Ca/sup 2 +/-activated /sup 86/Rb-efflux by 400%. The /sup 86/Rb-efflux was blocked by quinine sulfate, tetraethylammonium, and La/sup 3 +/ indicating the involvement of Ca/sup 2 +/-activated K/sup +/-channels. (-)Baclofen inhibited Ca/sup 2 +/-activated /sup 86/Rb-efflux in a stereospecific manner. The inhibitory effect of (-)baclofen was mediated by GABA/sub B/ receptor activation, since it was blocked by GABA/sub B/ antagonist phaclofen, but not by bicuculline. Further, pertussis toxin also blocked the ability of baclofen or depolarizing action to affect Ca/sup 2 +/-activated K/sup +/-channels. These results suggest that baclofen inhibits Ca/sup 2 +/-activated K/sup +/-channels in synaptosomes and these channels are regulated by G-proteins. This assay may provide an ideal in vitro model to study GABA/sub B/ receptor pharmacology.

  3. Phenibut dependence.

    Science.gov (United States)

    Samokhvalov, Andriy V; Paton-Gay, C Lindsay; Balchand, Kam; Rehm, Jürgen

    2013-01-01

    Phenibut is a γ-aminobutyric acid (GABA) agonist designed and used as an anxiolytic in Russia. In Western countries, phenibut is not a registered medication but is available through online stores as a supplement. We present a case of a patient who used phenibut to self-medicate anxiety, insomnia and cravings for alcohol. While phenibut was helpful initially, the patient developed dependence including tolerance, significant withdrawal symptoms within 3-4 h of last use and failure to fulfil his roles at work and at home. He finally sought medical assistance in our addictions clinic. We have gradually, over the course of 9 weeks, substituted phenibut with baclofen, which has similar pharmacological properties, and then successfully tapered the patient off baclofen. This required approximately 10 mg of baclofen for each gram of phenibut. PMID:23391959

  4. Venovenøs hæmodiafiltrering til baclofenforgiftet patient

    DEFF Research Database (Denmark)

    Nielsen, Simon Uhl; Jansen, Tejs; Johansen, Sys Stybe;

    2011-01-01

    Twice a young man was admitted to hospital upon having taken baclofen overdoses by intention. The ingested dose was 1,850 mg at the first episode and up to 2,500 mg at the second. In both cases the patient had severe overdose symptoms and scored 4-5 on the Glascow Coma Scale and was admitted to...... intensive care. Continuous venovenous hemodiafiltration (CVVHDF) was initiated. The elimination pharmacokinetics and toxicokinetics for baclofen is not fully known. During the second submission a shorter elimination half-life time was observed and it might be due to either compartmental distribution of...... baclofen, or more likely caused by an advantageous effect of the CVVHDF....

  5. Toxic Effects Of Some Antispastic Drugs on the EEG: Some Biochemical And Immunological Studies on Rats

    Directory of Open Access Journals (Sweden)

    Fathy El-Komey, Inass EL-Gaafarawi and Hanan Moustafa

    2005-09-01

    Full Text Available The toxicity of tizanidine and baclofen was studied on male rats. The oral clinical dose of tizanidine and baclofen( 0.216 and o.54 mg/ 100g body weight / day, respectivelywas given for one, two, three and four weeks. Chronic administration of the two drugs causes damage to the lung and a significant reduction in serum and lung levels of GSH , Vit E , Vit C and SOD activity . Four weeks treatment induced significant elevation of GPX activity and MDA levels. The two drugs, also, caused inhibitory activity on proliferation of splenocyte triggered by Con A, LPS and IL-2 production cell activities. They also produced several abnormal patterns in the EEG including increased epileptiform discharges and synchronous rhythmic activity . Diffuse slowing , with increased beta and delta activity and decreased alpha activity , with superimposed beta activity were recorded. Tizanidine had more prominent effect on the EEG than baclofen .

  6. Dysesthesia perceived as painful spasticity: A report of 3 cases.

    Science.gov (United States)

    Ordia, J I; Fischer, E; Adamski, E; Spatz, E L

    2001-05-01

    Lesions of the central nervous system often involve the pyramidal tracts and the sensory pathways to produce spasticity, paresthesias, and dysesthesia. Three patients with intractable spasticity were treated with intrathecal baclofen. Two had an implanted Medtronic SynchroMed pump for long-term delivery of the muscle relaxant. The third patient had undergone a screening trial in which the baclofen was delivered into the intrathecal space through a lumbar catheter. All had excellent relief of spasms on clinical examination, but they reported painful spasms particularly at night. Two of the patients were successfully treated for dysesthesia. PMID:11346852

  7. Electrical and pharmacological neuromodulation in patient with spinal cord injury pain (La neuromodulazione elettrica e farmacologica nel paziente con dolore post lesione midollare

    Directory of Open Access Journals (Sweden)

    Carmelo Costa

    2014-10-01

    Full Text Available The authors present the different kinds of pain following the spinal cord lesions (neuropathic, nociceptive, somatic, visceral; they describe the alterations that occur on spinal cord, brain and periphery; the methods to define the kinds of pain and to evaluate the pain intensity; the strumental and pharmacological treatments for pain relief. In detail data on the efficacy of spinal neurostimulation are compared with data on the efficacy of baclofen intrathecally administered. Based on results of his studies and on international literature data, the authors conclude that efficacy of treatment with baclofen intratecally administered with a programmable pump is higher than spinal neurostimulation treatment.

  8. GABAB receptor-mediated contractile effects resistant to tetrodotoxin in isolated cat ileum.

    Science.gov (United States)

    Pencheva, N; Venkova, K; Radomirov, R

    1990-06-21

    The effects of gamma-aminobutyric acid (GABA) and GABAergic drugs were studied on longitudinal strips from cat terminal ileum prepared after removing the myenteric plexus. GABA and baclofen exerted concentration-dependent contractile effects. Muscimol was ineffective, and bicuculline did not antagonize the effect of GABA. The complete elimination of the neural input to the smooth muscle cells by tetrodotoxin failed to prevent the action of GABA and baclofen. Pharmacological analyses of the effects indicated the existence of GABAB receptors on the smooth muscle cells in the longitudinal layer of cat terminal ileum. PMID:2169425

  9. Estudio comparativo del efecto de la Tizanidina y el Baclofeno sobre el control de la espasticidad en niños vistos por el servicio de habilitación en el Hospital de la Misericordia desde enero 2008 a junio de 2009 / Comparisson of Tizanidine and Baclofen for spasticity control in children seen at Hospital de la Misericordia from january 2008 to june 2009

    OpenAIRE

    Cuevas Mendoza, Hugo Alejandro

    2010-01-01

    La espasticidad es una secuela de lesiones del SNC que interfiere con la actividad voluntaria, ocasiona retraso o regresión del desarrollo, favorece la aparición de deformidades osteoarticulares y produce dolor. Los fármacos útiles en espasticidad se han estudiado poco en niños, los estudios que hay son comparaciones contra placebo, la tizanidina y el baclofeno son los más usados pero no se han comparado uno contra el otro. Objetivo: determinar la efectividad en la reducción de la espasticid...

  10. Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.

    Science.gov (United States)

    Hilliard, A; Stott, C; Wright, S; Guy, G; Pryce, G; Al-Izki, S; Bolton, C; Giovannoni, G

    2012-01-01

    This study investigated the antispasticity potential of Sativex in mice. Chronic relapsing experimental allergic encephalomyelitis was induced in adult ABH mice resulting in hind limb spasticity development. Vehicle, Sativex, and baclofen (as a positive control) were injected intravenously and the "stiffness" of limbs assessed by the resistance force against hind limb flexion. Vehicle alone caused no significant change in spasticity. Baclofen (5 mg/kg) induced approximately a 40% peak reduction in spasticity. Sativex dose dependently reduced spasticity; 5 mg/kg THC + 5 mg/kg CBD induced approximately a 20% peak reduction; 10 mg/kg THC + 10 mg/kg CBD produced approximately a 40% peak reduction in spasticity. Sativex has the potential to reduce spasticity in an experimental mouse model of multiple sclerosis (MS). Baclofen reduced spasticity and served as a positive control. Sativex (10 mg/kg) was just as effective as baclofen, providing supportive evidence for Sativex use in the treatment of spasticity in MS. PMID:22928118

  11. The role of GABAB receptors in the vestibular oculomotor system in mice.

    Science.gov (United States)

    Shimizu, Naoki; Wood, Scott; Kushiro, Keisuke; Perachio, Adrian; Makishima, Tomoko

    2016-04-01

    Systemic administration of a gamma-amino butyric acid type B (GABAB) receptor agonist, baclofen, affects various physiological and psychological processes. To date, the effects on oculomotor system have been well characterized in primates, however those in mice have not been explored. In this study, we investigated the effects of baclofen focusing on vestibular-related eye movements. Two rotational paradigms, i.e. sinusoidal rotation and counter rotation were employed to stimulate semicircular canals and otolith organs in the inner ear. Experimental conditions (dosage, routes and onset of recording) were determined based on the prior studies exploring the behavioral effects of baclofen in mice. With an increase in dosage, both canal and otolith induced ocular responses were gradually affected. There was a clear distinction in the drug sensitivity showing that eye movements derived from direct vestibulo-ocular reflex pathways were relatively unaltered, while the responses through higher-order neural networks in the vestibular system were substantially decreased. These findings were consistent with those observed in primates suggesting a well-conserved role of GABAB receptors in the oculomotor system across frontal-eyed and lateral-eyed animals. We showed here a previously unrecognized effect of baclofen on the vestibular oculomotor function in mice. When interpreting general animal performance under the drug, the potential contribution of altered balance system should be taken into consideration. PMID:26778789

  12. Radioprotective effect of GABA-tropic substances, γ-hydroxybutyrate and pyracetame

    International Nuclear Information System (INIS)

    From experiments in mice, it is shown that with a radiation dose of 8 Gy (LD96) the radioprotective effect was exerted by gamma-aminobutyric acid (GABA), substances that increase its concentration in tissues (progabide and valproate), and synthetic agonists of both receptor types, particularly baclofen, a GABA-receptor agonist. The radioprotective effect is also exerted by gamma-hydroxybutyrate, not pyracetame

  13. GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence

    Directory of Open Access Journals (Sweden)

    Roberta eAgabio

    2014-06-01

    Full Text Available The present paper summarizes the preclinical and clinical studies conducted to define the anti-alcohol pharmacological profile of the prototypic GABAB receptor agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder (AUD. Numerous studies have reported baclofen-induced suppression of alcohol drinking (including relapse- and binge-like drinking and alcohol reinforcing, motivational, stimulating, and rewarding properties in rodents and monkeys. The majority of clinical surveys conducted to date – including case reports, retrospective chart reviews, and randomized placebo-controlled studies – suggest the ability of baclofen to suppress alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. The recent identification of a positive allosteric modulatory binding site, together with the synthesis of in vivo effective ligands, represents a novel, and likely more favorable, option for pharmacological manipulations of the GABAB receptor. Accordingly, data collected to date suggest that positive allosteric modulators of the GABAB receptor reproduce several anti-alcohol effects of baclofen and display a higher therapeutic index (with larger separation – in terms of doses – between anti-alcohol effects and sedation.

  14. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors

    DEFF Research Database (Denmark)

    Jensen, Anders A.; Mosbacher, Johannes; Elg, Susanne;

    2002-01-01

    (B) receptor agonist baclofen, gabapentin was unable to inhibit transient lower esophageal sphincter relaxations in dogs. Because of high levels of GABA(B(1a)) in the canine nodose ganglion, this finding indirectly supports the inactivity of gabapentin on the GABA(B(1a,2)) heterodimer demonstrated in various...

  15. Activation of the GABAB receptor prevents nicotine-induced locomotor stimulation in mice

    Directory of Open Access Journals (Sweden)

    Carla eLobina

    2011-12-01

    Full Text Available Recent studies demonstrated that activation of the GABAB receptor, either by means of orthosteric agonists or positive allosteric modulators (PAMs, inhibited different nicotine-related behaviors, including intravenous self-administration and conditioned place preference, in rodents. The present study investigated whether the anti-nicotine effects of the GABAB receptor agonist, baclofen, and GABAB PAMs, CGP7930 and GS39783, extend to nicotine stimulant effects. To this end, CD1 mice were initially treated with baclofen (0, 1.25, and 2.5 mg/kg, i.p., CGP7930 (0, 25, and 50 mg/kg, i.g., or GS39783 (0, 25, and 50 mg/kg, i.g., then treated with nicotine (0 and 0.05 mg/kg, s.c., and finally exposed to an automated apparatus for recording of locomotor activity. Pretreatment with doses of baclofen, CGP7930, or GS39783 that did not alter locomotor activity when given with nicotine vehicle fully prevented hyperlocomotion induced by 0.05 mg/kg nicotine. These data extend to nicotine stimulant effects the capacity of baclofen and GABAB PAMs to block the reinforcing, motivational, and rewarding properties of nicotine. These data strengthen the hypothesis that activation of the GABAB receptor may represent a potentially useful, anti-smoking therapeutic strategy.

  16. Regulation of 3H-dopamine release by presynaptic GABA and glutamate heteroreceptors in rat brain nucleus accumbens synaptosomes

    International Nuclear Information System (INIS)

    The aim of this investigation was a neurochemical study of the effect of agonists of different types of GABA receptors - muscimol (type A receptor), baclofen (type B receptor), delta-aminolevulinic acid (DALA; GABA autoreceptor), and also of GABA itself - on tritium-labelled dopamine release, stimulated by potassium cations, from synaptosomes of the nuclei accumbenes of the rat brain

  17. Functional pharmacology of cloned heterodimeric GABA-B receptors expressed in mammalian cells

    DEFF Research Database (Denmark)

    Bräuner-Osborne, Hans; Krogsgaard-Larsen, P

    1999-01-01

    ((R)-baclofen)>(RS)-4-amino-3-(5-chloro-2-thienyl)butanoic acid (BCTG)>3-aminopropylphosphonic acid (3-APPA) and furthermore, the absolute agonist potency values were very close to each other. 3. 3-APPA was a partial agonist displaying maximal responses of 41 and 61% compared to GABA at GABABR1a and...

  18. Regulation of /sup 3/H-dopamine release by presynaptic GABA and glutamate heteroreceptors in rat brain nucleus accumbens synaptosomes

    Energy Technology Data Exchange (ETDEWEB)

    Kovalev, G.I.; Hetey, L.

    1987-06-01

    The aim of this investigation was a neurochemical study of the effect of agonists of different types of GABA receptors - muscimol (type A receptor), baclofen (type B receptor), delta-aminolevulinic acid (DALA; GABA autoreceptor), and also of GABA itself - on tritium-labelled dopamine release, stimulated by potassium cations, from synaptosomes of the nuclei accumbenes of the rat brain.

  19. Drug: D09791 [KEGG MEDICUS

    Lifescience Database Archive (English)

    Full Text Available fragile X syndrome and autism prodrug, active substance: Baclofen [DR:D00241] GABA-B receptor agonist [HSA:...D09791 Drug Arbaclofen (USAN) C10H12ClNO2 213.0557 213.6608 D09791.gif Treatment of

  20. Discordance in Informed Consent Response on the Basis of Demographic Factors: Brief Report

    Science.gov (United States)

    Nunez-Wallace, Karen R.; Gill, Chandler E.; Harrison, Courtney H.; Taylor, Henry M.; Charles, P. David

    2010-01-01

    During an outcomes study of spasticity treatment at a developmental center for 62 residents with profound intellectual disabilities, either botulinum toxin A (BTX-A), intrathecal baclofen (ITB), or both were recommended with physical and occupational therapy. Conservators consented to BTX-A more than ITB (p = 0.021). Court-appointed conservators…

  1. GABAA and GABAB receptor-mediated effects on the spontaneous activity of the longitudinal layer in cat terminal ileum.

    Science.gov (United States)

    Pencheva, N; Radomirov, R; Venkova, K

    1991-01-01

    1. GABA and GABAergic agonists-muscimol and (+/-)baclofen changed the spontaneous mechanical activity in isolated cat terminal ileum. 2. GABA at doses ranging from 5 microM to 2 mM produced concentration-dependent biphasic responses consisting of a transient relaxation followed by contractions with a tonic and a phasic components. 3. The GABA-induced relaxation was sensitive to bicuculline and picrotoxinin and was mimicked by muscimol, while the GABA-induced contractions were insensitive to bicuculline and picrotoxinin and were mimicked by (+/-)baclofen. Specific cross desensitization occurred between GABA and muscimol or GABA and (+/-)baclofen. 4. The bicuculline-sensitive relaxation induced by GABA and muscimol was abolished by atropine or tetrodotoxin (TTX), while the bicuculline-insensitive contractions induced by GABA and (+/-)baclofen were not antagonized by atropine or TTX, though they were slightly suppressed. 5. The GABA effects in the longitudinal layer of cat terminal ileum were mediated by the following receptors: -GABAA prejunctional receptors whose activation causes relaxation, probably through an inhibitory action on cholinergic neurons; -GABAB prejunctional receptors whose activation cause contractions; -GABAB postjunctional receptors located on the smooth muscle membrane whose activation induces tonic and phasic contractions. PMID:1646745

  2. Combinational Spinal GAD65 Gene Delivery and Systemic GABA-Mimetic Treatment for Modulation of Spasticity

    Czech Academy of Sciences Publication Activity Database

    Kakinohana, O.; Hefferan, M. P.; Miyanohara, A.; Nejime, T.; Marsala, S.; Juhás, Štefan; Juhásová, Jana; Motlík, Jan; Kucharova, K.; Strnádel, Ján; Platoshyn, O.; Lazar, P.; Galik, J.; Vinay, L.; Marsala, M.

    2012-01-01

    Roč. 7, č. 1 (2012), s. 1-13. E-ISSN 1932-6203 Institutional research plan: CEZ:AV0Z50450515 Keywords : INTRATHECAL BACLOFEN * CORD-INJURY * UPTAKE INHIBITOR Subject RIV: FH - Neurology Impact factor: 3.730, year: 2012

  3. GABAA and GABAB receptor-mediated effects in guinea-pig ileum.

    Science.gov (United States)

    Giotti, A; Luzzi, S; Spagnesi, S; Zilletti, L

    1983-03-01

    1 The effects of gamma-aminobutyric acid (GABA) and related substances were examined in guinea-pig ileum longitudinal muscle.2 GABA at doses ranging from 10(-7) M to 3 x 10(-6) M elicited a relaxation while at higher doses (3 x 10(-6) M - 10(-4) M), as previously described, it caused a contraction followed by relaxation.3 GABA-induced relaxation was bicuculline-insensitive, was mimicked by (-)-baclofen but not by homotaurine and muscimol. The effect of baclofen was stereospecific. GABA- and (-)-baclofen-induced relaxations were dose-dependent and their ED(50) values were similar. A specific cross-desensitization occurred between GABA and (-)-baclofen.4 The bicuculline-insensitive relaxation induced by GABA and (-)-baclofen was prevented by tetrodotoxin and hyoscine but not by phentolamine plus propranolol, naloxone or theophylline.5 In preparations in which the muscle tone was raised by histamine or prostaglandin F(2alpha), GABA and (-)-baclofen induced relaxation to the same extent as before increasing the tone. If the tone was raised by DMPP, a greater bicuculline-insensitive relaxation occurred.6 Contraction caused by GABA was bicuculline-sensitive and was mimicked by homotaurine and muscimol. Contraction was dose-dependent and muscimol was about three times more potent than GABA or homotaurine. A specific cross-desensitization occurred between the contractile effects of GABA and those of homotaurine or muscimol.7 Bicuculline competitively antagonized the contractile effects of GABA, homotaurine and muscimol and gave closely similar pA(2) values. The slope of the Schild plot for the above drugs was near 1, confirming the competitive nature of the antagonism.8 The bicuculline-sensitive contraction induced by GABA, homotaurine and muscimol was abolished by tetrodotoxin and was non-competitively antagonized by hyoscine, while it was unaffected by hexamethonium, mepyramine and methysergide.9 It is concluded that two receptors mediate the GABA effects in guinea

  4. Inhibition of transmitter release shortens the duration of the excitatory synaptic current at a calyceal synapse.

    Science.gov (United States)

    Otis, T S; Trussell, L O

    1996-11-01

    1. We investigated the effect of reducing transmitter release on the time course of multiquantal, evoked synaptic currents to test for transmitter "cross talk" between neighboring synaptic release sites within a calyceal synapse. By using a brain slice preparation, neurons in the chick nucleus magnocellularis (nMAG) were voltage clamped and individual presynaptic axons were stimulated to evoke excitatory postsynaptic currents (EPSCs). 2. Application of 100-microM baclofen or 50-microM GABA in the presence of a gamma-aminobutyric acid-A (GABAA) receptor antagonist produced an 85% reduction of EPSCs, consistent with the activation of presynaptic gamma-aminobutyric acid-B (GABAB) receptors. In parallel with the reduction in the amplitude of the EPSC by GABAB receptor activation, the normally strong paired pulse depression (PPD) of the EPSC was converted to facilitation. The reduction in EPSC amplitude by gamma-aminobutyric acid (GABA) or baclofen was accompanied by a 20% reduction in the exponential time constant of decay of the EPSC. Weaker effects on the EPSC time course were observed for synapses with the least PPD. 3. Cd2+ (5 microM), which inhibits presynaptic calcium current, also reduced EPSC amplitude by 85% and converted PPD to facilitation. EPSCs were narrower in Cd2+, though less so than in baclofen. 4. The time course of the EPSC was longer than that of miniature synaptic currents, even after significant block by baclofen, GABA or Cd2+, indicating that dispersion of quantal release may help shape the synaptic waveform. However, the narrowing of the EPSC by baclofen, GABA, and Cd2+ suggests that high levels of quantal release at the calyceal synapse may delay the removal of transmitter, further slowing the EPSC. PMID:8930299

  5. Comparison of gamma-aminobutyric acid effects in different parts of the cat ileum.

    Science.gov (United States)

    Pencheva, N; Itzev, D; Milanov, P

    1999-02-26

    The effects of gamma-aminobutyric acid (GABA) and those of a GABA(A) (muscimol) and a GABA(B) (baclofen) receptor agonists were determined on the spontaneous activity of longitudinally or circularly oriented preparations (segments) isolated from terminal, proximal and distal parts of the cat ileum. GABA applied at 1 microM to 2 mM caused dose-dependent biphasic changes (relaxation and contraction) in spontaneous activity of the longitudinal and circular layers in the terminal and distal parts of the cat ileum and monophasic changes (contraction) in the proximal part. The potency of GABA to elicit relaxant and/or contractile effects in different parts of the ileum showed a proximal-to-terminal increasing pattern. In the longitudinal layer of the distal and terminal ileum, muscimol (100 microM) mimicked the relaxation phase of the GABA effect, while baclofen (100 microM) simulated the contractile phase. Bicuculline, atropine and tetrodotoxin abolished GABA- and muscimol-induced relaxation and suppressed, but failed to prevent GABA- and baclofen-induced contractions. In addition, 2-hydroxysaclofen antagonized the baclofen-induced contractile effect, reduced the GABA-induced contractile phase but failed to prevent GABA- and muscimol-induced relaxation. In the circular layer of the same regions, muscimol mimicked the biphasic GABA effects, while baclofen was without effect. Bicuculline, atropine and tetrodotoxin completely prevented the GABA- and muscimol effects, while 2-hydroxysaclofen failed to antagonize them. In the longitudinal and circular layers of the proximal ileum, muscimol (100 microM) exerted a 'GABA-like' transient contractile effect, while baclofen (100 microM) did not elicit any response. Bicuculline, atropine and tetrodotoxin antagonized the GABA- and muscimol-induced contractile responses of longitudinal and circular layers, while 2-hydroxysaclofen was ineffective. The results suggested that the inhibitory and/or excitatory action of GABA on

  6. Pharmacological characterization of homobaclofen on wild type and mutant GABA(B)1b receptors coexpressed with the GABA(B)2 receptor

    DEFF Research Database (Denmark)

    Jensen, Anders A.; Madsen, Bo E.; Krogsgaard-Larsen, P;

    2001-01-01

    Homobaclofen (5-amino-3-(4-chlorophenyl) pentanoic acid) is a homologue of the classical GABA(B) receptor agonist baclofen. In a recent study, the two enantiomers of this compound were tested in a GABA(B) receptor selective [3H]gamma-aminobutyric acid ([3H]GABA) binding assay using rat brain...... rat GABA(B)1b receptors coexpressed with rat GABA(B)2 receptors. The results from this study correlate nicely with the binding data from rat brain. (R)-Homobaclofen was shown to act like (R)-baclofen albeit with 20-fold less potency, and (S)-homobaclofen was inactive on the receptor. The discrepancies...... between the data obtained in this study and those from the guinea pig ileum model could be ascribed to differences in amino acid sequence or receptor splicing of GABA(B) receptors between the two species. Another explanation for the observation is the possible existence of a novel yet uncloned GABA...

  7. [Regulation of the mouse aggressive behavior (pharmacologic analysis of the GABAergic mechanism)].

    Science.gov (United States)

    Belozertseva, I V; Andreev, B V

    1999-01-01

    Ethological procedures were used to study the effects of GABA-positive drugs on aggression in male albino mice kept in isolation (opponent test). The results revealed several variants of antiaggressive effects of the tested GAB Aergic drugs: 1) antiaggressive, re-socializing of GABAA agonists muscimol (0.125 and 0.5 mg/kg) and THIP (2.0 mg/kg), and GABAB agonist baclofen (2.5-10 mg/kg); 2) antiaggressive, sedative of GABAB agonists baclofen (12.5 mg/kg), phenibut (50-100 mg/kg), and inhibitor of GABA transamininase sodium valproate (100 mg/kg); 3) antiaggressive, anxiogenic for muscimol (1 mg/kg), THIP (5 mg/kg), and sodium valproate (25-50 mg/kg). PMID:10570533

  8. Complex regional pain syndrome with associated chest wall dystonia: a case report

    Directory of Open Access Journals (Sweden)

    Schwartzman Robert J

    2011-09-01

    Full Text Available Abstract Patients with complex regional pain syndrome (CRPS often suffer from an array of associated movement disorders, including dystonia of an affected limb. We present a case of a patient with long standing CRPS after a brachial plexus injury, who after displaying several features of the movement disorder previously, developed painful dystonia of chest wall musculature. Detailed neurologic examination found palpable sustained contractions of the pectoral and intercostal muscles in addition to surface allodynia. Needle electromyography of the intercostal and paraspinal muscles supported the diagnosis of dystonia. In addition, pulmonary function testing showed both restrictive and obstructive features in the absence of a clear cardiopulmonary etiology. Treatment was initiated with intrathecal baclofen and the patient had symptomatic relief and improvement of dystonia. This case illustrates a novel form of the movement disorder associated with CRPS with response to intrathecal baclofen treatment.

  9. Pharmacologic interventions for reducing spasticity in cerebral palsy.

    Science.gov (United States)

    Patel, Dilip R; Soyode, Olufemi

    2005-10-01

    Motor function abnormalities are a key feature of cerebral palsy. Spasticity is one of the main motor abnormalities seen in children with cerebral palsy. Spasticity is a velocity dependent increased resistance to movement. While in some children, spasticity may adversely impact the motor abilities, in others, it may help maintain posture and ability to ambulate. Thus, treatment to reduce spasticity requires careful consideration of various factors. Non-pharmacologic interventions used to reduce spasticity include physiotherapy, occupational therapy, use of adaptive equipment, various orthopedic surgical procedures and neurosurgical procedures. Pharmacologic interventions used for reducing spasticity in children with cerebral palsy reviewed in this article include oral administration of baclofen, diazepam, dantrolene and tizanidine, intrathecal baclofen, and local injections of botulinum toxin, phenol, and alcohol. PMID:16272661

  10. Comparison of Nootropic and Neuroprotective Features of Aryl-Substituted Analogs of Gamma-Aminobutyric Acid.

    Science.gov (United States)

    Tyurenkov, I N; Borodkina, L E; Bagmetova, V V; Berestovitskaya, V M; Vasil'eva, O S

    2016-02-01

    GABA analogs containing phenyl (phenibut) or para-chlorophenyl (baclofen) substituents demonstrated nootropic activity in a dose of 20 mg/kg: they improved passive avoidance conditioning, decelerated its natural extinction, and exerted antiamnestic effect on the models of amnesia provoked by scopolamine or electroshock. Tolyl-containing GABA analog (tolibut, 20 mg/kg) exhibited antiamnestic activity only on the model of electroshock-induced amnesia. Baclofen and, to a lesser extent, tolibut alleviated seizures provoked by electroshock, i.e. both agents exerted anticonvulsant effect. All examined GABA aryl derivatives demonstrated neuroprotective properties on the maximum electroshock model: they shortened the duration of coma and shortened the period of spontaneous motor activity recovery. In addition, these agents decreased the severity of passive avoidance amnesia and behavioral deficit in the open field test in rats exposed to electroshock. The greatest neuroprotective properties were exhibited by phenyl-containing GABA analog phenibut. PMID:26906198

  11. Percutaneous radiofrequency lesions adjacent to the dorsal root ganglion alleviate spasticity and pain in children with cerebral palsy: pilot study in 17 patients

    OpenAIRE

    van Rhijn Lodewijk W; Weber Wim E; Staal Heleen M; van Zundert Jan; van Kleef Maarten; Vles Johan S; Vles Georges F; Soudant Dan; Graham H Kerr; de Louw Anton J

    2010-01-01

    Abstract Background Cerebral palsy (CP) may cause severe spasticity, requiring neurosurgical procedures. The most common neurosurgical procedures are continuous infusion of intrathecal baclofen and selective dorsal rhizotomy. Both are invasive and complex procedures. We hypothesized that a percutaneous radiofrequency lesion of the dorsal root ganglion (RF-DRG) could be a simple and safe alternative treatment. We undertook a pilot study to test this hypothesis. Methods We performed an RF-DRG p...

  12. [GABA-ergic system in defense against excitatory kynurenines].

    Science.gov (United States)

    Lapin, I P

    1997-01-01

    Protection against the excitatory action of L-kynurenine and quinolinic acid in mice is related to the activation of GABA-B and dopamine receptors of the brain and to much lesser degree to the activation of GABA-A receptors. It is hardly believable that the anticonvulsant effect of phenibut (beta-phenyl-GABA), baclofen (CL-phenibut), sodium hydroxybutyrate and taurine against seizures induced by these two kynurenines is determined by alterations in metabolism of GABA. PMID:9503572

  13. Electrical and pharmacological neuromodulation in patient with spinal cord injury pain (La neuromodulazione elettrica e farmacologica nel paziente con dolore post lesione midollare)

    OpenAIRE

    Carmelo Costa; Gabriella Nicosia; Carmelo Petralia; Maria Pia Onesta

    2014-01-01

    The authors present the different kinds of pain following the spinal cord lesions (neuropathic, nociceptive, somatic, visceral); they describe the alterations that occur on spinal cord, brain and periphery; the methods to define the kinds of pain and to evaluate the pain intensity; the strumental and pharmacological treatments for pain relief. In detail data on the efficacy of spinal neurostimulation are compared with data on the efficacy of baclofen intrathecally administered. Based on r...

  14. Ontogenetic Development of GABA(B)-Receptor Signaling Cascade in Plasma Membranes Isolated From Rat Brain Cortex; the Number of GABA(B)-Receptors Is High Already Shortly After the Birth

    Czech Academy of Sciences Publication Activity Database

    Kagan, Dmytro; Dlouhá, Kateřina; Roubalová, Lenka; Svoboda, Petr

    2012-01-01

    Roč. 61, č. 6 (2012), s. 629-635. ISSN 0862-8408 R&D Projects: GA ČR(CZ) GBP304/12/G069; GA ČR(CZ) GAP207/12/0919 Institutional research plan: CEZ:AV0Z50110509 Institutional support: RVO:67985823 Keywords : postnatal development * GABAB-receptors * G-protein coupling/activation * baclofen * SKF97541 Subject RIV: CE - Biochemistry Impact factor: 1.531, year: 2012

  15. Two types of functionally different GABAA receptors mediate GABA modulation of cholinergic transmission in cat terminal ileum.

    Science.gov (United States)

    Radomirov, R; Pencheva, N

    1995-08-01

    1. The effects of GABA (1 microM-2 mM) on longitudinally or circularly oriented organ bath preparations of cat terminal ileum consisted of a relaxation phase with an inhibition of the rhythmic spontaneous phasic contractions, followed by a phase of contractions characterized by an elevation in basal tone and an increase in amplitude of the spontaneous phasic contractions. 2. Muscimol (100 microM), but not baclofen (100 microM), mimicked the relaxation phase of the response to applied GABA (100 microM) in all tissue preparations. In addition, muscimol induced a phase of contractile activity in the circular muscle layer whilst baclofen exerted a 'GABA-like' contractile effect on the longitudinal muscle layer. Bicuculline (30 microM) or picrotoxinin (30 microM) antagonized the GABA- or muscimol-induced relaxations in all preparations and decreased the GABA- but not the baclofen-induced contractions of the longitudinal muscle layer. 3. Tetrodotoxin (0.5 microM) or atropine (0.1 microM) prevented the bicuculline-sensitive phases of the GABA or muscimol effects on both muscle layers but not the contractile effect of baclofen on the longitudinal muscle layer. 4. The bicuculline-sensitive phases of the GABA effect on both muscle layers were almost completely eliminated by 1 nM pirenzepine. At this concentration pirenzepine did not affect the electrically-evoked cholinergic twitch contractions or contractile responses to applied acetylcholine of both muscle layers. 5. During electrically-evoked cholinergic twitch contractions of both muscle layers, GABA (100 microM) had an inhibitory effect. The inhibition occurred in the presence of pirenzepine (1 nM) but not of bicuculline (30 microM). 6. It is suggested that two types of functionally different bicuculline-sensitive GABAA receptors mediate an exitatory presynaptic and an inhibitory prejunctional action of GABA on the cholinergic transmission in cat terminal ileum. PMID:8576270

  16. G(o) transduces GABAB-receptor modulation of N-type calcium channels in cultured dorsal root ganglion neurons.

    Science.gov (United States)

    Menon-Johansson, A S; Berrow, N; Dolphin, A C

    1993-11-01

    High-voltage-activated (HVA) calcium channel currents (IBa) were recorded from acutely replated cultured dorsal root ganglion (DRG) neurons. IBa was irreversibly inhibited by 56.9 +/- 2.7% by 1 microM omega-conotoxin-GVIA (omega-CTx-GVIA), whereas the 1,4-dihydropyridine antagonist nicardipine was ineffective. The selective gamma-aminobutyric acidB (GABAB) agonist, (-)-baclofen (50 microM), inhibited the HVA IBa by 30.7 +/- 5.4%. Prior application of omega-CTx-GVIA completely occluded inhibition of the HVA IBa by (-)-baclofen, indicating that in this preparation (-)-baclofen inhibits N-type current. To investigate which G protein subtype was involved, cells were replated in the presence of anti-G protein antisera. Under these conditions the antibodies were shown to enter the cells through transient pores created during the replating procedure. Replating DRGs in the presence of anti-G(o) antiserum, raised against the C-terminal decapeptide of the G alpha o subunit, reduced (-)-baclofen inhibition of the HVA IBa, whereas replating DRGs in the presence of the anti-Gi antiserum did not. Using anti-G alpha o antisera (1:2000) and confocal laser microscopy, G alpha o localisation was investigated in both unreplated and replated neurons. G alpha o immunoreactivity was observed at the plasma membrane, neurites, attachment plaques and perinuclear region, and was particularly pronounced at points of cell-to-cell contact. The plasma membrane G alpha o immunoreactivity was completely blocked by preincubation with the immunising G alpha o undecapeptide (1 microgram.ml-1) for 1 h at 37 degrees C. A similar treatment also blocked recognition of G alpha o in brain membranes on immunoblots.(ABSTRACT TRUNCATED AT 250 WORDS) PMID:8309795

  17. Septal co-infusions of glucose with a GABAB agonist impair memory

    OpenAIRE

    Erickson, Erika J.; Watts, Kelly D; Parent, Marise B.

    2005-01-01

    Septal infusions of glucose exacerbate memory deficits produced by co-infusions of drugs that increase γ-aminobutyric acid (GABA)A receptor activity. To further understand the interaction between glucose and GABA, this experiment tested whether glucose would also potentiate spatial working memory deficits produced by septal infusions of the GABAB receptor agonist baclofen. Fifteen minutes prior to assessing spontaneous alternation (SA), male Sprague–Dawley derived rats were given septal infus...

  18. Does pain relief influence recovery of consciousness? A case report of a patient treated with ziconotide.

    Science.gov (United States)

    Lanzillo, Bernardo; Loreto, Vincenzo; Calabrese, Claudio; Estraneo, Anna; Moretta, Pasquale; Trojano, Luigi

    2016-04-01

    For people with cervical spinal cord injury (SCI), access to computers can be difficult, thus several devices have been developed to facilitate their Disorders of consciousness (DOC) are difficult to classify. The degree of consciousness varies from coma to vegetative state or unresponsive wakefulness syndrome (UWS) and minimally conscious state. Correct diagnosis has important ethical and legal implications, and pain may be cause of misdiagnosis. We describe here a patient with traumatic brain injury, classified as UWS. His clinical picture was dominated by spasticity, and pain. He underwent intrathecal treatment of spasticity with baclofen. Improvement was not that expected. However, there was a dramatic improvement when ziconotide was added to relieve pain; the patient began to eat by mouth, talk, and his tracheal tube could be removed and he is currently classified as having severe disability. The suspension of ziconotide caused a clear re-worsening of clinical condition, reverted by his reintroduction. Pain is an important factor in patients with DOC. Anecdotal reports of improved consciousness with intrathecal baclofen therapy may be due to pain relief. Reduction of pain in DOC is important and drugs should not interfere with cognition, and must be effective and manageable. Ziconotide may be one of the possible candidate due to its synergistic antispastic action in combination with baclofen when an intratecal pump has been implanted. PMID:25491316

  19. Initial characterization of receptors for molecules that induce the settlement and metamorphosis of Haliotis rufescens larvae

    International Nuclear Information System (INIS)

    Larvae of the marine gastropod mollusc Haliotis refescens are induced to undergo metamorphosis by γ-aminobutyric acid (GABA) and stereochemically related compounds. The most potent of these inducers is (-)-β-(parachlorophenyl)-GABA (baclofen). The inductive response exhibits positive cooperatively, and is subject to both facilitation (up-regulation) and habituation (down-regulation). Facilitation is brought about by diamino acids such as L-diaminopropionic acid (L-DAPA), and is characterized by decreased Hill coefficients (n/sub H/) and concentration requirements (EC50) for inducers. Facilitation does not require the simultaneous presence of facilitating and inducing compounds, and the facilitated state is persistent. Larvae are capable of being up-regulated 2 days before they are capable of undergoing settlement and metamorphosis. Habituation can be brought about by exposure of pre-competent larvae to GABA 4 days prior to the attainment of competence; it is then slowly reversible. Larvae specifically bind tritiated (-)-baclofen in a manner that is saturable with both increasing time of exposure of larvae to, and with increasing concentration of, this compound. Specific binding can be competed for by unlabeled GABA-mimetic inducing molecules; the order of effectiveness of these molecules as competitors for specific binding correlates well with their effectiveness as inducers of metamorphosis. Facilitation of larvae by exposure to diamino acids does not alter their specific binding of tritiated (-)-baclofen. It is concluded from these findings that Haliotis larvae possess receptors for GABA-mimetic compounds

  20. Interaction of Electromagnetic Field and Modulation of GABA-B Receptor on Serum Testosterone Concentration in Aggressive Rats

    Directory of Open Access Journals (Sweden)

    S Karimi

    2011-10-01

    Full Text Available Introduction: The aim of the present study is to investigate the effect of interaperitoneal injection of baclofen (GABA-B agonist and CGP35348 (GABA-B antagonist on serum testosterone concentration in aggressive rats exposed to electromagnetic field. Methods: Fifty five mature male rats weighing 200±20 grams were studied. Animals were divided into 2 main groups and four subgroups. Main groups composed of rats with and without exposure to electromagnetic field. Animals in the former group were exposed to electromagnetic field with 500 T intensity and 50Hz frequency for 8 hours a day for 30 days. Aggression was induced by applying 2mA current every 3 seconds for 5 minutes. Then serum testosterone concentration was measured by radioimmunoassay method. Results: Data showed that baclofen injection at 3mg/kg and CGP35348 at 100mg/kg significantly increased serum testosterone concentration in aggressive rats exposed to electromagnetic field. Conclusion: According to the simillar effect of baclofen and CGP35348 on testosterone secretion, it seems that GABA-B receptors in testes are two types, so it has caused similar effects. Also, electromagnetic exposure leads to increase in testosterone secretion.

  1. Walking with Neuropathic Pain: Paradoxical Shift from Burden to Support?

    Directory of Open Access Journals (Sweden)

    David J. Kopsky

    2015-01-01

    Full Text Available Baclofen 5% cream can be used for the treatment of neuropathic pain. We describe an unusual case of a neuropathic pain patient with spinal cord injury. A 71-year-old woman with a partial spinal cord injury lesion at L4 complained of tingling, pins and needles, and burning in her legs. She scored her pain as 6 before adding baclofen 5% cream to her pain medication (pregabalin 450 mg, acetaminophen 3000 mg, and diclofenac 150 mg daily. One month later she experienced complete pain relief, though experienced increased difficulties in walking, leading to frequent falls. Her steadier walking without stumbling and falling was more important to her than pain reduction. Thus she decided to stop using baclofen. This unusual case report discusses two important issues that relate to pain medicine and rehabilitation in patients with painful spinal cord lesions: (1 the presence of wide areas of sensory loss “covered” by the presence of painful sensations and (2 pathological sensations that can be used and integrated in the body schema to create an improved spatiovisual orientation and thus mobility. Both these aspects have to be taken into account when treating pain and design rehabilitation programs.

  2. STUDY OF ANTIDEPRESSANT LIKE EFFECT OF CORIANDRUM SATIVUM AND INVOLVEMENT OF MONOAMINONERGIC AND GABANERGIC SYSTEM

    Directory of Open Access Journals (Sweden)

    Naikwade Nilofer

    2011-02-01

    Full Text Available The aim of this study was to examine possible mechanism of action of aqueous extract of Coriandrum sativum seed central nervous system of mice. We investigated the antidepressant-like mechanism of Coriandrum sativum by the combination of the Sulpiride (a selective dopamine D2 receptor antagonist, Prazosin (a α1 adrenoceptor antagonist, and Baclofen (GABA agonist. The results show that Coriandrum sativum (200 mg/kg, 400mg/kg, p.o., significantly reduced the immobility time during Tail Suspension Test (TST. We also investigated the antidepressant-like mechanism of Coriandrum sativum by the combination of Sulpiride (a selective dopamine D2 receptor antagonist, Prazosin (a α1 adrenoceptor antagonist, and Baclofen (GABA agonist. The immobility time after treatment with Coriandrum sativum (200 mg/kg, 400mg/kg, p.o. in TST was augmented by Sulpiride, Baclofen, Prazosin. Our findings support the view that Coriandrum sativum exerts antidepressant-like effect. And the mechanism of action of Coriandrum sativum may be related to the increase in Nor adrenaline and serotonin levels in the hippocampus and frontal cortex.

  3. Tonic activation of presynaptic GABAB receptors on rat pallidosubthalamic terminals

    Institute of Scientific and Technical Information of China (English)

    Lei CHEN; Wing-ho YUNG

    2005-01-01

    Aim: The subthalamic nucleus plays a critical role in the regulation of movement,and abnormal activity of its neurons is associated with some basal ganglia motor symptoms. We examined the presence of functional presynaptic GABAB receptors on pallidosubthalamic terminals and tested whether they were tonically active in the in vitro subthalamic slices. Methods: Whole-cell patch-clamp recordings were applied to acutely prepared rat subthalamic nucleus slices. The effects of specific GABAB agonist and antagonist on action potential-independent inhibitory postsynapfic currents (IPSCs), as well as holding current, were examined.Results: Superfusion of baclofen, a GABAB receptor agonist, significantly reduced the frequency of GABAA receptor-mediated miniature IPSCs (mIPSCs), in a Cd2+-sensitive manner, with no effect on the amplitude, indicating presynaptic inhibition on GABA release. In addition, baclofen induced a weak outward current only in a minority of subthalamic neurons. Both the pre- and post-synaptic effects of baclofen were prevented by the specific GABAB receptor antagonist,CGP55845. Furthermore, CGP55845 alone increased the frequency of mIPSCs,but had no effect on the holding current. Conclusion: These findings suggest the functional dominance of presynaptic GABAB receptors on the pallidosubthalamic terminals over the postsynaptic GABAB receptors on subthalamic neurons.Furthermore, the presynaptic, but not the postsynaptic, GABAB receptors are tonically active, suggesting that the presynaptic GABAB receptors in the subthalamic nucleus are potential therapeutic target for the treatment of Parkinson disease.

  4. Initial characterization of receptors for molecules that induce the settlement and metamorphosis of Haliotis rufescens larvae

    Energy Technology Data Exchange (ETDEWEB)

    Trapido-Rosenthal, H.G.

    1985-01-01

    Larvae of the marine gastropod mollusc Haliotis refescens are induced to undergo metamorphosis by ..gamma..-aminobutyric acid (GABA) and stereochemically related compounds. The most potent of these inducers is (-)-..beta..-(parachlorophenyl)-GABA (baclofen). The inductive response exhibits positive cooperatively, and is subject to both facilitation (up-regulation) and habituation (down-regulation). Facilitation is brought about by diamino acids such as L-diaminopropionic acid (L-DAPA), and is characterized by decreased Hill coefficients (n/sub H/) and concentration requirements (EC/sub 50/) for inducers. Facilitation does not require the simultaneous presence of facilitating and inducing compounds, and the facilitated state is persistent. Larvae are capable of being up-regulated 2 days before they are capable of undergoing settlement and metamorphosis. Habituation can be brought about by exposure of pre-competent larvae to GABA 4 days prior to the attainment of competence; it is then slowly reversible. Larvae specifically bind tritiated (-)-baclofen in a manner that is saturable with both increasing time of exposure of larvae to, and with increasing concentration of, this compound. Specific binding can be competed for by unlabeled GABA-mimetic inducing molecules; the order of effectiveness of these molecules as competitors for specific binding correlates well with their effectiveness as inducers of metamorphosis. Facilitation of larvae by exposure to diamino acids does not alter their specific binding of tritiated (-)-baclofen. It is concluded from these findings that Haliotis larvae possess receptors for GABA-mimetic compounds.

  5. Management of motor problems in cerebral palsy: a critical update for the clinician.

    Science.gov (United States)

    Papavasiliou, Antigone S

    2009-09-01

    Currently there is no specific treatment for the brain insults leading to motor dysfunction in cerebral palsy. The available symptomatic therapeutic options place cerebral palsy among the costliest chronic childhood conditions. Therefore, it is necessary to make well-informed decisions in an effort to match cost-effectiveness with patient and family needs. This presentation aims to analyze the efficacy of rehabilitation therapy, orthoses, oral medications, botulinum toxin, intrathecal baclofen, complementary or alternative treatments and discuss guidelines for a goal oriented approach. Despite insufficient reporting of trials, physiotherapy has shifted from traditional to goal oriented approaches, based on principles of motor learning, strength and fitness training. Correct choice and use of orthoses is stressed, yet evidence from primary studies is limited. Pharmacological treatments of spasticity (oral agents, botulinum toxin, intrathecal baclofen) may be alternatives or supplements to orthopaedic surgery. There is evidence that botulinum toxin combined with conservative treatments reduces the number of complex orthopaedic interventions. Intrathecal baclofen effectively reduces spasticity; criteria describing the ideal candidate are needed. Complementary or alternative treatment use is widespread; research needs to determine what factors make these modalities desirable and effective in cerebral palsy. It is concluded that the introduction of new therapies facilitates an individualized management plan. Multimodal treatment is optimized with a multidisciplinary team. Outcome measurement according to the World Health Organization's new International Classification of Functioning, Disability and Health is emphasized. PMID:18778959

  6. Biphasic GABA-A receptor-mediated effect on the spontaneous activity of the circular layer in cat terminal ileum.

    Science.gov (United States)

    Pencheva, N; Radomirov, R

    1993-07-01

    1. The GABA and GABA-A receptor agonist muscimol changed the spontaneous mechanical activity of a circular layer isolated from cat terminal ileum, while the selective GABA-B receptor agonist (+/-)baclofen had no effect. 2. GABA at doses ranging from 1 microM to 2 mM elicited concentration-dependent biphasic responses which consisted of a relaxation followed by contraction, with a tonic and a phasic component. The EC50 values, calculated at 95% confidence limits (CL), were 94.9 microM (83.5-109.8 microM) and 66.0 microM (51.2-75.5 microM) for the relaxation and contractile phases, respectively. 3. The GABA-induced biphasic responses were sensitive to bicuculline and picrotoxinin and were entirely mimicked by muscimol. Bicuculline competitively antagonized the effects of GABA and gave closely similar pA2 values for both phases of these responses--inhibitory and stimulatory. Cross-desensitization occurred only between GABA and muscimol and not between (+/-)baclofen and GABA, or (+/-)baclofen and muscimol. 4. Both bicuculline-sensitive phases evoked by GABA and muscimol were abolished by tetrodotoxin or atropine, but were unaffected by guanethidine or naloxone. 5. The present results suggested that the biphasic GABA effect on the mechanical activity of the circular layer in cat terminal ileum was mediated by prejunctional GABA-A receptors, most probably through an action on the cholinergic pathway. PMID:8224749

  7. Differential involvement of GABAA and GABAB receptors in propofol self-administration in rats

    Institute of Scientific and Technical Information of China (English)

    Bo YANG; Ben-fu WANG; Miao-jun LAI; Fu-qiang ZHANG; Xiao-wei YANG; Wen-hua ZHOU; Qing-quan LIAN

    2011-01-01

    Propofol has shown abuse potential.The aim of the present study is to investigate the effects of GABAA antagonist and GABAB agonist on propofol reinforcement.Methods:Sprague-Dawley rats were trained to self-administer propofol at a dose of 1.7 mg/kg per infusion under a fixed ratio (FR1) schedule of reinforcement for 14 d.In a separate set of experiments,food-maintained self-administration under a fixed ratio (FR5) schedule and locomotor activities of Sprague-Dawley rats were examined.Results:GABAA receptor antagonist bicuculline (0.25 mg/kg,ip) significantly increased the number of injections and active responses.Pretreatment with GABAB receptor agonist baclofen (3 mg/kg,ip) significantly decreased the number of active responses and total infusions of propofol during the training session.Moreover,microinjection of baclofen (50 and 100 ng/side) into the ventral tegmental area (VTA) significantly decreased the number of active responses and total infusions of propofol.Neither baclofen (1-3 mg/kg,ip) nor bicuculline (0.25-1 mg/kg,ip) affected food-maintained responses or motor activities.Conclusion:Propofol maintains its reward properties partially through GABAA receptor activation.Stimulation of GABA~ receptors in VTA may counteract the reinforcing properties of propofol.

  8. Simultaneous stimulation of GABA and beta adrenergic receptors stabilizes isotypes of activated adenylyl cyclase heterocomplex

    Directory of Open Access Journals (Sweden)

    Robichon Alain

    2004-06-01

    Full Text Available Abstract Background We investigated how the synthesis of cAMP, stimulated by isoproterenol acting through β-adrenoreceptors and Gs, is strongly amplified by simultaneous incubation with baclofen. Baclofen is an agonist of δ-aminobutyric acid type B receptors [GABAB], known to inhibit adenylyl cyclase via Gi. Because these agents have opposite effects on cAMP levels, the unexpected increase in cAMP synthesis when they are applied simultaneously has been intensively investigated. From previous reports, it appears that cyclase type II contributes most significantly to this phenomenon. Results We found that simultaneous application of isoproterenol and baclofen specifically influences the association/dissociation of molecules involved in the induction and termination of cyclase activity. Beta/gamma from [GABA]B receptor-coupled Gi has a higher affinity for adenylyl cyclase isoform(s when these isoforms are co-associated with Gs. Our data also suggest that, when beta/gamma and Gαs are associated with adenylyl cyclase isoform(s, beta/gamma from [GABA]B receptor-coupled Gi retards the GTPase activity of Gαs from adrenergic receptor. These reciprocal regulations of subunits of the adenylyl cyclase complex might be responsible for the drastic increase of cAMP synthesis in response to the simultaneous signals. Conclusions Simultaneous signals arriving at a particular synapse converge on molecular detectors of coincidence and trigger specific biochemical events. We hypothesize that this phenomenon comes from the complex molecular architectures involved, including scaffolding proteins that make reciprocal interactions between associated molecules possible. The biochemistry of simultaneous signaling is addressed as a key to synaptic function.

  9. The bradycardic and hypotensive responses to serotonin are reduced by activation of GABAA receptors in the nucleus tractus solitarius of awake rats

    Directory of Open Access Journals (Sweden)

    Callera J.C.

    2005-01-01

    Full Text Available We investigated the effects of bilateral injections of the GABA receptor agonists muscimol (GABA A and baclofen (GABA B into the nucleus tractus solitarius (NTS on the bradycardia and hypotension induced by iv serotonin injections (5-HT, 2 µg/rat in awake male Holtzman rats. 5-HT was injected in rats with stainless steel cannulas implanted bilaterally in the NTS, before and 5, 15, and 60 min after bilateral injections of muscimol or baclofen into the NTS. The responses to 5-HT were tested before and after the injection of atropine methyl bromide. Muscimol (50 pmol/50 nl, N = 8 into the NTS increased basal mean arterial pressure (MAP from 115 ± 4 to 144 ± 6 mmHg, did not change basal heart rate (HR and reduced the bradycardia (-40 ± 14 and -73 ± 26 bpm at 5 and 15 min, respectively, vs -180 ± 20 bpm for the control and hypotension (-11 ± 4 and -14 ± 4 mmHg, vs -40 ± 9 mmHg for the control elicited by 5-HT. Baclofen (12.5 pmol/50 nl, N = 7 into the NTS also increased basal MAP, but did not change basal HR, bradycardia or hypotension in response to 5-HT injections. Atropine methyl bromide (1 mg/kg body weight injected iv reduced the bradycardic and hypotensive responses to 5-HT injections. The stimulation of GABA A receptors in the NTS of awake rats elicits a significant increase in basal MAP and decreases the cardiac Bezold-Jarisch reflex responses to iv 5-HT injections.

  10. Opioid and GABAB receptors differentially couple to an adenylyl cyclase/protein kinase A downstream effector after chronic morphine treatment.

    Directory of Open Access Journals (Sweden)

    Elena Elizabeth Bagley

    2014-06-01

    Full Text Available Opioids are intensely addictive, and cessation of their chronic use is associated with a highly aversive withdrawal syndrome. A cellular hallmark of withdrawal is an opioid sensitive protein kinase A-dependent increase in GABA transporter-1 (GAT-1 currents in periaqueductal gray (PAG neurons. Elevated GAT-1 activity directly increases GABAergic neuronal excitability and synaptic GABA release, which will enhance GABAergic inhibition of PAG output neurons. This reduced activity of PAG output neurons to several brain regions, including the hypothalamus and medulla, contributes to many of the PAG-mediated signs of opioid withdrawal. The GABAB receptor agonist baclofen reduces some of the PAG mediated signs of opioid withdrawal. Like the opioid receptors the GABAB receptor is a Gi/Go coupled G-protein coupled receptor. This suggests it could be modulating GAT-1 activity in PAG neurons through its inhibition of the adenylyl cyclase/protein kinase A pathway. Opioid modulation of the GAT-1 activity can be detected by changes in the reversal potential of opioid membrane currents. We found that when opioids are reducing the GAT-1 cation conductance and increasing the GIRK conductance the opioid agonist reversal potential is much more negative than Ek. Using this approach for GABAB receptors we show that the GABAB receptor agonist, baclofen, does not couple to inhibition of GAT-1 currents during opioid withdrawal. It is possible this differential signaling of the two Gi/Go coupled G-protein coupled receptors is due to the strong compartmentalization of the GABAB receptor that does not favor signaling to the adenylyl cyclase/protein kinase A/GAT-1 pathway. This highlights the importance of studying the effects of G-protein coupled receptors in native tissue with endogenous G-protein coupled receptors and the full complement of relevant proteins and signaling molecules. This study suggests that baclofen reduces opioid withdrawal symptoms through a non-GAT-1

  11. Paroxysmal Autonomic Instability with Dystonia after Pneumococcal Meningoencephalitis

    Directory of Open Access Journals (Sweden)

    Layal Safadieh

    2012-01-01

    Full Text Available Streptococcus pneumoniae is a common cause of bacterial meningitis, frequently resulting in severe neurological impairment. A seven-month-old child presenting with Streptococcus pneumoniae meningoencephalitis developed right basal ganglia and hypothalamic infarctions. Daily episodes of agitation, hypertension, tachycardia, diaphoresis, hyperthermia, and decerebrate posturing were observed. The diagnosis of paroxysmal autonomic instability with dystonia was established. The patient responded to clonidine, baclofen, and benzodiazepines. Although this entity has been reported in association with traumatic brain injury, and as a sequel to some nervous system infections, this is the first case, to our knowledge, associated with pneumococcal meningoencephalitis.

  12. Glutamic acid decarboxylase antibody-positive paraneoplastic stiff limb syndrome associated with carcinoma of the breast

    Directory of Open Access Journals (Sweden)

    Agarwal Pankaj

    2010-01-01

    Full Text Available Stiff limb syndrome (SLS is a rare "focal" variant of stiff person syndrome which presents with rigidity and painful spasms of a distal limb, and abnormal fixed foot or hand postures. Anti-glutamic acid decarboxylase antibodies (GAD-Ab are variably present in most cases. Most reported cases of SLS are unassociated with cancer. We describe a patient with SLS as a paraneoplastic manifestation of breast carcinoma, in whom GAD-Ab was present. The patient responded very well to oral diazepam, baclofen and steroids.This is the third reported case of SLS as a paraneoplastic accompaniment to cancer.

  13. [2015 Update in ambulatory general internal medicine].

    Science.gov (United States)

    Pasche, Sephora; Favrod-Coune, Thierry; Lanier, Cédric; Spechbach, Hervé; Siewe, Sandrine Tchokoteu; Vieira De Melo-Pulla, Drenusha; Wagner, Élise; Jackson, Yves

    2016-01-20

    This article summarizes a selection of recently published clinical and public health articles of interest to primary care physicians. It touches upon the use of new oral anticoagulant in atrial fibrillation, the efficacy of baclofen for alcohol dependence, the pathogen identification in community acquired pneumonia, the accuracy of emergency room diagnosis in patients with ill-defined symptoms, the relationship between sleep and susceptibility to infection, the benefits of smoking cessation and of a new vaccine against zoster in elderly patients and finally the distribution of health literacy in Europe. PMID:26946787

  14. Stereoselective reaction of 2-carboxythioesters-1,3-dithiane with nitroalkenes: an organocatalytic strategy for the asymmetric addition of a glyoxylate anion equivalent.

    Science.gov (United States)

    Massolo, Elisabetta; Benaglia, Maurizio; Genoni, Andrea; Annunziata, Rita; Celentano, Giuseppe; Gaggero, Nicoletta

    2015-05-28

    An efficient organocatalytic methodology has been developed to perform the stereoselective addition of 2-carboxythioesters-1,3-dithiane to nitroalkenes. Under mild reaction conditions γ-nitro-β-aryl-α-keto esters with up to 92% ee were obtained, realizing a formal catalytic stereoselective conjugate addition of the glyoxylate anion synthon. The reaction products are versatile starting materials for further synthetic transformations; for example, the simultaneous reduction of the nitro group and removal of the dithiane ring was accomplished, allowing the preparation of a GABAB receptor agonist baclofen. PMID:25883074

  15. ANTIAMNESIC EFFECT OF THE TWO NOVEL K-OPIOID AGONISTS, VA-100 AND VA-101, IN THE MOUSE PASSIVE AVOIDANCE TEST

    OpenAIRE

    Ghelardini, C; Galeotti, N; Di Cesare Mannelli, L.; A. Cappelli; M.ANZINI; Bartolini, A.

    2001-01-01

    The effects of the administration of the two novel k-opioid agonists (VA-100, VA-101) on memory processes were evaluated with the mouse passive avoidance test. The administration of VA-100 (50–100 mg kg–1 p.o.) and VA-101 (100 mg kg–1 p.o.) administered 20 min before the training session prevented nor-binaltorphimine (4.9 mg per mouse i.c.v.), scopolamine (1.5 mg kg–1 i.p.), mecamylamine (20 mg kg–1 i.p.), diphenhydramine (20 mg kg–1 i.p.), and baclofen (2 mg kg–1 i.p.) amnesia. A...

  16. AG-4:A NICOTINIC AGONIST ENDOWED WITH ANTIAMNESIC PROPERTIES

    OpenAIRE

    Ghelardini, C; Galeotti, N; Di Cesare Mannelli, L.; S. Dei; F. GUALTIERI; Bartolini, A.

    2000-01-01

    The effect of the nicotinic agonist AG-4 on memory processes was evaluated in the mouse passive avoidance test. AG-4 (100 mg per mouse icv) prevented amnesia induced by scopolamine (1.5 mg kg–1 ip), mecamylamine (20 mg kg–1 ip), and dihydro-b-erythroidine (10 mg per mouse icv). In the same experimental conditions, AG-4 (100 mg per mouse icv) also prevented baclofen (2 mg kg–1 ip), clonidine (0.125 mg kg–1 ip), and diphenhydramine (20 mg kg–1 ip) amnesia in mice. AG-4 exerted an an...

  17. ANTIAMNESIC ACTIVITY OF THE NICOTINIC AGONIST DBO-83 IN MICE

    OpenAIRE

    Ghelardini, C; Galeotti, N; Giuliani, F.; D. Barlocco; Bartolini, A.

    1998-01-01

    The effect of administration of DBO-83 on memory processes was evaluated in the mouse passive avoidance test. DBO-83 (1–5 mgkg–1 ip) prevented amnesia induced by scopolamine (1.5 mgkg–1 ip), mecamylamine (20 mgkg–1 ip) and dihydro-b-erythroidine (10 mg per mouse i.c.v.). In the same experimental conditions, DBO-83 (10 mgkg–1 ip) also prevented baclofen (2 mgkg–1 ip), clonidine (0.125 mgkg–1 ip) and diphenhydramine (20 mgkg–1 ip) amnesia in mice. The antiamnesic effect of DBO-83 wa...

  18. Mechanism of inhibition of calcium channels in rat nucleus tractus solitarius by neurotransmitters.

    OpenAIRE

    Rhim, H; Toth, P. T.; Miller, R. J.

    1996-01-01

    1. High-threshold Ca2+ channel currents were measured every 15 s following a 200 ms voltage step from -80 mV to 0 mV in order to study the coupling mechanism between neurotransmitter receptors and Ca2+ channels in neurones acutely isolated from the nucleus tractus solitarius (NTS) of the rat. 2. Application of 30 microM baclofen (GABAB receptor agonist) caused 38.9 +/- 1.2% inhibition of the peak inward Ba2+ current (IBa2+) in most NTS cells tested (n = 85 of 88). Somatostatin, 300 nM, also r...

  19. The interaction of central nitrergic and GABAergic systems on food intake in neonatal layer-type chicks.

    Science.gov (United States)

    Mokhtarpouriani, Kasra; Zendehdel, Morteza; Jonaidi, Hossein; Babapour, Vahab; Shayan, Parviz

    2016-05-01

    Most physiological behaviors such as food intake are controlled by the hypothalamus and its nuclei. It has been demonstrated that injection of the paraventricular nucleus of the hypothalamus with nitric oxide (NO) donors elicited changes in the concentration of some amino acids, including GABA. Also, central nitrergic and GABAergic systems are known to provide inputs to the paraventricular nucleus and are involved in food intake control. Therefore, the present study examines the probable interaction of central nitrergic and GABAergic systems on food intake in neonatal layer-type chicks. The results of this study showed that intracerebroventricular (ICV) injection of L-arginine (400 and 800 nmol), as a NO donor, significantly decreased food intake (P baclofen (0.2 µg), a GABAB agonist, did not change in ICV co-injection of L-arginine (200 nmol) or L-NAME (100 nmol) with baclofen (0.2 µg) (P > 0.05). Also, the hypophagic effect of L-arginine (800 nmol) was significantly amplified in ICV co-injection of picrotoxin (0.5 µg), a GABAA antagonist, or CGP54626 (21 ng), a GABAB antagonist, with L-arginine (800 nmol) (P < 0.001). These results probably suggest an interaction of central nitrergic and GABAergic systems on food intake in neonatal layer-type chicks and GABAA receptors play a major role in this interaction. PMID:26832169

  20. The comparative effects of aminoglycoside antibiotics and muscle relaxants on electrical field stimulation response in rat bladder smooth muscle.

    Science.gov (United States)

    Min, Chang Ho; Min, Young Sil; Lee, Sang Joon; Sohn, Uy Dong

    2016-06-01

    It has been reported that several aminoglycoside antibiotics have a potential of prolonging the action of non-depolarizing muscle relaxants by drug interactions acting pre-synaptically to inhibit acetylcholine release, but antibiotics itself also have a strong effect on relaxing the smooth muscle. In this study, four antibiotics of aminoglycosides such as gentamicin, streptomycin, kanamycin and neomycin were compared with skeletal muscle relaxants baclofen, tubocurarine, pancuronium and succinylcholine, and a smooth muscle relaxant, papaverine. The muscle strips isolated from the rat bladder were stimulated with pulse trains of 40 V in amplitude and 10 s in duration, with pulse duration of 1 ms at the frequency of 1-8 Hz, at 1, 2, 4, 6, 8 Hz respectively. To test the effect of four antibiotics on bladder smooth muscle relaxation, each of them was treated cumulatively from 1 μM to 0.1 mM with an interval of 5 min. Among the four antibiotics, gentamicin and neomycin inhibited the EFS response. The skeletal muscle relaxants (baclofen, tubocurarine, pancuronium and succinylcholine) and inhibitory neurotransmitters (GABA and glycine) did not show any significant effect. However, papaverine, had a significant effect in the relaxation of the smooth muscle. It was suggested that the aminoglycoside antibiotics have inhibitory effect on the bladder smooth muscle. PMID:27260628

  1. The role of piriform associative connections in odor categorization.

    Science.gov (United States)

    Bao, Xiaojun; Raguet, Louise Lg; Cole, Sydni M; Howard, James D; Gottfried, Jay

    2016-01-01

    Distributed neural activity patterns are widely proposed to underlie object identification and categorization in the brain. In the olfactory domain, pattern-based representations of odor objects are encoded in piriform cortex. This region receives both afferent and associative inputs, though their relative contributions to odor perception are poorly understood. Here, we combined a placebo-controlled pharmacological fMRI paradigm with multivariate pattern analyses to test the role of associative connections in sustaining olfactory categorical representations. Administration of baclofen, a GABA(B) agonist known to attenuate piriform associative inputs, interfered with within-category pattern separation in piriform cortex, and the magnitude of this drug-induced change predicted perceptual alterations in fine-odor discrimination performance. Comparatively, baclofen reduced pattern separation between odor categories in orbitofrontal cortex, and impeded within-category generalization in hippocampus. Our findings suggest that odor categorization is a dynamic process concurrently engaging stimulus discrimination and generalization at different stages of olfactory information processing, and highlight the importance of associative networks in maintaining categorical boundaries. PMID:27130519

  2. Clinical safety of magnetic resonance imaging in patients with implanted SynchroMed EL infusion pumps

    Energy Technology Data Exchange (ETDEWEB)

    Diehn, Felix E.; Wood, Christopher P.; Watson, Robert E.; Hunt, Christopher H. [Mayo Clinic, Department of Radiology, Rochester, MN (United States); Mauck, William D. [Mayo Clinic, Department of Anesthesiology, Rochester, MN (United States); Burke, Michelle M. [Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN (United States)

    2011-02-15

    Patients with implanted SynchroMed spinal infusion pumps (Medtronic, Inc., Minneapolis, MN) routinely undergo magnetic resonance imaging at our institution. In August 2008, Medtronic issued an urgent medical device correction report regarding several pumps. Because of the rare potential ''for a delay in the return of proper drug infusion'' and ''for a delay in the logging of motor stall events,'' ''a patient's pump must be interrogated after MRI exposure in order to confirm proper pump functionality.'' This is particularly important in patients receiving intrathecal baclofen, for whom a delay in return of proper pump infusion could lead to life-threatening baclofen withdrawal syndrome. The objective of this report is to present our experience and protocol of performing magnetic resonance imaging in patients with implanted SynchroMed EL pumps. We retrospectively reviewed records of 86 patients with implanted SynchroMed EL spinal infusion pumps who underwent 112 examinations on 1.5-T magnetic resonance imaging scanners from September 1, 1998 to July 7, 2004. No SynchroMed EL pumps were damaged by magnetic resonance imaging, and the programmable settings remained unchanged in all patients. Our data suggest that SynchroMed EL pump malfunction is indeed rare after routine clinical 1.5-T magnetic resonance imaging examinations. However, based on the Medtronic correction report, we perform pump interrogation before and after imaging. (orig.)

  3. Presynaptic control of nociceptor signalling: Differential influence of Mu Opioid and GABAergic Systems

    Directory of Open Access Journals (Sweden)

    Ruth C Riley

    2000-01-01

    Full Text Available The relative contribution of pre- and postsynaptic controls to the flow of nociceptive information at the level of the spinal cord has been one of Ron Melzack's longstanding interests and a key issue in the formulation of the gate control theory. The authors review their own studies, in which they monitored internalization of the neurokinin-1 receptor to examine specifically the action of two classically inhibitory systems - mu opioid and gamma-amino butyric acid (GABA - on noxious stimulus-evoked tachykinin signalling in the rat spinal cord. Evidence that opioids and GABAergic controls operate differently on the central consequences of any noxious stimulus-induced substance P release is provided. Whereas at least 80% of the tachykinin signalling remained intact after even the highest concentration of spinal morphine or D-Ala2, NMe-phe4, Glyol5-enkephalin administration, spinal administration of the GABAB receptor agonist baclofen had a dramatic inhibitory effect. These findings are discussed in light of the disappointing clinical utility of baclofen and neurokinin-1 receptor antagonists to combat pain.

  4. GABA in Paraventricular Nucleus Regulates Adipose Afferent Reflex in Rats.

    Directory of Open Access Journals (Sweden)

    Lei Ding

    Full Text Available Chemical stimulation of white adipose tissue (WAT induces adipose afferent reflex (AAR, and thereby causes a general sympathetic activation. Paraventricular nucleus (PVN is important in control of sympathetic outflow. This study was designed to investigate the role of γ-aminobutyric acid (GABA in PVN in regulating the AAR.Experiments were carried out in anesthetized rats. Renal sympathetic nerve activity (RSNA and mean arterial pressure (MAP were continuously recorded. AAR was evaluated by the RSNA and MAP responses to electrical stimulation of the right epididymal WAT (eWAT afferent nerve. Electrical stimulation of eWAT afferent nerve increase RSNA. Bilateral microinjection of the GABAA receptor agonist isoguvacine or the GABAB receptor agonist baclofen attenuated the AAR. The effect of isoguvacine on the AAR was greater than that of baclofen. The GABAA receptor antagonist gabazine enhanced the AAR, while the GABAB receptor antagonist CGP-35348 had no significant effect on the AAR. Bilateral PVN microinjection of vigabatrin, a selective GABA-transaminase inhibitor, to increase endogenous GABA levels in the PVN abolished the AAR. The inhibitory effect of vigabatrin on the AAR was attenuated by the pretreatment with gabazine or CGP-35348. Pretreatment with combined gabazine and CGP-35348 abolished the effects of vigabatrin.Activation of GABAA or GABAB receptors in the PVN inhibits the AAR. Blockade of GABAA receptors in the PVN enhances the AAR. Endogenous GABA in the PVN plays an important role in regulating the AAR.

  5. Neural Mechanisms and Delayed Gastric Emptying of Liquid Induced Through Acute Myocardial Infarction in Rats

    International Nuclear Information System (INIS)

    In pathological situations, such as acute myocardial infarction, disorders of motility of the proximal gut can trigger symptoms like nausea and vomiting. Acute myocardial infarction delays gastric emptying (GE) of liquid in rats. Investigate the involvement of the vagus nerve, α 1-adrenoceptors, central nervous system GABAB receptors and also participation of paraventricular nucleus (PVN) of the hypothalamus in GE and gastric compliance (GC) in infarcted rats. Wistar rats, N = 8-15 in each group, were divided as INF group and sham (SH) group and subdivided. The infarction was performed through ligation of the left anterior descending coronary artery. GC was estimated with pressure-volume curves. Vagotomy was performed by sectioning the dorsal and ventral branches. To verify the action of GABAB receptors, baclofen was injected via icv (intracerebroventricular). Intravenous prazosin was used to produce chemical sympathectomy. The lesion in the PVN of the hypothalamus was performed using a 1mA/10s electrical current and GE was determined by measuring the percentage of gastric retention (% GR) of a saline meal. No significant differences were observed regarding GC between groups; vagotomy significantly reduced % GR in INF group; icv treatment with baclofen significantly reduced %GR. GABAB receptors were not conclusively involved in delaying GE; intravenous treatment with prazosin significantly reduced GR% in INF group. PVN lesion abolished the effect of myocardial infarction on GE. Gastric emptying of liquids induced through acute myocardial infarction in rats showed the involvement of the vagus nerve, alpha1- adrenergic receptors and PVN

  6. Effect of gamma-aminobutyric acid on neurally mediated contraction of guinea pig trachealis smooth muscle.

    Science.gov (United States)

    Tamaoki, J; Graf, P D; Nadel, J A

    1987-10-01

    To determine whether gamma-aminobutyric acid (GABA) affects the contractile properties of airway smooth muscle and, if so, what the mechanism of action is, the authors studied guinea pig tracheal rings under isometric conditions in vitro. GABA and related substances, baclofen and muscimol, had no effect on the resting tension but reversibly depressed contractions induced by electrical field stimulation in a dose-dependent fashion, IC50 values (mean +/- S.E.) being 5.6 +/- 1.4 X 10(-6) M, 6.8 +/- 0.9 X 10(-6) M and 8.5 +/- 1.5 X 10(-5) M, respectively. In contrast, GABA did not alter the response to exogenous acetylcholine or the nonadrenergic noncholinergic inhibitory component. Pretreatment of tissues with bicuculline antagonized the inhibitory effect of GABA as well as that of baclofen. This inhibitory effect was not modified by propranolol, phentolamine, hemicholinium-3 or naloxone, but it was blocked by the Cl channel blocker furosemide and by the substitution of external Cl. These results suggest that GABA decreases the contractile response of airway smooth muscle to cholinergic nerve stimulation by inhibiting the evoked release of acetylcholine and that this effect is exerted by activating Cl-dependent, bicuculline-sensitive GABA receptors. PMID:3668869

  7. Clinical safety of magnetic resonance imaging in patients with implanted SynchroMed EL infusion pumps

    International Nuclear Information System (INIS)

    Patients with implanted SynchroMed spinal infusion pumps (Medtronic, Inc., Minneapolis, MN) routinely undergo magnetic resonance imaging at our institution. In August 2008, Medtronic issued an urgent medical device correction report regarding several pumps. Because of the rare potential ''for a delay in the return of proper drug infusion'' and ''for a delay in the logging of motor stall events,'' ''a patient's pump must be interrogated after MRI exposure in order to confirm proper pump functionality.'' This is particularly important in patients receiving intrathecal baclofen, for whom a delay in return of proper pump infusion could lead to life-threatening baclofen withdrawal syndrome. The objective of this report is to present our experience and protocol of performing magnetic resonance imaging in patients with implanted SynchroMed EL pumps. We retrospectively reviewed records of 86 patients with implanted SynchroMed EL spinal infusion pumps who underwent 112 examinations on 1.5-T magnetic resonance imaging scanners from September 1, 1998 to July 7, 2004. No SynchroMed EL pumps were damaged by magnetic resonance imaging, and the programmable settings remained unchanged in all patients. Our data suggest that SynchroMed EL pump malfunction is indeed rare after routine clinical 1.5-T magnetic resonance imaging examinations. However, based on the Medtronic correction report, we perform pump interrogation before and after imaging. (orig.)

  8. Advances in the management of MS symptoms: recently proposed clinical management algorithms.

    Science.gov (United States)

    Vermersch, Patrick

    2015-01-01

    Guidelines from both the German and Spanish Neurology Societies for managing patients with multiple sclerosis (MS) spasticity emphasize the importance of setting clear objectives and use evidence levels and grades to support their recommendations. Swedish guidelines for MS spasticity also reflect the need to establish treatment aims and recommend use of validated scales to measure symptom changes. Treatment of generalized MS spasticity, beyond physiotherapy, tends to begin with baclofen, tizanidine and/or diazepam, adding Sativex (THC:CBD) oromucosal spray for moderate-to-severe cases. The European Federation of Neurological Societies/European Academy of Neurology Taskforce on Spasticity in Multiple Sclerosis is currently reviewing the literature supporting the pharmacological treatment of MS spasticity and aims to publish recommendations in the near future to guide clinicians in their treatment choices. PMID:26611268

  9. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.

    Science.gov (United States)

    Koehler, Jürgen; Amato, Maria P; Oreja-Guevara, Celia; Lycke, Jan

    2013-12-01

    Spasticity is one of the main symptoms associated with multiple sclerosis (MS). Epidemiological studies indicate that approximately two-thirds of MS patients experience spasticity and, in a relevant proportion of this group, spasticity is moderate to severe. Yet, spasticity remains largely undertreated. The most commonly used oral antispasticity agents (e.g., baclofen, tizanidine, gabapentin) generally do not reduce spasticity adequately at dosages that are well tolerated by patients. This review of MS spasticity cases from around Europe presents current knowledge of considerations for administration of a new agent (tetrahydrocannabinol/cannabidiol-based nabiximols [Sativex®] oromucosal spray) for management of MS spasticity, with the aim of ensuring appropriate and optimal use for best outcomes. Assessment of the European clinical experience is intended to provide a better understanding of the prescribing regulations for MS spasticity treatments, facilitate identification of suitable candidate patients for Sativex and increase awareness of alternative management approaches for MS-related spasticity. PMID:24289846

  10. Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!

    Science.gov (United States)

    Russo, Margherita; Rifici, Carmela; Sessa, Edoardo; D'Aleo, Giangaetano; Bramanti, Placido; Calabrò, Rocco Salvatore

    2015-01-01

    Nabiximols (Sativex) is an oromucosal spray, containing delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), used as treatment for unresponsive spasticity in multiple sclerosis (MS) patients. Sativex is thought to not affect cognition or induce any psychiatric problem at the doses generally used. Nonetheless, it is known that the concomitant use of more than one muscle-relaxant drugs can result in additive neuropsychiatric effects. Herein we describe a case of a woman affected by MS and treated with baclofen and methylprednisolone, who developed important behavioral changes, including suicidal ideation, after 4 weeks of Sativex administration. We are not completely able to state if Sativex alone was responsible for our patient's psychiatric symptoms, in reason of the concomitant use of the other drugs.In conclusion, physicians should pay more attention when prescribing drugs to MS patients affected by spasticity, including Sativex, since neurobehavioral side effects may emerge especially in predisposed individuals. PMID:25881038

  11. Idiopathic stuttering priapism treated with salbutamol orally: a case report.

    Science.gov (United States)

    Migliorini, F; Porcaro, A B; Baldassarre, R; Artibani, W

    2016-03-01

    Recurrent ischaemic priapism also known as stuttering priapism is an uncommon form of ischaemic priapism, and its treatment is not yet clearly defined. If left untreated, it may evolve into classic form of acute ischaemic priapism and lead to erectile dysfunction due to fibrosis of corpora cavernosa. Several drugs have been proposed with variable results and only supported with level three or four of evidence. Hormonal therapy such as cyproterone acetate, oestrogen, bicalutamide or Lh-Rh agonist are often effective but can cause side effects such as hypogonadal state and infertility. Other medical options are 5-alpha-reductase and phosphodiesterase-5 inhibitors, ketoconazole, baclofen, digoxin, gabapentin and beta-2-agonist terbutaline. We report the first case of stuttering priapism treated with beta-2-agonist salbutamol. PMID:26032021

  12. Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

    Science.gov (United States)

    Sinclair, Julia M A; Chambers, Sophia E; Shiles, Celia J; Baldwin, David S

    2016-07-01

    Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk-benefit profile in each case. PMID:27023898

  13. Synthesis of high specific activity tritium labelled compounds

    International Nuclear Information System (INIS)

    Tritiated methyl iodide of high specific activity is synthetized by Fischer-Tropsch reaction of tritium with carbon monoxide, tritiated methanol obtained is reacted with hydriodic acid. It is used for the synthesis of S-adenosyl L-methionine 3H-methyl and of diazepam 3H-methyl derivatives. Synthesis of 3-PPP3H: (hydroxy-3 phenyl)-3N-n propyl [3H-2.3] piperidine [3H-2.3] with a specific activity of 4.25 T Bq/mM (115 Ci/mM) and of baclofene 3H with a specific activity of 0.925 TBq (25 Ci/mM) are also described

  14. Stereospecific potentiation of opiate analgesia by cocaine: predominant role of noradrenaline.

    Science.gov (United States)

    Misra, A L; Pontani, R B; Vadlamani, N L

    1987-01-01

    Cocaine hydrochloride (50 mg) pellets implanted subcutaneously in male Wistar rats potentiated the analgesia of morphine, levorphanol, methadone and buprenorphine as measured by the tail-withdrawal test. Potentiated opiate analgesia was abolished by naloxone and further enhanced by desipramine and phenoxybenzamine. Yohimbine, alpha-methyl p-tyrosine, haloperidol, zimelidine, methysergide, p-chlorophenylalanine produced no significant effect on potentiated opiate analgesia. Pseudo-cocaine (dextro-cocaine), which is several-fold less potent than cocaine as an inhibitor of noradrenaline and dopamine reuptake in the CNS, had no significant effect on opiate analgesia. Analgesia produced by low doses of baclofen, a GABA agonist, was also not potentiated by cocaine. This study suggests a predominant role for noradrenaline in the stereospecific potentiation of opiate analgesia by cocaine. PMID:3822492

  15. [A decreased frequency of peeking out from the dark compartment--the only constant index of the effect of anxiogens on the behavior of mice in a "light-darkness" chamber].

    Science.gov (United States)

    Lapin, I P

    1999-01-01

    Special measurements of the effects of anxiolytics and anxiogens on the commonly used parameters of behavior of mice in a dark-light chamber (the rate of transitions and time spent in a dark and light compartments) demonstrated their low reproducibility in consecutive experiments. Therefore, these indices are not reliable (Lapin, 1992). One more parameter was tested in the present study. A decrease in the rate of leanings out of the dark compartment appeared to be a constant effect of standard anxiety-inducing drugs: caffeine, pentylenetetrazole, yohimbine, and a putative endogenous anxiogen phenylethylamine. Increase in the rate of leanings out, like increase in the rate of transitions and shortening of the time spent in a dark compartment produced by anxiolytics diazepam, chlordiazepoxide, hydroxyzine, phenibut and baclofen were not significant in the majority of experiments. That is why these effects of anxiolytics are not reliable for measuring the activity of anxiolytics in a dark-light chamber. PMID:10420565

  16. [The pharmacological differences between kynurenine- and korazol-induced seizures (the participation of GABA-B receptors and dopamine)].

    Science.gov (United States)

    Lapin, I P

    1998-01-01

    In experiments of male SHR (nonbred) and C57B1/6 mice [correction of rats] bicucullin intensified corasole-induced convulsions but had no effect on kynurenine convulsions, removed the anticonvulsive effect of phenibut against kynurenine and did not affect the anticonvulsive effect of diazepam against corasole. Phenibut and baclofen reduced the anticonvulsive effect of diazepam against corasole and caffeine. Haloperidol increased kynurenine-induced convulsions and had no effect on those caused by corasole. Dopamine removed the effect of haloperidol. Haloperidol and 6-oxydopamine weakened the sedative effect of phenibut. Blockade of GAMAB-receptors and weakening of dopaminergic activity are important in the mechanisms of kynurenine convulsions, and blockage of GABAA-receptors unrelated to it is important in the mechanisms of corasole convulsions. A functional antagonism in anticonvulsive activity may exist between these receptors. Bicucullin may probably have an effect both on GABAA- and GABAB-receptors. PMID:9621167

  17. Invasive Treatment Modalities for Spasticity and Pain in Spinal Cord Injury - Education

    Directory of Open Access Journals (Sweden)

    Sabri Aydın

    2010-12-01

    Full Text Available Spasticity secondary to spinal cord injury may impair function or ease of care or may cause discomfort or poor body image. The treatment of spasticity and pain requires a multidisciplinary approach with treatment aimed at modulating the movement disorder through oral medication, injectable drugs, surgical intervention and physical therapy. Surgical treatment of the neurologic effects of the central movement disorders include selective dorsal rhizotomy, intrathecal baclofen pump placement, and potentially deep brain stimulation. Techniques may be combined for greater efficacy and better tailoring to the needs of the patient. This article provides an overview of each approach, with a review of significant research findings in support of each. Turk J Phys Med Rehab 2010; 56 Suppl 2: 102-4

  18. GABAB受体与腺苷酸环化酶偶联环节的脱敏研究%STUDIES ON DESENSITIZATION OF GABAB RECEPTOR COUPLED ADENYLATE CYCLASE

    Institute of Scientific and Technical Information of China (English)

    俞在芳; 程冠军; 胡本荣

    1997-01-01

    将突触体膜与佛波酯(PMA),GABAB受体激动剂巴氯芬(Baclofen,BAL)预孵育一定时间后,BAL对腺苷酸环化酶(AC)基础活性及forskolin刺激的AC活性的抑制率显著降低(脱敏);而forskolin预孵育时,BAL对基础及forskolin刺激的AC活性的抑制率不变,表明GABAB受体与AC偶联环节的脱敏机制涉及蛋白激酶C(PKC)激活,而与蛋白激酶A无关,脱敏时GABAB受体的Kd值增加.本实验提示,可能由于PKC激活导致GABAB受体结构或构象改变,使受体-G蛋白脱偶联而出现脱敏现象.

  19. Childhood-onset (Juvenile Huntington′s disease: A rare case report

    Directory of Open Access Journals (Sweden)

    Kailash Chandra Patra

    2015-01-01

    Full Text Available Huntington′s disease (HD is a rare dominantly inherited neurodegenerative disorder characterized clinically by a combination of abnormal involuntary (choreic movements, neuropsychiatric manifestations, and dementia. It is caused by an unstable CAG repeat expansion in the gene IT15 which encodes a Huntingtin protein. We present a case of a 9 year old boy who had developmental regression starting from the age of 8 years of age along with resistant seizures and signs of cerebellar involvement with absence of chorea and is on anticonvulsants, baclofen, and tetrabenzine. As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions.

  20. Neurochemical correlates of. gamma. -aminobutyrate (GABA) inhibition in cat visual cortex

    Energy Technology Data Exchange (ETDEWEB)

    Balcar, V.J.; Dreher, B. (Univ. of Sydney (Australia))

    1990-01-01

    High affinity binding of ({sup 3}H){gamma}-aminobutyric acid (GABA) to neuronal membranes from different parts of cat visual cortex was tested for sensitivity to GABA{sub A} agonists isoguvacine and THIP, GABA{sub A} antagonist SR95531 and GABA{sub B} agonist baclofen. Some of the GABA{sub A}-binding sites were found to have a very low affinity for THIP, suggesting the presence and, possibly, uneven distribution of non-synaptic GABA{sub A} receptors in cat visual cortex. There were no differences in K{sub m} and V{sub max} values of high affinity uptake of GABA and in the potency of K{sup +}-stimulated release of GABA, between primary and association cortices. Consequently, the present results indicate that despite the anatomical and physiological differences between the primary and association feline visual cortices the neurochemical characteristics of GABAergic inhibition are very similar in the two regions.

  1. Prevention of Alzheimer's disease

    Directory of Open Access Journals (Sweden)

    V A Parfenov

    2011-01-01

    Full Text Available The paper gives the data available in the literature on the treatment of spasticity in poststroke patients. Therapeutic exercises that should be started just on the first days of stroke are noted to play a leading role in the treatment of poststroke spasticity. The local administration of botulinum toxin preparations (botox, dysport, xeomin may be effective for managing local spasticity that deteriorates motor functions. Baclofen (baklosan, tizanidine (sirdalud, and tolperisone hydrochloride (mydocalm may be used as oral medications. The paper also presents the results of a placebo-controlled trial that has indicated that mydocalm given in a dose of 300 to 900 mg/day may be effective in treating poststroke spasticity.

  2. G protein-coupled inwardly rectifying potassium channels in dorsal root ganglion neurons

    Institute of Scientific and Technical Information of China (English)

    Xiao-fei GAO; Hai-lin ZHANG; Zhen-dong YOU; Chang-lin LU; Cheng HE

    2007-01-01

    Aim: G protein-coupled inwardly rectifying potassium channels (GIRK) are important for neuronal signaling and membrane excitability. In the present study, we intend to find whether GIRK channels express functionally in adult rat dorsal root ganglion (DRG) neurons. Methods: We used RT-PCR to detect mRNA for4 subunits of GIRK in the adult DRG. The whole-cell patch clamp recording was used to confirm GIRK channels functionally expressed. Results: The mRNA for the 4 subunits of GIRK were detected in the adult DRG. GTPγS enhanced inwardly rectifying potassium (K+) currents of the DRG neurons, while Ba2+inhibited such currents. Furthermore, the GIRK channels were shown to be coupled to the GABAB receptor, a member of the G protein-coupled receptor family, as baclofen increased the inwardly rectifying K+ currents. Conclusion: GIRK channels are expressed and functionally coupled with GABAB receptors in adult rat DRG neurons.

  3. Low doses of alcohol potentiate GABA sub B inhibition of spontaneous activity of hippocampal CA1 neurons in vivo

    Energy Technology Data Exchange (ETDEWEB)

    Criado, J.R.; Thies, R. (Univ. of Oklahoma, Oklahoma City (United States))

    1991-03-11

    Low doses of alcohol facilitate firing of hippocampal neurons. Such doses also enhance the inhibitory actions of GABA. Alcohol is known to potentiate inhibition via GABA{sub A} receptors. However, the effects of alcohol on GABA{sub B} receptor function are not understood. Spontaneous activity of single units was recorded from CA1 neurons of male rats anesthetized with 1.0% halothane. Electrical recordings and local application of drugs were done with multi-barrel pipettes. CA1 pyramidal neurons fired spontaneous bursts of action potentials. Acute alcohol decreased the interval between bursts, a mild excitatory action. Alcohol also more than doubled the period of complete inhibition produced by local application of both GABA and baclofen. These data suggest that GABA{sub B}-mediated inhibition is also potentiated by low doses of alcohol.

  4. The Child with Cerebral Palsy and Anaesthesia

    Directory of Open Access Journals (Sweden)

    A Rudra

    2008-01-01

    Full Text Available Cerebral palsy (CP is the result of an injury to the developing brain during the antenatal, perinatal or postnatal period. Clinical manifestation relate to the areas affected. Patients with CP often present for elective surgical proce-dures to correct various deformities. Anaesthetic concerns of anaesthesia are intraoperative hypothermia , and slow emergence. Suxamethonium does not cause hyperkalaemia in these patients, and a rapid sequence induction may be indicated. Temperature should be monitored and an effort made to keep the patient warm. Cerebral abnormalities may lead to slow awakening; the patient should remain intubated until fully awake and airway reflexes have returned. Pulmonary infection can complicate the postoperative course. Postoperative pain management and the prevention of muscle spasms are important and drugs as baclofen and botulinum toxin are discussed. Epidural analgesia is particu-larly valuable when major orthopaedic procedures are performed.

  5. Neurochemical correlates of γ-aminobutyrate (GABA) inhibition in cat visual cortex

    International Nuclear Information System (INIS)

    High affinity binding of [3H]γ-aminobutyric acid (GABA) to neuronal membranes from different parts of cat visual cortex was tested for sensitivity to GABAA agonists isoguvacine and THIP, GABAA antagonist SR95531 and GABAB agonist baclofen. Some of the GABAA-binding sites were found to have a very low affinity for THIP, suggesting the presence and, possibly, uneven distribution of non-synaptic GABAA receptors in cat visual cortex. There were no differences in Km and Vmax values of high affinity uptake of GABA and in the potency of K+-stimulated release of GABA, between primary and association cortices. Consequently, the present results indicate that despite the anatomical and physiological differences between the primary and association feline visual cortices the neurochemical characteristics of GABAergic inhibition are very similar in the two regions

  6. Neuroimaging the Effectiveness of Substance Use Disorder Treatments.

    Science.gov (United States)

    Cabrera, Elizabeth A; Wiers, Corinde E; Lindgren, Elsa; Miller, Gregg; Volkow, Nora D; Wang, Gene-Jack

    2016-09-01

    Neuroimaging techniques to measure the function and biochemistry of the human brain such as positron emission tomography (PET), proton magnetic resonance spectroscopy ((1)H MRS), and functional magnetic resonance imaging (fMRI), are powerful tools for assessing neurobiological mechanisms underlying the response to treatments in substance use disorders. Here, we review the neuroimaging literature on pharmacological and behavioral treatment in substance use disorder. We focus on neural effects of medications that reduce craving (e.g., naltrexone, bupropion hydrochloride, baclofen, methadone, varenicline) and that improve cognitive control (e.g., modafinil, N-acetylcysteine), of behavioral treatments for substance use disorders (e.g., cognitive bias modification training, virtual reality, motivational interventions) and neuromodulatory interventions such as neurofeedback and transcranial magnetic stimulation. A consistent finding for the effectiveness of therapeutic interventions identifies the improvement of executive control networks and the dampening of limbic activation, highlighting their values as targets for therapeutic interventions in substance use disorders. PMID:27184387

  7. Refractory Case of Paroxysmal Autonomic Instability With Dystonia Syndrome Secondary to Hypoxia.

    Science.gov (United States)

    Kern, John; Bodek, Daniel; Niazi, Osama Tariq; Maher, James

    2016-02-01

    Paroxysmal autonomic instability with dystonia (PAID) is a syndrome commonly related to traumatic brain injury (TBI) and rarely to anoxia associated with symptoms of dystonia, tachycardia, tachypnea, and diaphoresis. This is a case of a 20-year-old man who was stabbed in the heart. He underwent surgical repair of a ventricular septal defect and mitral valve replacement. Postoperatively, he developed dystonia with tachycardia and tachypnea consistent with PAID syndrome, secondary to prolonged hypoxia. Traditionally, this poorly understood syndrome is treated with morphine, clonazepam, and nonselective β-blockers. Second-line medications commonly used are baclofen, dantrolene, and gabapentin, which are aimed at the dystonia itself. In this case, both first- and second-line agents were ineffective. A 72-hour dexmedetomidine infusion resulted in complete resolution of symptoms. This is the first case of anoxia-induced PAID syndrome to be effectively treated with dexmedetomidine, which was previously used in a case induced by TBI. PMID:26867852

  8. Identification and management of alcohol withdrawal syndrome.

    Science.gov (United States)

    Mirijello, Antonio; D'Angelo, Cristina; Ferrulli, Anna; Vassallo, Gabriele; Antonelli, Mariangela; Caputo, Fabio; Leggio, Lorenzo; Gasbarrini, Antonio; Addolorato, Giovanni

    2015-03-01

    Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6-24 h after the abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from autonomic hyperactivity and agitation to delirium tremens. The gold-standard treatment for AWS is with benzodiazepines (BZDs). Among the BZDs, different agents (i.e., long-acting or short-acting) and different regimens (front-loading, fixed-dose or symptom-triggered) may be chosen on the basis of patient characteristics. Severe withdrawal could require ICU admission and the use of barbiturates or propofol. Other drugs, such as α2-agonists (clonidine and dexmetedomidine) and β-blockers can be used as adjunctive treatments to control neuroautonomic hyperactivity. Furthermore, neuroleptic agents can help control hallucinations. Finally, other medications for the treatment for AWS have been investigated with promising results. These include carbamazepine, valproate, sodium oxybate, baclofen, gabapentin and topiramate. The usefulness of these agents are discussed. PMID:25666543

  9. Phenprobamate dependence: a case report.

    Science.gov (United States)

    Demir, Bahadir; Demir, Yasemin; Aksoy, Ihsan; Kilic, Osman Hasan Tahsin; Gucyetmez, Volkan; Savas, Haluk A

    2015-06-01

    Phenprobamate (3-phenylpropylcarbamate) is a centrally acting muscle relaxant with mild sedative and anticonvulsant effects. Muscle relaxants can enhance and prolong the effect of narcotic drugs and enable to obtain same effect with a smaller amount of alcohol or illicit substance. Almost all of the centrally acting muscle relaxants have varying sedative effects on which their abuse potential mainly depends. Data related to abuse of carisoprodol, meprobamate, baclofen takes place in the literature. However, to our knowledge this is the first case report about abuse of and tolerance to phenprobamate. We aimed to attract attention to important points of prescribing drugs that have abuse potential like in our case who was using up to 16000 mg/day phenprobamate. PMID:25727392

  10. The inhibitory neurotransmitter GABA evokes long-lasting Ca(2+) oscillations in cortical astrocytes.

    Science.gov (United States)

    Mariotti, Letizia; Losi, Gabriele; Sessolo, Michele; Marcon, Iacopo; Carmignoto, Giorgio

    2016-03-01

    Studies over the last decade provided evidence that in a dynamic interaction with neurons glial cell astrocytes contribut to fundamental phenomena in the brain. Most of the knowledge on this derives, however, from studies monitoring the astrocyte Ca(2+) response to glutamate. Whether astrocytes can similarly respond to other neurotransmitters, including the inhibitory neurotransmitter GABA, is relatively unexplored. By using confocal and two photon laser-scanning microscopy the astrocyte response to GABA in the mouse somatosensory and temporal cortex was studied. In slices from developing (P15-20) and adult (P30-60) mice, it was found that in a subpopulation of astrocytes GABA evoked somatic Ca(2+) oscillations. This response was mediated by GABAB receptors and involved both Gi/o protein and inositol 1,4,5-trisphosphate (IP3 ) signalling pathways. In vivo experiments from young adult mice, revealed that also cortical astrocytes in the living brain exibit GABAB receptor-mediated Ca(2+) elevations. At all astrocytic processes tested, local GABA or Baclofen brief applications induced long-lasting Ca(2+) oscillations, suggesting that all astrocytes have the potential to respond to GABA. Finally, in patch-clamp recordings it was found that Ca(2+) oscillations induced by Baclofen evoked astrocytic glutamate release and slow inward currents (SICs) in pyramidal cells from wild type but not IP3 R2(-/-) mice, in which astrocytic GABAB receptor-mediated Ca(2+) elevations are impaired. These data suggest that cortical astrocytes in the mouse brain can sense the activity of GABAergic interneurons and through their specific recruitment contribut to the distinct role played on the cortical network by the different subsets of GABAergic interneurons. PMID:26496414

  11. Spinal GABA-B receptor modulates neutrophil recruitment to the knee joint in zymosan-induced arthritis.

    Science.gov (United States)

    Bassi, Gabriel S; do C Malvar, David; Cunha, Thiago M; Cunha, Fernando Q; Kanashiro, Alexandre

    2016-08-01

    Recent studies have demonstrated that the central nervous system controls inflammatory responses by activating complex efferent neuroimmune pathways. The present study was designed to evaluate the role that central gamma-aminobutyric acid type B (GABA-B) receptor plays in neutrophil migration in a murine model of zymosan-induced arthritis by using different pharmacological tools. We observed that intrathecal administration of baclofen, a selective GABA-B agonist, exacerbated the inflammatory response in the knee after zymosan administration characterized by an increase in the neutrophil recruitment and knee joint edema, whereas saclofen, a GABA-B antagonist, exerted the opposite effect. Intrathecal pretreatment of the animals with SB203580 (an inhibitor of p38 mitogen-activated protein kinase) blocked the pro-inflammatory effect of baclofen. On the other hand, systemic administration of guanethidine, a sympatholytic drug that inhibits catecholamine release, and nadolol, a beta-adrenergic receptor antagonist, reversed the effect of saclofen. Moreover, saclofen suppressed the release of the pro-inflammatory cytokines into the knee joint (ELISA) and pain-related behaviors (open field test). Since the anti-inflammatory effect of saclofen depends on the sympathetic nervous system integrity, we observed that isoproterenol, a beta-adrenergic receptor agonist, mimics the central GABA-B blockade decreasing knee joint neutrophil recruitment. Together, these results demonstrate that the pharmacological manipulation of spinal GABAergic transmission aids control of neutrophil migration to the inflamed joint by modulating the activation of the knee joint-innervating sympathetic terminal fibers through a mechanism dependent on peripheral beta-adrenergic receptors and central components, such as p38 MAPK. PMID:27106212

  12. Resolution of chronic migraine headaches with intrathecal ziconotide: a case report

    Directory of Open Access Journals (Sweden)

    Narain S

    2015-09-01

    Full Text Available Sachin Narain,1 Lama Al-Khoury,2 Eric Chang3–6 1Department of Anesthesiology and Perioperative Care, 2Department of Neurology, 3Department of Physical Medicine and Rehabilitation, 4Department of Neurosurgery, 5Department of Orthopedics, 6Reeve-Irvine Research Center for Spinal Cord Injury, University of California Irvine, Irvine, CA, USA Background: Migraine headaches are a common and functionally debilitating disorder affecting approximately 17% of women and 5.6% of men. Compared to episodic migraine patients, chronic migraineurs are more likely to be occupationally disabled, miss family activities, have comorbid anxiety and/or chronic pain disorders, and utilize significantly more health care dollars. Ziconotide is a calcium channel blocker used for the treatment of chronic severe pain without issues of tolerance or dependency found with opioid therapy. Case: A 59-year-old female had an intrathecal baclofen pump placed for spasticity secondary to multiple sclerosis. Her symptoms also included lower extremity neuropathic pain and severe migraine headaches with 22 migraine headache days per month. Prior treatments included nonsteroidal anti-inflammatory drugs, triptans, anticonvulsants, antihypertensives, and Botox injections which reduced her symptoms to four migraine days per month at best. While her spasticity had markedly improved with intrathecal baclofen, ziconotide was added to help her neuropathic pain complaints. Following initiation of low-dose ziconotide (1 µg/day, the patient noted both lower extremity pain improvement and complete resolution of migraine headaches resulting in zero migraine days per month. She has now been migraine free for 8 months. Conclusion: Upon review of the available literature, there are no published cases of migraine improvement with intrathecal ziconotide. This represents the first case describing resolution of migraine symptoms with low-dose ziconotide. Keywords: ziconotide, migraine, symptoms, chronic

  13. SynchroMed II intrathecal pump memory errors due to repeated magnetic resonance imaging.

    Science.gov (United States)

    Kosturakis, Alyssa; Gebhardt, Rodolfo

    2012-01-01

    Cancer patients with severe refractory pain are often managed with implantable drug delivery systems (IDDS). The only drugs with US Food and Drug Administration approval for intrathecal use are morphine, ziconotide, and baclofen. Other drugs used and mixed include, hydromorphone, bupivacaine, sufentanil, and fentanyl. These patients often undergo magnetic resonance imaging (MRI) for disease-related monitoring and diagnoses. Although uncommon, IDDS can fail to resume normal functioning after MRI, potentially causing complications. The magnetic field of an MRI will temporarily stop the rotor of the pump motor and suspend drug delivery for the duration of the MRI exposure. The pump should resume normal operation when removed from the MRI magnetic field, but there is a potential for a delay in the return of proper drug infusion and a delay in the logging of motor stall events after an MRI in the SynchroMed II pumps. A 57-year-old man who underwent multiple MRIs with an implanted IDDS experienced 2 separate memory failures leading to multiple complications. After the first pump malfunction, the patient developed withdrawal symptoms and was treated in the emergency department. The first time, a memory reset resolved the problem. The second time, 29 months later, the patient was admitted to the hospital to manage withdrawal symptoms and the pump had to be exchanged with a new device. Post-MRI pump interrogation should be performed on all patients with IDDS to ensure proper functioning of the pump. Special attention should be paid to patients receiving baclofen, as acute withdrawal can be very serious, even deadly. PMID:23159963

  14. Modulation of the inhibitory effect of phenylethylamine on spontaneous motor activity in mice by CPP-(+/-)-3-(2-carboxypiperazin-4-YL)-propyl-1-phosphonic acid.

    Science.gov (United States)

    Lapin, I P; Yuwiler, A

    1997-02-01

    Beta-phenyl-ethylamine (PEA) at dose of 50 mg/kg inhibits spontaneous, motor activity in mice. CPP- (+/-)-3-(2-Carboxypiperazin-4-yl)-propyl-1-phosphonic acid, a selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, in doses of 0.2-10 mg/kg dose-dependently antagonizes this inhibitory effect of PEA. This effect of CPP appeared to be selective because the inhibitory action of PEA was not altered by pretreament with noncompetitive antagonists of NMDA receptors, such as dizocilpine (MK-801), phencyclidine (PCP), 1-phenylcyclohexylamine (PCA) or by antagonists of other behavioral effects of PEA such as haloperidol, baclofen and phenibut (beta-phenyl-GABA). CPP failed to antagonize the inhibitory effect of other tested drugs such as diazepam, haloperidol, baclofen and phenibut. Intracerebroventricularly administered NMDA (0.2 microM), an agonist of NMDA receptors, suppressed the antagonistic effects of CPP against PEA. This suggests that anti-PEA effect of CPP is related to NMDA receptors. Anti-PEA effect of CPP is not due to accelerated deamination of PEA in CPP-treated mice. When small doses of PEA (5 and 10 mg/kg) and CPP (0.2 and 1 mg/kg) were used, the synergism of two drugs was observed. CPP (1 mg/kg) and deprenyl (0.5 mg/kg) an inhibitor monoamine oxidase of B type (MAO-B), had additive effects on PEA-induced inhibition of locomotion. This effect was not associated with any further inhibition of activity of brain MAO-B (over the inhibition induced by deprenyl alone-by 65%) under high (80 microM) or low (4.3 microM) concentration of PEA as a substrate in the medium. Mechanism of the interaction of CPP and PEA, two drugs belonging to different groups of biologically active compounds, deserves further studies. PMID:9050075

  15. 针康法对脑卒中后痉挛状态的影响%Effect of Cluster Needling of Scalp Acupuncture Combined with Rehabilitation on Spasticity after Stroke

    Institute of Scientific and Technical Information of China (English)

    关莹; 张立; 邢艳丽; 唐强

    2011-01-01

    目的探讨针康法对腩卒中后痉挛状态的作用.方法将39例脑卒中后肢体痉挛的患者随机分为观察组和对照组.观察组采用针康法抗痉挛针法配合康复治疗方法,对照组采用巴氯芬配合康复治疗.用改良Ashworth法和Barthel指数评定肌张力、日常生活活动能力(ADL)和临床疗效.结果与对照组比较,观察组肌张力分级、ADL评分、临床疗效无显著性差异(P>0.05).结论针康法在改善卒中后痉挛方面与药物治疗效果相同,且无严重副作用.%Objective To explore the effect of cluster needling of scalp acupuncture combined with rehabilitation (Tang's Approach) on the spasticity after stroke. Methods 39 stroke patients with spasm were divided into observation group and control group.The observation group received anti-spasm acupuncture combined with rehabilitation therapy, while the control group received baclofen combined with rehabilitation therapy. Spasm and activities of daily living(ADL) and therapeutical effect were assessed with the Modified Ashworth Scale and Barthel Index. Results There was no significant difference between the two groups (P>0. 05).Conclusion Tang's Approach has the same effect as baclofen to improve the spasm after stroke without serious side-effect.

  16. Sleep-deprivation regulates α-2 adrenergic responses of rat hypocretin/orexin neurons.

    Directory of Open Access Journals (Sweden)

    Aaron Uschakov

    Full Text Available We recently demonstrated, in rat brain slices, that the usual excitation by noradrenaline (NA of hypocretin/orexin (hcrt/orx neurons was changed to an inhibition following sleep deprivation (SD. Here we describe that in control condition (CC, i.e. following 2 hours of natural sleep in the morning, the α(2-adrenergic receptor (α(2-AR agonist, clonidine, had no effect on hcrt/orx neurons, whereas following 2 hours of SD (SDC, it hyperpolarized the neurons by activating G-protein-gated inwardly rectifying potassium (GIRK channels. Since concentrations of clonidine up to a thousand times (100 µM higher than those effective in SDC (100 nM, were completely ineffective in CC, a change in the availability of G-proteins is unlikely to explain the difference between the two conditions. To test whether the absence of effect of clonidine in CC could be due to a down-regulation of GIRK channels, we applied baclofen, a GABA(B agonist known to also activate GIRK channels, and found that it hyperpolarized hcrt/orx neurons in that condition. Moreover, baclofen occluded the response to clonidine in SDC, indicating that absence of effect of clonidine in CC could not be attributed to down-regulation of GIRK channels. We finally tested whether α(2-ARs were still available at the membrane in CC and found that clonidine could reduce calcium currents, indicating that α(2-ARs associated with calcium channels remain available in that condition. Taken together, these results suggest that a pool of α(2-ARs associated with GIRK channels is normally down-regulated (or desensitized in hcrt/orx neurons to only become available for their inhibition following sleep deprivation.

  17. 孕烯醇酮和孕烯醇酮硫酸盐对小鼠不同脑区3H-GABA与GABAB受体结合的影响%Effects of Pregnenolone and Pregnenolone Sulfate on 3H-GABA Bound with GABAB Receptor in Different Areas of Mice Brain

    Institute of Scientific and Technical Information of China (English)

    周雪瑞

    2001-01-01

    By using radioactive ligand-receptor binding assay, this paperreported the effects of pregnenolong (Pe) and pregnenolone sulfate (Pes) on 3H-GABA bound with GABAB receptor in different areas of mice brain. The result showed that Pe decreased the binding of 3H-GABA with GABAB receptor, and it could be blocked and turned over by baclofen. Pes markedly decreased the binding of 3H-GABA with GABAB receptor in cerebral cortex and hippocampus and increased the binding in hypothalamus of mice brain. Baclofen could blocked the inhibition effect, enhance the effects of increase. These results suggested that major effects of Pe and Pes on 3H-GABA bound with GABAB receptor in different areas of mice brain were inhibition effects.%采用放射配体受体结合分析法,研究了孕烯醇酮(Pe)和孕烯醇酮硫酸盐(Pes)对小鼠不同脑区3H-GABA与GABAB受体结合的影响.结果显示,Pe对小鼠下丘脑、大脑皮层、海马、小脑GABAB受体的结合均有抑制效应,且能被GABAB受体激动剂巴氯芬(Bac)所阻断并翻转.Pes对大脑皮层、海马、小脑GABAB受体的结合有抑制作用,而对下丘脑则有促进作用.Bac能阻断Pes的抑制作用(海马除外),加强Pes的促进作用.实验结果提示,Pe,Pes对各脑区GABAB受体的结合具有一定的影响作用,且多为抑制效应.

  18. Dihydrocodeine / Agonists for Alcohol Dependents

    Directory of Open Access Journals (Sweden)

    Albrecht eUlmer

    2012-03-01

    Full Text Available Objective: Alcohol addiction too often remains insufficiently treated. It shows the same profile as severe chronic diseases, but no comparable, effective basic treatment has been established up to now. Especially patients with repeated relapses, despite all therapeutic approaches, and patients who are not able to attain an essential abstinence to alcohol, need a basic medication. It seems necessary to acknowledge that parts of them need any agonistic substance, for years, possibly lifelong. For >14 years, we have prescribed such substances with own addictive character for these patients.Methods: We present a documented best possible practice, no designed study. Since 1997, we prescribed Dihydrocodeine (DHC to 102 heavily alcohol addict-ed patients, later, also Buprenorphine, Clomethiazole (>6 weeks, Baclofen and in one case Amphetamine, each on individual indication. This paper focuses on the data with DH, especially. The Clomethiazole-data has been submitted to a German journal. The number of treatments with the other substances is still low. Results: The 102 patients with the DHC-treatment had 1367 medically assisted detoxifications and specialized therapies before! The 4 years-retention rate was 26.4%, including 2.8% successfully terminated treatments. In our 12-step scale on clinical impression, we noticed a significant improvement from mean 3.7 to 8.4 after 2 years. The demand for medically assisted detoxifications in the 2 years remaining patients was reduced by 65.5%. Mean GGT improved from 206.6 U/l at baseline to 66.8 U/l after 2 years. Experiences with the other substances are similar but different in details.Conclusions: Similar to the Italian studies with GHB and Baclofen, we present a new approach, not only with new substances, but also with a new setting and much more trusting attitude. We observe a huge improvement, reaching an almost optimal, stable, long term status in around ¼ of the patients already. Many further

  19. Neural Mechanisms and Delayed Gastric Emptying of Liquid Induced Through Acute Myocardial Infarction in Rats

    Directory of Open Access Journals (Sweden)

    Wilson Ranu Ramirez Nunez

    2015-02-01

    Full Text Available Background: In pathological situations, such as acute myocardial infarction, disorders of motility of the proximal gut can trigger symptoms like nausea and vomiting. Acute myocardial infarction delays gastric emptying (GE of liquid in rats. Objective: Investigate the involvement of the vagus nerve, α 1-adrenoceptors, central nervous system GABAB receptors and also participation of paraventricular nucleus (PVN of the hypothalamus in GE and gastric compliance (GC in infarcted rats. Methods: Wistar rats, N = 8-15 in each group, were divided as INF group and sham (SH group and subdivided. The infarction was performed through ligation of the left anterior descending coronary artery. GC was estimated with pressure-volume curves. Vagotomy was performed by sectioning the dorsal and ventral branches. To verify the action of GABAB receptors, baclofen was injected via icv (intracerebroventricular. Intravenous prazosin was used to produce chemical sympathectomy. The lesion in the PVN of the hypothalamus was performed using a 1mA/10s electrical current and GE was determined by measuring the percentage of gastric retention (% GR of a saline meal. Results: No significant differences were observed regarding GC between groups; vagotomy significantly reduced % GR in INF group; icv treatment with baclofen significantly reduced %GR. GABAB receptors were not conclusively involved in delaying GE; intravenous treatment with prazosin significantly reduced GR% in INF group. PVN lesion abolished the effect of myocardial infarction on GE. Conclusion: Gastric emptying of liquids induced through acute myocardial infarction in rats showed the involvement of the vagus nerve, alpha1- adrenergic receptors and PVN.

  20. Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of garlic extract in mice

    Directory of Open Access Journals (Sweden)

    Dhingra Dinesh

    2008-01-01

    Full Text Available Objectives: The present study was undertaken to investigate the effect of the ethanolic extract of Allium sativum L. (Family: Lilliaceae, commonly known as garlic, on depression in mice. Materials and Methods: Ethanolic extract of garlic (25, 50 and 100 mg/kg was administered orally for 14 successive days to young Swiss albino mice of either sex and antidepressant-like activity was evaluated employing tail suspension test (TST and forced swim test (FST. The efficacy of the extract was compared with standard antidepressant drugs like fluoxetine and imipramine. The mechanism of action of the extract was investigated by co-administration of prazosin (α1-adrenoceptor antagonist, sulpiride (selective D2-receptor antagonist, baclofen (GABA B agonist and p-CPA (serotonin antagonist separately with the extract and by studying the effect of the extract on brain MAO-A and MAO-B levels. Results: Garlic extract (25, 50 and 100 mg/kg significantly decreased immobility time in a dose-dependent manner in both TST and FST, indicating significant antidepressant-like activity. The efficacy of the extract was found to be comparable to fluoxetine (20 mg/kg p.o. and imipramine (15 mg/kg p.o. in both TST and FST. The extract did not show any significant effect on the locomotor activity of the mice. Prazosin, sulpiride, baclofen and p-CPA significantly attenuated the extract-induced antidepressant-like effect in TST. Garlic extract (100 mg/kg administered orally for 14 successive days significantly decreased brain MAO-A and MAO-B levels, as compared to the control group. Conclusion: Garlic extract showed significant antidepressant-like activity probably by inhibiting MAO-A and MAO-B levels and through interaction with adrenergic, dopaminergic, serotonergic and GABAergic systems.

  1. Effect of activation of γ-aminobutyric acid B receptors on glutamate release in spinal dorsal horn neurons in rats with diabetic neuropathic pain%激活γ-氨基丁酸B受体对糖尿病神经痛大鼠脊髓背角神经元谷氨酸递质释放的影响

    Institute of Scientific and Technical Information of China (English)

    王秀丽; 吴川; 郭跃先; 王秋筠; 刘飞飞; 曹倩倩; 张兆龙

    2012-01-01

    目的 探讨激活γ-氨基丁酸B(γ-aminobutyric acid B,GABAB)受体对糖尿病神经痛大鼠脊髓背角谷氨酸能神经元递质释放中的影响.方法 30只(4周龄,150 g~170 g)雄性Sprague-Dawley( SD)大鼠,采用随机数字表法随机分为2组(每组15只):正常对照组(N组)、糖尿病神经痛组(D组).D组通过腹腔注射链脲佐菌素(streptozotocin,STZ)50 mg/kg制备糖尿病神经痛模型,N组腹腔给予等量生理盐水,两组分别于腹腔注射后第3~4周测定空腹血糖、机械缩足阈值(paw withdrawal mechanical threshold,PWMT);然后处死大鼠取腰1~5脊髓,制备脊髓薄片,采用全细胞膜片钳技术,记录脊髓Ⅱ板层单突触神经元谷氨酸能诱发兴奋性突触后电流(evoked excitatory postsynaptic currents,eEPSCs).细胞封接后稳定5 min开始记录,灌流液中加入终浓度为1、10、20、50μmol/L的Baclofen(GABAB受体特异性激动剂),于给药前对照、给予上述浓度药后各时点及洗脱后5 min,记录上述各时点eEPSCs的波幅变化,比较Baclofen对两组大鼠eEPSCs波幅的抑制率,并观察CGP55845 (GABAB 受体特异性阻断剂,1 μmol/L)对Baclofen(50 μmol/L)eEPSCs作用的影响.结果 与N组比较,D组大鼠血糖显著增高,PWT明显降低(P<0.05).电生理共记录30个神经元(每组15个),1 μmol/L~50 μmol/L的Baclofen均以剂量依赖方式降低两组大鼠eEPSCs波幅(P<0.05),N、D两组在1、10、20、50 μmol/L Baclofen时点波幅抑制率均明显下降(P<0.05),两组上述时点比较,D组显著低于N组(P<0.05),分别为:(47±7)vs(21±7),(55±6)vs(50±6),(92±6)vs(72±9),(95±8)vs(88±8),1μmol/LCGP55845可完全去除50 μmol/L Baclofen对两组神经元(每组12个)eEPSCs的作用.结论 激活GABAB受体可明显抑制脊髓背角神经元谷氨酸递质释放,但对糖尿病神经痛大鼠其抑制作用减弱.%Objective To explore the effect of activation of γ-aminobutyric acid B (GABAB) receptors on glutamate

  2. Weakened rate-dependent depression of Hoffmann's reflex and increased motoneuron hyperactivity after motor cortical infarction in mice.

    Science.gov (United States)

    Lee, S; Toda, T; Kiyama, H; Yamashita, T

    2014-01-01

    Abnormal reflexes associated with spasticity are considered a major determinant of motor impairments occurring after stroke; however, the mechanisms underlying post-stroke spasticity remain unclear. This may be because of the lack of suitable rodent models for studying spasticity after cortical injuries. Thus, the purpose of the present study was to establish an appropriate post-stroke spasticity mouse model. We induced photothrombotic injury in the rostral and caudal forelimb motor areas of mice and used the rate-dependent depression (RDD) of Hoffmann's reflex (H-reflex) as an indicator of spastic symptoms. To detect motoneuron excitability, we examined c-fos mRNA levels and c-Fos immunoreactivity in affected motoneurons using quantitative real-time reverse transcription PCR and immunohistochemical analysis, respectively. To confirm the validity of our model, we confirmed the effect of the anti-spasticity drug baclofen on H-reflex RDDs 1 week post stroke. We found that 3 days after stroke, the RDD was significantly weakened in the affected muscles of stroke mice compared with sham-operated mice, and this was observed for 8 weeks. The c-fos mRNA levels in affected motoneurons were significantly increased in stroke mice compared with sham-operated mice. Immunohistochemical analysis revealed a significant increase in the number of c-Fos-positive motoneurons in stroke mice compared with sham-operated mice at 1, 2, 4, and 8 weeks after stroke; however, the number of c-Fos-positive motoneurons on both sides of the brain gradually decreased over time. Baclofen treatment resulted in recovery of the weakened RDD at 1 week post stroke. Our findings suggest that this is a viable animal model of post-stroke spasticity. PMID:24434515

  3. GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex.

    Science.gov (United States)

    Storer, R J; Akerman, S; Goadsby, P J

    2001-10-01

    1. GABA (gamma-aminobutyric acid) receptors involved in craniovascular nociceptive pathways were characterised by in vivo microiontophoresis of GABA receptor agonists and antagonists onto neurones in the trigeminocervical complex of the cat. 2. Extracellular recordings were made from neurones in the trigeminocervical complex activated by supramaximal electrical stimulation of superior sagittal sinus, which were subsequently stimulated with L-glutamate. 3. Cell firing evoked by microiontophoretic application of L-glutamate (n=30) was reversibly inhibited by GABA in every cell tested (n=19), the GABA(A) agonist muscimol (n=10) in all cells tested, or both where tested, but not by iontophoresis of either sodium or chloride ions at comparable ejection currents. Inhibited cells received wide dynamic range (WDR) or nociceptive specific input from cutaneous receptive fields on the face or forepaws. 4. The inhibition of trigeminal neurones by GABA or muscimol could be antagonized by the GABA(A) antagonist N-methylbicuculline, 1(S),9(R) in all but two cells tested (n=16), but not by the GABA(B) antagonist 2-hydroxysaclofen (n=11). 5. R(-)-baclofen, a GABA(B) agonist, inhibited the firing of three out of seven cells activated by L-glutamate. Where tested, this inhibition could be antagonized by 2-hydroxysaclofen. These baclofen-inhibited cells were characterized as having low threshold mechanoreceptor/WDR input. 6. GABA thus appears to modulate nociceptive input to the trigeminocervical complex mainly through GABA(A) receptors. GABA(A) receptors may therefore provide a target for the development of new therapeutic agents for primary headache disorders. PMID:11606331

  4. Neural Mechanisms and Delayed Gastric Emptying of Liquid Induced Through Acute Myocardial Infarction in Rats

    Energy Technology Data Exchange (ETDEWEB)

    Nunez, Wilson Ranu Ramirez; Ozaki, Michiko Regina; Vinagre, Adriana Mendes; Collares, Edgard Ferro; Almeida, Eros Antonio de, E-mail: erosaa@cardiol.br [Universidade Estadual de Campinas, Campinas, SP (Brazil)

    2015-02-15

    In pathological situations, such as acute myocardial infarction, disorders of motility of the proximal gut can trigger symptoms like nausea and vomiting. Acute myocardial infarction delays gastric emptying (GE) of liquid in rats. Investigate the involvement of the vagus nerve, α 1-adrenoceptors, central nervous system GABA{sub B} receptors and also participation of paraventricular nucleus (PVN) of the hypothalamus in GE and gastric compliance (GC) in infarcted rats. Wistar rats, N = 8-15 in each group, were divided as INF group and sham (SH) group and subdivided. The infarction was performed through ligation of the left anterior descending coronary artery. GC was estimated with pressure-volume curves. Vagotomy was performed by sectioning the dorsal and ventral branches. To verify the action of GABA{sub B} receptors, baclofen was injected via icv (intracerebroventricular). Intravenous prazosin was used to produce chemical sympathectomy. The lesion in the PVN of the hypothalamus was performed using a 1mA/10s electrical current and GE was determined by measuring the percentage of gastric retention (% GR) of a saline meal. No significant differences were observed regarding GC between groups; vagotomy significantly reduced % GR in INF group; icv treatment with baclofen significantly reduced %GR. GABA{sub B} receptors were not conclusively involved in delaying GE; intravenous treatment with prazosin significantly reduced GR% in INF group. PVN lesion abolished the effect of myocardial infarction on GE. Gastric emptying of liquids induced through acute myocardial infarction in rats showed the involvement of the vagus nerve, alpha1- adrenergic receptors and PVN.

  5. γ-aminobutyric acid B receptor (GABABR)ameliorated liver fibrosis by inhibiting hepatic cell migration%γ-氨基丁酸B受体抑制大鼠肝细胞迁移并改善肝纤维化

    Institute of Scientific and Technical Information of China (English)

    樊文梅; 石炳毅; 冯凯; 马锡慧; 魏红山; 黄海燕; 何秀云

    2012-01-01

    Objective To investigate the role of r-aminobutyric acid B receptor in the development of liver fibrosis.Methods Thirty-two Sprague-Dawley (SD) rats were divided into four groups including a control group,a model group,a baclofen group,and a CGP35348 group.Liver fibrosis was then induced by carbon tetrachloride (CCl4).Baclofen and CGP35348 treatment were carried out after the formation of liver fibrosis,followed by complete extraction of the eyeball to obtain blood sample to test liver function.Liver tissue specimens were cut and stored for histological staining,histochemistry,real-time polymerase chain-reaction (RT-PCR),and western blot analysis.Results Histological staining indicated that the degree of liver fibrosis was more severe in the CGP35348 group than in the baclofen group (P<0.001).The levels of alanine transaminase (ALT),aspartate aminotransferase (AST),gamma-glutamyl transferase (GGT),total bilirubin (TBil),and direct bilirubin (DBil) were significantly lower in the baclofen group than in the CGP35348 group (P<0.01).The levels of ALT,AST,GGT,TBil,and DBil were significantly higher in the CGP35348 group than in the model group (P<0.05).Immunofluorescence results show that the hepatic cell migration was inhibited in the baclofen group.Western blot results showed that the expression levels of α-SMA protein were significantly lowered in the baclofen group when compared to that of the CGP35348 group and model group (P<0.01).Conclusion GABAB receptor might play a role in the liver protection by inhibition of migration of hepatic cells in liver fibrosis.Further studies into the mechanism behind this function are further needed and may be a potential source of future anti-fibrotic treatment.%目的 探讨发现γ-氨基丁酸B(GABAB)受体对肝纤维化的调控作用.方法 32只SD 大鼠分为4组,每组8只,分别为对照组、模型组、baclofen处理组和CGP35348处理组.用四氯化碳(CCl4)溶液诱导肝纤维化,baclofen和CGP35348处

  6. γ-氨基丁酸及B受体在胃癌SGC-7901细胞中表达及对细胞迁移能力的影响%Influence of the expressions of GABA and GABABR1 in gastric cancer SGC-7901 cells on cell migration ability

    Institute of Scientific and Technical Information of China (English)

    史良会; 张才全

    2011-01-01

    目的 观察GABA,GAD65,GABABR1在胃癌SGC-7901细胞中的表达及对细胞迁移能力的影响.方法 RT-PCR、IF及Western印迹检测胃癌细胞SGC-7901中GABA、GAD65及GABABRI mRNA及蛋白表达;不同浓度GABA,Baclofen及CGP35348作用于胃癌细胞SGC-7901细胞24h,transwell细胞迁移小室检测细胞迁移能力的变化.结果 GAD65,GABABR1 mRNA及蛋白表达于SGC-7901细胞中;GABA,GABABR1及GAD65蛋白定位于SGC-7901细胞胞膜、胞质;与空白组比较,随着GABA浓度的增加,细胞迁移能力增强;5μmol/L及50 μmol/L baelofen作用后,亦可促进细胞迁移;而随着CGP35348浓度的增加,细胞穿膜数量减少(P<0.01).5μmol/L baclofen对细胞的迁移促进作用可被100 μmol/L的CGP35348逆转.结论 GABA及其B受体在SGC-7901细胞中的高表达可促进细胞迁移.%Objective To investigate the expressions of GABA, GAD65 and GABABR1 in SGC-7901 cells and the effects of cell migration. Methods RT-PCR, IF and Western blot were used to detect the expressions of GABA, GAD65 and GABABR1 in gastric cancer cells SGC-7901. SGC-7901 cells were cultured in transwell chamer for 24 h with different concentrations of GABA, baclofen and CGP35348. The number of cells which migrated through micropores and stayed on the outer bottom side of insert systems were observed and counted. Results The mRNA and protein expressions of GABA, GAD65 and GABRP in SGC-7901 cells were significantly higher than those in normal gastric mucosa (P<0. 01). GABA, GAD65 and GABRP protein levels were predominantly localized on the cell membrane and cell cytoplasm of SGC-7901. Compared with that of blank group, the migration capability of SGC-7901 was obviously increased by the higher concentration of GABA and 5, 50 μmol/L Baclofen, but significantly inhibited by 5, 50 (μmol/L Bicuculline (P <0. 01). The effect of 5 μmol/L Baclofen was blocked by pretreatment with 100 μmol/L CGP35348. Conclusions Higher expressions of GABA and GABRP in

  7. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.

    Science.gov (United States)

    Gold, Ralf; Oreja-Guevara, Celia

    2013-12-01

    Symptomatic therapy of multiple sclerosis (MS) is an important part of a comprehensive treatment plan that aims to improve patients' quality of life. In the current era of medical progress, several factors have led to the development of guidelines for MS management. There is continued need for an evidence-based approach supported by high-quality data from controlled clinical trials. Most healthcare systems require this approach and include it in the reimbursement process. Guidelines are usually committed by national or continental neurological societies. The Spanish Society of Neurology demyelinating diseases working group has developed a consensus document on spasticity in patients with MS. MS experts from the group used the metaplan method to sum up the most important recommendations about spasticity for inclusion in the guidance. Recommendations were classified according to the Scottish Intercollegiate Guidelines Network system and approved by all members of the group. In Germany, the guideline panel of the German Neurological Society endorsed the national competence network for multiple sclerosis (Krankheitsbezogenes Kompetenznetz Multiple Sklerose) to update the existing recommendations. The most recent fifth edition of the guidelines (dated April 2012) now also includes recommendations for treatment of key symptoms such as spasticity. More than 30 MS neurologists contributed to the new edition reflecting the need for broad expertise. After a first round in which key topics were defined, a web-based decision process was undertaken to further develop individual topics such as symptomatic therapy. The draft manuscript was reviewed once again by the group prior to submission to the official review process. The aims of spasticity treatment are to improve mobility and dexterity, achieve physiological movement patterns, reduce pain, facilitate nursing measures and avoid complications such as contractures. Representative antispasticity medications include baclofen

  8. Thoracic 9 Spinal Transection-Induced Model of Muscle Spasticity in the Rat: A Systematic Electrophysiological and Histopathological Characterization

    Science.gov (United States)

    Corleto, Jose A.; Bravo-Hernández, Mariana; Kamizato, Kota; Kakinohana, Osamu; Santucci, Camila; Navarro, Michael R.; Platoshyn, Oleksandr; Cizkova, Dasa; Lukacova, Nadezda; Taylor, Julian; Marsala, Martin

    2015-01-01

    The development of spinal hyper-reflexia as part of the spasticity syndrome represents one of the major complications associated with chronic spinal traumatic injury (SCI). The primary mechanism leading to progressive appearance of muscle spasticity is multimodal and may include loss of descending inhibitory tone, alteration of segmental interneuron-mediated inhibition and/or increased reflex activity to sensory input. Here, we characterized a chronic thoracic (Th 9) complete transection model of muscle spasticity in Sprague-Dawley (SD) rats. Isoflurane-anesthetized rats received a Th9 laminectomy and the spinal cord was transected using a scalpel blade. After the transection the presence of muscle spasticity quantified as stretch and cutaneous hyper-reflexia was identified and quantified as time-dependent changes in: i) ankle-rotation-evoked peripheral muscle resistance (PMR) and corresponding electromyography (EMG) activity, ii) Hoffmann reflex, and iii) EMG responses in gastrocnemius muscle after paw tactile stimulation for up to 8 months after injury. To validate the clinical relevance of this model, the treatment potency after systemic treatment with the clinically established anti-spastic agents baclofen (GABAB receptor agonist), tizanidine (α2-adrenergic agonist) and NGX424 (AMPA receptor antagonist) was also tested. During the first 3 months post spinal transection, a progressive increase in ankle rotation-evoked muscle resistance, Hoffmann reflex amplitude and increased EMG responses to peripherally applied tactile stimuli were consistently measured. These changes, indicative of the spasticity syndrome, then remained relatively stable for up to 8 months post injury. Systemic treatment with baclofen, tizanidine and NGX424 led to a significant but transient suppression of spinal hyper-reflexia. These data demonstrate that a chronic Th9 spinal transection model in adult SD rat represents a reliable experimental platform to be used in studying the

  9. R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects.

    Science.gov (United States)

    Zvejniece, Liga; Vavers, Edijs; Svalbe, Baiba; Veinberg, Grigory; Rizhanova, Kristina; Liepins, Vilnis; Kalvinsh, Ivars; Dambrova, Maija

    2015-10-01

    Phenibut is clinically used anxiolytic, mood elevator and nootropic drug. R-phenibut is responsible for the pharmacological activity of racemic phenibut, and this activity correlates with its binding affinity for GABAB receptors. In contrast, S-phenibut does not bind to GABAB receptors. In this study, we assessed the binding affinities of R-phenibut, S-phenibut, baclofen and gabapentin (GBP) for the α2-δ subunit of the voltage-dependent calcium channel (VDCC) using a subunit-selective ligand, radiolabelled GBP. Binding experiments using rat brain membrane preparations revealed that the equilibrium dissociation constants (Kis) for R-phenibut, S-phenibut, baclofen and GBP were 23, 39, 156 and 0.05μM, respectively. In the pentylenetetrazole (PTZ)-induced seizure test, we found that at doses up to 100mg/kg, R-phenibut did not affect PTZ-induced seizures. The anti-nociceptive effects of R-phenibut were assessed using the formalin-induced paw-licking test and the chronic constriction injury (CCI) of the sciatic nerve model. Pre-treatment with R-phenibut dose-dependently decreased the nociceptive response during both phases of the test. The anti-nociceptive effects of R-phenibut in the formalin-induced paw-licking test were not blocked by the GABAB receptor-selective antagonist CGP35348. In addition, treatment with R- and S-phenibut alleviated the mechanical and thermal allodynia induced by CCI of the sciatic nerve. Our data suggest that the binding affinity of R-phenibut for the α2-δ subunit of the VDCC is 4 times higher than its affinity for the GABAB receptor. The anti-nociceptive effects of R-phenibut observed in the tests of formalin-induced paw licking and CCI of the sciatic nerve were associated with its effect on the α2-δ subunit of the VDCC rather than with its effects on GABAB receptors. In conclusion, our results provide experimental evidence for GBP-like, anti-nociceptive properties of R-phenibut, which might be used clinically to treat neuropathic pain

  10. Tratamento da doença de Meige com droga agonista de receptores GABA

    Directory of Open Access Journals (Sweden)

    Luiz Augusto Franco de Andrade

    1985-09-01

    Full Text Available A doença de Meige é distúrbio de movimento que consiste no aparecimento espontâneo de blefarospasmo associado a movimentos distônicos de musculatura orofacial. Associadamene podem ser encontrados torcicolo espasmódico, disfonia espástica e distonia de extremidades. Várias hipóteses foram formuladas para explicar esse distúrbio, tendo em vista a resposta a drogas com ação conhecida nos sistemas de neurotransmissores do cérebro. Algumas evidências apontam para um estado de preponderância dopaminérgica e, nesse sentido, justifica-se a estimulação da atividade GABA, sabendo-se que esse neurotrans-missor age sobre uma das alças de controle da produção de dopamina na substância negra. Por essa razão investigamos a ação de um agonista GABA, o baclofen, sobre a doença de Meige. Foram incluídos no protocolo 5 pacientes, 4 mulheres e um homem, com idade variando entre 50 e 63 anos e duração da doença variando entre 4 meses e 18 anos. Todos apresentavam blefaros-pasmo-distonia orofacial e, além disso três apresentavam disfonia espástica e um distonia de extremidades. A droga era iniciada em dose de 20mg/dia, aumentada em lOmg a cada três dias até ser obtida resposta ou surgirem efeitos colaterais. Um dos pacientes apresentou melhora marcada do blefaros-pasmo-distonia orofacial e outro melhora moderada dos mesmos sintomas, em avaliação 30 dias após estabilização da dose. Não houve melhora da disfonia espástica e ocorreu melhora moderada da distonia de extremidades. Não podemos afirmar que a melhora observada ao fim de um mês se mantenha, ou mesmo que melhora mais significativa fosse observada em avaliação feita mais tardiamente. Concluimos que o baclofen pode ser útil, pelo menos por algum tempo, na doença de Meige.

  11. 苍白球GABAB受体对氟哌啶醇制备帕金森病模型大鼠姿势行为的影响%EFFECT OF ACTIVATION OF GABAB RECEPTOR IN GLOBUS PALLIDUS ON POSTURE BEHAVIOR IN RATS

    Institute of Scientific and Technical Information of China (English)

    王宏韬; 崔巧玲; 陈蕾

    2008-01-01

    目的 观察苍白球γ-氨基丁酸B型(GABAB)受体激活对氟哌啶醇诱发的帕金森病大鼠姿势行为的影响.方法 单侧苍白球埋置套管,恢复3 d后,腹腔注射氟哌啶醇(1 mg/kg)诱发帕金森病僵硬大鼠模型.于4组模型大鼠苍白球分别微量注射生理盐水、GABAB受体激动剂baclofen (1 mmol/L)、GABAB受体阻断剂CGP55845(0.1 mmol/L)、CGP55845和baclofen的混合物,注射体积为0.5 μL,观察其偏转行为的变化.结果单侧苍白球微量注射baclofen,大鼠立刻出现明显的同侧偏转行为,与盐水对照组比较,差异有统计学意义(u=8.5,P<0.001);而单侧苍白球微量注射CGP55845可产生明显的对侧偏转行为(u=22.0,P<0.001);同时注入baclofen和CGP55845混合物,动物呈现微弱的对侧偏转行为,与单纯注射baclofen相比,差异有统计学意义(u=3.5,P<0.001).结论 阻断苍白球GABAB受体可减轻氟哌啶醇所致的神经元兴奋性降低,从而解除基底神经节对丘脑及大脑皮质运动区的抑制效应,导致运动功能增强,提示其可能起抗帕金森病的作用.

  12. Modulation of non-adrenergic, non-cholinergic neural bronchoconstriction in guinea-pig airways via GABAB-receptors.

    Science.gov (United States)

    Belvisi, M G; Ichinose, M; Barnes, P J

    1989-08-01

    1. Evidence suggests that gamma-aminobutyric acid (GABA) and its receptors are present in the peripheral nervous system. We have now investigated the effect of GABA and related substances on non-adrenergic, non-cholinergic (NANC) neurally-evoked bronchoconstriction in the anaesthetised guinea-pig. 2. Bilateral vagal stimulation (5 V, 5 ms, 3 or 5 Hz) for 30 s, after propranolol (1 mg kg-1 i.v.) and atropine (1 mg kg-1 i.v.) evoked a NANC bronchoconstrictor response manifest as a mean tracheal pressure rise of 21.9 +/- 1.04 cmH2O (n = 70). The bronchoconstrictor response was reproducible for any given animal. 3. GABA (10 micrograms-10 mg kg-1 i.v.) did not alter basal tracheal pressure but reduced the NANC bronchoconstrictor response to vagal stimulation in a dose-dependent manner (ED50 = 186 micrograms kg-1 with a maximal inhibition of 74 +/- 3.4% at 10 mg kg-1). Neither the opioid antagonist naloxone (1 mg kg-1 i.v.) nor the alpha-adrenoceptor antagonist phentolamine (2.5 mg kg-1 i.v.) had any significant effect on the inhibitory response produced by GABA (500 micrograms kg-1). 4. GABA-induced inhibition was not antagonised by the GABAA-antagonist bicuculline (2 mg kg-1 i.v.). 5. The GABAB-agonist baclofen (10 micrograms-3 mg kg-1 i.v.) caused a dose-dependent inhibition of the NANC response (ED50 = 100 micrograms kg-1 with a maximal inhibition of 35.5 +/- 2.8% at 3 mg kg-1). The GABAA-agonist, 4,5,6,7-tetrahydroisoxazolo[5,4-C] pyridin-3-ol (THIP), also inhibited the NANC bronchoconstrictor response. However, the dose of THIP required for this effect was high (3 mg kg- ') and the effect ( Substance P (SP; 5upgkg-1 or 25pgkg-1), produced a bronchoconstrictor response equivalent to that produced by NANC vagal stimulation. This response was significantly increased by injection of GABA. Baclofen had no significant effect on responses evoked by exogenous SP. 7. We conclude that GABA inhibits the release of transmitter from NANC nerves via an action at GABAB receptors

  13. In vivo electroretinographic studies of the role of GABAC receptors in retinal signal processing.

    Science.gov (United States)

    Wang, Jing; Mojumder, Deb Kumar; Yan, Jun; Xie, An; Standaert, Robert F; Qian, Haohua; Pepperberg, David R; Frishman, Laura J

    2015-10-01

    All three classes of receptors for the inhibitory neurotransmitter GABA (GABAR) are expressed in the retina. This study investigated roles of GABAR, especially GABACR (GABA(A)-ρ), in retinal signaling in vivo by studying effects on the mouse electroretinogram (ERG) of genetic deletion of GABACR versus pharmacological blockade using receptor antagonists. Brief full-field flash ERGs were recorded from anesthetized GABACR(-/-) mice, and WT C57BL/6 (B6) mice, before and after intravitreal injection of GABACR antagonists, TPMPA, 3-APMPA, or the more recently developed 2-AEMP; GABAAR antagonist, SR95531; GABABR antagonist, CGP, and agonist, baclofen. Intravitreal injections of TPMPA and SR95531 were also made in Brown Norway rats. The effect of 2-AEMP on GABA-induced current was tested directly in isolated rat rod bipolar cells, and 2-AEMP was found to preferentially block GABACR in those cells. Maximum amplitudes of dark (DA) and light-adapted (LA) ERG b-waves were reduced in GABACR(-/-) mice, compared to B6 mice, by 30-60%; a-waves were unaltered and oscillatory potential amplitudes were increased. In B6 mice, after injection of TPMPA (also in rats), 3-APMPA or 2-AEMP, ERGs became similar to ERGs of GABACR(-/-) mice. Blockade of GABAARs and GABABRs, or agonism of GABABRs did not alter B6 DA b-wave amplitude. The negative scotopic threshold response (nSTR) was slightly less sensitive in GABACR(-/-) than in B6 mice, and unaltered by 2-AEMP. However, amplitudes of nSTR and photopic negative response (PhNR), both of which originate from inner retina, were enhanced by TPMPA and 3-APMPA, each of which has GABAB agonist properties, and further increased by baclofen. The finding that genetic deletion of GABACR, the GABACR antagonist 2-AEMP, and other antagonists all reduced ERG b-wave amplitude, supports a role for GABACR in determining the maximum response amplitude of bipolar cells contributing to the b-wave. GABACR antagonists differed in their effects on nSTR and Ph

  14. GABA transporters control GABAergic neurotransmission in the mouse subplate.

    Science.gov (United States)

    Unichenko, P; Kirischuk, S; Luhmann, H J

    2015-09-24

    The subplate is a transient layer between the cortical plate and intermediate zone in the developing cortex. Thalamo-cortical axons form temporary synapses on subplate neurons (SPns) before invading the cortical plate. Neuronal activity within the subplate is of critical importance for the development of neocortical circuits and architecture. Although both glutamatergic and GABAergic inputs on SPns were reported, short-term plasticity of GABAergic transmission has not been investigated yet. GABAergic postsynaptic currents (GPSCs) were recorded from SPns in coronal neocortical slices prepared from postnatal day 3-4 mice using whole-cell patch-clamp technique. Evoked GPSCs (eGPSCs) elicited by electrical paired-pulse stimulation demonstrated paired-pulse depression at all interstimulus intervals tested. Baclofen, a specific GABAB receptor (GABABR) agonist, reduced eGPSC amplitudes and increased paired-pulse ratio (PPR), suggesting presynaptic location of functional GABABRs. Baclofen-induced effects were alleviated by (2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino-2-hydroxypropyl](phenylmethyl)phosphinic acid (CGP55845), a selective GABABR blocker. Moreover, CGP55845 increased eGPSC amplitudes and decreased PPR even under control conditions, indicating that GABABRs are tonically activated by ambient GABA. Because extracellular GABA concentration is mainly regulated by GABA transporters (GATs), we asked whether GATs release GABA. 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid (NNC-711) (10μM), a selective GAT-1 blocker, increased eGPSC decay time, decreased eGPSC amplitudes and PPR. The two last effects but not the first one were blocked by CGP55845, indicating that GAT-1 blockade causes an elevation of extracellular GABA concentration and in turn activation of extrasynaptic GABAARs and presynaptic GABABRs. 1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-(S)-3-piperidinecarboxylic acid (SNAP-5114), a specific GAT-2/3 blocker, failed

  15. Thoracic 9 Spinal Transection-Induced Model of Muscle Spasticity in the Rat: A Systematic Electrophysiological and Histopathological Characterization.

    Directory of Open Access Journals (Sweden)

    Jose A Corleto

    Full Text Available The development of spinal hyper-reflexia as part of the spasticity syndrome represents one of the major complications associated with chronic spinal traumatic injury (SCI. The primary mechanism leading to progressive appearance of muscle spasticity is multimodal and may include loss of descending inhibitory tone, alteration of segmental interneuron-mediated inhibition and/or increased reflex activity to sensory input. Here, we characterized a chronic thoracic (Th 9 complete transection model of muscle spasticity in Sprague-Dawley (SD rats. Isoflurane-anesthetized rats received a Th9 laminectomy and the spinal cord was transected using a scalpel blade. After the transection the presence of muscle spasticity quantified as stretch and cutaneous hyper-reflexia was identified and quantified as time-dependent changes in: i ankle-rotation-evoked peripheral muscle resistance (PMR and corresponding electromyography (EMG activity, ii Hoffmann reflex, and iii EMG responses in gastrocnemius muscle after paw tactile stimulation for up to 8 months after injury. To validate the clinical relevance of this model, the treatment potency after systemic treatment with the clinically established anti-spastic agents baclofen (GABAB receptor agonist, tizanidine (α2-adrenergic agonist and NGX424 (AMPA receptor antagonist was also tested. During the first 3 months post spinal transection, a progressive increase in ankle rotation-evoked muscle resistance, Hoffmann reflex amplitude and increased EMG responses to peripherally applied tactile stimuli were consistently measured. These changes, indicative of the spasticity syndrome, then remained relatively stable for up to 8 months post injury. Systemic treatment with baclofen, tizanidine and NGX424 led to a significant but transient suppression of spinal hyper-reflexia. These data demonstrate that a chronic Th9 spinal transection model in adult SD rat represents a reliable experimental platform to be used in studying the

  16. Thoracic 9 Spinal Transection-Induced Model of Muscle Spasticity in the Rat: A Systematic Electrophysiological and Histopathological Characterization.

    Science.gov (United States)

    Corleto, Jose A; Bravo-Hernández, Mariana; Kamizato, Kota; Kakinohana, Osamu; Santucci, Camila; Navarro, Michael R; Platoshyn, Oleksandr; Cizkova, Dasa; Lukacova, Nadezda; Taylor, Julian; Marsala, Martin

    2015-01-01

    The development of spinal hyper-reflexia as part of the spasticity syndrome represents one of the major complications associated with chronic spinal traumatic injury (SCI). The primary mechanism leading to progressive appearance of muscle spasticity is multimodal and may include loss of descending inhibitory tone, alteration of segmental interneuron-mediated inhibition and/or increased reflex activity to sensory input. Here, we characterized a chronic thoracic (Th 9) complete transection model of muscle spasticity in Sprague-Dawley (SD) rats. Isoflurane-anesthetized rats received a Th9 laminectomy and the spinal cord was transected using a scalpel blade. After the transection the presence of muscle spasticity quantified as stretch and cutaneous hyper-reflexia was identified and quantified as time-dependent changes in: i) ankle-rotation-evoked peripheral muscle resistance (PMR) and corresponding electromyography (EMG) activity, ii) Hoffmann reflex, and iii) EMG responses in gastrocnemius muscle after paw tactile stimulation for up to 8 months after injury. To validate the clinical relevance of this model, the treatment potency after systemic treatment with the clinically established anti-spastic agents baclofen (GABAB receptor agonist), tizanidine (α2-adrenergic agonist) and NGX424 (AMPA receptor antagonist) was also tested. During the first 3 months post spinal transection, a progressive increase in ankle rotation-evoked muscle resistance, Hoffmann reflex amplitude and increased EMG responses to peripherally applied tactile stimuli were consistently measured. These changes, indicative of the spasticity syndrome, then remained relatively stable for up to 8 months post injury. Systemic treatment with baclofen, tizanidine and NGX424 led to a significant but transient suppression of spinal hyper-reflexia. These data demonstrate that a chronic Th9 spinal transection model in adult SD rat represents a reliable experimental platform to be used in studying the

  17. Incidence estimate and guideline-oriented treatment for post-stroke spasticity: an analysis based on German statutory health insurance data

    Directory of Open Access Journals (Sweden)

    Egen-Lappe V

    2013-03-01

    Full Text Available Veronika Egen-Lappe, Ingrid Köster, Ingrid SchubertPMV Research Group, Department of Child and Adolescence Psychiatry and Psychotherapy, University of Cologne, Cologne, GermanyBackground: Spasticity after stroke has been internationally recognized as an important health problem causing impairment of mobility, deformity, and pain. The aim of this study was to assess the frequency of first-ever and recurrent stroke and of subsequent spastic and flaccid paresis. Factors influencing the development of spasticity were analyzed. A further major aim was to provide a "real-life" assessment of the treatment of spasticity in Germany and to discuss this in view of the treatment recommended by German and international clinical guidelines.Methods: The database used in this study comprised a cohort of 242,090 insurants from a large statutory health insurance fund in the federal state of Hesse, Germany. A first hospital discharge diagnosis in 2009 with any of the International Classification of Diseases, Tenth Revision (ICD-10 codes I60–I64 was used to identify patients with acute stroke (hemorrhage and ischemic. These patients were followed up six months after stroke to monitor whether they developed spastic or flaccid paresis (hospital or ambulatory care diagnoses ICD-10 code G81–G83 [excluding G82.6/G83.4/G83.8]. For patients with spastic paresis after stroke the spasticity treatment was analyzed for a six-month period (physiotherapy, oral muscle relaxants, intrathecal baclofen, and botulinum toxin.Results: Standardized to the population of Germany, 3.7 per 1000 persons suffered a stroke in 2009 (raw 5.2/1000. Of all surviving patients, 10.2% developed spasticity within 6 months. Cox regression revealed no significant influence of patient age, gender, morbidity (diabetes, hypertensive diseases, ischemic heart diseases or type of stroke on development of spasticity. 97% of surviving patients with spasticity received physiotherapy (inpatient care 89

  18. Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

    Science.gov (United States)

    Fontenelle, Leonardo F; Oostermeijer, Sanne; Harrison, Ben J; Pantelis, Christos; Yücel, Murat

    2011-05-01

    ), glutamate (e.g. topiramate), serotonin (e.g. ondansetron) or γ-aminobutyric acid (e.g. baclofen and topiramate) systems, may prove to show some benefit in certain forms of OCD. Based on the available evidence, we suggest that the treatment of patients with these disorders must account for alterations in the underlying motivations and neurobiology of the condition. We provide an initial guide to the specific treatments that future clinical trials might consider in patients with OCD. For example, it might be wise to test naltrexone in patients with co-morbid SUD and ICD, topiramate in patients with co-morbid ICD and eating disorders, and baclofen in patients with co-morbid Tourette's syndrome. These trials could also include scales aimed at assessing underlying impulsivity (e.g. Barratt Impulsiveness Scale) to check whether this construct might predict response to drugs acting on the reward system. PMID:21568361

  19. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.

    Science.gov (United States)

    Di Marzo, Vincenzo

    2011-04-01

    Endocannabinoids are endogenous agonists of the mammalian cannabinoid receptors CB(1) and CB(2), and they appear to be produced in tissues as an adaptive reaction to re-establish normal homeostasis when this is acutely altered. However, the production of endocannabinoids can be altered pathologically. The two most widely studied endocannabinoids are anandamide and 2-arachidonoyl glycerol. The levels of these endogenous modulators are regulated in different and sometimes opposing ways, and alterations in cerebrospinal fluid and/or spinal cord levels have been documented in animal models of neurodegenerative diseases and in samples from patients with multiple sclerosis (MS). Modulation of the endocannabinoid system has been shown to have therapeutic potential in a number of disease states. Sativex(®) (nabiximols, USAN name) contains the two main phytocannabinoids from Cannabis sativa, tetrahydrocannabinol and cannabidiol in a 1:1 ratio, and it acts as an endocannabinoid system modulator. In an experimental mouse model of MS-related spasticity, Sativex dose-dependently improved hind limb flexion/stiffness and a dosage of 10 mg/kg was shown to be as effective as the most widely established anti-spasticity treatment baclofen (5 mg/kg). These findings with Sativex are very promising and offer encouragement for MS patients, the majority of whom will develop spasticity-related disabling and recalcitrant symptoms. Furthermore, research into the endocannabinoid system may offer potential in other neurodegenerative, inflammatory and pain disorders. PMID:21449854

  20. Management of refractory typical GERD symptoms.

    Science.gov (United States)

    Scarpellini, Emidio; Ang, Daphne; Pauwels, Ans; De Santis, Adriano; Vanuytsel, Tim; Tack, Jan

    2016-05-01

    The management of patients with refractory GERD (rGERD) is a major clinical challenge for gastroenterologists. In up to 30% of patients with typical GERD symptoms (heartburn and/or regurgitation), acid-suppressive therapy does not provide clinical benefit. In this Review, we discuss the current management algorithm for GERD and the features and management of patients who do not respond to treatment (such as those individuals with an incorrect diagnosis of GERD, inadequate PPI intake, persisting acid reflux and persisting weakly acidic reflux). Symptom response to existing surgical techniques, novel antireflux procedures, and the value of add-on medical therapies (including prokinetics and reflux inhibitors) for rGERD symptoms are discussed. Pharmaceutical agents targeting oesophageal sensitivity, a condition that can contribute to symptom generation in rGERD, are also discussed. Finally, on the basis of available published data and our expert opinion, we present an outline of a current, usable algorithm for management of patients with rGERD that considers the timing and diagnostic use of pH-impedance monitoring on or off PPI, additional diagnostic tests, the clinical use of baclofen and the use of add-on neuromodulators (tricyclic agents and selective serotonin reuptake inhibitors). PMID:27075264

  1. [Limb torsion and developmental regression for one month after hand, foot and mouth disease in an infant].

    Science.gov (United States)

    Feng, Li-Fang; Chen, Xiao-Hong; Li, Dong-Xiao; Ding, Yuan; Jin, Ying; Song, Jin-Qing; Yang, Yan-Ling

    2016-05-01

    A one-year-old girl visited the hospital due to limb torsion and developmental regression for one month after hand, foot and mouth disease. At the age of 11 months, she visited a local hospital due to fever for 5 days and skin rash with frequent convulsions for 2 days and was diagnosed with severe hand, foot and mouth disease, viral encephalitis, and status epilepticus. Brain MRI revealed symmetric abnormal signals in the bilateral basal ganglia, bilateral thalamus, cerebral peduncle, bilateral cortex, and hippocampus. She was given immunoglobulin, antiviral drugs, and anticonvulsant drugs for 2 weeks, and the effect was poor. Blood and urine screening for inherited metabolic diseases were performed to clarify the etiology. The analysis of urine organic acids showed significant increases in glutaric acid and 3-hydroxyglutaric acid, which suggested glutaric aciduria type 1, but her blood glutarylcarnitine was normal, and free carnitine significantly decreased. After the treatment with low-lysine diets, L-carnitine, and baclofen for 1 month, the patient showed a significant improvement in symptoms. Hand, foot and mouth disease is a common viral infectious disease in children, and children with underlying diseases such as inherited metabolic diseases and immunodeficiency may experience serious complications. For children with hand, foot and mouth disease and unexplained encephalopathy, inherited metabolic diseases should be considered. PMID:27165592

  2. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.

    Science.gov (United States)

    Vijayakumar, Dhanya; Jankovic, Joseph

    2016-05-01

    Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. Levodopa-induced dyskinesia (LID) is one of the main types of drug-induced dyskinesia, occurring in patients with Parkinson's disease (PD) who have been treated with levodopa for long time, but this side effect may be encountered even within a few weeks or months after initiation of levodopa therapy. Based on the temporal pattern in relationship to levodopa dosing, LIDs are divided into "peak-dose dyskinesia," "diphasic dyskinesia," and "wearing off" or "off-period" dyskinesia, of which peak-dose dyskinesia is the most common, followed by off-period, and then diphasic dyskinesia. Treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias, occurring particularly in patients with young-onset PD, are the most difficult to treat. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs. A variety of emerging (experimental) drugs currently in development promise to provide better control of LIDs and other levodopa-related complications in the near future. PMID:27091215

  3. Intrathecal drug administration in chronic pain syndromes.

    Science.gov (United States)

    Ver Donck, Ann; Vranken, Jan H; Puylaert, Martine; Hayek, Salim; Mekhail, Nagy; Van Zundert, Jan

    2014-06-01

    Chronic pain may recur after initial response to strong opioids in both patients with cancer and patients without cancer or therapy may be complicated by intolerable side effects. When minimally invasive interventional pain management techniques also fail to provide satisfactory pain relief, continuous intrathecal analgesic administration may be considered. Only 3 products have been officially approved for long-term intrathecal administration: morphine, baclofen, and ziconotide. The efficacy of intrathecal ziconotide for the management of patients with severe chronic refractory noncancer pain was illustrated in 3 placebo-controlled trials. A randomized study showed this treatment option to be effective over a short follow-up period for patients with pain due to cancer or AIDS. The efficacy of intrathecal opioid administration for the management of chronic noncancer pain is mainly derived from prospective and retrospective noncontrolled trials. The effect of intrathecal morphine administration in patients with pain due to cancer was compared with oral or transdermal treatment in a randomized controlled trial, which found better pain control and fewer side effects with intrathecal opioids. Other evidence is derived from cohort studies. Side effects of chronic intrathecal therapy may either be technical (catheter or pump malfunction) or biological (infection). The most troublesome complication is, however, the possibility of granuloma formation at the catheter tip that may induce neurological damage. Given limited studies, the evidence for intrathecal drug administration in patients suffering from cancer-related pain is more compelling than that of chronic noncancer pain. PMID:24118774

  4. Acute withdrawal: diagnosis and treatment.

    Science.gov (United States)

    Brust, John C M

    2014-01-01

    Symptoms of alcohol withdrawal range in severity from mild "hangover" to fatal delirium tremens (DTs). Tremor, hallucinosis, and seizures usually occur within 48 hours of abstinence. Seizures tend to be generalized without focality, occurring singly or in a brief cluster, but status epilepticus is not unusual. DTs usually appears after 48 hours of abstinence and consists of marked inattentiveness, agitation, hallucinations, fluctuating level of alertness, marked tremulousness, and sympathetic overactivity. The mainstay of treatment for alcohol withdrawal is benzodiazepine pharmacotherapy, which can be used to control mild early symptoms, to prevent progression to DTs, or to treat DTs itself. Alternative less evidence-based pharmacotherapies include phenobarbital, anticonvulsants, baclofen, gamma-hydroxybutyric acid, beta-blockers, alpha-2-agonists, and N-methyl-d-aspartate receptor blockers. Treatment of DTs is a medical emergency requiring heavy sedation in an intensive care unit, with close attention to autonomic instability, fever, fluid loss, and electrolyte imbalance. Frequent comorbid disorders include hypoglycemia, liver failure, pancreatitis, sepsis, meningitis, intracranial hemorrhage, and Wernicke-Korsakoff syndrome. PMID:25307572

  5. The GABAB1a isoform mediates heterosynaptic depression at hippocampal mossy fiber synapses

    DEFF Research Database (Denmark)

    Guetg, Nicole; Seddik, Riad; Vigot, Réjan;

    2009-01-01

    GABA(B) receptor subtypes are based on the subunit isoforms GABA(B1a) and GABA(B1b), which associate with GABA(B2) subunits to form pharmacologically indistinguishable GABA(B(1a,2)) and GABA(B(1b,2)) receptors. Studies with mice selectively expressing GABA(B1a) or GABA(B1b) subunits revealed that...... GABA(B(1a,2)) receptors are more abundant than GABA(B(1b,2)) receptors at glutamatergic terminals. Accordingly, it was found that GABA(B(1a,2)) receptors are more efficient than GABA(B(1b,2)) receptors in inhibiting glutamate release when maximally activated by exogenous application of the agonist...... baclofen. Here, we used a combination of genetic, ultrastructural and electrophysiological approaches to analyze to what extent GABA(B(1a,2)) and GABA(B(1b,2)) receptors inhibit glutamate release in response to physiological activation. We first show that at hippocampal mossy fiber (MF)-CA3 pyramidal...

  6. Transient inactivation of the posterior paraventricular nucleus of the thalamus blocks cocaine-seeking behavior.

    Science.gov (United States)

    Matzeu, A; Weiss, F; Martin-Fardon, R

    2015-11-01

    Originally studied for its role in energy homeostasis, the paraventricular nucleus of the thalamus (PVT) has recently gained attention because of its involvement in the modulation of drug-directed behavior. The posterior part of the PVT (pPVT) is connected with brain structures that modulate motivated behavior, and we tested whether the pPVT plays a pivotal role in cocaine seeking. The aim of the present study was to investigate whether transient inactivation of the pPVT prevents cue-induced reinstatement of cocaine seeking but not natural reward seeking. Male Wistar rats were trained to associate a discriminative stimulus (S(+)) with the availability of cocaine or a highly palatable conventional reinforcer, sweetened condensed milk (SCM). Following extinction, the cocaine S(+) and SCM S(+) elicited comparable levels of reinstatement. Intra-pPVT administration of the γ-aminobutyric acid-A (GABAA) and GABAB receptor agonists muscimol and baclofen (0.06 and 0.6mM, respectively) prior to the presentation of the cocaine or SCM S(+) completely prevented the reinstatement of cocaine seeking, with no statistically significant effects on SCM seeking. These data show that the pPVT plays an important role in neuronal mechanisms that drive cocaine-seeking behavior. PMID:26455867

  7. Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease.

    Science.gov (United States)

    Gitto, Stefano; Golfieri, Lucia; Caputo, Fabio; Grandi, Silvana; Andreone, Pietro

    2016-01-01

    Alcohol use disorder is a significant health problem being a cause of increased morbidity and mortality worldwide. Alcohol-related illness has a relevant economic impact on the society and a negative influence on the life of patients and their family members. Psychosocial support might be useful in the management of people affected by alcohol use disorder since psychiatric and pharmaceutical approaches show some limits. In fact, many drugs are accessible for the treatment of alcohol disorder, but only Baclofen is functional as an anti-craving drug in patients with advanced liver disease. The alcohol-related liver damage represents the most frequent cause of advanced liver disease in Europe, and it is the main cause of death among adults with high alcohol consumption. The multidisciplinary action of clinical-psychologists, psychiatrics and hepatologists, is essential in the management of patients with alcohol liver disease especially in the case of liver transplantation. In general, the multidisciplinary approach is necessary in prevention, in framing patients and in the treatment. More resources should be used in prevention and research with the main aim of decreasing the harmful alcohol consumption. PMID:26784248

  8. [Influence of GABA derivatives on some indices of lipid peroxidation in immunocompetent organs under experimental immunopathology conditions].

    Science.gov (United States)

    Samotrueva, M A; Magomedov, M M; Khlebtsova, E B; Tiurenkov, I N

    2011-01-01

    The effects of GABA derivatives phenotropil (25 mg/kg), phenibut (25 mg/kg), and baclofen (2 mg/kg) on the process of lipid peroxidation (LPO), as manifested by the initial level of malonic dialdehyde, velocity of spontaneous and ascorbate-dependent LPO, and the catalase activity in the homogenates of thymus and spleen, have been studied on rats of the Wistar line with cyclophosphamide (CPHA) immunodepression and lipopolysacharide (LPS) immune stress. It is established that, under the action of CPHA and LPS, activation of the LPO processes takes place in the immune organs. Under these conditions, changes of the catalase activity exhibited some specific features: in the animals under LPS action, the catalase activity increased in the spleen, while being decreased in the thymus; under the influence of CPHA, the activity of this enzyme decreased in both organs. An analysis of the antioxidant activity of GABA derivatives under the conditions of CPHA-induced immunodepression showed that all substances upon intraperitoneal introduction for 5 days favored the elimination of disturbances by suppressing the LPO processes and increasing the antioxidant protection activity. On the background of LPS-induced immune stress, all the tested substances showed a correcting action with respect to indicated biochemical processes in the thymus, while only phenibut activated the antioxidant system in the spleen. PMID:22232912

  9. [A pharmaco-ethological study of the GABA-ergic mechanisms regulating the depression-like behavior of mice].

    Science.gov (United States)

    Belozertseva, I V; Andreev, B V

    1997-01-01

    It is known that repeated stress may result in depression-like alterations of behavior. This behavior is characterized by decreased social exploratory activity and increase in occurrence of defensive postures in a social interaction test in mice. The passive defensive behavior is effectively antagonized by antidepressant drugs thus providing a useful animal model of depression. Effects of several GABAergic drugs were studied in opponent test in individually housed male mice. For two weeks preceding the test, mice were repeatedly exposed to foot shock stimulation and/or social confrontation with an aggressive mouse. Muscimol, a selective agonist of GABA(A) receptors, decreased the frequency and duration of defensive postures and increased the duration of some forms of individual activity (grooming and eating), like the agonist of GABA(B) receptors baclofen. Muscimol was the only compound that facilitated exploratory activity towards an unfamiliar partner and did not suppress the locomotion. Effects of another agonist of GABA(B) receptors phenibut and inhibitor of GABA transaminase valproate Na were less specific and consisted in general suppression of behavior (prevalence of static forms of behavior). It can be thought that GABA(A) receptors are essential for regulation of depression-like behavior of mice. PMID:9472168

  10. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.

    Science.gov (United States)

    Lapin, I

    2001-01-01

    Phenibut (beta-phenyl-gamma-aminobutyric acid HCl) is a neuropsychotropic drug that was discovered and introduced into clinical practice in Russia in the 1960s. It has anxiolytic and nootropic (cognition enhancing) effects. It acts as a GABA-mimetic, primarily at GABA(B) and, to some extent, at GABA(A) receptors. It also stimulates dopamine receptors and antagonizes beta-phenethylamine (PEA), a putative endogenous anxiogenic. The psychopharmacological activity of phenibut is similar to that of baclofen, a p-Cl-derivative of phenibut. This article reviews the structure-activity relationship of phenibut and its derivatives. Emphasis is placed on the importance of the position of the phenyl ring, the role of the carboxyl group, and the activity of optical isomers. Comparison of phenibut with piracetam and diazepam reveals similarities and differences in their pharmacological and clinical effects. Phenibut is widely used in Russia to relieve tension, anxiety, and fear, to improve sleep in psychosomatic or neurotic patients; as well as a pre- or post-operative medication. It is also used in the therapy of disorders characterized by asthenia and depression, as well as in post-traumatic stress, stuttering and vestibular disorders. PMID:11830761

  11. CXCL12 chemokine and GABA neurotransmitter systems crosstalk and their putative roles

    Directory of Open Access Journals (Sweden)

    Guyon eAlice

    2014-04-01

    Full Text Available Since CXCL12 and its receptors, CXCR4 and CXCR7, have been found in the brain, the role of this chemokine has been expanded from chemoattractant in the immune system to neuromodulatory in the brain. Several pieces of evidence suggest that this chemokine system could crosstalk with the GABAergic system, known to be the main inhibitory neurotransmitter system in the brain. Indeed, GABA and CXCL12 as well as their receptors are colocalized in many cell types including neurons and there are several examples in which these two systems interact. Several mechanisms can be proposed to explain how these systems interact, including receptor-receptor interactions, crosstalk at the level of second messenger cascades, or direct pharmacological interactions, as GABA and GABAB receptor agonists/antagonists have been shown to be allosteric modulators of CXCR4.The interplay between CXCL12/CXCR4-CXCR7 and GABA/GABAA-GABAB receptors systems could have many physiological implications in neurotransmission, cancer and inflammation. In addition, the GABAB agonist baclofen is currently used in medicine to treat spasticity in patients with spinal cord injury, cerebral palsy, traumatic brain injury, multiple sclerosis and other disorders. More recently it has also been used in the treatment of alcohol dependence and withdrawal. The allosteric effects of this agent on CXCR4 could contribute to these beneficial effects or at the opposite, to its side effects.

  12. An analysis of [3H]gamma-aminobutyric acid (GABA) binding in the human brain.

    Science.gov (United States)

    Lloyd, K G; Dreksler, S

    1979-03-01

    The binding of [3H]GABA to membranes prepared from human brains obtained post morten was examined. This binding was independent of patient sex, age (16--80 years), postmortem interval (4--33 h) or storage time when frozen (0-64 months). In preparations from cerebellar cortex various compounds displaced [3H]GABA binding with the following order of potency: muscimol greater than 3-aminopropanesulfonic acid greater than GABA greater than imidazoleacet acid greater than delta-amino-n-valeric acid greater than 3-hydroxyGABA greater than bicuculline. Other compounds active 'in vitro' included strychnine, homocarnosine and some (e.g. clozapine, thioridazine, pimozide) but not all (chlorpromazine, haloperiodol) neuroleptics. Compounds inactive 'in vitro' included aminooxyacetic acid, baclofen, picrotoxin, anticholinergics, metrazole, anticonvulsants and naloxone. Triton X-100 augmented the [3H]GABA binding (25 nM) by about 10--20-fold in most brain regions. [3H]GABA binding (IC50) was altered in Huntington's chorea and Reye's syndrome, but not in schizophrenics (4-neuroleptic-treated patients) or sudden infant death syndrome. The data presented strongly support the proposal that the measurement of [3H]GABA binding in postmortem human brain offers a reflection of the state of the physiologically relevant GABA receptor. PMID:218679

  13. EAT PINEAPPLE A DAY TO KEEP DEPRESSION AT BAY

    Directory of Open Access Journals (Sweden)

    Parle Milind

    2010-12-01

    Full Text Available Pineapple, a juicy and tasty fruit, belonging to family Bromeliaceae is scientifically known as Ananas cosmosus. The Pineapples are traditionally used as a blood purifier, to aid digestion, for gastro-intestinal disorders, diseases of the larynx and pharynx, as a mild antiseptic and to treat diabetes. There are no reports in literature pertaining to CNS actions of Ananas cosmosus fruit. In the light of above, the present study was undertaken to test the antidepressant potential of Ananas cosmosus fruit juice. Ananas cosmosus juice (ACJ was administered at various concentrations ranging from 5% to 20% v/v to Swiss albino mice for 15 days and wistar rats for 8 successive days. The antidepressant activity was measured using forced swim test (FST, tail suspension test (TST and reserpine induced hypothermia. The efficacy of Pineapple juice was compared with standard anti-depressant agents viz: fluoxetine (20 mg/kg and imipramine (15 mg/kg. The results showed that Pineapple juice significantly decreased immobility time in both FST and TST models. It also reversed the hypothermia induced by reserpine. The efficacy of Pineapple juice was found to be comparable to fluoxetine and imipramine. Prazosin, sulpiride, baclofen and p-CPA antagonized the antidepressant effect of Pineapple juice in tail suspension test. Furthermore, Ananas cosmosus juice inhibited the monoamine oxidase MAO-A and MAO-B activity and reduced significantly malondialdehyde (MDA levels. These findings reveal the anti-depressant potential of Pineapple.

  14. Effect of Gamma Aminobutyric Acid B Receptor on Brain Damage Induced by Recurrent Febrile Seizures%γ-氨基丁酸B受体在反复热性惊厥脑损伤中的作用

    Institute of Scientific and Technical Information of China (English)

    韩颖; 秦炯; 卜定方; 常杏芝; 杨志仙

    2005-01-01

    目的探讨γ-氨基丁酸B受体(γ-aminobutyric acid B receptor,GABABR)对反复热性惊厥(febrile seizures,FS)脑损伤的影响.方法SD大鼠随机分为对照组、FS组、FS+氯苯氨丁酸(baclofen)组、FS+法克罗芬(phaclofen)组.采用热水浴诱导大鼠FS,隔日诱导1次,共10次.记录大鼠惊厥潜伏期、持续时间及强度;用原位杂交和免疫组织化学方法分别观察c-fos基因和Fos蛋白表达情况.结果与FS组相比,FS+baclofen组大鼠惊厥潜伏期延长、惊厥持续时间缩短、惊厥强度减轻;而FS+phaclofen组大鼠惊厥潜伏期缩短、惊厥持续时间延长、惊厥强度加重.baclofen干预使c-fos基因和Fos蛋白表达降低,而phaclofen 干预使其表达增强.结论应用GABABR激动剂baclofen和抑制剂phaclofen干预研究表明,GABABR与热性惊厥脑损伤的发生、发展密切相关.

  15. The role of brain magnetic resonance imaging in the diagnosis of pantothenate kinase deficiency (previously Hallervorden-Spatz disease): case report

    International Nuclear Information System (INIS)

    Panthotenate kinase deficiency is a rare metabolic disorder from the group of neuroaxonal dystrophy. It is characterized by symptoms of extrapiramidal system impairment, general dystonia, progressive gait disturbances, limbs rigidity, dyskinesias, choreoatetotic movements, dysarthria and progressive dementia. On the brain MRI, T2 - weighted images demonstrate typical, symmetrical '' eye of the tiger '' sign with hyperintensive signals from the central parts of the pallidum, surrounded by low signals in the pallidum and accompanied by hypointensity in substantia nigra resulting from iron deposition. We present a case of 13.5 year old boy with gait disturbances, increase muscles tone, dysartria, aggressive behavior and learning difficulties progressing from the early childhood. In the differential diagnosis a number of inborn errors of metabolism was excluded. Finding on the brain MRI in T2- weighted images typical picture of '' eye of the tiger '' led to a diagnosis of panthotenate kinase deficiency. In subsequent years of observation, despite attempts of baclofen and calcium panthotenate treatment, progression of pyramidal-extrapyramidal syndrome is observed. In children with symptoms of progressive extrapyramidal tract impairment, a sign of '' eye of the tiger '' with hyperintensive signals from the central parts of the pallidum, surrounded by low signals in the remaining part of the pallidum and accompanied by similar lesions in substantia nigra is typical for panthotenate kinase deficiency - a rare neurodegenerative disorder of central nervous system. (author)

  16. Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease

    Directory of Open Access Journals (Sweden)

    Stefano Gitto

    2016-01-01

    Full Text Available Alcohol use disorder is a significant health problem being a cause of increased morbidity and mortality worldwide. Alcohol-related illness has a relevant economic impact on the society and a negative influence on the life of patients and their family members. Psychosocial support might be useful in the management of people affected by alcohol use disorder since psychiatric and pharmaceutical approaches show some limits. In fact, many drugs are accessible for the treatment of alcohol disorder, but only Baclofen is functional as an anti-craving drug in patients with advanced liver disease. The alcohol-related liver damage represents the most frequent cause of advanced liver disease in Europe, and it is the main cause of death among adults with high alcohol consumption. The multidisciplinary action of clinical-psychologists, psychiatrics and hepatologists, is essential in the management of patients with alcohol liver disease especially in the case of liver transplantation. In general, the multidisciplinary approach is necessary in prevention, in framing patients and in the treatment. More resources should be used in prevention and research with the main aim of decreasing the harmful alcohol consumption.

  17. Modulation of Visceral Nociception, Inflammation and Gastric Mucosal Injury by Cinnarizine

    Directory of Open Access Journals (Sweden)

    Omar M.E. Abdel-Salam

    2007-01-01

    Full Text Available The effect of cinnarizine, a drug used for the treatment of vertigo was assessed in animal models of visceral nociception, inflammation and gastric mucosal injury. Cinnarizine (1.25–20 mg/kg, s.c. caused dose-dependent inhibition of the abdominal constrictions evoked by i.p. injection of acetic acid by 38.7–99.4%. This effect of cinnarizine (2.5 mg/kg was unaffected by co-administration of the centrally acting dopamine D2 receptor antagonists, sulpiride, haloperidol or metoclopramide, the peripherally acting D2 receptor antagonist domperidone, but increased by the D2 receptor agonist bromocryptine and by the non-selective dopamine receptor antagonist chlorpromazine. The antinociception caused by cinnarizine was naloxone insenstive, but enhanced by propranolol, atropine and by yohimbine. The antinociceptive effect of cinnarizine was prevented by co-treatment with the adenosine receptor blocker theophylline or by the ATP-sensitive potassium channel (KATP blocker glibenclamide. Cinnarizine at 2.5 mg/kg reversed the baclofen-induced antinociception. Cinnarizine at 2.5 mg/kg reduced immobility time in the Porsolt’s forced-swimming test by 24%. Cinnarizine inhibited the paw oedema response to carrageenan and reduced gastric mucosal lesions caused by indomethacin in rats. It is suggested that cinnarizine exerts anti-infl ammatory, antinociceptive and gastric protective properties. The mechanism by which cinnarizine modulates pain transmission is likely to involve adenosine receptors and KATP channels.

  18. Neutral amino acid transport across brain microvessel endothelial cell monolayers

    International Nuclear Information System (INIS)

    Brain microvessel endothelial cells (BMEC) which form the blood-brain barrier (BBB) possess an amino acid carrier specific for large neutral amino acids (LNAA). The carrier is important for facilitating the delivery of nutrient LNAA's and centrally acting drugs that are LNAA's, to the brain. Bovine BMEC's were isolated and grown up to complete monolayers on regenerated cellulose-membranes in primary culture. To study the transendothelial transport of leucine, the monolayers were placed in a side-by-side diffusion cell, and transport across the monolayers followed with [3H]-leucine. The transendothelial transport of leucine in this in vitro model was determined to be bidirectional, and time-, temperature-, and concentration-dependent. The transport of leucine was saturable and the apparent K/sub m/ and V/sub max/, 0.18 mM and 6.3 nmol/mg/min, respectively. Other LNAA's, including the centrally acting drugs, α-methyldopa, L-DOPA, α-methyl-tyrosine, and baclofen, inhibited leucine transport. The leucine carrier was also found to be stereospecific and not sensitive to inhibitors of active transport. These results are consistent with previous in vitro and in vivo studies. Primary cultures of BMEC's appear to be a potentially important tool for investigating at the cellular level, the transport mechanisms of the BBB

  19. GABA-noradrenergic interaction: evidence for differential sites of action for GABA-A and GABA-B receptors

    International Nuclear Information System (INIS)

    Treatment of mice with DSP4 (a neurotoxin that abolishes the presynaptic noradrenergic neuron; Dooley et al., 1983) resulted in: (A) a decrease in the Bsub(max) for the low affinity GABA-B receptor site in the cerebal cortex and hippocampus, whereas the Bsub(max) for the high affinity GABA-B receptor site was unaffected; (B) a greater potentiation of norepinephrine stimulated adenylate cyclase by baclofen in cerebal cortex slices; and (C) a decrease in the Bsub(max) for both the high and low affinity GABA-A receptor sites in the cerebal cortex and hippocampus. These data, coupled with previous work from our laboratory, suggest that the GABA-B receptor may be associated with both the noradrenergic nerve terminal and the post-synaptic neuron receiving noradrenergic input, whereas the GABA-B receptor may be associated with the noradrenergic nerve terminal. These data further suggest a functional coupling between the noradrenergic and GABA-ergic systems. (Author)

  20. Regulation of (/sup 3/H)GABA release from strips of guinea pig urinary bladder

    Energy Technology Data Exchange (ETDEWEB)

    Shirakawa, J.; Taniyama, K.; Iwai, S.; Tanaka, C.

    1988-12-01

    The presence of receptors that regulate the release of gamma-aminobutyric acid (GABA) was studied in strips of the guinea pig urinary bladder. GABA (10(-8)-10(-5) M) and muscimol (10(-8)-10(-5) M), but not baclofen (10(-5) M), reduced the Ca2+-dependent, tetrodotoxin-resistant release of (/sup 3/H)GABA evoked by high K+ from the urinary bladder strips preloaded with (/sup 3/H)GABA. The inhibitory effect of muscimol was antagonized by bicuculline and potentiated by diazepam, clonazepam, and pentobarbital sodium. The potentiating effect of clonazepam was antagonized by Ro 15-1788. Acetylcholine (ACh) inhibited the high K+-evoked release of (/sup 3/H)GABA. The inhibitory effect of ACh was antagonized by atropine sulfate and pirenzepine but not by hexamethonium. Norepinephrine (NE) inhibited the evoked release of (/sup 3/H)GABA. The inhibitory effect of NE was mimicked by clonidine, but not by phenylephrine, and was antagonized by yohimbine but not by prazosin. These results provide evidence that the release of GABA from strips of guinea pig urinary bladder is regulated via the bicuculline-sensitive GABAA receptor, M1-muscarinic, and alpha 2-adrenergic receptors.

  1. Modulation of acetylcholine release from rat striatal slices by the GABA/benzodiazepine receptor complex

    Energy Technology Data Exchange (ETDEWEB)

    Supavilai, P.; Karobath, M.

    1985-02-04

    GABA, THIP and muscimol enhance spontaneous and inhibit electrically induced release of tritium labelled compounds from rat striatal slices which have been pre-labelled with /sup 3/H-choline. Baclofen is inactive in this model. Muscimol can inhibit electrically induced release of tritiated material by approximately 75% with half maximal effects at 2 ..mu..M. The response to muscimol can be blocked by the GABA antagonists bicuculline methobromide, picrotoxin, anisatin, R 5135 and CPTBO (cyclopentylbicyclophosphate). Drugs which act on the benzodiazepine receptor (BR) require the presence of muscimol to be effective and they modulate the effects of muscimol in a bidirectional manner. Thus BR agonists enhance and inverse BR agonists attenuate the inhibitory effects of muscimol on electrically induced release. Ro15-1788, a BR antagonist, does not modulate the inhibitory effects of muscimol but antagonizes the actions of clonazepam, a BR agonist, and of DMCM, an inverse BR agonist. These results demonstrate that a GABA/benzodiazepine receptor complex can modulate acetylcholine release from rat striatal slices in vitro. 24 references, 3 figures, 5 table.

  2. A functional assay to measure postsynaptic gamma-aminobutyric acidB responses in cultured spinal cord neurons: Heterologous regulation of the same K+ channel

    Energy Technology Data Exchange (ETDEWEB)

    Kamatchi, G.L.; Ticku, M.K. (Univ. of Texas Health Science Center, San Antonio (USA))

    1991-02-01

    The stimulation of postsynaptic gamma-aminobutyric acid (GABA)B receptors leads to slow inhibitory postsynaptic potentials due to the influx of K(+)-ions. This was studied biochemically, in vitro in mammalian cultured spinal cord neurons by using 86Rb as a substitute for K+. (-)-Baclofen, a GABAB receptor agonist, produced a concentration-dependent increase in the 86Rb-influx. This effect was stereospecific and blocked by GABAB receptor antagonists like CGP 35 348 (3-aminopropyl-diethoxymethyl-phosphonic acid) and phaclofen. Apart from the GABAB receptors, both adenosine via adenosine1 receptors and 5-hydroxytryptamine (5-HT) via 5-HT1 alpha agonists also increased the 86Rb-influx. These agonists failed to show any additivity between them when they were combined in their maximal concentration. In addition, their effect was antagonized specifically by their respective antagonists without influencing the others. These findings suggest the presence of GABAB, adenosine1 and 5-HT1 alpha receptors in the cultured spinal cord neurons, which exhibit a heterologous regulation of the same K(+)-channel. The effect of these agonists were antagonized by phorbol 12,13-didecanoate, an activator of protein kinase C, and pretreatment with pertussis toxin. This suggests that these agonists by acting on their own receptors converge on the same K(+)-channel through the Gi/Go proteins. In summary, we have developed a biochemical functional assay for studying and characterizing GABAB synaptic pharmacology in vitro, using spinal cord neurons.

  3. 巴氯芬并奥美拉唑治疗NERD的疗效观察

    Institute of Scientific and Technical Information of China (English)

    李新练

    2013-01-01

    目的 探讨巴氯芬(Baclofen)并奥美拉唑治疗非糜烂性胃食管反流病(NERD)的疗效.方法 96例患者随机分为治疗组50例和对照组46例.治疗组为巴氯芬并奥美拉唑治疗,对照组为奥美拉唑治疗,观察2组临床症状缓解和食管PH值、胃镜检查情况.结果 治疗组总有效率84%(42/50)均明显高于对照组58.7%(27/46),差异有统计学意义(P<0.05).结论 巴氯芬并奥美拉唑治疗NERD与对照组比较疗效满意,有一定的临床价值.

  4. Reduction of GABA/sub B/ receptor binding induced by climbing fiber degeneration in the rat cerebellum

    International Nuclear Information System (INIS)

    When the rat cerebellar climbing fibers degenerated, as induced by lesioning the inferior olive with 3-acetylpyridine (3-AP), GABA/sub B/ receptor binding determined with 3H-(+/-)baclofen was reduced in the cerebellum but not in the cerebral cortex of rats. Computer analysis of saturation data revealed two components of the binding sites, and indicated that decrease of the binding in the cerebellum was due to reduction in receptor density, mainly of the high-affinity sites, the B/sub max/ of which was reduced to one-third that in the control animals. In vitro treatment with 3-AP, of the membranes prepared from either the cerebellum or the cerebral cortex, induced no alteration in the binding sites, thereby indicating that the alteration of GABA/sub B/ sites induced by in vivo treatment with 3-AP is not due to a direct action of 3-AP on the receptor. GABA/sub A/ and benzodiazepine receptor binding labelled with 3H-muscimol and 3H-diazepam, respectively, in both of brain regions was not affected by destruction of the inferior olive. These results provide evidence that some of the GABA/sub B/ sites but neither GABA/sub A/ nor benzodiazepine receptors in the cerebellum are located at the climbing fiber terminals. 28 references, 4 figures, 2 tables

  5. Cardiovascular effects of lateral intracerebroventricular injection of L-securinine%侧脑室注射一叶萩碱的心血管效应及作用机制

    Institute of Scientific and Technical Information of China (English)

    赵晓燕; 蒋正尧; 彭建中

    2000-01-01

    在麻醉大鼠侧脑室注射左旋一叶萩碱(L-Sec), 记录动脉血压(AP)、心率(HR)及肾交感神经放电(RSND), 观察前脑室周系统GABA能紧张性活动改变引起的心血管效应.结果如下: (1) L-Sec可引起RSND增加、AP升高和HR加快, 并呈一定剂量-效应关系; 但L-Sec作用明显弱于bicuculline (Bic).(2) L-Sec 既能拮抗muscimol (Mus), 又能拮抗baclofen (Bac)引起的交感抑制和降压反应.上述结果提示: (1) 前脑室周部位存在GABA能抑制机制, 对交感心血管系统具有紧张性抑制作用, L-Sec解除了这种抑制, 使交感神经系统传出活动增强, 因而产生升压作用.(2) L-Sec可能是一种非选择性的GABA受体拮抗剂.

  6. Regional selectivity of a gamma-aminobutyric acid-induced (/sup 3/H)acetylcholine release sensitive to inhibitors of gamma-aminobutyric acid uptake

    Energy Technology Data Exchange (ETDEWEB)

    Bonanno, G.; Raiteri, M.

    1987-05-01

    The effects of gamma-aminobutyric acid (GABA) on the release of (/sup 3/H)acetylcholine ((/sup 3/H)ACh) were studied in synaptosomes prepared from rat hippocampus, cerebral cortex, hypothalamus, and striatum and prelabelled with (/sup 3/H)choline. When synaptosomes were exposed in superfusion to exogenous GABA (0.01-0.3 mM) the basal release of newly synthesized (/sup 3/H)ACh was increased in a concentration-dependent way in hippocampus, cortex, and hypothalamus nerve endings. In contrast, the release of (/sup 3/H)ACh was not significantly affected by GABA in striatal synaptosomes. The effect of GABA was not antagonized significantly by bicuculline or picrotoxin. Muscimol caused only a slight not significant increase of (/sup 3/H)ACh release when tested at 0.3 mM whereas, at this concentration, (-)-baclofen was totally inactive. The GABA-induced release of (/sup 3/H)ACh was counteracted by SKF 89976A, SKF 100561, and SKF 100330A, three strong and selective GABA uptake inhibitors. The data suggest that, in selective areas of the rat brain, GABA causes release of (/sup 3/H)ACh following penetration into cholinergic nerve terminals through a GABA transport system.

  7. A functional assay to measure postsynaptic gamma-aminobutyric acidB responses in cultured spinal cord neurons: Heterologous regulation of the same K+ channel

    International Nuclear Information System (INIS)

    The stimulation of postsynaptic gamma-aminobutyric acid (GABA)B receptors leads to slow inhibitory postsynaptic potentials due to the influx of K(+)-ions. This was studied biochemically, in vitro in mammalian cultured spinal cord neurons by using 86Rb as a substitute for K+. (-)-Baclofen, a GABAB receptor agonist, produced a concentration-dependent increase in the 86Rb-influx. This effect was stereospecific and blocked by GABAB receptor antagonists like CGP 35 348 (3-aminopropyl-diethoxymethyl-phosphonic acid) and phaclofen. Apart from the GABAB receptors, both adenosine via adenosine1 receptors and 5-hydroxytryptamine (5-HT) via 5-HT1 alpha agonists also increased the 86Rb-influx. These agonists failed to show any additivity between them when they were combined in their maximal concentration. In addition, their effect was antagonized specifically by their respective antagonists without influencing the others. These findings suggest the presence of GABAB, adenosine1 and 5-HT1 alpha receptors in the cultured spinal cord neurons, which exhibit a heterologous regulation of the same K(+)-channel. The effect of these agonists were antagonized by phorbol 12,13-didecanoate, an activator of protein kinase C, and pretreatment with pertussis toxin. This suggests that these agonists by acting on their own receptors converge on the same K(+)-channel through the Gi/Go proteins. In summary, we have developed a biochemical functional assay for studying and characterizing GABAB synaptic pharmacology in vitro, using spinal cord neurons

  8. Regulation of [3H]GABA release from strips of guinea pig urinary bladder

    International Nuclear Information System (INIS)

    The presence of receptors that regulate the release of gamma-aminobutyric acid (GABA) was studied in strips of the guinea pig urinary bladder. GABA (10(-8)-10(-5) M) and muscimol (10(-8)-10(-5) M), but not baclofen (10(-5) M), reduced the Ca2+-dependent, tetrodotoxin-resistant release of [3H]GABA evoked by high K+ from the urinary bladder strips preloaded with [3H]GABA. The inhibitory effect of muscimol was antagonized by bicuculline and potentiated by diazepam, clonazepam, and pentobarbital sodium. The potentiating effect of clonazepam was antagonized by Ro 15-1788. Acetylcholine (ACh) inhibited the high K+-evoked release of [3H]GABA. The inhibitory effect of ACh was antagonized by atropine sulfate and pirenzepine but not by hexamethonium. Norepinephrine (NE) inhibited the evoked release of [3H]GABA. The inhibitory effect of NE was mimicked by clonidine, but not by phenylephrine, and was antagonized by yohimbine but not by prazosin. These results provide evidence that the release of GABA from strips of guinea pig urinary bladder is regulated via the bicuculline-sensitive GABAA receptor, M1-muscarinic, and alpha 2-adrenergic receptors

  9. Neutral amino acid transport across brain microvessel endothelial cell monolayers

    Energy Technology Data Exchange (ETDEWEB)

    Audus, K.L.; Borchardt, R.T.

    1986-03-01

    Brain microvessel endothelial cells (BMEC) which form the blood-brain barrier (BBB) possess an amino acid carrier specific for large neutral amino acids (LNAA). The carrier is important for facilitating the delivery of nutrient LNAA's and centrally acting drugs that are LNAA's, to the brain. Bovine BMEC's were isolated and grown up to complete monolayers on regenerated cellulose-membranes in primary culture. To study the transendothelial transport of leucine, the monolayers were placed in a side-by-side diffusion cell, and transport across the monolayers followed with (/sup 3/H)-leucine. The transendothelial transport of leucine in this in vitro model was determined to be bidirectional, and time-, temperature-, and concentration-dependent. The transport of leucine was saturable and the apparent K/sub m/ and V/sub max/, 0.18 mM and 6.3 nmol/mg/min, respectively. Other LNAA's, including the centrally acting drugs, ..cap alpha..-methyldopa, L-DOPA, ..cap alpha..-methyl-tyrosine, and baclofen, inhibited leucine transport. The leucine carrier was also found to be stereospecific and not sensitive to inhibitors of active transport. These results are consistent with previous in vitro and in vivo studies. Primary cultures of BMEC's appear to be a potentially important tool for investigating at the cellular level, the transport mechanisms of the BBB.

  10. GABA Receptor Agonists Rescued Cortical Neurons from Oxygen-Glucose Deprivation%GABA受体激动剂对氧-葡萄糖剥夺诱导皮层神经元死亡的保护作用

    Institute of Scientific and Technical Information of China (English)

    吴翠莹; 李树基; 高天明

    2010-01-01

    目的:研究GABA受体激动剂对氧-葡萄糖剥夺诱导皮层神经元死亡的保护作用.方法: 培养12d的皮层神经元更换为Earle's 平衡盐溶液(Earle's balanced salts ,EBSS)后置于37℃三气缺氧(N2:CO2:O2= 94%:5%:1%)培养箱内培养,4h后恢复正常条件培养,同时在培养液内加入GABA A受体和B受体激动剂作用24h,用Hoechst33342/PI的染色方法检测其死亡情况.结果: GABA A受体激动剂(muscimol)和GABA B受体激动剂(baclofen)均分别能显著降低神经细胞死亡率49.9%和35.3%. 结论: GABA A受体激动剂和B受体激动剂对氧-葡萄糖剥夺诱导的皮层神经元死亡均有显著的保护作用.

  11. Actions of insecticides on the insect GABA receptor complex

    International Nuclear Information System (INIS)

    The actions of insecticides on the insect gamma-aminobutyric acid (GABA) receptor were investigated using [35S]t-butylbicyclophosphorothionate [( 35S]TBPS) binding and voltage-clamp techniques. Specific binding of [35S]TBPS to a membrane homogenate derived from the brain of Locusta migratoria locusts is characterised by a Kd value of 79.3 ± 2.9 nM and a Bmax value of 1770 ± 40 fmol/mg protein. [35S]TBPS binding is inhibited by mM concentrations of barbiturates and benzodiazepines. In contrast dieldrin, ivermectin, lindane, picrotoxin and TBPS are inhibitors of [35S]TBPS binding at the nanomolar range. Bicuculline, baclofen and pyrethroid insecticides have no effect on [35S]TBPS binding. These results are similar to those obtained in electrophysiological studies of the current elicited by GABA in both Locusta and Periplaneta americana central neurones. Noise analysis of the effects of lindane, TBPS, dieldrin and picrotoxin on the cockroach GABA responses reveals that these compounds decrease the variance of the GABA-induced current but have no effect on its mean open time. All these compounds, with the exception of dieldrin, significantly decrease the conductance of GABA-evoked single current

  12. 选择性脊神经后根切断术解痉治疗的研究进展

    Institute of Scientific and Technical Information of China (English)

    段平国

    2010-01-01

    @@ 脑性瘫痪(cerebral palsy,CP)简称脑瘫,指发生在发育期胎儿或婴儿大脑非进展性缺陷或损害所致的运动及姿势发育持久障碍而引起活动受限的一组综合征[1].痉挛型CP的主要症状就是痉挛,是由牵张反射过度兴奋所致[2].其治疗方法包括物理治疗、鞘内注射巴氯芬(intrathecal baclofen,ITB)、矫形术以及选择性脊神经后根切断术(selective posterior rhizotomy,SPR).其中惟一可持久解痉的方法就是SPR[3].因此,本文就SPR的解痉机制、目前状况、疗效以及并发症等方面的进展进行综述.

  13. Reduction of GABA/sub B/ receptor binding induced by climbing fiber degeneration in the rat cerebellum

    Energy Technology Data Exchange (ETDEWEB)

    Kato, K.; Fukuda, H.

    1985-07-22

    When the rat cerebellar climbing fibers degenerated, as induced by lesioning the inferior olive with 3-acetylpyridine (3-AP), GABA/sub B/ receptor binding determined with /sup 3/H-(+/-)baclofen was reduced in the cerebellum but not in the cerebral cortex of rats. Computer analysis of saturation data revealed two components of the binding sites, and indicated that decrease of the binding in the cerebellum was due to reduction in receptor density, mainly of the high-affinity sites, the B/sub max/ of which was reduced to one-third that in the control animals. In vitro treatment with 3-AP, of the membranes prepared from either the cerebellum or the cerebral cortex, induced no alteration in the binding sites, thereby indicating that the alteration of GABA/sub B/ sites induced by in vivo treatment with 3-AP is not due to a direct action of 3-AP on the receptor. GABA/sub A/ and benzodiazepine receptor binding labelled with /sup 3/H-muscimol and /sup 3/H-diazepam, respectively, in both of brain regions was not affected by destruction of the inferior olive. These results provide evidence that some of the GABA/sub B/ sites but neither GABA/sub A/ nor benzodiazepine receptors in the cerebellum are located at the climbing fiber terminals. 28 references, 4 figures, 2 tables.

  14. Modulation of acetylcholine release from rat striatal slices by the GABA/benzodiazepine receptor complex

    International Nuclear Information System (INIS)

    GABA, THIP and muscimol enhance spontaneous and inhibit electrically induced release of tritium labelled compounds from rat striatal slices which have been pre-labelled with 3H-choline. Baclofen is inactive in this model. Muscimol can inhibit electrically induced release of tritiated material by approximately 75% with half maximal effects at 2 μM. The response to muscimol can be blocked by the GABA antagonists bicuculline methobromide, picrotoxin, anisatin, R 5135 and CPTBO (cyclopentylbicyclophosphate). Drugs which act on the benzodiazepine receptor (BR) require the presence of muscimol to be effective and they modulate the effects of muscimol in a bidirectional manner. Thus BR agonists enhance and inverse BR agonists attenuate the inhibitory effects of muscimol on electrically induced release. Ro15-1788, a BR antagonist, does not modulate the inhibitory effects of muscimol but antagonizes the actions of clonazepam, a BR agonist, and of DMCM, an inverse BR agonist. These results demonstrate that a GABA/benzodiazepine receptor complex can modulate acetylcholine release from rat striatal slices in vitro. 24 references, 3 figures, 5 table

  15. 鞘内注射巴氯酚治疗痉挛型脑瘫的临床应用

    Institute of Scientific and Technical Information of China (English)

    刘建军; 吴卫红; 纪树荣

    2003-01-01

    @@ 脑瘫是造成儿童残疾的重要疾患之一.尽管在过去20年中围产期医学得到了发展,但脑瘫(cerebral palsy,CP)的发病率没有明显改变,仍在1.5‰-2.5‰左右[1].脑瘫患儿60%-80%是痉挛型,如何缓解痉挛一直是康复医师所面临的重要课题.过去只重视痉挛后果的治疗,现在开始重视痉挛本身的治疗[2],出现了选择性脊神经后根切除术、肉毒毒素注射[3]等方法.Penn等人于1984年首次报道了鞘内注射巴氯酚(intrathecal baclofen,ITB)缓解痉挛[3],开辟了一条治疗痉挛的新路.后来发展为将巴氯酚泵植入患者皮下,实现了连续给药,长时间缓解痉挛.

  16. GABAB receptor subunit GB1 at the cell surface independently activates ERK1/2 through IGF-1R transactivation.

    Directory of Open Access Journals (Sweden)

    Guillaume A Baloucoune

    Full Text Available BACKGROUND: Functional GABA(B receptor is believed to require hetero-dimerization between GABA(B1 (GB1 and GABA(B2 (GB2 subunits. The GB1 extracellular domain is required for ligand binding, and the GB2 trans-membrane domain is responsible for coupling to G proteins. Atypical GABA(B receptor responses observed in GB2-deficient mice suggested that GB1 may have activity in the absence of GB2. However the underlying mechanisms remain poorly characterized. METHODOLOGY/PRINCIPAL FINDINGS: Here, by using cells overexpressing a GB1 mutant (GB1asa with the ability to translocate to the cell surface in the absence of GB2, we show that GABA(B receptor agonists, such as GABA and Baclofen, can induce ERK1/2 phosphorylation in the absence of GB2. Furthermore, we demonstrate that GB1asa induces ERK1/2 phosphorylation through Gi/o proteins and PLC dependent IGF-1R transactivation. CONCLUSIONS/SIGNIFICANCE: Our data suggest that GB1 may form a functional receptor at the cell surface in the absence of GB2.

  17. Actions of insecticides on the insect GABA receptor complex

    Energy Technology Data Exchange (ETDEWEB)

    Bermudez, I.; Hawkins, C.A.; Taylor, A.M.; Beadle, D.J. (School of Biological and Molecular Sciences, Oxford Polytechnic, Headington, Oxford (England))

    1991-01-01

    The actions of insecticides on the insect gamma-aminobutyric acid (GABA) receptor were investigated using (35S)t-butylbicyclophosphorothionate (( 35S)TBPS) binding and voltage-clamp techniques. Specific binding of (35S)TBPS to a membrane homogenate derived from the brain of Locusta migratoria locusts is characterised by a Kd value of 79.3 {plus minus} 2.9 nM and a Bmax value of 1770 {plus minus} 40 fmol/mg protein. (35S)TBPS binding is inhibited by mM concentrations of barbiturates and benzodiazepines. In contrast dieldrin, ivermectin, lindane, picrotoxin and TBPS are inhibitors of (35S)TBPS binding at the nanomolar range. Bicuculline, baclofen and pyrethroid insecticides have no effect on (35S)TBPS binding. These results are similar to those obtained in electrophysiological studies of the current elicited by GABA in both Locusta and Periplaneta americana central neurones. Noise analysis of the effects of lindane, TBPS, dieldrin and picrotoxin on the cockroach GABA responses reveals that these compounds decrease the variance of the GABA-induced current but have no effect on its mean open time. All these compounds, with the exception of dieldrin, significantly decrease the conductance of GABA-evoked single current.

  18. [Case of painful muscle spasm induced by thoracic vertebral fracture: successful treatment with lumbar sympathetic ganglia block].

    Science.gov (United States)

    Shimizu, Fumitaka; Kawai, Motoharu; Koga, Michiaki; Ogasawara, Jun-ichi; Negoro, Kiyoshi; Kanda, Takashi

    2008-10-01

    We report a 70-year-old man, who developed painful involuntary muscle contraction of the left leg after the lumbar discectomy, which exacerbated after a vertebral fracture of Th12. This involuntary movement was accompanied with the abnormal position of left leg simulating triple flexion response, and was induced by active or passive movement of his left knee and foot joints. Several drugs including benzodiazepines and dantrolene were ineffective, although treatment with baclofen or carbamazepine was effective. These findings suggest that hyperexcitability of the anterior horn cells following the disturbance of spinal inhibitory interneurons was involved. Electophysiological studies suggested the disturbance of left lumber nerve roots. The spinal root blocks from L3 to S1 were performed, after which the painful involuntary muscle spasm was resolved. The lumbar sympathetic ganglia block was also effective; suggesting that abnormal afferent neuronal input to spinal cord was caused by the nerve root trauma which triggered the formation of secondary abnormal network in the spine. Lumbar sympathetic ganglia block should be recommended to a therapeutic option for the refractory painful muscle spasm of the leg. PMID:19086429

  19. ALCOHOL DEPENDENCE--NEUROBIOLOGY AND TREATMENT.

    Science.gov (United States)

    Michalak, Agnieszka; Biała, Grazyna

    2016-01-01

    The consequences of alcohol dependence concern serious health care, social and economic problems. The scope of many studies is to better understand mechanisms underlying alcohol addiction in order to work out new, more effective treatment strategies. Alcohol affects many neurotransmission systems within the brain. In general, acute alcohol enhances inhibitory transmission, up-regulating the GABAergic system and impairing glutamatergic function, therefore interfering the balance between excitatory and inhibitory synaptic inputs. Chronic alcohol consumption, meanwhile, in order to restore equilibrium leads to neuroadaptive changes caus- ing both decreased GABAergic and increased glutamatergic activity. Also function of other neurotransmitters and modulators is modified by the presence of alcohol, including glycine, adenosine, serotonin and dopamine. Moreover, a significant impact of alcohol on the endogenous opioid system, nicotinic cholinergic transmission and the endocannabinoids system has been also established. At present, only four medications are approved for the treatment of alcohol dependence in Europe, that is naltrexone, acamprosate, disulfiram and the most recent nalmefene. Among other promising strategies the following drugs are mentioned: baclofen, topiramate, ondansetron, aripiprazole, rimonabant and varenicline. Additionally, the role of appetite-regulating hormones, neuroimmune modulators or the body's stress-response system modulators in reducing alcohol consumption is currently of great interest, however, further investigations are needed. PMID:27008795

  20. Involvement of the rostral agranular insular cortex in nicotine self-administration in rats.

    Science.gov (United States)

    Pushparaj, Abhiram; Kim, Aaron S; Musiol, Martin; Trigo, Jose M; Le Foll, Bernard

    2015-09-01

    Our prior work demonstrated the involvement of the caudal granular subregion of the insular cortex in a rat model of nicotine self-administration. Recent studies in various animal models of addiction for nicotine and other drugs have identified a role for the rostral agranular subregion (RAIC). The current research was undertaken to examine the involvement of the RAIC in a rat model of nicotine self-administration. We investigated the inactivating effects of local infusions of a γ-aminobutyric acid agonist mixture (baclofen/muscimol) into the RAIC on nicotine self-administration under a fixed-ratio 5 (FR-5) schedule and on reinstatement of nicotine seeking induced by nicotine-associated cues in rats. We also evaluated the effects of RAIC inactivation on food self-administration under an FR5 schedule as a control. Inactivation of the RAIC decreased nicotine, but not food, self-administration. RAIC inactivation also prevented the reinstatement, after extinction, of nicotine seeking induced by nicotine-associated cues. Our study indicates that the RAIC is involved in nicotine-taking and nicotine-seeking in rats. Modulating insular cortex function appears to be a promising approach for nicotine dependence treatment. PMID:25934486

  1. Update on pediatric dystonias: etiology, epidemiology, and management

    Directory of Open Access Journals (Sweden)

    Nardocci N

    2012-04-01

    Full Text Available Emilio Fernández-Alvarez1, Nardo Nardocci21Neuropediatric Department, Hospital San Juan de Dios, Barcelona, Spain; 2Child Neurology Department, Fondazione IRCCS Istituto Neurologico "C. Besta", Milano, ItalyAbstract: Dystonia is a movement disorder characterized by sustained muscle contractions producing twisting, repetitive, and patterned movements or abnormal postures. Dystonia is among the most commonly observed movement disorders in clinical practice both in adults and children. It is classified on the basis of etiology, age at onset of symptoms, and distribution of affected body regions.Etiology: The etiology of pediatric dystonia is quite heterogeneous. There are many different genetic syndromes and several causes of symptomatic syndromes. Dystonia can be secondary to virtually any pathological process that affects the motor system, and particularly the basal ganglia.Classification: The etiological classification distinguishes primary dystonia with no identifiable exogenous cause or evidence of neurodegeneration and secondary syndromes.Treatment: Treatment for most forms of dystonia is symptomatic and includes drugs (systemic or focal treatments, such as botulinum toxin and surgical procedures. There are several medications including anticholinergic, dopamine-blocking and depleting agents, baclofen, and benzodiazepines. In patients with dopamine synthesis defects L-dopa treatment may be very useful. Botulinum toxin treatment may be helpful in controlling the most disabling symptoms of segmental or focal dystonia. Long-term electrical stimulation of the globus pallidum internum appears to be especially successful in children suffering from generalized dystonia.Keywords: movement disorders, pediatric dystonia, primary dystonias, secondary dystonias

  2. Pharmacotherapy of methamphetamine addiction: an update.

    Science.gov (United States)

    Elkashef, Ahmed; Vocci, Frank; Hanson, Glen; White, Jason; Wickes, Wendy; Tiihonen, Jari

    2008-01-01

    Methamphetamine dependence is a serious public health problem worldwide for which there are no approved pharmacological treatments. Psychotherapy is still the mainstay of treatment; however, relapse rates are high. The search for effective pharmacological treatment has intensified in the last decade. This review will highlight progress in pharmacological interventions to treat methamphetamine dependence as well as explore new pharmacological targets. Published data from clinical trials for stimulant addiction were searched using PubMed and summarized, as well as highlights from a recent symposium on methamphetamine pharmacotherapy presented at the ISAM 2006 meeting, including interim analysis data from an ongoing D-amphetamine study in Australia. Early pilot data are encouraging for administering D-amphetamine and methylphenidate as treatment for heavy amphetamine users. Abilify at 15 mg/day dose increased amphetamine use in an outpatient pilot study. Sertraline, ondansetron, baclofen, tyrosine, and imipramine were ineffective in proof-of-concept studies. Development of pharmacotherapy for methamphetamine dependence is still in an early stage. Data suggesting D-amphetamine and methylphenidate as effective pharmacotherapy for methamphetamine addiction will need to be confirmed by larger trials. Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies. PMID:19042205

  3. Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?

    Science.gov (United States)

    Ciurleo, Rosella; Bramanti, Placido; Calabrò, Rocco Salvatore

    2013-11-01

    Disorders of consciousness, including the coma state, vegetative state and minimally conscious state, are among the least understood and least curable conditions in modern neurology. Structural or functional injuries may produce impairments in the neuronal circuits (the ascending reticular activating system and thalamocortical loops) responsible for maintaining the wakefulness state and awareness, associated with a change in neurotransmitter concentrations. Pharmacological agents that are able to restore the levels of neurotransmitters and, consequently, neural synaptic plasticity and functional connectivity of consciousness networks, may play an important role as drugs useful in improving the consciousness state. Currently, there is growing interest in the scientific community with regard to pharmacological agents that act on the gamma amino-butyric acid (GABA) system, such as zolpidem and baclofen, and monoamine systems, such as dopaminergic agents and some antidepressants. The purpose of this article is to provide a comprehensive overview of these potential 'awakening' drugs in patients with disorders of consciousness. The possible mechanisms by which these drugs may exert their effects in promoting recovery of consciousness are discussed, highlighting how many findings are often the result of sporadic events rather than prospective controlled trials or implementation of standard treatment guidelines. PMID:24170667

  4. Targeting the Glutamatergic System to Treat Pathological Gambling: Current Evidence and Future Perspectives

    Directory of Open Access Journals (Sweden)

    Mauro Pettorruso

    2014-01-01

    Full Text Available Pathological gambling or gambling disorder has been defined by the DSM-5 as a behavioral addiction. To date, its pathophysiology is not completely understood and there is no FDA-approved treatment for gambling disorders. Glutamate is the principal excitatory neurotransmitter in the nervous system and it has been recently involved in the pathophysiology of addictive behaviors. In this paper, we review the current literature on a class of drugs that act as modulating glutamate system in PG. A total of 19 studies have been included, according to inclusion and exclusion criteria. Clinical trial and case series using glutamatergic drugs (N-acetylcysteine, memantine, amantadine, topiramate, acamprosate, baclofen, gabapentin, pregabalin, and modafinil will be presented to elucidate the effectiveness on gambling behaviors and on the related clinical dimensions (craving, withdrawal, and cognitive symptoms in PG patients. The results have been discussed to gain more insight in the pathophysiology and treatment of PG. In conclusion, manipulation of glutamatergic neurotransmission appears to be promising in developing improved therapeutic agents for the treatment of gambling disorders. Further studies are required. Finally, we propose future directions and challenges in this research area.

  5. Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of Tinospora cordifolia in mice

    Directory of Open Access Journals (Sweden)

    Dhingra D

    2008-01-01

    Full Text Available The present study was taken up to investigate the effect of petroleum ether extract of Tinospora cordifolia (Wild. Miers, on depression in mice. The extract (50, 100 and 200 mg/kg, p.o. was administered for 14 successive days to Swiss young albino mice (either sex and evaluated for antidepressant-like activity using tail suspension test and forced swim test. Petroleum ether extract at all three doses produced significant antidepressant-like effect in tail suspension test as well as in forced swim test and their efficacies were found to be comparable to imipramine (15 mg/kg, p.o. and sertraline (20 mg/kg, p.o.. The extract at a dose of 50 mg/kg showed most potent effect and did not show any significant change in locomotor functions of mice as compared to control. The antidepressant-like effect of the extract was significantly reversed by pretreatment of animals with prazosin (a α1 -adrenoceptor antagonist, sulpiride (a selective dopamine D 2 -receptor antagonist, p-CPA (a serotonin synthesis inhibitor and baclofen (GABA-B agonist, when tested in tail suspension test. Moreover, petroleum ether extract also reduced the mouse whole brain monoamine oxidase (MAO-A and MAO-B activities as compared to control, resulting in increase in the levels of brain monoamines. Therefore, the extract may have potential therapeutic value for the management of depressive disorders.

  6. [Treatment of blepharospasm with botulinum toxin].

    Science.gov (United States)

    Pikielny, R T; Micheli, F E; Fernández Pardal, M M; Casas Parera, I; Giannaula, R J; Gatto, M

    1990-01-01

    Blepharospasm is a relatively frequent cranial dystonia which may be seen either alone or related to orofacial-mandibular dystonia (Meige's syndrome). In its maximum degree it can cause functional blindness.Twelve patients with blepharospasm (4 essential and 8 Meige's syndrome) who had been previously treated unsuccessfully with drugs (trihexyphenidyl, biperiden, carbamazepine, lithium, baclofen, lisuride, imipramine, clonazepam and butyrophenones) were treated for 12 months with periocular injections of botulinum toxin (BOTOX). A "low" dose of 12,5 U per eye was employed. With this dose, eleven out of twelve patients experienced significant improvement which lasted from five to fifteen weeks. The only nonresponder obtained complete relief upon duplicating the dose. The only side effect was uni or bilateral ptosis in six patients which improved completely in seven to twenty one days. One patient developed a peripheral facial palsy with complete remission in nineteen days. No systemic side effects were noted. There was only one desertion from this study due to depression enhanced by prolonged (21 days) ptosis. All patients (including the deserter) agreed that treatment with BOTOX provided more relief than any other previous therapeutic method. Our results confirm those obtained by others but a more prolonged study is needed to better evaluate long term effects. PMID:2101846

  7. Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions.

    Science.gov (United States)

    Berner, Laura A; Bocarsly, Miriam E; Hoebel, Bartley G; Avena, Nicole M

    2011-01-01

    Binge eating behavior has been noted in some eating disorders as well as in obesity. The goal of this paper is to review current, non-serotonergic pharmaceutical approaches to treat binge eating. Further, using information derived from preclinical models, we discuss candidate neurotransmitter systems for study as targets for the treatment of binge eating. Dopaminergic circuits have been implicated in both laboratory animal models and human studies of binge eating, though existing medications specifically targeting the dopaminergic system have been found to have adverse side effects. Opioidergic and gamma-aminobutyric acid (GABA) systems also appear to be highly involved in aspects of binge eating; further, opioid antagonists, such as naloxone and naltrexone, and GABA agonists, such as baclofen, have all been shown to be effective in treating alcohol dependence and may be equally efficacious in attenuating binge eating. Preclinical evidence, and some clinical evidence, suggests that cannabinoid antagonism may also be useful in the treatment of binge eating, although the specific effect of antagonists, on binge consumption remains unclear. Overall, each of these neurotransmitter systems provides a promising avenue for new pharmacotherapy development for binge eating, and preclinical and human studies provide a strong rationale for the development of highly-selective drugs that target this neurocircuitry. PMID:21492094

  8. GERD is becoming a challenge for the medical profession: is there any remedy?

    Science.gov (United States)

    Yasawy, Mohammad Ismail; Randhawa, Mohammad Akram

    2014-09-01

    Gastroesophageal reflux disease is becoming a common and serious problem. Proton pump inhibitors are considered as drugs of choice however, long term use leads to complications. Transient lower esophageal sphincter relaxation inhibitors, i.e., gamma-aminobutyric acid B receptor agonists, baclofen, and metabotropic glutamate receptor 5 antagonists, ADX10059, were tried in resistant cases, but caused central nervous and hepatic side effects, respectively. Irregular dietary habits possess the strongest association with GERD, because intake of food in between meals aggravates gastric distention in upper stomach and generates TLESRs, triggering reflux. During fasting, migrating myoelectrical complex clears stomach of food. Considering relationship between irregular dietary habits and GERD pathophysiology, it is suggested that two regular meals a day with only fluids in between will reduce reflux and lead to healing of inflammation caused by repeated refluxes. Initially, the suggested regimen eliminated symptoms of GERD in 4 cases in 10 days. Later, in a pilot study on 20 patients of endoscopically diagnosed GERD, it benefitted 15 cases; 100% of Los Angles grade ‘a’, 66% of grade ‘b’ and 33% of grade ‘c’. Long term studies are proposed to confirm usefulness of this dietary regimen for management of GERD, alone and in combination with drugs. PMID:25436353

  9. [A case of prolonged paroxysmal sympathetic hyperactivity].

    Science.gov (United States)

    Yamamoto, Akiko; Ide, Shuhei; Iwasaki, Yuji; Kaga, Makiko; Arima, Masataka

    2016-03-01

    We report the case of a 4-year-old girl who presented with paroxysmal sympathetic hyperactivity (PSH), after developing severe hypoxic-ischemic-encephalopathy because of cardiopulmonary arrest. She showed dramatic paroxysmal sympathetic activity with dystonia. She was treated with wide variety of medications against PSH, which were found to be effective in previous studies. Among them, morphine, bromocriptine, propranolol, and clonidine were effective in reducing the frequency of her attacks while gabapentin, baclofen, dantrolene, and benzodiazepine were ineffective. Though the paroxysms decreased markedly after the treatment, they could not be completely controlled beyond 500 days. Following the treatment, levels of plasma catecholamines and their urinary metabolites decreased to normal during inter- paroxysms. However, once a paroxysm had recurred, these levels were again very high. This case study is considered significant for two rea- sons. One is that PSH among children have been rarely reported, and the other is that this case of prolonged PSH delineated the transition of plasma catecholamines during the treatment. The excitatory: inhibitory ratio (EIR) model proposed by Baguley was considered while dis- cussing drug sensitivity in this case. Accumulation of similar case studies will help establish more effective treatment strategies and elucidate the pathophysiology of PSH. PMID:27149743

  10. Decreased GABA receptor in the cerebral cortex of epileptic rats: effect of Bacopa monnieri and Bacoside-A

    Directory of Open Access Journals (Sweden)

    Mathew Jobin

    2012-02-01

    Full Text Available Abstact Background Gamma amino butyric acid (GABA, the principal inhibitory neurotransmitter in the cerebral cortex, maintains the inhibitory tones that counter balances neuronal excitation. When this balance is perturbed, seizures may ensue. Methods In the present study, alterations of the general GABA, GABAA and GABAB receptors in the cerebral cortex of the epileptic rat and the therapeutic application of Bacopa monnieri were investigated. Results Scatchard analysis of [3H]GABA, [3H]bicuculline and [3H]baclofen in the cerebral cortex of the epileptic rat showed significant decrease in Bmax (P Aά1, GABAAγ, GABAAδ, GABAB and GAD where down regulated (P Aά5 subunit and Cyclic AMP responsible element binding protein were up regulated. Confocal imaging study confirmed the decreased GABA receptors in epileptic rats. Epileptic rats have deficit in radial arm and Y maze performance. Conclusions Bacopa monnieri and Bacoside-A treatment reverses epilepsy associated changes to near control suggesting that decreased GABA receptors in the cerebral cortex have an important role in epileptic occurrence; Bacopa monnieri and Bacoside-A have therapeutic application in epilepsy management.

  11. Formulación de mezclas intratecales para el tratamiento del dolor Compounding of drug admixtures for intrathecal treatment of pain

    Directory of Open Access Journals (Sweden)

    M. P. Ortega-García

    2012-08-01

    intrathecal analgesia are recommended in international consensus, but there are few studies about their stability and safety. The objectives of this review are to evaluate specific considerations for compounded formulations for intrathecal pumps and to review stability studies of drug combinations recommended. Compounding formulations for intrathecal pumps has specific recommendations: avoiding preservatives, antioxidants, and solubility enhancers, using buffers that are compatible with the delivery system, using a pH that is physiologically appropriate and is consistent with the delivery system, normally between 4 and 8, using solutions isotonic with normal CSF, preparing the solution in a manner that does not alter the solubility of the constituents, verifying the chemical and physical stability of the preparation under relevant conditions in accordance with literature and verifying the sterility of the preparation in accordance with the United States Pharmacopeia (Chapter 797 and American Society of Health-System Pharmacist publications. But pharmacist, moreover compounding, play an important role in maintaining quality assurance of intrathecal drug use, validating prescriptions and using standard procedures for ordering and compounding medications, checking dose calculations and monitoring of patients outcomes. Drug combinations for intrathecal analgesia with stability studies are: morphine and ziconotide, morphine and clonidine, ziconotide and bupivacaine, morphine, bupivacaine and clonidine, morphine, ziconotide and clonidine, baclofen and clonidine, ziconotide and baclofen, ziconotide and clonidine, ziconotide and fentanyl. Except for ziconotide combinations, concentration of drugs remains over 90% during 90 days. But ziconotide is very unstable and admixtures with other drugs can accelerate the rate of ziconotide degradation.

  12. INHIBITORY EFFECT OF GABA ON FIRING ACTIVITY OF ROSTRAL VENTROLATERAL MEDULLARY NEURONS OF RAT IN VITRO%γ-氨基丁酸对离体大鼠延髓头端腹外侧区神经元单位放电的抑制作用

    Institute of Scientific and Technical Information of China (English)

    储祥平; 李鹏; 徐宁善

    1998-01-01

    Extracellular single-unit discharges were obtained from 106 spontaneously active neurons in the region of the rostral ventrolateral medulla (RVLM) by glass microelectrode from 73 brain slices of Sprague-Dawley rats. Exogenous γ-aminobutyric acid (GABA, 0.1 ~ 3.0 mmol/L) inhibited the electrical activity of 84 out of 106 RVLM neurons dose-dependently. The inhibitory effect of GABA could be blocked by GABAA with BMI or PTX alone, the firing rates of most of the RVLM neurons were significantly increased. In 41 neurons responding to GABA, baclofen (0.1 ~ 3.0 μmol/L), a GABAB receptor selective agonist, inhibited the discharges of 33 of the neurons dose-dependently. GABAB receptor antagonist CGP35348 ( n = 13) blocked the inhibition due to baclofen ( n = 21). After perfused with CGP35348 alone, the firing rates of most of the RVLM neurons were significantly increased. Taken together, the inhibition of GABA on RVLM neurons is mediated through either GABAA or GABAB receptors and some intrinsic GABA neurons exert tonic inhibition activity.%在73张脑片上观察了γ-氨基丁酸(GABA)对106个延髓头端腹外侧区(RVLM)神经元单位放电的影响.外源性的GABA(0.1~3.0 mmol/L)抑制了106神经元中的84个神经元的电活动,这些抑制效应呈剂量-反应关系.GABA的抑制效应大部分可被GABAA受体选择性拮抗剂荷苞牡丹碱甲基碘化物(BMI)和Cl-通道阻断剂印防己毒素(PTX)所阻断,而单独灌流BMI和PTX对RVLM神经元主要起兴奋作用.在41个对GABA有抑制效应的RVLM神经元上,GABAB受体选择性激动剂苯氯丁氨酸(0.1~3.0 μmoL/L)抑制了其中33个神经元的单位放电,也呈剂量-反应关系.GABAB受体选择性拮抗剂CGP35348(n=13)可阻断苯氯丁氨酸的抑制效应(n=21),而单独灌流CGP35348对RVLM神经元主要起兴奋作用.上述结果提示:GABA对RVLM神经元的抑制效应,不仅可以通过GABAA受体,而且可以通过GABAB受体起作用;内源性的GABA参与了紧张性的抑制作用.

  13. Clinical characteriscs of stiff-person syndrome%僵人综合征4例分析及文献回顾

    Institute of Scientific and Technical Information of China (English)

    冯兵; 李洵桦; 龙健中; 杨培全; 李欣明

    2011-01-01

    Objective The clinical features of stiff-person syndrome (SPS) were described in order to improve the diagnosis.Methods The clinical manifestations, typical electromyogram (EMG) findings and the therapeutic effects of the 4 cases were summarize.Results In the 4 cases,3 were males and 1 was female.Their ages were between 29 to 51.One case had the onset of the disease after catching a cold, other cases had no inducement.No special past history or family history was found.2 cases had subacute onset and 2 had chronic onset of the disease.The durations of the disease were between 1 to 13 months.The chief clinical manifestations were paroxysmal or persistant stiffness and pain in the muscles of proximal limbs and trunk, and then dyskinesia of the relevant sites.Persistant MUAPs were recorded in EMG at rest,but disappeared after valium injection.After treated by benzodiazepines and baclofen,2 cases were recovered, and 2 cases had no progression of the symptoms.Conclusions Stiff-person syndrome is a rare muscle disease which is easy to mistake in diagnosis.Benzodiazepines and baclofen could have good curative effect.%目的 总结僵人综合征的临床特点,提高对该病的认识和诊断水平.方法 分析4例病例,总结其临床表现、典型的肌电图表现及治疗效果.结果 4例患者3名男性,1名女性,年龄29岁~51岁,1例为受凉约2w后出现症状,3例无明显诱发因素.4例既往均无特殊疾病史,亦无家族同类病史.2例为亚急性起病,2例为慢性起病,病程分别为1~13个月.主要表现为躯干、四肢近端肌肉出现阵发或持续性僵硬和疼痛,从而引起相应部位的运动障碍.4例均行常规肌电图检查,显示在放松状态下时有持续运动单位电位,应用安定后消失.经苯二氮草类、巴氯芬治疗后2例可痊愈,另2例亦无反复发作及恶化.结论 僵人综合征是一种罕见的肌肉疾病,易误诊,苯二氮草类、巴氯芬治疗可获良好效果.

  14. Distonias: aspectos clínicos e terapêuticos em 64 pacientes Dystonias: clinical and therapeutic features in 64 patients

    Directory of Open Access Journals (Sweden)

    James Pitágoras de Mattos

    1996-03-01

    Full Text Available Os Autores apresentam a experiência em 64 pacientes, com as várias formas clínicas de apresentação de distonias, acompanhados no Setor de Doenças Extrapiramidais do Serviço de Neurologia do Hospital Universitário Clementino Fraga Filho da UFRJ, assim como, revisam a literatura, cotejando os resultados. O acompanhamento desses pacientes durante 5 anos e 6 meses resultou nas seguintes observações: 33 do sexo masculino e 31 do feminino; 48 brancos, 10 pardos e 6 negros; a média do tempo de doença foi 9 anos e 8 meses. Quanto à distribuição do movimento anormal, 30 (46,9% eram focais; 17 (26,6%, segmentares; 13 (20,3%, generalizadas; 3 (4,7%, hemidistonias; 1 (1,5%, multifocal. Quanto à idade de início, em 11 (17,2% se apresentou antes dos 12 anos; em 6 (9,4%, entre 13 e 20 anos; e em 47 (73,4%, após os 20 anos. Correspondiam à origem idiopática esporádica, 39 (60,9%; idiopática familiar, 6 (9,4%; sintomática, 19 (29,7%. No que se refere à abordagem terapêutica destes pacientes, destacamos o emprego de anticolinérgicos, de agonistas e antagonistas dopaminérgicos e do baclofen isolado ou associado aos anticolinérgicos para as formas generalizadas. Para as distonias focais, os Autores concluem ser a toxina botulínica do tipo A o agente terapêutico mais eficaz aconselhado atualmente.The experience with 64 patients with dystonia seen at the Extrapyramidal Diseases Sector of the Neurology Department of the Hospital Universitário Clementino Fraga Filho of the UFRJ is presented as well as the pertinent review of the literature. The five-and-a-half-year of follow-up showed that 33 were male and 31 female; 48 were white, 10 mulatto and 6 negro; the mean time of disease was 9 years and 8 months. According to the distribution of the movement disorder, 30 (46.9% were focal, 17 (26.6% segmental, 13 (20.3% generalized, 3 (4.7% hemidystonia and 1 (1.5% multifocal. In 11 (17.2% the age of onset was before 12 years old, in 6 (9

  15. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.

    Science.gov (United States)

    García-Merino, Antonio

    2013-02-01

    Spasticity is a disabling complication of multiple sclerosis. Some commonly used oral medications include baclofen, tizanidine, anticonvulsants and benzodiazepines, but their benefits are modest. Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) is a unique cannabinoid-based medicine with two main active ingredients; 9-δ-tetrahydrocannabinol, which acts mainly on cannabinoid 1 receptors in the CNS and plays a key role in the modulation of spasticity and spasms, and cannabidiol, which has different properties, including minimization of the psychoactivity associated with 9-δ-tetrahydrocannabinol. Sativex is indicated for symptomatic improvement in adult patients with moderate-to-severe multiple sclerosis-related spasticity who have not responded adequately to other first- or second-line antispasticity medications, and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Over the past couple of years, Sativex has been approved for use in a number of European countries and ongoing postmarketing studies are evaluating the possible risks associated with Sativex treatment by systematically collecting all suspected adverse reactions that occur in patients from the start of treatment. Interim data from the UK as well as Spanish Sativex safety registries confirm that clinical benefit is maintained over the longer term despite the expected trend for deterioration owing to disease progression. Even after more than 2 years of use, no new safety/tolerability signals have emerged with Sativex, including no evidence of driving impairment and no relevant incidence of falls or other adverse events of concern, such as psychiatric or nervous system events. Sativex appears to be a well-tolerated and useful add-on therapy in patients who have not achieved an adequate response with traditional antispastic agents. PMID:23369054

  16. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.

    Science.gov (United States)

    Haas, Judith

    2011-04-01

    Spasticity is one of the most common and disabling symptoms associated with multiple sclerosis (MS). MS spasticity occurs through both myelin and nerve fiber (axonal) degradation, which commence in the early stages of the disease. More than 80% of MS patients experienced spasticity in a large UK survey, with more than 50% of patients reporting their spasticity to be `moderate' or `severe'. Data from a large US registry show that patients with moderate-to-severe MS spasticity experience levels of disability that correlate closely with being wheelchair-bound and/or bedridden. The Ashworth scale is the most commonly used scale for assessing the degree of MS spasticity. However, the validity, reliability and sensitivity of this scale have been challenged and it is not considered an ideal scale for assessing the severity of MS spasticity. The numerical rating scale, a well-established standard pain assessment tool, provides a reliable, valid and simplified scale for patient self-rated assessment of the mean level of spasticity over the previous 24 h (0 = no spasticity, 10 = worst possible spasticity). According to data from the German MS Register, almost a third of MS patients with spasticity were untreated. Despite the availability of oral agents for generalized spasticity (often used in conjunction with physical/rehabilitation management strategies), including baclofen, tizanidine, dantrolene and gabapentin, there is limited clinical evidence to support their use and there is a need for improved and better tolerated pharmacological therapies for MS spasticity. The endocannabinoid system modulator, Sativex(®) (nabiximols, USAN name), provides an alternative therapeutic approach in the management of MS spasticity. PMID:21449853

  17. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.

    Science.gov (United States)

    Litten, Raye Z; Wilford, Bonnie B; Falk, Daniel E; Ryan, Megan L; Fertig, Joanne B

    2016-01-01

    Alcohol use disorder (AUD), as currently defined in the Diagnostic and Statistical Manual, 5th Edition (DSM-5), is a heterogeneous disorder stemming from a complex interaction of neurobiological, genetic, and environmental factors. As a result of this heterogeneity, there is no one treatment for AUD that will work for everyone. During the past 2 decades, efforts have been made to develop a menu of medications to give patients and clinicians more choices when seeking a therapy that is both effective and which has limited side effects. To date, 3 medications have been approved by the US Food and Drug Administration (FDA) to treat alcohol dependence: disulfiram, naltrexone, and acamprosate. In addition to these approved medications, researchers have identified new therapeutic targets and, as a result, a number of alternative medications are now being evaluated for treatment of AUD in human studies. Although not approved by the FDA for the treatment of AUD, in some cases, these alternative medications are being used off-label by clinicians for this purpose. These potential medications are reviewed here. They include nalmefene, varenicline, gabapentin, topiramate, zonisamide, baclofen, ondansetron, levetiracetam, quetiapine, aripiprazole, and serotonin reuptake inhibitors. The effectiveness of these medications has been mixed-some show good efficacy with side effects that are mild to moderate in intensity; others have mixed or promising results but are awaiting findings from ongoing studies; and still others show poor efficacy, despite promising preliminary results. Medications development remains a high priority. Key initiatives for the National Institute on Alcohol Abuse and Alcoholism (NIAAA) include supporting the discovery and development of more effective and safer medications, advancing the field of personalized medicine, and forging public and private partnerships to investigate new and more effective compounds. PMID:26928397

  18. Treatment of alcohol use disorder patients affected by liver cirrhosis and/or hepatocellular carcinoma awaiting liver transplantation.

    Science.gov (United States)

    Testino, Gianni; Leone, Silvia; Borro, Paolo

    2016-08-01

    Alcohol is one of the top three priority areas for public health worldwide. Alcohol is the second leading cause of liver disease, and 45-60% of cirrhosis deaths are alcohol related. In the United States it represents 30% of liver transplants and in Europe 50%. Twenty to 40% of cases of steatosis evolve into steatohepatitis, and l8-20% directly into liver cirrhosis; 20-40% of cases of steatohepatitis evolve into cirrhosis and 4-5% into hepatocellular carcinoma. This cascade of events takes 5 to 40 years. The temporal variability is related to the genetic pattern of the subject and the presence of associated risk factors. Thirty to 40% of patients with alcoholic liver disease (ALD) suffer from HCV, and 70% of HCV patients have a history of risky / harmful alcohol consumption. A severe clinical condition is certainly the overlap of acute alcoholic hepatitis (AAH) with a framework of HCV-related chronic hepatitis: acute chronic liver failure (ACLF). In the case of decompensated cirrhosis, severe AAH or ACLF non responder to medical therapy the indication, in selected patients, is certainly liver transplantation (LT). ALD treatment is important, but not very effective if abstention is not reached. In case of liver disease related or correlated to LT such as decompensated cirrhosis, severe AAH or ACLF the possibility of anticraving therapy is restricted to metadoxine and baclofen. In all alcohol use disorder patients with ALD psycho-social therapy and attendance at SHG groups it is mandatory, even in post-transplant period. PMID:27148681

  19. Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine.

    Science.gov (United States)

    Soyka, Michael; Mutschler, Jochen

    2016-10-01

    Substance use disorders are common, but only a small minority of patients receive adequate treatment. Although psychosocial therapies are effective, relapse is common. This review focusses on novel pharmacological and other treatments for patients with alcohol, opioid, or cocaine use disorders who do not respond to conventional treatments. Disulfiram, acamprosate, and the opioid antagonist naltrexone have been approved for the treatment of alcoholism. A novel, "as needed" approach is the use of the mu-opioid antagonist and partial kappa agonist nalmefene to reduce alcohol consumption. Other novel pharmacological approaches include the GABA-B receptor agonist baclofen, anticonvulsants such as topiramate and gabapentin, the partial nicotine receptor agonist varenicline, and other drugs. For opioid dependence, opioid agonist therapy with methadone or buprenorphine is the first-line treatment option. Other options include oral or depot naltrexone, morphine sulfate, depot or implant formulations, and heroin (diacetylmorphine) in treatment-refractory patients. To date, no pharmacological treatment has been approved for cocaine addiction; however, 3 potential pharmacological treatments are being studied, disulfiram, methylphenidate, and modafinil. Pharmacogenetic approaches may help to optimize treatment response in otherwise treatment-refractory patients and to identify which patients are more likely to respond to treatment, and neuromodulation techniques such as repeated transcranial magnetic stimulation and deep brain stimulation also may play a role in the treatment of substance use disorders. Although no magic bullet is in sight for treatment-refractory patients, some novel medications and brain stimulation techniques have the potential to enrich treatment options at least for some patients. PMID:26577297

  20. AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons.

    Science.gov (United States)

    Shen, Ke-Zhong; Wu, Yan-Na; Munhall, Adam C; Johnson, Steven W

    2016-08-25

    AMP-activated protein kinase (AMPK) is a master enzyme that regulates ATP-sensitive K(+) (K-ATP) channels in pancreatic beta-cells and cardiac myocytes. We used patch pipettes to record currents and potentials to investigate effects of AMPK on K-ATP currents in substantia nigra compacta (SNC) dopamine neurons in slices of rat midbrain. When slices were superfused repeatedly with the K-ATP channel opener diazoxide, we were surprised to find that diazoxide currents gradually increased in magnitude, reaching 300% of the control value 60min after starting whole-cell recording. However, diazoxide current increased significantly more, to 472% of control, when recorded in the presence of the AMPK activator A769662. Moreover, superfusing the slice with the AMPK blocking agent dorsomorphin significantly reduced diazoxide current to 38% of control. Control experiments showed that outward currents evoked by the K-ATP channel opener NN-414 also increased over time, but not currents evoked by the GABAB agonist baclofen. Delaying the application of diazoxide after starting whole-cell recording correlated with augmentation of current. Loose-patch recording showed that diazoxide produced a 34% slowing of spontaneous firing rate that did not intensify with repeated applications of diazoxide. However, superfusion with A769662 significantly augmented the inhibitory effect of diazoxide on firing rate. We conclude that K-ATP channel function is augmented by AMPK, which is activated during the process of making whole-cell recordings. Our results suggest that AMPK and K-ATP interactions may play an important role in regulating dopamine neuronal excitability. PMID:27267246

  1. Vestibular paroxysmia: a treatable neurovascular cross-compression syndrome.

    Science.gov (United States)

    Brandt, Thomas; Strupp, Michael; Dieterich, Marianne

    2016-04-01

    The leading symptoms of vestibular paroxysmia (VP) are recurrent, spontaneous, short attacks of spinning or non-spinning vertigo that generally last less than one minute and occur in a series of up to 30 or more per day. VP may manifest when arteries in the cerebellar pontine angle cause a segmental, pressure-induced dysfunction of the eighth nerve. The symptoms are usually triggered by direct pulsatile compression with ephaptic discharges, less often by conduction blocks. MR imaging reveals the neurovascular compression of the eighth nerve (3D constructive interference in steady state and 3D time-of-flight sequences) in more than 95 % of cases. A loop of the anterior inferior cerebellar artery seems to be most often involved, less so the posterior inferior cerebellar artery, the vertebral artery, or a vein. The frequent attacks of vertigo respond to carbamazepine or oxcarbazepine, even in low dosages (200-600 mg/d or 300-900 mg/d, respectively), which have been shown to also be effective in children. Alternative drugs to try are lamotrigine, phenytoin, gabapentin, topiramate or baclofen or other non-antiepileptic drugs used in trigeminal neuralgia. The results of ongoing randomized placebo-controlled treatment studies, however, are not yet available. Surgical microvascular decompression of the eighth nerve is the "ultima ratio" for medically intractable cases or in exceptional cases of non-vascular compression of the eighth nerve by a tumor or cyst. The International Barany Society for Neuro-Otology is currently working on a consensus document on the clinical criteria for establishing a diagnosis of VP as a clinical entity. PMID:27083889

  2. Magnetic fields and intrathecal pump malfunction.

    Science.gov (United States)

    Huh, Billy; Roldan, Carlos J

    2016-01-01

    Medical technology has impacted the overall life expectancy. Many conditions traditionally considered fatal are now curable. Surviving chronic diseases and aging of the population have increased the number of people with chronic pain. Many devices are also available to manage severe refractory pain. As such, implantable drug-delivery system (IDDS) is a small battery-powered, programmable pump implanted under the subcutaneous tissue of the abdomen and connected to a small catheter tunneled into the spine. Implantable drug-delivery system is used for the administration of morphine, ziconotide, baclofen, or their mixtures into the cerebrospinal fluid. Like many medical devices, IDDS has technical glitch which limits its performance under certain conditions. Implantable drug-delivery system is susceptible to magnetic field such as a magnetic resonance imaging (MRI) which can temporarily stall the rotor of the pump motor and suspend drug delivery. We encountered a patient from out of town seen at emergency department with increased pain and symptoms of opiates withdrawal after intermittent IDDS malfunction. He denied any exposure to magnetic fields or MRI. However, the pump interrogation showed multiple motor stall events in the event log. After a detailed inquiry, the most likely cause of pump malfunction appears to be frequent placement of a laptop computer on his abdomen close to the pump. The magnets in the laptop speakers may have caused the rotor of the pump motor to stall during the computer use, and frequent stall has caused symptoms of withdrawal. No other mechanical failures were found. The patient was discharged home after the symptoms resolved, and the pump was reprogrammed. PMID:26008580

  3. The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse.

    Science.gov (United States)

    Rogers, J L; Ghee, S; See, R E

    2008-01-24

    Reinstatement of extinguished drug-seeking has been utilized in the study of the neural substrates of relapse to drugs of abuse, particularly cocaine. However, limited studies have examined the circuitry that drives the reinstatement of heroin-seeking behavior in the presence of conditioned cues, or by heroin itself. In order to test the hypothesis that the circuitry underlying reinstatement in heroin-experienced animals would show overlapping, yet distinct differences from cocaine-experienced animals, we used transient inhibition of several cortical, striatal, and limbic brain regions during reinstatement of heroin-seeking produced by heroin-paired cues, or by a single priming dose of heroin. Rats lever pressed for i.v. heroin discretely paired with a conditioned stimulus (CS) during daily 3-h sessions for a period of 2 weeks, followed by daily extinction of lever responding. Subsequent reinstatement of heroin-seeking was measured as lever responding in the absence of heroin reinforcement. The first set of reinstatement tests involved response-contingent CS presentations following bilateral intracranial infusion of either a combination of GABA receptor agonists (baclofen-muscimol, B/M) or vehicle (saline) into one of 13 different brain regions. The second set of reinstatement tests involved a single heroin injection (0.25 mg/kg, s.c.) following either B/M or vehicle infusions. Our results showed that vehicle-infused animals reinstated to both CS presentations and a priming injection of heroin, while B/M inactivation of several areas known to be important for the reinstatement of cocaine-seeking also attenuated heroin-seeking in response to CS presentations and/or a priming dose of heroin. However, as predicted, inactivation of areas previously shown to not affect cocaine-seeking significantly attenuated heroin-seeking, supporting the hypothesis that the circuitry underlying the reinstatement of heroin-seeking is more diffusely distributed than that for cocaine

  4. Group II metabotropic glutamate receptor antagonism prevents the antiallodynic effects of R-isovaline.

    Science.gov (United States)

    Asseri, K A; Puil, E; Schwarz, S K W; MacLeod, B A

    2015-05-01

    We previously showed that isovaline is a peripheral analgesic which acts in vivo and in brain slices as an atypical metabotropic GABA(B) agonist. Peripheral inhibitory group II and III metabotropic glutamate receptors (mGluRs) belong to the same family C as GABA(B) receptors; therefore, we hypothesized that isovaline's analgesic effects could include their activation. We examined the effects of R-isovaline on mechanical allodynia produced by prostaglandin E2 in the mouse paw. Subcutaneous R-isovaline produced dose-dependent antiallodynia restricted to the injected hindlimb. This antiallodynia was blocked by co-injection with a selective group II mGluR antagonist, LY341495, but not a group III mGluR antagonist (MAP-4). The antiallodynic effect of R-isovaline was potentiated by co-administration of a group II mGluR-positive allosteric modulator, LY487379. Injection of a group II mGluR agonist (LY354740) produced an antiallodynic effect which was completely reversed by group II antagonism, but was not affected by group III or GABA(B) (CGP35348) antagonism. Similarly, group II mGluR antagonism did not alter the antiallodynia produced by the prototypical GABA(B) agonist, baclofen. Hence, there was no apparent crosstalk between group II mGluRs and GABA(B) receptors. Previous studies have demonstrated that peripheral GABA(B) receptor activation by isovaline produces antiallodynia. In addition, the present results indicate that activation of peripheral group II mGluRs by R-isovaline produces antiallodynia. PMID:25701709

  5. Statistical design of experiments on fabrication of bilayer tablet of narrow absorption window drug: Development and In vitro characterisation

    Directory of Open Access Journals (Sweden)

    R R Jivani

    2012-01-01

    Full Text Available The current study involves the fabrication of oral bioadhesive bilayer matrices of narrow absorption window drug baclofen and the optimisation of their in vitro drug release and characterisation. Statistical design of experiments, a computer-aided optimisation technique, was used to identify critical factors, their interactions and ideal process conditions that accomplish the targeted response(s. A central composite design was employed to systematically optimise the drug delivery containing a polymer, filler and compression force. The values of ratio of different grades of hydroxypropyl methylcellulose, microcrystalline cellulose and compression force were varied to be fitted in design. Drug release at 1 h (Q 1 , 4 h (Q 4 , 8 h (Q 8 , 12 h (Q 12 , and hardness were taken as responses. Tablets were prepared by direct compression methods. The compressed tablets were evaluated for their hardness, weight variation, friability, content uniformity and diameter. Counter plots were drawn and optimum formulation was selected by desirability function. The formulations were checked for their ex vivo mucoadhesion. The experimental value of Q 1 , Q 4 , Q 8 , Q 12 and hardness for check-point batch was found to be 31.64, 45.82, 73.27, 98.95% and 4.4 kg/cm 2 , respectively. The release profile indicates Highuchi kinetics (Fickian transport mechanism. The results of the statistical analysis of the data demonstrated significant interactions amongst the formulation variables, and the desirability function was demonstrated to be a powerful tool to predict the optimal formulation for the bilayer tablet.

  6. A negative allosteric modulator modulates GABAB-receptor signalling through GB2 subunits.

    Science.gov (United States)

    Sun, Bing; Chen, Linhai; Liu, Lei; Xia, Zhixiong; Pin, Jean-Philippe; Nan, Fajun; Liu, Jianfeng

    2016-03-15

    An γ-aminobutyric acid type B (GABAB)-receptor mediates slow and prolonged synaptic inhibition in the central nervous system, which represents an interesting target for the treatment of various diseases and disorders of the central nervous system. To date, only one activator of the GABAB-receptor, baclofen, is on the market for the treatment of spasticity. Inhibitors of the GABAB-receptor, such as antagonists, show anti-absence seizure activity and pro-cognitive properties. In a search for allosteric compounds of the GABAB-receptor, although several positive allosteric modulators have been developed, it is only recently that the first negative allosteric modulator (NAM), CLH304a (also named Compound 14), has been reported. In the present study, we provide further information on the mechanism of action of CLH304a, and also show the possibility of designing more NAMs, such as CLH391 and CLH393, based on the structure of CLH304a. First we show that CLH304a inhibits native GABAB-receptor activity in cultured cerebellar granular neurons. We then show that CLH304a has inverse agonist properties and non-competitively inhibits the effect of agonists, indicating that it binds at a different site to GABA. The GABAB-receptor is a mandatory heterodimer made of GB1 subunits, in which agonists bind, and GB2 subunits, which activate G-proteins. By using various combinations made up of wild-type and/or mutated GB1 and GB2 subunits, we show that CLH304a acts on the heptahelical domain of GB2 subunits. These data revealed the possibility of designing innovative NAMs acting in the heptahelical domain of the GB2 subunits, offering novel possibilities for therapeutic intervention based on GABAB-receptor inhibition. PMID:26772870

  7. Comparative pharmacological activity of optical isomers of phenibut.

    Science.gov (United States)

    Dambrova, Maija; Zvejniece, Liga; Liepinsh, Edgars; Cirule, Helena; Zharkova, Olga; Veinberg, Grigory; Kalvinsh, Ivars

    2008-03-31

    Phenibut (3-phenyl-4-aminobutyric acid) is a GABA (gamma-aminobutyric acid)-mimetic psychotropic drug which is clinically used in its racemic form. The aim of the present study was to compare the effects of racemic phenibut and its optical isomers in pharmacological tests and GABAB receptor binding studies. In pharmacological tests of locomotor activity, antidepressant and pain effects, S-phenibut was inactive in doses up to 500 mg/kg. In contrast, R-phenibut turned out to be two times more potent than racemic phenibut in most of the tests. In the forced swimming test, at a dose of 100 mg/kg only R-phenibut significantly decreased immobility time. Both R-phenibut and racemic phenibut showed analgesic activity in the tail-flick test with R-phenibut being slightly more active. An GABAB receptor-selective antagonist (3-aminopropyl)(diethoxymethyl)phosphinic acid (CGP35348) inhibited the antidepressant and antinociceptive effects of R-phenibut, as well as locomotor depressing activity of R-phenibut in open field test in vivo. The radioligand binding experiments using a selective GABAB receptor antagonist [3H]CGP54626 revealed that affinity constants for racemic phenibut, R-phenibut and reference GABA-mimetic baclofen were 177+/-2, 92+/-3, 6.0+/-1 microM, respectively. We conclude that the pharmacological activity of racemic phenibut relies on R-phenibut and this correlates to the binding affinity of enantiomers of phenibut to the GABAB receptor. PMID:18275958

  8. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.

    Science.gov (United States)

    Cohen, Shlomi; Bueno de Mesquita, Mirjam; Mimouni, Francis B

    2015-08-01

    Gastroesophageal reflux (GER) is commonly observed in children, particularly during the first year of life. Pharmacological therapy is mostly reserved for symptomatic infants diagnosed with GER disease (GERD), usually as defined in a recent consensus statement. The purpose of the present article was to review the reported adverse effects of pharmacological agents used in the treatment of paediatric GERD. We conducted this review using the electronic journal database Pubmed and Cochrane database systematic reviews using the latest 10-year period (1 January 2003 to 31 December 2012). Our search strategy included the following keywords: omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, rantidine, cimetidine, famotidine, nizatidine, domperidone, metoclopramide, betanechol, erythromycin, baclofen, alginate. We used Pubmed's own filter of: 'child: birth-18 years'. All full articles were reviewed and we only included randomized controlled trials retrieved from our search. We addressed a summary of our search on a drug-by-drug basis with regard to its mechanism of action and clinical applications, and reviewed all of the adverse effects reported and the safety profile of each drug. Adverse effects have been reported in at least 23% of patients treated with histamine H2 receptor antagonists (H2 RAs) and 34% of those treated with proton pump inhibitors (PPIs), and mostly include headaches, diarrhoea, nausea (H2 RAs and PPIs) and constipation (PPIs). Acid suppression may place immune-deficient infants and children, or those with indwelling catheters, at risk for the development of lower respiratory tract infections and nosocomial sepsis. Prokinetic agents have many adverse effects, without major benefits to support their routine use. PMID:25752807

  9. Developing a model of limited-access nicotine consumption in C57Bl/6J mice.

    Science.gov (United States)

    Kasten, C R; Frazee, A M; Boehm, S L

    2016-09-01

    Although United States smoking rates have been on the decline over the past few decades, cigarette smoking still poses a critical health and economic threat. Very few treatment options for smoking exist, and many of them do not lead to long-term abstinence. Preclinical models are necessary for understanding the effects of nicotine and developing treatments. Current self-administration models of nicotine intake may require surgical procedures and often result in low levels of intake. Further, they do not lend themselves to investigating treatments. The current study sought to develop a limited-access model of nicotine intake using the Drinking-in-the-Dark paradigm, which results in high levels of binge-like ethanol consumption that can be pharmacologically manipulated. The present study found that mice will consume nicotine under a range of parameters. Intakes under the preferred condition of 0.14mg/ml nicotine in 0.2% saccharin reached over 6mg/kg in two hours and were reduced by an injection of R(+)-baclofen. Mecamylamine did not significantly affect nicotine consumption. As nicotine and ethanol are often co-abused, nicotine intake was also tested in the presence of ethanol. When presented in the same bottle, mice altered nicotine intake under various concentrations to maintain consistent levels of ethanol intake. When nicotine and ethanol were presented in separate bottles, mice greatly reduced their nicotine intake while maintaining ethanol intake. In conclusion, these studies characterize a novel model of limited-access nicotine intake that can be pharmacologically manipulated. PMID:27242276

  10. Extremity and Truncal Dystonias: Botulinum Toxin Applications

    Directory of Open Access Journals (Sweden)

    Nurten UZUN ADATEPE

    2010-12-01

    Full Text Available Extremity dystonia (ED is a disabling condition that may represent an isolated focal symptom or may be part of generalized dystonia. It may develop secondary to any process affecting the contralateral basal ganglia or may be idiopathic. Diffuse or severe dystonia generally improves by administration of various medications and only in rare cases, stereotaxic surgery may be needed. Idiopathic forms or focal symptoms frequently respond to botulinum toxin (BoNT injections. BoNT type A injection decreases pain and spasms in more than 80% of cases and results in 50-66% functional improvement in daily living activities and motor performance. Furthermore, BoNT injection also provides improvement in some symptoms of generalized dystonia and relieves disabling posture, skin lacerations and pain in more than 80% of patients. BoNT may also be used to accelerate recovery in the postoperative period for a short time since it prevents the spasms.Truncal dystonia frequently accompanies segmental or generalized dystonia and it rarely presents as an isolated form. Axial involvement is mostly seen in neuroleptic use. This form of truncal dystonia is often severely painful and disabling and rarely responds to oral medications. BoNT is the treatment of choice in truncal dystonia, similar to the other focal dystonias. Clinical status improves dramatically by targeting proper muscles and using appropriate doses. In case of failure of BoNT treatment, the first alternative should be oral medications and, physiotherapy may additionally decrease the symptoms. Continuous intrathecal baclofen pump is known to be beneficial, while the effect of epidural spinal electrostimulation is still unclear and surgery should be the last option. (Archives of Neuropsychiatry 2010; 47 Supplement: 19-26

  11. Effect of Brewer's Yeast-Induced Pyrexia on Aminophylline-Elicited Convulsions in Mice

    Directory of Open Access Journals (Sweden)

    Araki,Hiroaki

    2009-10-01

    Full Text Available Theophylline-associated convulsions have been observed most frequently in children with fever, but the mechanism is not fully understood. In this study, we investigated the basic mechanism of aminophylline [theophylline-2-ethylenediamine]-induced convulsions and the effects of Brewer's yeast-induced pyrexia in mice. Diazepam (5-10mg/kg, i.p., a benzodiazepine receptor agonist, significantly prolonged the onset and significantly decreased the incidence of convulsions induced by aminophylline (350mg/kg, i.p.. However, the gamma aminobutyric acid (GABAA receptor agonist muscimol (1-4mg/kg, i.p., the GABAB receptor agonist baclofen (2-4mg/kg, i.p. and the N-methyl-D-aspartic acid receptor antagonist dizocilpine (0.1-0.3mg/kg, i.p. failed to protect against the convulsions. 20% Brewer's yeast (0.02ml/g, s.c. increased body temperature by 1.03, and also significantly shortened the onset and significantly increased the incidence of convulsions induced by aminophylline. The anticonvulsant action of diazepam (2.5-10mg/kg, i.p. on the convulsions induced by aminophylline was reduced by Brewer's yeast-induced pyrexia. The proconvulsant actions of the GABAA receptor antagonists picrotoxin (3-4mg/kg, i.p. and pentylenetetrazol (40-60mg/kg, i.p. were enhanced by Brewer's yeast. These results suggest that the anticonvulsant action of diazepam against aminophylline is reduced by Brewer's yeast-induced pyrexia, and that GABAA receptors are involved in the aggravation of the convulsions by Brewer's yeast in mice.

  12. Evaluation of usefulness of scintigraphic imaging in diagnosis of intrathecal drug delivery system malfunction – a preliminary report

    International Nuclear Information System (INIS)

    Implantable intrathecal drug delivery systems (IDDS) are basic tool enabling chronic intrathecal pharmacotherapy. Lack of expected clinical results of IDDS therapy necessitates search for the cause with the help of diagnostic imaging methods among other things. Beside radiological techniques, it is also possible to visually assess IDDS systems by nuclear medicine methods. In this study we assess utility of radioisotopic methods in differential diagnosis of failure of therapy with IDDS systems. Scintigraphic studies were performed in selected patients with neurological diseases associated with spasticity, who had IDDS system implanted and were unable to maintain satisfying clinical effect of inrathecally infused baclofen. After emptying the IDDS system of the drug, radiotracer (99mTc-DTPA) solution was injected into the pump reservoir. Subsequently, a series of scintigraphic images was registered, demonstrating passage and distribution of the infused radiotracer. In all investigated cases, scintigraphic study resulted in acquiring relevant additional diagnostic information. Normal or disrupted distribution of radiotracer in spinal canal allowed for a diagnosis drug resistance or demonstrated presence of arachnoid adhesions respectively. Early appearance of radiotracer in blood was considered a proof of leak. Our examinations had decisive influence on further patient treatment, allowing for diagnosis of drug resistance in one patient or complication related to IDDS system in three other cases including breakage of a catheter, pump malfunction and arachnoid adhesions. Scintigraphic methods carry significant amount of information facilitating final diagnosis of the cause of IDDS therapy failure. They should become an important element complementing the diagnostic strategy in patients with suspected failure of intrathecal drug administration systems. Interpretation of radioisotopic studies, since they are purely functional, must be performed in strict relation to

  13. Modulation of the release of norepinephrine by gamma-aminobutyric acid and morphine in the frontal cerebral cortex of the rat

    Energy Technology Data Exchange (ETDEWEB)

    Peoples, R.W.

    1989-01-01

    Agents that enhance gamma-aminobutyric acid, or GABA, neurotransmission modulate certain effects of opioids, such as analgesia. Opioid analgesia is mediated in part by norepinephrine in the forebrain. In this study, the interactions between morphine and GABAergic agents on release of ({sup 3}H) norepinephrine from rat frontal cerebral cortical slices were examined. GABA, 5 {times} 10{sup {minus}5}-10{sup {minus}3} M, enhanced potassium stimulated ({sup 3}H) norepinephrine release and reversed the inhibitory effect of morphine in a noncompetitive manner. GABA did not enhance release of ({sup 3}H) norepinephrine stimulated by the calcium ionophore A23187. The effect of GABA was reduced by the GABA{sub A} receptor antagonists bicuculline methiodide or picrotoxin, and by the selective inhibitor of GABA uptake SKF 89976A, but was blocked completely only when bicuculline methiodide and SKF 89976A were used in combination. The GABA{sub A} agonist muscimol, 10{sup {minus}4} M, mimicked the effect of GABA, but the GABA{sub B} agonist ({plus minus})baclofen, 10{sup {minus}4} M, did not affect the release of ({sup 3}H) norepinephrine in the absence or the presence of morphine. Thus GABA appears to produce this effect by stimulating GABA uptake and GABA{sub A}, but not GABA{sub B}, receptors. In contrast to the results that would be predicted for an event involving GABA{sub A} receptors, however, the effect of GABA did not desensitize, and benzodiazepine agonists did not enhance the effect of GABA at any concentration tested between 10{sup {minus}8} and 10{sup {minus}4} M. Thus these receptors may constitute a subclass of GABA{sub A} receptors. These results support a role of GABA uptake and GABA{sub A} receptors in enhancing the release of norepinephrine and modulating its inhibition by opioids in the frontal cortex of the rat.

  14. A Gut Feeling about GABA: Focus on GABAB receptors

    Directory of Open Access Journals (Sweden)

    Niall P Hyland

    2010-10-01

    Full Text Available Gamma-Aminobutyric acid (GABA is the main inhibitory neurotransmitter in the body and hence GABA-mediated neurotransmission regulates many physiological functions, including those in the gastrointestinal (GI tract. GABA is located throughout the GI tract and is found in enteric nerves as well as in endocrine-like cells, implicating GABA as both a neurotransmitter and an endocrine mediator influencing GI function. GABA mediates its effects via GABA receptors which are either ionotropic GABAA or metabotropic GABAB. The latter which respond to the agonist baclofen have been least characterised, however accumulating data suggest that they play a key role in GI function in health and disease. Like GABA, GABAB receptors have been detected throughout the gut of several species in the enteric nervous system, muscle and epithelial layers as well as on endocrine-like cells. Such widespread distribution of this metabotropic GABA receptor is consistent with its significant modulatory role over intestinal motility, gastric emptying and acid secretion, transient lower esophageal sphincter relaxation and visceral sensation of painful colonic stimuli. More intriguing findings, the mechanisms underlying which have yet to be determined, suggest GABAB receptors inhibit GI carcinogenesis and tumour growth. Therefore, the diversity of GI functions regulated by GABAB receptors makes it a potentially useful target in the treatment of several GI disorders. In light of the development of novel compounds such as peripherally acting GABAB receptor agonists, positive allosteric modulators of the GABAB receptor and GABA producing enteric bacteria, we review and summarize current knowledge on the function of GABAB receptors within the GI tract.

  15. Evaluation of GABA Receptors of Ventral Tegmental Area in Cardiovascular Responses in Rat

    Directory of Open Access Journals (Sweden)

    Minoo Rasoulpanah

    2015-07-01

    Full Text Available Background: The ventral tegmental area (VTA is well known for its role in cardiovascular control. It is demonstrated that about 20-30% of the VTA neurons are GABAergic though their role in cardiovascular control is not yet understood. This study is carried out to find the effects of GABA A and GABA B receptors on cardiovascular response of the VTA. Methods: Experiments were performed on urethane anesthetized male Wistar rats. Drugs were microinjected unilaterally into the VTA. The average changes in mean arterial pressure (MAP and heart rate (HR were compared between the case and the control groups using t test and with the pre-injection values using paired t test. Results: Microinjection of muscimol, a GABAA agonist (500, 1500 and 2500 pmol/100nl into the VTA had no significant effect on MAP and HR compared with the saline group and pre-injection values. Injection of bicuculline methiodide (BMI, 100 and 200 pmol/100 nl, a GABAA antagonist, caused a significant increase in the MAP (11.1±1.95mmHg, P<0.5 and a decrease in HR (-32.07±10.2, P<0.01. Microinjection of baclofen a GABAB receptor agonist (500 or 1000 pmole/100 nl and phaclofen a GABAB receptor antagonist (500 or 1000 pmole/100 nl had no significant effects on MAP and HR. Conclusion: For the first time it was demonstrated that GABA system of the VTA inhibits the cardiovascular system through the activation of GABAA but not the GABAB receptors.

  16. At immature mossy fibers-CA3 connections, activation of presynaptic GABAB receptors by endogenously released GABA contributes to synapses silencing

    Directory of Open Access Journals (Sweden)

    Victoria F Safiulina

    2009-02-01

    Full Text Available Early in postnatal life correlated GABAergic activity in the hippocampus is thought to play a crucial role in synaptogenesis and in the development of adult neuronal networks. Unlike adulthood, at this developmental stage, mossy fibers (MF which are the axons of granule cells, release GABA into CA3 principal cells and interneurons. Here, we tested the hypothesis that at MF-CA3 connections, tonic activation of GABAB autoreceptors by GABA is responsible for the low probability of release and synapse silencing. Blocking GABAB receptors with CGP55845 enhanced the probability of GABA release and switched on silent synapses while the opposite was observed with baclofen. Both these effects were presynaptic and were associated with changes in paired-pulse ratio and coefficient of variation. In addition, enhancing the extracellular GABA concentration by repetitive stimulation of MF or by blocking the GABA transporter GAT-1, switched off active synapses, an effect that was prevented by CGP55845. In the presence of CGP55845, stimulation of MF induced synaptic potentiation. The shift of EGABA from the depolarizing to the hyperpolarizing direction with bumetanide, a blocker of the cation-chloride co-transporter NKCC1, prevented synaptic potentiation and caused synaptic depression, suggesting that the depolarizing action of GABA observed in the presence of CGP55845 is responsible for the potentiating effect. It is proposed that, activation of GABAB receptors by spillover of GABA from MF terminals reduces the probability of release and contributes to synapses silencing. This would act as a filter to prevent excessive activation of the auto-associative CA3 network and the emergence of seizures.

  17. GABA increases electrical excitability in a subset of human unmyelinated peripheral axons.

    Directory of Open Access Journals (Sweden)

    Richard W Carr

    Full Text Available BACKGROUND: A proportion of small diameter primary sensory neurones innervating human skin are chemosensitive. They respond in a receptor dependent manner to chemical mediators of inflammation as well as naturally occurring algogens, thermogens and pruritogens. The neurotransmitter GABA is interesting in this respect because in animal models of neuropathic pain GABA pre-synaptically regulates nociceptive input to the spinal cord. However, the effect of GABA on human peripheral unmyelinated axons has not been established. METHODOLOGY/PRINCIPAL FINDINGS: Electrical stimulation was used to assess the effect of GABA on the electrical excitability of unmyelinated axons in isolated fascicles of human sural nerve. GABA (0.1-100 microM increased electrical excitability in a subset (ca. 40% of C-fibres in human sural nerve fascicles suggesting that axonal GABA sensitivity is selectively restricted to a sub-population of human unmyelinated axons. The effects of GABA were mediated by GABA(A receptors, being mimicked by bath application of the GABA(A agonist muscimol (0.1-30 microM while the GABA(B agonist baclofen (10-30 microM was without effect. Increases in excitability produced by GABA (10-30 microM were blocked by the GABA(A antagonists gabazine (10-20 microM, bicuculline (10-20 microM and picrotoxin (10-20 microM. CONCLUSIONS/SIGNIFICANCE: Functional GABA(A receptors are present on a subset of unmyelinated primary afferents in humans and their activation depolarizes these axons, an effect likely due to an elevated intra-axonal chloride concentration. GABA(A receptor modulation may therefore regulate segmental and peripheral components of nociception.

  18. A clinical analysis of treating 28 cases of central intractable hiccups by press Cuanzhu point%按压攒竹穴治疗中枢性顽固性呃逆28例分析

    Institute of Scientific and Technical Information of China (English)

    张志艳; 连学雷

    2014-01-01

    目的:评价攒竹穴治疗中枢性顽固性呃逆的有效性和安全性。方法:选择60例符合条件的顽固性呃逆患者,将其随机分为治疗组(30例)和对照组(30例),治疗组给予按压攒竹穴治疗,对照组给予巴氯芬治疗。观察两组治疗前后临床症状疗效。结果:治疗组总有效率为98.1%,对照组总有效率为81.5%,两组之间疗效比较,差异有统计学意义(P<0.05)。结论:按压攒竹穴治疗中枢性顽固性呃逆临床疗效确切,且操作简单,无任何副作用。%Objective:To evaluate clinical efficacy and safety of Cuanzhu pressed on intractable hiccups. Methods:60 patients were randomly divided into two groups, 30 cases for each. The treatment was given Cuanzhu point pressed, while the control was given Baclofen. Results: The total efficacy in the treatment was 98.1%, in another it was 81.5%, the difference was statistically significant (P<0.05). Conclusion:The therapy was effective on intractable hiccups, easy to operate with no side reactions.

  19. Characterization of GABA/sub A/ receptor-mediated /sup 36/chloride uptake in rat brain synaptoneurosomes

    Energy Technology Data Exchange (ETDEWEB)

    Luu, M.D.; Morrow, A.L.; Paul, S.M.; Schwartz, R.D.

    1987-09-07

    ..gamma..-Aminobutyric acid (GABA) receptor-mediated /sup 36/chloride (/sup 36/Cl/sup -/) uptake was measured in synaptoneurosomes from rat brain. GABA and GABA agonists stimulated /sup 36/Cl/sup -/ uptake in a concentration-dependent manner with the following order of potency: Muscimol>GABA>piperidine-4-sulfonic acid (P4S)>4,5,6,7-tetrahydroisoxazolo-(5,4-c)pyridin-3-ol (THIP)=3-aminopropanesulfonic acid (3APS)>>taurine. Both P4S and 3APS behaved as partial agonists, while the GABA/sub B/ agonist, baclofen, was ineffective. The response to muscimol was inhibited by bicuculline and picrotoxin in a mixed competitive/non-competitive manner. Other inhibitors of GABA receptor-opened channels or non-neuronal anion channels such as penicillin, picrate, furosemide and disulfonic acid stilbenes also inhibited the response to muscimol. A regional variation in muscimol-stimulated /sup 36/Cl/sup -/ uptake was observed; the largest responses were observed in the cerebral cortex, cerebellum and hippocampus, moderate responses were obtained in the striatum and hypothalamus and the smallest response was observed in the pons-medulla. GABA receptor-mediated /sup 36/Cl/sup -/ uptake was also dependent on the anion present in the media. The muscinol response varied in media containing the following anions: Br/sup -/>Cl/sup -/greater than or equal toNO/sub 3//sup -/>I/sup -/greater than or equal toSCN/sup -/>>C/sub 3/H/sub 5/OO/sup -/greater than or equal toClO/sub 4//sup -/>F/sup -/, consistent with the relative anion permeability through GABA receptor-gated anion channels and the enhancement of convulsant binding to the GABA receptor-gated Cl/sup -/ channel. 43 references, 4 figures, 3 tables.

  20. Transient inactivation of the medial prefrontal cortex affects both anxiety and decision-making in male Wistar rats

    Directory of Open Access Journals (Sweden)

    Leonie ede Visser

    2011-09-01

    Full Text Available In both humans and rats high levels of anxiety impair decision-making in the Iowa Gambling Task (IGT in male subjects. Expression of the immediate early gene c-fos as marker of neural activity in rat studies indicated a role of the medial prefrontal cortex (prelimbic and infralimbic region; mPFC in mediating the relationship between anxiety and decision-making. To delineate this relationship further and assess the underlying neurobiology in more detail, we inactivated in the present study the mPFC in male rats using a mixture of the GABA-receptor agonists muscimol and baclofen. Rats were exposed to the elevated plus maze (EPM to measure effects on anxiety and to the rodent version of the IGT (r-IGT. Inactivation led to increased levels of anxiety on the EPM, while not affecting general activity. The effect in the r-IGT (trials 61-120 was dependent on levels of performance prior to inactivation (trial 41-60: inactivation of the mPFC hampered task-performance in rats, which already showed a preference for the advantageous option, but not in rats which were still choosing in a random manner. These data suggest that the mPFC becomes more strongly involved as rats have learned task-contingencies, i.e. choose for the best long-term option. Furthermore they suggest, along with the data of our earlier study, that both anxiety and decision-making in rats are mediated through a neural circuitry including at least the mPFC. The data are discussed in relation to recent data of rodent studies on the neural circuitry underlying decision-making.

  1. An integrative pharmacological approach to radio telemetry and blood sampling in pharmaceutical drug discovery and safety assessment

    Directory of Open Access Journals (Sweden)

    Kamendi Harriet W

    2011-01-01

    Full Text Available Abstract Background A successful integration of the automated blood sampling (ABS and telemetry (ABST system is described. The new ABST system facilitates concomitant collection of physiological variables with blood and urine samples for determination of drug concentrations and other biochemical measures in the same rat without handling artifact. Method Integration was achieved by designing a 13 inch circular receiving antenna that operates as a plug-in replacement for the existing pair of DSI's orthogonal antennas which is compatible with the rotating cage and open floor design of the BASi Culex® ABS system. The circular receiving antenna's electrical configuration consists of a pair of electrically orthogonal half-toroids that reinforce reception of a dipole transmitter operating within the coil's interior while reducing both external noise pickup and interference from other adjacent dipole transmitters. Results For validation, measured baclofen concentration (ABST vs. satellite (μM: 69.6 ± 23.8 vs. 76.6 ± 19.5, p = NS and mean arterial pressure (ABST vs. traditional DSI telemetry (mm Hg: 150 ± 5 vs.147 ± 4, p = NS variables were quantitatively and qualitatively similar between rats housed in the ABST system and traditional home cage approaches. Conclusion The ABST system offers unique advantages over traditional between-group study paradigms that include improved data quality and significantly reduced animal use. The superior within-group model facilitates assessment of multiple physiological and biochemical responses to test compounds in the same animal. The ABST also provides opportunities to evaluate temporal relations between parameters and to investigate anomalous outlier events because drug concentrations, physiological and biochemical measures for each animal are available for comparisons.

  2. Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain

    Directory of Open Access Journals (Sweden)

    Treharne GJ

    2002-06-01

    Full Text Available Abstract Background Continuous intrathecal drug delivery has been shown in open studies to improve pain and quality of life in those with intractable back pain who have had spinal surgery. There is limited data on long term effects and and even less for patients with mechanical back pain without prior spinal surgery. Methods We have investigated spinal drug administration systems for patients with failed back syndrome and chronic mechanical low back pain by patient questionnaire study of the efficacy of this therapy and a case notes review. Results 36 patients (97% of 37 approached completed questionnaires, 24 with failed back syndrome and 12 with chronic mechanical low back pain. Recalled pre-treatment levels with current post-treatment levels of pain and a range of quality of life measures (recorded on 11-point numerical rating scales were compared. Pain improved significantly in both groups (Wilcoxan signed ranks test, p 0.005, Wilcoxan signed ranks test with Bonferroni correction. Diamorphine was used in all 37 patients, bupivacaine in 32, clonidine in 27 and baclofen in 3. The mean dose of diamorphine increased for the first 2 years but did not change 2–6 years post implant, averaging 4.5 mg/day. Revision surgery was required in 24% of cases, but reduced to 12% in the later years of our experience. Conclusions We conclude that spinal drug administration systems appear to be of benefit in alleviating pain in the failed back syndrome and chronic mechanical low back pain but need to be examined prospectively.

  3. Conditional gene deletion reveals functional redundancy of GABAB receptors in peripheral nociceptors in vivo

    Directory of Open Access Journals (Sweden)

    Bettler Bernhard

    2009-11-01

    Full Text Available Abstract Background γ-aminobutyric acid (GABA is an important inhibitory neurotransmitter which mainly mediates its effects on neurons via ionotropic (GABAA and metabotropic (GABAB receptors. GABAB receptors are widely expressed in the central and the peripheral nervous system. Although there is evidence for a key function of GABAB receptors in the modulation of pain, the relative contribution of peripherally- versus centrally-expressed GABAB receptors is unclear. Results In order to elucidate the functional relevance of GABAB receptors expressed in peripheral nociceptive neurons in pain modulation we generated and analyzed conditional mouse mutants lacking functional GABAB(1 subunit specifically in nociceptors, preserving expression in the spinal cord and brain (SNS-GABAB(1-/- mice. Lack of the GABAB(1 subunit precludes the assembly of functional GABAB receptor. We analyzed SNS-GABAB(1-/- mice and their control littermates in several models of acute and neuropathic pain. Electrophysiological studies on peripheral afferents revealed higher firing frequencies in SNS-GABAB(1-/- mice compared to corresponding control littermates. However no differences were seen in basal nociceptive sensitivity between these groups. The development of neuropathic and chronic inflammatory pain was similar across the two genotypes. The duration of nocifensive responses evoked by intraplantar formalin injection was prolonged in the SNS-GABAB(1-/- animals as compared to their control littermates. Pharmacological experiments revealed that systemic baclofen-induced inhibition of formalin-induced nociceptive behaviors was not dependent upon GABAB(1 expression in nociceptors. Conclusion This study addressed contribution of GABAB receptors expressed on primary afferent nociceptive fibers to the modulation of pain. We observed that neither the development of acute and chronic pain nor the analgesic effects of a systematically-delivered GABAB agonist was significantly

  4. Modulation of the release of norepinephrine by gamma-aminobutyric acid and morphine in the frontal cerebral cortex of the rat

    International Nuclear Information System (INIS)

    Agents that enhance gamma-aminobutyric acid, or GABA, neurotransmission modulate certain effects of opioids, such as analgesia. Opioid analgesia is mediated in part by norepinephrine in the forebrain. In this study, the interactions between morphine and GABAergic agents on release of [3H] norepinephrine from rat frontal cerebral cortical slices were examined. GABA, 5 x 10-5-10-3 M, enhanced potassium stimulated [3H] norepinephrine release and reversed the inhibitory effect of morphine in a noncompetitive manner. GABA did not enhance release of [3H] norepinephrine stimulated by the calcium ionophore A23187. The effect of GABA was reduced by the GABAA receptor antagonists bicuculline methiodide or picrotoxin, and by the selective inhibitor of GABA uptake SKF 89976A, but was blocked completely only when bicuculline methiodide and SKF 89976A were used in combination. The GABAA agonist muscimol, 10-4 M, mimicked the effect of GABA, but the GABAB agonist (±)baclofen, 10-4 M, did not affect the release of [3H] norepinephrine in the absence or the presence of morphine. Thus GABA appears to produce this effect by stimulating GABA uptake and GABAA, but not GABAB, receptors. In contrast to the results that would be predicted for an event involving GABAA receptors, however, the effect of GABA did not desensitize, and benzodiazepine agonists did not enhance the effect of GABA at any concentration tested between 10-8 and 10-4 M. Thus these receptors may constitute a subclass of GABAA receptors. These results support a role of GABA uptake and GABAA receptors in enhancing the release of norepinephrine and modulating its inhibition by opioids in the frontal cortex of the rat

  5. Effect of 4-aminoantipyrine on gastric compliance and liquid emptying in rats

    Directory of Open Access Journals (Sweden)

    A.M. Vinagre

    2007-07-01

    Full Text Available Dipyrone (Dp delays gastric emptying (GE in rats. There is no information about whether 4-aminoantipyrine (AA, one of its metabolites, has the same effect. The objectives of the present study were to assess the effects of AA and Dp on GE when administered intravenously (iv and intracerebroventricularly (icv (240 µmol/kg and 4 µmol/animal, respectively and on gastric compliance when administered iv (240 µmol/kg. GE was determined in male Wistar rats weighing 250-300 g (5-10 per group after icv or iv injection of the drug by measuring percent gastric retention (GR of a saline meal labeled with phenol red 10 min after administration by gavage. Gastric compliance was estimated in anesthetized rats (10-11 per group, with the construction of volume-pressure curves during intragastric infusion of a saline meal. Compliance was significantly greater in animals receiving Dp (mean ± SEM = 0.26 ± 0.009 mL/mmHg and AA (0.24 ± 0.012 mL/mmHg than in controls (0.19 ± 0.009 mL/mmHg. AA and Dp administered iv significantly increased GR (64.4 ± 2.5 and 54.3 ± 3.8%, respectively compared to control (34 ± 2.2%, a phenomenon observed only with Dp after icv administration. Subdiaphragmatic vagotomy reduced the effect of AA (GR = 31.4 ± 1.5% compared to sham-treated animals. Baclofen, a GABA B receptor agonist, administered icv significantly reduced the effect of AA (GR = 28.1 ± 1.3%. We conclude that Dp and AA increased gastric compliance and AA delayed GE, with the participation of the vagus nerve, through a pathway that does not involve a direct action of the drug on the central nervous system.

  6. PROTECTING EFFECT OF 2-OH-SACLOFEN ON HIPPOCAMPAL NEURONAL ULTRASTRUCTURE OF THE RATS WITH CHRONIC STRESS%2-OH-saclofen对慢性应激大鼠海马神经元超微结构的保护作用

    Institute of Scientific and Technical Information of China (English)

    金玉祥; 姚敏; 程琰; 姜虹; 钟利强

    2005-01-01

    为了观察GABAB受体抑制剂2-OH-saclofen和GABAB受体激动剂baclofen对慢性应激大鼠海马神经元超微结构变化的作用.我们采用足底电击结合噪声的方法制备应激动物模型,同时分别经腹腔注射2-OH-saclofen(100 μg/kg)或baclofen(40mg/kg),应激40 d后取材,在透射电镜下观察海马神经元超微结构的变化,另外采用酶联免疫法检测慢性应激过程中血浆皮质醇含量的变化.结果表明,单纯应激组和应激+baclofen组大鼠海马神经元都有一定的变性改变,如出现了细胞核固缩、线粒体肿胀和线粒体嵴断裂、髓鞘变形,突触结构不清等;而应激+2-OH-saclofen组大鼠海马不同区域的神经元与正常对照组相比无明显改变.单纯应激组和应激+baclofen组血浆皮质醇含量在慢性应激过程中呈升高趋势,而应激+2-OH-saclofen组血浆皮质醇含量在慢性应激过程中呈降低趋势.提示GABAB受体抑制剂2-OH-saclofen对慢性应激大鼠海马神经元有保护作用.

  7. Percutaneous radiofrequency lesions adjacent to the dorsal root ganglion alleviate spasticity and pain in children with cerebral palsy: pilot study in 17 patients

    Directory of Open Access Journals (Sweden)

    van Rhijn Lodewijk W

    2010-06-01

    Full Text Available Abstract Background Cerebral palsy (CP may cause severe spasticity, requiring neurosurgical procedures. The most common neurosurgical procedures are continuous infusion of intrathecal baclofen and selective dorsal rhizotomy. Both are invasive and complex procedures. We hypothesized that a percutaneous radiofrequency lesion of the dorsal root ganglion (RF-DRG could be a simple and safe alternative treatment. We undertook a pilot study to test this hypothesis. Methods We performed an RF-DRG procedure in 17 consecutive CP patients with severe hip flexor/adductor spasms accompanied by pain or care-giving difficulties. Six children were systematically evaluated at baseline, and 1 month and 6 months after treatment by means of the Modified Ashworth Scale (MAS, Gross Motor Function Measure (GMFM and a self-made caregiver's questionnaire. Eleven subsequent children were evaluated using a Visual Analogue Scale (VAS for spasticity, pain and ease of care. Results A total of 19 RF-DRG treatments were performed in 17 patients. We found a small improvement in muscle tone measured by MAS, but no effect on the GMFM scale. Despite this, the caregivers of these six treated children unanimously stated that the quality of life of their children had indeed improved after the RF-DRG. In the subsequent 11 children we found improvements in all VAS scores, in a range comparable to the conventional treatment options. Conclusion RF-DRG is a promising new treatment option for severe spasticity in CP patients, and its definitive effectiveness remains to be defined in a randomised controlled trial.

  8. Effects of centrally acting antihypertensive drugs on the microcirculation of spontaneously hypertensive rats

    Directory of Open Access Journals (Sweden)

    Estato V.

    2004-01-01

    Full Text Available We investigated the acute effects of centrally acting antihypertensive drugs on the microcirculation of pentobarbital-anesthetized spontaneously hypertensive rats (SHR. The effects of the sympatho-inhibitory agents clonidine and rilmenidine, known to activate both alpha2-adrenoceptors and nonadrenergic I1-imidazoline binding sites (I1BS in the central nervous system, were compared to those of dicyclopropylmethyl-(4,5-dimethyl-4,5-dihydro-3H -pyrrol-2-yl-amine hydrochloride (LNP 509, which selectively binds to the I1BS. Terminal mesenteric arterioles were observed by intravital microscopy. Activation of the central sympathetic system with L-glutamate (125 µg, ic induced marked vasoconstriction of the mesenteric microcirculation (27 ± 3%; N = 6, P < 0.05. In contrast, the marked hypotensive and bradycardic effects elicited by intracisternal injection of clonidine (1 µg, rilmenidine (7 µg and LNP 509 (60 µg were accompanied by significant increases in arteriolar diameter (12 ± 1, 25 ± 10 and 21 ± 4%, respectively; N = 6, P < 0.05. The vasodilating effects of rilmenidine and LNP 509 were two-fold higher than those of clonidine, although they induced an identical hypotensive effect. Central sympathetic inhibition elicited by baclofen (1 µg, ic, a GABA B receptor agonist, also resulted in vasodilation of the SHR microvessels. The acute administration of clonidine, rilmenidine and LNP 509 also induced a significant decrease of cardiac output, whereas a decrease in systemic vascular resistance was observed only after rilmenidine and LNP 509. We conclude that the normalization of blood pressure in SHR induced by centrally acting antihypertensive agents is paralleled by important vasodilation of the mesenteric microcirculation. This effect is more pronounced with substances acting preferentially (rilmenidine or exclusively (LNP 509 upon I1BS than with those presenting important alpha2-adrenergic activity (clonidine.

  9. 乙醇对小鼠不同脑区3H-GABA与GABAA受体结合的影响

    Institute of Scientific and Technical Information of China (English)

    周雪瑞; 李晓煜; 秦晓东; 朱剑琴

    1999-01-01

    采用放射配体受体结合分析法,研究急性注射乙醇对小鼠不同脑区GABAA受体饱和曲线以及与3H-GABA结合的影响.结果表明,急性注射乙醇30min后,GABAA受体饱和曲线出现大幅度上移,乙醇能明显提高3H-GABA与GABAA受体的结合,对小脑、下丘脑、海马及大脑皮层分别提高20%、16%、30%、和28%.乙醇能逆转GGABAA受体拮抗剂如印防己毒素(Picrotoxin)、荷包牡丹碱(Bicuculline)等对受体结合的抑制作用,其中对Pic作用最为显著.戊巴比妥钠(Barbitufal[e)、蝇蕈醇(Muscimol)、氨氧乙酸(Amincoxyacetic acid)在乙醇作用下均不同程度地提高受体的结合量.巴氯芬(Baclofen)对GABAA受体的结合有一定程度的降低作用.说明乙醇能通过提高GABA与GABAA受体的结合,实现对中枢的抑制作用。

  10. Identification of rat ventral tegmental area GABAergic neurons.

    Directory of Open Access Journals (Sweden)

    Elyssa B Margolis

    Full Text Available The canonical two neuron model of opioid reward posits that mu opioid receptor (MOR activation produces reward by disinhibiting midbrain ventral tegmental area (VTA dopamine neurons through inhibition of local GABAergic interneurons. Although indirect evidence supports the neural circuit postulated by this model, its validity has been called into question by growing evidence for VTA neuronal heterogeneity and the recent demonstration that MOR agonists inhibit GABAergic terminals in the VTA arising from extrinsic neurons. In addition, VTA MOR reward can be dopamine-independent. To directly test the assumption that MOR activation directly inhibits local GABAergic neurons, we investigated the properties of rat VTA GABA neurons directly identified with either immunocytochemistry for GABA or GAD65/67, or in situ hybridization for GAD65/67 mRNA. Utilizing co-labeling with an antibody for the neural marker NeuN and in situ hybridization against GAD65/67, we found that 23±3% of VTA neurons are GAD65/67(+. In contrast to the assumptions of the two neuron model, VTA GABAergic neurons are heterogeneous, both physiologically and pharmacologically. Importantly, only 7/13 confirmed VTA GABA neurons were inhibited by the MOR selective agonist DAMGO. Interestingly, all confirmed VTA GABA neurons were insensitive to the GABA(B receptor agonist baclofen (0/6 inhibited, while all confirmed dopamine neurons were inhibited (19/19. The heterogeneity of opioid responses we found in VTA GABAergic neurons, and the fact that GABA terminals arising from neurons outside the VTA are inhibited by MOR agonists, make further studies essential to determine the local circuit mechanisms underlying VTA MOR reward.

  11. Characterization of GABA/sub A/ receptor-mediated 36chloride uptake in rat brain synaptoneurosomes

    International Nuclear Information System (INIS)

    γ-Aminobutyric acid (GABA) receptor-mediated 36chloride (36Cl-) uptake was measured in synaptoneurosomes from rat brain. GABA and GABA agonists stimulated 36Cl- uptake in a concentration-dependent manner with the following order of potency: Muscimol>GABA>piperidine-4-sulfonic acid (P4S)>4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridin-3-ol (THIP)=3-aminopropanesulfonic acid (3APS)>>taurine. Both P4S and 3APS behaved as partial agonists, while the GABA/sub B/ agonist, baclofen, was ineffective. The response to muscimol was inhibited by bicuculline and picrotoxin in a mixed competitive/non-competitive manner. Other inhibitors of GABA receptor-opened channels or non-neuronal anion channels such as penicillin, picrate, furosemide and disulfonic acid stilbenes also inhibited the response to muscimol. A regional variation in muscimol-stimulated 36Cl- uptake was observed; the largest responses were observed in the cerebral cortex, cerebellum and hippocampus, moderate responses were obtained in the striatum and hypothalamus and the smallest response was observed in the pons-medulla. GABA receptor-mediated 36Cl- uptake was also dependent on the anion present in the media. The muscinol response varied in media containing the following anions: Br->Cl-≥NO3->I-≥SCN->>C3H5OO-≥ClO4->F-, consistent with the relative anion permeability through GABA receptor-gated anion channels and the enhancement of convulsant binding to the GABA receptor-gated Cl- channel. 43 references, 4 figures, 3 tables

  12. The role of GABAC receptors in the regulation of cerebellar metabolism

    International Nuclear Information System (INIS)

    Full text: GABAC (γ-aminobutyric acid) receptors are characterised by their insensitivity to the GABAA-selective antagonist, bicuculline and the GABAB-selective agonist, baclofen. These receptors are composed of a homo- or hetero-oligomeric assembly of novel subunits termed ρ1 and ρ2. The subunit ρ1 is located mainly in the retina, although it has been identified in Purkinje cells of the cerebellum, whilst ρ2 is more widely expressed in the CNS (cerebellum, hippocampus and cortex). The functional role of these receptors has yet to be established. They may be involved in the regulation of the sleep-wake cycle, modulation of excitatory neurotransmitter release and in the inhibition of pre-synaptic calcium currents. The present study investigated the potential role of GABAC receptors in guinea pig cerebellar tissue slice metabolism by analysing the fate of 13C from [3-13C]pyruvate by NMR spectroscopy, in the absence (control) and presence (20 μM) of the GABAC selective antagonist, (1,2,5,6-tetrahydropyridin-4-yl)methyl-phosphonic acid TPMPA). Net flux and fractional enrichment of Glu, GABA, Gln, Ala and Asp isotopomers was measured by NMR spectroscopy and the rate of efflux of amino acids into the buffer was estimated by HPLC. Net flux of 13C into Glu C3 and C4 significantly increased, but release of Glu into the buffer was decreased by TPMPA. There was no increase of net flux into Gln C4, and net flux into Ala C3 was decreased. These data suggest that TPMPA-sensitive GABAC receptors influence the release of neurotransmitter glutamate in the cerebellum

  13. Effect of gamma-aminobutyric acid B receptor on nitric oxide/nitric oxide synthase system during recurrent febrile seizures%反复热性惊厥过程中γ-氨基丁酸B受体对一氧化氮/一氧化氮合酶体系的调节作用

    Institute of Scientific and Technical Information of China (English)

    韩颖; 秦炯; 卜定方; 杨志仙; 常杏芝; 杜军保

    2006-01-01

    目的:探讨γ-氨基丁酸B受体(γ-aminobutyric acid B receptor,GABABR)对热性惊厥(febrile seizure,FS)大鼠一氧化氮(nitric oxide,NO)/一氧化氮合酶(nitric oxide synthase,NOS)体系表达的影响.方法:将21 d龄SD大鼠随机分为对照组、FS组、FS+巴氯芬(baclofen)组和FS+法克罗芬(phaclofen)组.采用热水浴诱导大鼠FS,隔日诱导1次,共10次.采用分光光度计法测定大鼠血浆中NO含量;用原位杂交方法观察神经元型一氧化氮合酶(neuronal nitric oxide synthase,nNOS)mRNA表达情况;用免疫组化方法观察nNOS蛋白表达情况.结果:FS+baclofen组NO含量低于FS组[(19.02±9.31)μmol/L比(40.03±9.12)μmol/L],同时nNOS蛋白和mRNA表达也较FS组减弱;而FS+phaclofen组NO含量高于FS组[(66.46±8.15)μmol/L比(40.03±9.12)μmol/L],同时nNOS蛋白和mRNA表达也较FS组增强.结论:反复热性惊厥过程中,GABABR的改变可影响NO/NOS体系的表达.

  14. Evidence for a neurotransmitter function of acetylcholine in rabbit superior colliculus.

    Science.gov (United States)

    Wichmann, T; Illing, R B; Starke, K

    1987-12-01

    Acetylcholinesterase staining and studies on the uptake of [3H]choline into the subsequent efflux of tritium from collicular slices were carried out in order to provide evidence for a neurotransmitter function of acetylcholine in rabbit superior colliculus. Acetylcholinesterase staining was dense and homogeneous in superficial layers whereas the staining was arranged in patches with slightly higher density caudally than rostrally in the intermediate layers. The accumulation of tritium in slices incubated with [3H]choline depended on time, temperature and concentration, and was inhibited by hemicholinium-3. Accumulation was slightly higher in caudal than in rostral slices. Electrical stimulation enhanced tritium outflow from slices preincubated with [3H]choline. Tetrodotoxin and a low calcium medium inhibited the evoked overflow whereas hemicholinium-3 caused an enhancement. Oxotremorine decreased the evoked overflow; atropine prevented this effect. The opioids [D-Ala2, MePhe4, Glycol5]enkephalin, [D-Ala2, D-Leu5]enkephalin and ethylketocyclazocine caused an inhibition. The effects of the latter two agonists were antagonized by naloxone. The GABAB-receptor-agonist (-)-baclofen decreased the evoked overflow at lower concentrations than GABA, whereas the GABAA-receptor-agonist muscimol was ineffective. Serotonin produced an inhibition which was prevented by metitepin, alpha- and beta-adrenoceptor as well as dopamine-receptor ligands caused no change. It is concluded that in the rabbit superior colliculus the pattern of acetylcholinesterase staining is comparable, but not identical to the distribution in other species. The accumulation of [3H]choline, as well as the tetrodotoxin-sensitive and calcium-dependent overflow of tritium upon electrical stimulation (reflecting presumably release of [3H]acetylcholine) indicate that acetylcholine has a neurotransmitter function in this tissue. The release of [3H]acetylcholine was modulated by various transmitter substances and

  15. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission.

    Science.gov (United States)

    Riga, Maurizio S; Sánchez, Connie; Celada, Pau; Artigas, Francesc

    2016-09-01

    The antidepressant vortioxetine is a 5-HT3-R, 5-HT7-R and 5-HT1D-R antagonist, 5-HT1B-R partial agonist, 5-HT1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT3-R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT3-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT3-R blockade. Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT3-R agonist) and was mimicked by ondansetron (5-HT3-R antagonist) and by escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT neurons express GABAB receptors, we examined their putative involvement in controlling 5-HT release after 5-HT3-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in vHPC. The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotransmission in rat forebrain by blocking 5-HT3 receptors in GABA interneurons. PMID:27106166

  16. Context-induced reinstatement of methamphetamine seeking is associated with unique molecular alterations in Fos-expressing dorsolateral striatum neurons.

    Science.gov (United States)

    Rubio, F Javier; Liu, Qing-Rong; Li, Xuan; Cruz, Fabio C; Leão, Rodrigo M; Warren, Brandon L; Kambhampati, Sarita; Babin, Klil R; McPherson, Kylie B; Cimbro, Raffaello; Bossert, Jennifer M; Shaham, Yavin; Hope, Bruce T

    2015-04-01

    Context-induced reinstatement of drug seeking is a well established animal model for assessing the neural mechanisms underlying context-induced drug relapse, a major factor in human drug addiction. Neural activity in striatum has previously been shown to contribute to context-induced reinstatement of heroin, cocaine, and alcohol seeking, but not yet for methamphetamine seeking. In this study, we found that context-induced reinstatement of methamphetamine seeking increased expression of the neural activity marker Fos in dorsal but not ventral striatum. Reversible inactivation of neural activity in dorsolateral but not dorsomedial striatum using the GABA agonists muscimol and baclofen decreased context-induced reinstatement. Based on our previous findings that Fos-expressing neurons play a critical role in conditioned drug effects, we assessed whether context-induced reinstatement was associated with molecular alterations selectively induced within context-activated Fos-expressing neurons. We used fluorescence-activated cell sorting to isolate reinstatement-activated Fos-positive neurons from Fos-negative neurons in dorsal striatum and used quantitative PCR to assess gene expression within these two populations of neurons. Context-induced reinstatement was associated with increased expression of the immediate early genes Fos and FosB and the NMDA receptor subunit gene Grin2a in only Fos-positive neurons. RNAscope in situ hybridization confirmed that Grin2a, as well as Grin2b, expression were increased in only Fos-positive neurons from dorsolateral, but not dorsomedial, striatum. Our results demonstrate an important role of dorsolateral striatum in context-induced reinstatement of methamphetamine seeking and that this reinstatement is associated with unique gene alterations in Fos-expressing neurons. PMID:25855177

  17. Involvement of inward rectifier and M-type currents in carbachol-induced epileptiform synchronization.

    Science.gov (United States)

    Cataldi, Mauro; Panuccio, Gabriella; Cavaccini, Anna; D'Antuono, Margherita; Taglialatela, Maurizio; Avoli, Massimo

    2011-03-01

    Exposure to cholinergic agonists is a widely used paradigm to induce epileptogenesis in vivo and synchronous activity in brain slices maintained in vitro. However, the mechanisms underlying these effects remain unclear. Here, we used field potential recordings from the lateral entorhinal cortex in horizontal rat brain slices to explore whether two different K(+) currents regulated by muscarinic receptor activation, the inward rectifier (K(IR)) and the M-type (K(M)) currents, have a role in carbachol (CCh)-induced field activity, a prototypical model of cholinergic-dependent epileptiform synchronization. To establish whether K(IR) or K(M) blockade could replicate CCh effects, we exposed slices to blockers of these currents in the absence of CCh. K(IR) channel blockade with micromolar Ba(2+) concentrations induced interictal-like events with duration and frequency that were lower than those observed with CCh; by contrast, the K(M) blocker linopirdine was ineffective. Pre-treatment with Ba(2+) or linopirdine increased the duration of epileptiform discharges induced by subsequent application of CCh. Baclofen, a GABA(B) receptor agonist that activates K(IR), abolished CCh-induced field oscillations, an effect that was abrogated by the GABA(B) receptor antagonist CGP 55845, and prevented by Ba(2+). Finally, when applied after CCh, the K(M) activators flupirtine and retigabine shifted leftward the cumulative distribution of CCh-induced event duration; this effect was opposite to what seen during linopirdine application under similar experimental conditions. Overall, our findings suggest that K(IR) rather than K(M) plays a major regulatory role in controlling CCh-induced epileptiform synchronization. PMID:21144855

  18. ANTI-DEPRESSANT POTENTIAL OF GHIYA

    Directory of Open Access Journals (Sweden)

    Kaur Satbir

    2012-04-01

    Full Text Available Lagenaria siceraria (Cucurbitaceae, popularly known as bottle gourd, lauki or ghiya, is a climbing plant, which bears hard-shelled and bottle-shaped gourds as fruits. Ghiya forms an excellent diet for people having digestive problems being rich in vitamins, iron and minerals. Since, it contains low calories, bottle gourd is an awesome foodstuff for shedding extra calories. The fruit possesses diuretic, emetic, and refrigerant properties. The ghiya (lauki juice is helpful in constipation, premature graying hair, urinary disorders and insomnia. However, there are no reports in literature pertaining to CNS actions of Lagenaria siceraria fruit. In the light of above, the present study was undertaken to test the anti-depressant potential of Lagenaria siceraria juice (LSJ. Lagenaria siceraria juice was administered at various concentrations ranging from 4%-16% v/v orally to Swiss mice (30g, once daily for 15 successive days. The anti-depressant activity was measured using Forced Swim Test (FST and Tail Suspension Test (TST. The efficacy of Lagenaria siceraria was compared to standard anti-depressant drugs viz: fluoxetine (20mg/kg, p.o, imipramine (15mg/kg, p.o and phenelzine (20 mg/kg, p.o. Lagenaria siceraria significantly reduced the immobility time of mice in both FST and TST. Prazosin, Baclofen, Sulpiride and p-CPA significantly antagonized this reduction in immobility duration. Furthermore, Lagenaria siceraria juice inhibited the monoamine oxidase (MAO enzyme and reduced significantly malondialdehyde (MDA levels. These findings reveal the anti-depressant potential of ghiya.

  19. Pharmacological modulation of the state of awareness in patients with disorders of consciousness: an overview.

    Science.gov (United States)

    Mura, Elisa; Pistoia, Francesca; Sara, Marco; Sacco, Simona; Carolei, Antonio; Govoni, Stefano

    2014-01-01

    The neurobiological approach to consciousness moves from the assumption that all phenomenal experiences are based on neuronal activity in the brain. Consciousness has two main components: wakefulness and awareness. While it may be relatively easy to determine the neuronal correlates of wakefulness, it is not the same for awareness, of which the neural correlates are poorly understood. Knowledge of the circuitry and the neurochemistry of the sleep/wake condition is necessary but not sufficient to understand the circuitry and neurochemistry of consciousness. Disorders of consciousness (DOCs) include coma, vegetative state and minimally conscious state. The study of DOCs and of the electrophysiological changes underlying general anaesthesia-induced loss of consciousness may help in understanding the neuronal correlates of consciousness. In turn, the understanding of the neural bases of consciousness may help in designing interventions aimed at restoring consciousness in DOC patients. Sporadic cases of recovery from a DOC have been reported after the administration of various pharmacological agents (baclofen, zolpidem, amantadine etc.). This review provides an overview of such drugs, which are from various and diverging classes but can be grouped into two main categories: CNS stimulants and CNS depressants. The available data seem to suggest an awakening effect obtained with CNS depressants rather than stimulants, the latter being more effective at improving functional cognitive and behavioral recovery in patients who have spontaneously regained an appreciable level of consciousness. There is a need for more rigorous systematic trials and further investigation of the above treatments, with particular attention paid to their mechanisms of action and the neurotransmitters involved. PMID:24025054

  20. Understanding and treating patients with alcoholic cirrhosis: an update.

    Science.gov (United States)

    Addolorato, Giovanni; Russell, Marcia; Albano, Emanuele; Haber, Paul S; Wands, Jack R; Leggio, Lorenzo

    2009-07-01

    Alcoholic cirrhosis represents the terminal stage of alcoholic liver disease (ALD) and one of the main causes of death among alcohol abusers. The aim of this review was to provide an update on alcoholic cirrhosis, with an emphasis on recent findings. Increased alcohol consumption in developing countries is expected to increase cirrhosis mortality. There is a need, therefore, to develop new approaches to the prevention of ALD, including more attention to co-factors that may increase risk of ALD (i.e., obesity and diabetes, chronic HCV infection, and smoking). Furthermore, a better understanding of the pathological mechanisms on the basis of alcohol cirrhosis represents a cornerstone in order to develop new pharmacological treatments. Inflammatory and immune responses along with oxidative stress and alterations in adipokine secretion might contribute in different ways to the evolution of alcohol-induced fibrosis/cirrhosis. As of this date, patients with severe alcoholic hepatitis with a Maddrey Discriminant Factor (MDF) 32 should be offered pentoxifylline and/or corticosteroids unless contraindications exist. For ambulatory patients, S-adenosylmethionine (SAMe) may be considered in a motivated patient with nutritional support. Current studies do not support use of anti-tumor necrosis factor (TNF)-alpha antibody. Finally, achieving total alcohol abstinence should represent the main aim in the management of patients affected by any stage of cirrhosis. In the last decades, several drugs able to increase abstinence and prevent alcohol relapse have been evaluated and some of them have obtained approval for alcohol dependence. Patients with alcoholic cirrhosis; however, are usually excluded from such treatments. A recent study demonstrated the efficacy and safety of baclofen in inducing and maintaining alcohol abstinence in cirrhotic alcohol-dependent patients with cirrhosis. All together the information available suggests the need of a multimodal approach in the clinical

  1. Pituitary Adenylate-Cyclase Activating Polypeptide Regulates Hunger- and Palatability-Induced Binge Eating.

    Science.gov (United States)

    Hurley, Matthew M; Maunze, Brian; Block, Megan E; Frenkel, Mogen M; Reilly, Michael J; Kim, Eugene; Chen, Yao; Li, Yan; Baker, David A; Liu, Qing-Song; Choi, SuJean

    2016-01-01

    While pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the hypothalamic ventromedial nuclei (VMN) has been shown to regulate feeding, a challenge in unmasking a role for this peptide in obesity is that excess feeding can involve numerous mechanisms including homeostatic (hunger) and hedonic-related (palatability) drives. In these studies, we first isolated distinct feeding drives by developing a novel model of binge behavior in which homeostatic-driven feeding was temporally separated from feeding driven by food palatability. We found that stimulation of the VMN, achieved by local microinjections of AMPA, decreased standard chow consumption in food-restricted rats (e.g., homeostatic feeding); surprisingly, this manipulation failed to alter palatable food consumption in satiated rats (e.g., hedonic feeding). In contrast, inhibition of the nucleus accumbens (NAc), through local microinjections of GABA receptor agonists baclofen and muscimol, decreased hedonic feeding without altering homeostatic feeding. PACAP microinjections produced the site-specific changes in synaptic transmission needed to decrease feeding via VMN or NAc circuitry. PACAP into the NAc mimicked the actions of GABA agonists by reducing hedonic feeding without altering homeostatic feeding. In contrast, PACAP into the VMN mimicked the actions of AMPA by decreasing homeostatic feeding without affecting hedonic feeding. Slice electrophysiology recordings verified PACAP excitation of VMN neurons and inhibition of NAc neurons. These data suggest that the VMN and NAc regulate distinct circuits giving rise to unique feeding drives, but that both can be regulated by the neuropeptide PACAP to potentially curb excessive eating stemming from either drive. PMID:27597817

  2. Gateways to Clinical Trials. June 2002.

    Science.gov (United States)

    Bayes, M; Rabasseda, X; Prous, J R

    2002-06-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Abacavir sulfate, abarelix, abciximab, alicaforsen sodium, almotriptan, alteplase, amlodipine, amoxicillin trihydrate, amprenavir, argatroban monohydrate, aspirin, atorvastatin calcium, azathioprine; Baclofen, benidipine hydrochloride, benserazide, BMS-214662, bosentan, botulinum toxin type B; Candesartan cilexetil, carbamazepine, carbidopa, carboplatin, ceftriaxone sodium, celecoxib, cetirizine hydrochloride, clarithromycin, clavulanate potassium, clopidogrel hydrogensulfate, clozapine, CPI-1189, cyclophosphamide, cytarabine; Darbepoetin alfa, denileukin diftitox, dexamethasone, dipyridamole, droperidol, DW-166HC; Ebastine, efalizumab, efavirenz, eletriptan, enalapril maleate, enfuvirtide, enoxaparin sodium, enrasentan, entacapone, epoetin, eprosartan mesilate, etanercept, etoricoxib; Fenofibratefexofenadine hydrochloride, filgrastim, fludarabine phosphate, fluoxetine hydrochloride fluvoxamine maleate, frovatriptan, furosemide; Gabapentin, galantamine hydrobromide, gatifloxacin, gefitinib, ghrelin (human), glatiramer acetate; Haloperidol; Ibuprofen, ibuprofen, guaiacol ester, idarubicin hydrochloride, imipramine hydrochloride, imiquimod, interferon beta, interferon beta-1a, interferon beta-1b, interferon omega, irbesartan, itraconazole; Ketorolac, ketorolac tromethamine; Lamifiban, lamotrigine, lanoteplase, lansoprazole, leflunomide, leuprorelin acetate, levetiracetam, levocetirizine, levodopa, lisinopril, loratadine; Manidipine, methylprednisolone, metronidazole, mirtazapine, mizolastine, modafinil, morphine sulfate; Naproxen sodium, naratriptan hydrochloride, nifedipine, NSC-683864; Ofloxacin, olanzapine

  3. GABAB Receptors Expressed in Human Aortic Endothelial Cells Mediate Intracellular Calcium Concentration Regulation and Endothelial Nitric Oxide Synthase Translocation

    Directory of Open Access Journals (Sweden)

    Xu-Ping Wang

    2014-01-01

    Full Text Available GABAB receptors regulate the intracellular Ca2+ concentration ([Ca2+]i in a number of cells (e.g., retina, airway epithelium and smooth muscle, but whether they are expressed in vascular endothelial cells and similarly regulate the [Ca2+]i is not known. The purpose of this study was to investigate the expression of GABAB receptors, a subclass of receptors to the inhibitory neurotransmitter γ-aminobutyric acid (GABA, in cultured human aortic endothelial cells (HAECs, and to explore if altering receptor activation modified [Ca2+]i and endothelial nitric oxide synthase (eNOS translocation. Real-time PCR, western blots and immunofluorescence were used to determine the expression of GABAB1 and GABAB2 in cultured HAECs. The effects of GABAB receptors on [Ca2+]i in cultured HAECs were demonstrated using fluo-3. The influence of GABAB receptors on eNOS translocation was assessed by immunocytochemistry. Both GABAB1 and GABAB2 mRNA and protein were expressed in cultured HAECs, and the GABAB1 and GABAB2 proteins were colocated in the cell membrane and cytoplasm. One hundred μM baclofen caused a transient increase of [Ca2+]i and eNOS translocation in cultured HAECs, and the effects were attenuated by pretreatment with the selective GABAB receptor antagonists CGP46381 and CGP55845. GABAB receptors are expressed in HAECs and regulate the [Ca2+]i and eNOS translocation. Cultures of HAECs may be a useful in vitro model for the study of GABAB receptors and vascular biology.

  4. GABAB Receptors, Schizophrenia and Sleep Dysfunction

    Science.gov (United States)

    Kantrowitz, Joshua; Citrome, Leslie; Javitt, Daniel

    2016-01-01

    minimal investigation of GABAB receptor agonists such as baclofen or γ-hydroxybutyric acid and their effects on sleep architecture, cognition and negative symptoms in patients with schizophrenia. Further study is needed. PMID:19594197

  5. Behavioral and Biochemical Evidences for Antidepressant-Like Activity of Celastrus Paniculatus Seed Oil in Mice

    Science.gov (United States)

    Valecha, Rekha; Dhingra, Dinesh

    2016-01-01

    Introduction: Celastrus paniculatus seed oil, commonly known as Malkangni or Jyotishmati, was in use from time immemorial to treat brain related disorders. Celastrus paniculatus seed oil has significant antidepressant-like activity in chronic unpredictable stressed mice. The present study was undertaken to evaluate the antidepressant-like effect of Celastrus paniculatus seed oil in unstressed mice and to explore its mechanism of action. Methods: The seed oil (50, 100, and 200 mg/kg, PO) and fluoxetine per se were administered for 14 successive days to Swiss young albino mice. On the 14th day, 60 min after drug administration, animals were subjected to Tail Suspension Test (TST) and Forced Swim Test (FST). The mechanism of action was also studied. Results: The oil significantly decreased immobility period of mice in both tail suspension test and forced swim test, indicating its significant antidepressant-like activity. The efficacy was found to be comparable to fluoxetine (P<0.0001). ED50 value of celastrus seed oil using FST and TST were 17.38 and 31.62 mg/kg, respectively. The oil did not show any significant effect on locomotor activity. It significantly inhibited brain MAO–A activity and decreased plasma corticosterone levels. Sulpiride (selective D2-receptor antagonist), p-CPA (tryptophan hydroxylase inhibitor), and baclofen (GABAB agonist) significantly attenuated the oil-induced antidepressant-like effect, when assessed during TST. Discussion: Celastrus paniculatus seed oil produced significant antidepressant-like effect in mice possibly through interaction with dopamine D2, serotonergic, and GABAB receptors; as well as inhibition of MAO–A activity and decrease in plasma corticosterone levels. PMID:27303599

  6. 大鼠生后MGBv神经元主动膜特性的变化及GABA受体激动剂的影响%Alteration of membrane properties of MGBv neurons and the effect of GABA receptor agonist on them during postnatal development in rats

    Institute of Scientific and Technical Information of China (English)

    姚小红; 万子兵; 熊鹰

    2005-01-01

    Objective To observe membrane properties of ventral partition of the medial geniculate body (MGBv) in Wistar rat and the effect of GABA receptor agonist on them during postnatal development. Methods Whole-cell patch clamp recording was used to record waveform of action potential (AP) and the effect of GABA receptor agonist on them from neurons in the MGBv of rats ( postnatal days 3-30). Results There was a difference in AP firing pattern in rat MGBv neurons of different postnatal day. We only recorded low threshold Ca2+ spikes (LTS) in P3 MGBv neurons, but recorded AP in P6-30 MGBv neurons after depolarizing currents application; AP was recorded at the start phase of pulse and with a long-last after hyperpolarization potential (AHP) in P8, in P20 AP was recorded after a delay and it appeared on depolarizing ramp with a shorter-last AHP compared with P8. The GABAA receptor agonist, muscimol, and the GABAB receptor agonist, baclofen, had effects on responses evoked by depolarizing current in the MGBv neurons in P6 and P15 rats. Muscimol and baclofen reduced AP firing rather than AP amplitude in P6 MGBv neurons, however, in P15 MGBv neurons baclofen had little effect on AP firing while muscimol greatly reduced the size of voltage shift produced by positive or negative current injection. Conclusion The AP waveform of MGBv neurons matures rapidly during first two postnatal weeks. A similar rapid maturation also has been observed in rat neocortical and hippocampal pyramidal neurons as well as in ferret dorsal lateral geniculate nucleus (LGNd) neurons. These results suggest that in the central nervous system of small mammals, AP waveforms mature rapidly in many types of neurons, thus, coordinated activities in neuronal circuits may occur. In early postnatal development, GABA receptor mainly mediates an excitation effect, depolarizes P6 MGBv neurons and dramatically increases the frequency of AP firing. Inhibition of GABA receptor matures slowly along with increment of

  7. GABAB R活性水平对致痫大鼠认知功能及Arc/Arg3.1表达的影响%Effects of GABAB receptor expression level on cognitive impairment and Arc/Arg3.1 expression in induced epileptic rats model

    Institute of Scientific and Technical Information of China (English)

    兰彦平; 孙涛; 张春; 袁聪聪; 杨征; 王峰

    2016-01-01

    目的 探讨GABABR活性变化对癫痫大鼠认知功能及Arc/Arg3.1的影响.方法 建立氯化锂-匹罗卡品致痫模型,随机分成正常组、巴氯酚组、CGP组、单纯点燃组.避暗、水迷宫实验观察大鼠认知情况,免疫组化、荧光定量PCR、免疫印迹检测海马组织内GABABR(GB1、GB2)、Arc/Arg3.1蛋白及mRNA表达情况.结果 避暗实验:4组大鼠穿梭次数为:6.8±0.6、1.2土0.2、5.4±0.5及3.6±0.3,潜伏期为:26.1 ±3.9、152.2±12.9、65.8 ±7.0、91.2±9.1,与水迷宫行为学变化趋势一致,显示致痫大鼠认知功能减退,巴氯酚进一步抑制致痫大鼠学习和记忆获取能力,CGP35348可改善致痫大鼠认知功能.Arc/Arg3.1及GB1、GB2相对表达量检测显:致痫大鼠较正常大鼠Arc/Arg3.1及GB1、GB2表达量明显增高,致痫组大鼠相对比,巴氯酚组Arc/Arg3.1表达量下降,GB1、GB2增高;而CGP35348组Arc/Arg3.1表达量增高,GB1、GB2降低.结论 GABABR活性水平可以调控Arc/Arg3.1表达,并影响致痫大鼠认知功能.%Objective To investigate the effects of GABAB receptor on cognitive impairment by using pilocarpine induced kindled rats model and also to check early gene (Arc/Arg3.1) expression.Methods Pilocarpine induced kindled rats were divided into four groups (Group normal,Baclofen,CGP and Kindled) randomly,and every group included 20 rats.We checked their cognitive impairment by using passive avoidance test and water maze test.The expression of GABAB receptor (GB1,GB2) and Arc/Arg3.1 was tested by immunohistochemical staining,RT-PCR and Western blot.Results Passive avoidance test showed four Group rats shuttle times were 6.8 ± 0.6,1.2 ± 0.2,5.4 ± 0.5,3.6 ± 0.3,incubation period were 26.1 ±3.9,152.2 ± 12.9,65.8 ±7.0,91.2 ±9.1,and water maze test had the same trend,with values in epilepsy groups significantly lower than the normal group of rats,which meant cognitive dysfunction.The above results also showed Baclofen further inhibited the learning

  8. Effect of γ-aminobutyric acid B receptors on the expression of brain-derived neurotrophic factor in hippocampus of rats with diabetic neuropathic pain with depression%γ-氨基丁酸B型受体对糖尿病神经痛合并抑郁大鼠海马脑源性神经生长因子表达的影响

    Institute of Scientific and Technical Information of China (English)

    白惠萍; 刘朋; 杨淑红; 吴川; 任伟; 郭跃先; 王秀丽

    2014-01-01

    Objective To investigate the effect γ-aminobutyric acid B (GABAB) receptors on the expression of brain-derived neurotrophic factor (BDNF) in rats with diabetic neuropathic pain (DNP) with depression by using GABAB receptors agonist (baclofen) and antagonists (CGP55845).Methods 100 male SD rats were randomly divided into two groups:normal control group (C group) and DNP with depression model group (D group),in which the rats were intraperitonealy injected with saline or streptozocin (STZ) respectively.The DNP with depression models were established in 80 rats three weeks after the forced swimming test (FST),and 80 rats were randomly divided into 4 subgroups (n =20,each group) according to the given medicines:saline 10 μl + saline 10 μl injected intrathecally in D1 group,baclofen 0.5 μg + saline 10 μl in D2 group,CGP55845 10 μg + saline 10 μl in D3 group,and CGP55845 10 μg +baclofen 0.5 μg in D4 group.Saline 10 μl + saline 10 μl were injected intrathecally in 20 normal rats (C group).There was an interval of 15 min between twice intrathecal injections in five groups for 4 days.The paw withdrawal threshold (PWT) and immobility time of FST (IMFST) were measured two h (T1) and two weeks after intrathecal injection (T2) respectively.The hippocampi of rats were removed after measurements of PWT and IMFST for detection of BDNF expression.Results As compared with C group,the PWT was significantly reduced [(13.02 ± 1.68) g vs.(3.46 ±0.84) g,P <0.05],the IMFST was significantly prolonged [(47.14 ±3.65) s vs.(178.12 ± 12.49) s,P <0.05],and the expression of BDNF was decreased (P < 0.05) in D group.As compared with D1 group,the IMFST was significantly shortened (P < 0.05) in D2 and D3 groups,the expression of BDNF was increased (P < 0.05) in D2 and D3 groups,and the PWT was significantly increased (P < 0.05) in D2 group but showed no significant change in D3 group.The PWT,IMFST and expression of BDNF showed no significant change in D4 group as

  9. Effect of activating γ-aminobutyric acid B receptors on the expression of phosphorylated cyclic adenosine monophosphate response element binding protein and N-methyl-D-aspartate receptor subunit 2B in the spinal dorsal horn in rats with diabetic neuropathic pain%激活γ-氨基丁酸B型受体对糖尿病神经痛大鼠脊髓背角磷酸化环磷酸腺苷反应元件结合蛋白和N-甲基-D-天冬氨酸受体2B亚基表达的影响

    Institute of Scientific and Technical Information of China (English)

    刘朋; 郭闻亚; 赵晓南; 吕艳霞; 魏淑明; 王秀丽

    2013-01-01

    binding protein (p-CREB) and N-methyl-D-aspartate receptor subunit 2B (NR2B) receptors in the spinal dorsal horn in rats with diabetic neuropathic pain (DNP) by using GABAB receptors agonist (baclofen) and atagonist (CGP55845).Methods Sixty-two male SD rats were randomly divided into two groups:normal control group (C group) and DNP nodel group (D group),which were intraperitonealy injected with saline and streptozocin (STZ) respectively.Fifty rats were intraperitonealy injected with STZ (60 mg/kg),and 4weeks later,DNP models were successfully established in 36 rats which were randomly divided into 3 groups (n = 12 each) according to the injected medicines:saline 10 μ1 + saline 10 μl were injected intrathecally in D1 group,saline 10 μl + baclofen 0.5 μg in D2 group,CGP55845 10 μg + baclofen 0.5 μg in D3 group.Saline 10 μl + saline 10 μl were injected intrathecally in 12 normal rats as C group.There was an interval of 15 min between twice intrathecal injections in four groups.The PWT was measured at 30 min before and after intrathecal injection for 4 days,and the time points were as follows:T1,T2,T3and T4.The spinal cord dorsal horns of rats were removed after measurement of PWT for detection of the expression of p-CREB,cyclic adenosine monophosphate response element binding protein (CREB) and NR2B receptor.Results As compared with C group,the expression levels of NR2B and p-CREB protein were significantly increased,while PWT was significantly decreased at each time point (T1-T4) in D1 and D3 groups (P<0.05).As compared with D1 group [p-CREB protein (0.76 ±0.13),NR2B protein (1.28 ±0.14),and NR2B mRNA (0.83 ± 0.10)],the protein expression levels of NR2B (0.88 ±0.13) and p-CREB (0.45 ± 0.08) and NR2B mRNA expression (0.53 ± 0.08) were significantly decreased,and PWT was significantly increased at each time point (T1-T4) in D2 group (P < 0.05).The expression levels of CREB had no significant diffierence among the four groups (P > 0.05).Conclusion

  10. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

    Science.gov (United States)

    Pozzilli, Carlo

    2013-12-01

    Although spasticity of varying severity affects up to 80% of patients with multiple sclerosis (MS) during the course of their disease, the symptom is often overlooked and undertreated. Despite the availability of oral antispasticity treatments (baclofen, tizanidine and others), approximately one-third of MS patients in Europe and the USA experience moderate or severe nonfocalized spasticity. At present, a thorough clinical evaluation of MS-related spasticity that takes into account the patient's own perception of spasms, spasticity-related pain and other associated symptoms is not common in daily neurological practice. Some of the usual spasticity scales, such as the Ashworth and modified Ashworth scales, reflect the observer's measurement of spasticity at a particular point in time. Herbal (smoked) cannabis has long been recognized as a possible option for relief of spasticity and neuropathic pain, but pertinent concerns about psychoactive effects and addiction risk have prevented its common use. An innovative method of benefiting from the mode of action of cannabinoids while limiting their drawbacks is to reduce peak plasma levels of 9-delta-tetrahydrocannabinol and counteract psychoactivity with higher than naturally occurring proportions of a second cannabinoid, cannabidiol. Sativex® oromucosal spray (1:1 ratio of 9-delta-tetrahydrocannabinol/cannabidiol) has recently been approved in a number of EU countries and elsewhere for use in patients with MS-related spasticity who are resistant to treatment with other antispasticity medications. In clinical trials, Sativex provided initial relief of spasticity symptoms within the first 4 weeks of treatment (trial period) in up to about half of patients resistant to other available oral antispasticity medications and demonstrated clinically significant improvement in spasticity (30% or higher reduction from baseline) in three-quarters of the initial responders. Adverse events were limited mainly to mild or moderate

  11. Ongoing behavioral state information signaled in the lateral habenula guides choice flexibility in freely moving rats.

    Science.gov (United States)

    Baker, Phillip M; Oh, Sujean E; Kidder, Kevan S; Mizumori, Sheri J Y

    2015-01-01

    The lateral habenula (LHb) plays a role in a wide variety of behaviors ranging from maternal care, to sleep, to various forms of cognition. One prominent theory with ample supporting evidence is that the LHb serves to relay basal ganglia and limbic signals about negative outcomes to midbrain monoaminergic systems. This makes it likely that the LHb is critically involved in behavioral flexibility as all of these systems have been shown to contribute when flexible behavior is required. Behavioral flexibility is commonly examined across species and is impaired in various neuropsychiatric conditions including autism, depression, addiction, and schizophrenia; conditions in which the LHb is thought to play a role. Therefore, a thorough examination of the role of the LHb in behavioral flexibility serves multiple functions including understanding possible connections with neuropsychiatric illnesses and additional insight into its role in cognition in general. Here, we assess the LHb's role in behavioral flexibility through comparisons of the roles its afferent and efferent pathways are known to play. Additionally, we provide new evidence supporting the LHb contributions to behavioral flexibility through organization of specific goal directed actions under cognitively demanding conditions. Specifically, in the first experiment, a majority of neurons recorded from the LHb were found to correlate with velocity on a spatial navigation task and did not change significantly when reward outcomes were manipulated. Additionally, measurements of local field potential (LFP) in the theta band revealed significant changes in power relative to velocity and reward location. In a second set of experiments, inactivation of the LHb with the gamma-aminobutyric acid (GABA) agonists baclofen and muscimol led to an impairment in a spatial/response based repeated probabilistic reversal learning task. Control experiments revealed that this impairment was likely due to the demands of repeated

  12. Ongoing behavioral state information signaled in the lateral habenula guides choice flexibility in freely moving rats

    Directory of Open Access Journals (Sweden)

    Phillip Michael Baker

    2015-11-01

    Full Text Available The lateral habenula (LHb plays a role in a wide variety of behaviors ranging from maternal care, to sleep, to various forms of cognition. One prominent theory with ample supporting evidence is that the LHb serves to relay basal ganglia and limbic signals about negative outcomes to midbrain monoaminergic systems. This makes it likely that the LHb is critically involved in behavioral flexibility as all of these systems have been shown to contribute when flexible behavior is required. Behavioral flexibility is commonly examined across species and is impaired in various neuropsychiatric conditions including autism, depression, addiction, and schizophrenia; conditions in which the LHb is thought to play a role. Therefore, a thorough examination of the role of the LHb in behavioral flexibility serves multiple functions including understanding possible connections with neuropsychiatric illnesses and additional insight into its role in cognition in general. Here we assess the LHb’s role in behavioral flexibility through comparisons of the roles its afferent and efferent pathways are known to play. Additionally, we provide new evidence supporting the LHb contributions to behavioral flexibility through organization of specific goal directed actions under cognitively demanding conditions. Specifically, in the first experiment, a majority of neurons recorded from the LHb were found to correlate with velocity on a spatial navigation task and did not change significantly when reward outcomes were manipulated. Additionally, measurements of local field potential in the theta band revealed significant changes in power relative to velocity and reward location. In a second set of experiments, inactivation of the LHb with the GABA agonists baclofen and muscimol led to an impairment in a spatial/response based repeated probabilistic reversal learning task. Control experiments revealed that this impairment was likely due to the demands of repeated switching

  13. 脑缺血激活氯苯氨丁酸对ORP150蛋白及海马CA1区神经元的影响

    Institute of Scientific and Technical Information of China (English)

    陈群娥; 何艳芳; 张文辉; 徐艳; 王军; 王文静

    2013-01-01

    目的:探讨脑缺血激活氯苯氨丁酸(baclofen)对氧调节蛋白150(Oxygen-regulated proteins,ORP150)表达量及海马CA1区神经元的影响。方法:四动脉结扎建立大鼠全脑缺血模型,实验动物随机分为假手术组、缺血再灌注组(I/R)、溶剂对照组、氯苯氨丁酸(baclofen)处理组;缺血5min后腹腔注射baclofen 20mg/kg,Western blot法检测大鼠海马CA1区OPR150和Bcl-2的表达情况;NeuN染色和TUNEL法分别观察海马CA1区神经元的存活和凋亡情况。结果:缺血再灌注30min,baclofen处理组的OPR150蛋白表达水平较I/R组显著升高(P<0.05);缺血再灌注6h,baclofen处理组的Bcl-2蛋白表达水平较I/R组显著升高(P<0.05)。baclofen处理组海马CA1区存活神经元细胞较I/R组明显增加(P<0.05),其凋亡样损伤神经元较I/R组显著减少(P<0.05)。结论:氯苯氨丁酸通过增强OPR150蛋白表达水平来减少脑缺血诱导的神经细胞凋亡。

  14. Alcohol abuse and related disorders treatment of alcohol dependence

    Directory of Open Access Journals (Sweden)

    Yu. P. Sivolap

    2014-01-01

    medications, including baclofen, gabapentin, pregabalin, ondansetron, modafinil, and aripiprazole, are able to decrease alcoholic needs and to alleviate the manifestations of alcohol dependence. The Russian narcological practice in using antipsychotics to suppress a craving for alcohol (as well as other psychoactive substances contradicts the principles of evidence-based medicine and has no scientific base.

  15. Current responses mediated by endogenous GABAB and GABAC receptors in Xenopus oocytes%非洲爪蟾卵母细胞GABAB和GABAC受体介导的电流反应

    Institute of Scientific and Technical Information of China (English)

    杨青; 李之望; 魏劲波

    2001-01-01

    实验应用双电极电压箝技术,在具有滤泡膜的非洲爪蟾(Xenopuslaevis)卵母细胞上记录到γ-氨基丁酸(γ-aminobutyricacid,GABA)-激活电流。此GABA-激活电流的特点及有关GABA受体类型的研究和分析如下:(1)在35.5%(55/155)的受检细胞外加GABA可引起一慢的浓度依赖性的外向电流。(2)GABAA受体的选择性拮抗剂bicuculline(10-5mol/L)对GABA(10-5mol/L)引起的外向电流无阻断作用(n=6)。(3)GABAB受体的选择性拮抗剂2-hydroxysaclofen(10-4mol/L)能将GABA(10-5mol/L)引起的外向电流可逆性地转变为内向电流,后者又可被GABAC受体的选择性拮抗剂I4AA(10-5mol/L)所消除(n=6)。(4)GABAB受体的特异性激动剂baclofen可引起部分(20%,12/60)受检细胞产生一慢的浓度依赖性的外向电流。3×10-6、3×10-5及3×10-4mol/L2-hydroxysaclofen分别阻断baclofen(10-5mol/L)-激活电流(6.3±3.2)%,(44.1±2.2)%及(86.0±1.6)%(n=6)。(5)baclofen激活电流的I-V曲线显示逆转电位在-96.8±7.2mV左右,此电流可分别被TEA(5mmol/L)和BaCl2(2mmol/L)所阻断。以上结果提示:在非洲爪蟾的卵母细胞上存在内源性GABAB和GABAC受体,GABAB受体介导的为外向电流,而GABAC受体介导的为内向电流。

  16. Development of spasticity with age in a total population of children with cerebral palsy

    Directory of Open Access Journals (Sweden)

    Wagner Philippe

    2008-11-01

    Full Text Available Abstract Background The development of spasticity with age in children with cerebral palsy (CP has, to our knowledge, not been studied before. In 1994, a register and a health care program for children with CP in southern Sweden were initiated. In the programme the child's muscle tone according to the modified Ashworth scale is measured twice a year until six years of age, then once a year. We have used this data to analyse the development of spasticity with age in a total population of children with cerebral palsy. Methods All measurements of muscle tone in the gastrocnemius-soleus muscle in all children with CP from 0 to 15 years during the period 1995–2006 were analysed. The CP subtypes were classified according to the Surveillance of Cerebral Palsy in Europe network system. Using these criteria, the study was based on 6218 examinations in 547 children. For the statistical analysis the Ashworth scale was dichotomized. The levels 0–1 were gathered in one category and levels 2–4 in the other. The pattern of development with age was evaluated using piecewise logistic regression in combination with Akaike's An Information Criterion. Results In the total sample the degree of muscle tone increased up to 4 years of age. After 4 years of age the muscle tone decreased each year up to 12 years of age. A similar development was seen when excluding the children operated with selective dorsal rhizotomy, intrathecal baclofen pump or tendo Achilles lengthening. At 4 years of age about 47% of the children had spasticity in their gastro-soleus muscle graded as Ashworth 2–4. After 12 years of age 23% of the children had that level of spasticity. The CP subtypes spastic bilateral and spastic unilateral CP showed the same pattern as the total sample. Children with dyskinetic type of CP showed an increasing muscle tone up to age 6, followed by a decreasing pattern up to age 15. Conclusion In children with CP, the muscle tone as measured with the Ashworth

  17. Uptake of 3-[125I]iodo-α-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs

    International Nuclear Information System (INIS)

    Introduction: We examined 3-[123I]iodo-α-methyl-L-tyrosine ([123I]IMT) uptake and inhibition by amino acids and amino acid-like drugs in the human DLD-1 colon cancer cell line, to discuss correlation between the inhibition effect and structure. Methods: Expression of relevant neutral amino acid transporters was examined by real-time PCR with DLD-1 cells. The time course of [125I]IMT uptake, contributions of transport systems, concentration dependence and inhibition effects by amino acids and amino acid-like drugs (1 mM) on [125I]IMT uptake were examined. Results: Expression of system L (4F2hc, LAT1 and LAT2), system A (ATA1, ATA2) and system ASC (ASCT1) was strongly detected; system L (LAT3, LAT4) and MCT8 were weakly detected; and B0AT was not detected. [125I]IMT uptake in DLD-1 cells involved Na+-independent system L primarily and Na+-dependent system(s). Uptake of [125I]IMT in Na+-free buffer followed Michaelis-Menten kinetics, with a Km of 78 μM and Vmax of 333 pmol/106 cells per minute. Neutral D- and L-amino acids with branched or aromatic large side chains inhibited [125I]IMT uptake. Tyrosine analogues, tryptophan analogues, L-phenylalanine and p-halogeno-L-phenylalanines, and gamma amino acids [including 3,4-dihydroxy-L-phenylalanine (L-DOPA), DL-threo-β-(3,4-dihydroxyphenyl)serine (DOPS), 4-[bis(2-chloroethyl)amino]-L-phenylalanine and 1-(aminomethyl)-cyclohexaneacetic acid] strongly inhibited [125I]IMT uptake, but L-tyrosine methyl ester and R(+)/S(-)-baclofen weakly inhibited uptake. The substrates of system ASC and A did not inhibit [125I]IMT uptake except L-serine and D/L-cysteine. Conclusions: [125I]IMT uptake in DLD-1 cells involves mostly LAT1 and its substrates' (including amino acid-like drugs derived from tyrosine, tryptophan and phenylalanine) affinity to transport via LAT1. Whether transport of gamma amino acid analogues is involved in LAT1 depends on the structure of the group corresponding to the amino acid residue. Beta-hydroxylation may

  18. Combinational spinal GAD65 gene delivery and systemic GABA-mimetic treatment for modulation of spasticity.

    Directory of Open Access Journals (Sweden)

    Osamu Kakinohana

    Full Text Available BACKGROUND: Loss of GABA-mediated pre-synaptic inhibition after spinal injury plays a key role in the progressive increase in spinal reflexes and the appearance of spasticity. Clinical studies show that the use of baclofen (GABA(B receptor agonist, while effective in modulating spasticity is associated with major side effects such as general sedation and progressive tolerance development. The goal of the present study was to assess if a combined therapy composed of spinal segment-specific upregulation of GAD65 (glutamate decarboxylase gene once combined with systemic treatment with tiagabine (GABA uptake inhibitor will lead to an antispasticity effect and whether such an effect will only be present in GAD65 gene over-expressing spinal segments. METHODS/PRINCIPAL FINDINGS: Adult Sprague-Dawley (SD rats were exposed to transient spinal ischemia (10 min to induce muscle spasticity. Animals then received lumbar injection of HIV1-CMV-GAD65 lentivirus (LVs targeting ventral α-motoneuronal pools. At 2-3 weeks after lentivirus delivery animals were treated systemically with tiagabine (4, 10, 20 or 40 mg/kg or vehicle and the degree of spasticity response measured. In a separate experiment the expression of GAD65 gene after spinal parenchymal delivery of GAD65-lentivirus in naive minipigs was studied. Spastic SD rats receiving spinal injections of the GAD65 gene and treated with systemic tiagabine showed potent and tiagabine-dose-dependent alleviation of spasticity. Neither treatment alone (i.e., GAD65-LVs injection only or tiagabine treatment only had any significant antispasticity effect nor had any detectable side effect. Measured antispasticity effect correlated with increase in spinal parenchymal GABA synthesis and was restricted to spinal segments overexpressing GAD65 gene. CONCLUSIONS/SIGNIFICANCE: These data show that treatment with orally bioavailable GABA-mimetic drugs if combined with spinal-segment-specific GAD65 gene overexpression can

  19. Uptake of 3-[{sup 125}I]iodo-{alpha}-methyl-L-tyrosine into colon cancer DLD-1 cells: characterization and inhibitory effect of natural amino acids and amino acid-like drugs

    Energy Technology Data Exchange (ETDEWEB)

    Shikano, Naoto [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan)], E-mail: sikano@ipu.ac.jp; Ogura, Masato [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Okudaira, Hiroyuki [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan); Nakajima, Syuichi; Kotani, Takashi [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kobayashi, Masato [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan); Nakazawa, Shinya [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Baba, Takeshi; Yamaguchi, Naoto [Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kubota, Nobuo [Department of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Iwamura, Yukio [Center for Humanities and Sciences, Ibaraki Prefectural University of Health Sciences, Ami-machi, Inashiki-gun, Ibaraki 300-0394 (Japan); Kawai, Keiichi [School of Health Sciences, Faculty of Medicine, Kanazawa University, Kanazawa 920-0942 (Japan)

    2010-02-15

    Introduction: We examined 3-[{sup 123}I]iodo-{alpha}-methyl-L-tyrosine ([{sup 123}I]IMT) uptake and inhibition by amino acids and amino acid-like drugs in the human DLD-1 colon cancer cell line, to discuss correlation between the inhibition effect and structure. Methods: Expression of relevant neutral amino acid transporters was examined by real-time PCR with DLD-1 cells. The time course of [{sup 125}I]IMT uptake, contributions of transport systems, concentration dependence and inhibition effects by amino acids and amino acid-like drugs (1 mM) on [{sup 125}I]IMT uptake were examined. Results: Expression of system L (4F2hc, LAT1 and LAT2), system A (ATA1, ATA2) and system ASC (ASCT1) was strongly detected; system L (LAT3, LAT4) and MCT8 were weakly detected; and B{sup 0}AT was not detected. [{sup 125}I]IMT uptake in DLD-1 cells involved Na{sup +}-independent system L primarily and Na{sup +}-dependent system(s). Uptake of [{sup 125}I]IMT in Na{sup +}-free buffer followed Michaelis-Menten kinetics, with a K{sub m} of 78 {mu}M and V{sub max} of 333 pmol/10{sup 6} cells per minute. Neutral D- and L-amino acids with branched or aromatic large side chains inhibited [{sup 125}I]IMT uptake. Tyrosine analogues, tryptophan analogues, L-phenylalanine and p-halogeno-L-phenylalanines, and gamma amino acids [including 3,4-dihydroxy-L-phenylalanine (L-DOPA), DL-threo-{beta}-(3,4-dihydroxyphenyl)serine (DOPS), 4-[bis(2-chloroethyl)amino]-L-phenylalanine and 1-(aminomethyl)-cyclohexaneacetic acid] strongly inhibited [{sup 125}I]IMT uptake, but L-tyrosine methyl ester and R(+)/S(-)-baclofen weakly inhibited uptake. The substrates of system ASC and A did not inhibit [{sup 125}I]IMT uptake except L-serine and D/L-cysteine. Conclusions: [{sup 125}I]IMT uptake in DLD-1 cells involves mostly LAT1 and its substrates' (including amino acid-like drugs derived from tyrosine, tryptophan and phenylalanine) affinity to transport via LAT1. Whether transport of gamma amino acid analogues is

  20. Hypoxanthine-guanine phosophoribosyltransferase (HPRT deficiency: Lesch-Nyhan syndrome

    Directory of Open Access Journals (Sweden)

    Puig Juan G

    2007-12-01

    lack of precise understanding of the neurological dysfunction has precluded development of useful therapies. Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen. Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended. Self-injurious behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical treatments.

  1. A Systematic Review of Pharmacological Treatments of Pain Following Spinal Cord Injury

    Science.gov (United States)

    Teasell, Robert W.; Mehta, Swati; Aubut, Jo-Anne L.; Foulon, Brianne; Wolfe, Dalton L.; Hsieh, Jane T.C.; Townson, Andrea F.; Short, Christine

    2011-01-01

    pain in depressed individuals. Intrathecal baclofen reduced musculoskeletal pain associated with spasticity; however there was conflicting evidence for the reduction in neuropathic pain. Studies assessing the effectiveness of opioids were limited and revealed only small benefits. Cannabinoids showed conflicting evidence in improving spasticity related pain. Clonidine and morphine, when given together, had a significant synergistic neuropathic pain-relieving effect. PMID:20434623

  2. Adjuncts to opioid therapy.

    Science.gov (United States)

    Goldstein, Frederick J

    2002-09-01

    Administration of opioids to alleviate moderate to severe acute pain and chronic cancer pain is an established management process. However, advancements in clinical pharmacologic research have shown that opioids are also effective in chronic noncancerous pain. Many patients properly treated for prolonged periods with opioids develop tolerance and subsequently, physical dependence. This process is not necessarily harmful to the patient and will not cause the patient to develop an addiction (properly defined as psychologic dependence). For many patients who have been on opioid therapy for months or years, analgesic effectiveness tragically becomes less. In addition, opioid-induced constipation can be severe and cause pain; patients do not develop tolerance to this adverse reaction. Therefore, such issues become a management problem and require additional intervention. Currently, many different classes of drugs can serve as effective adjuncts to opioids for treatment of pain. Adding adjunctive medication to opioid therapy improves pain management primarily by nonopioid mechanisms of action. Clinical outcomes of such combinations include greater analgesia and attenuation of opioid-induced adverse reactions such as nausea and vomiting, constipation, sedation, and respiratory depression. Adjuncts include acetaminophen, antiarrhythmics, anticonvulsants, antidepressants, antipsychotics, baclofen, benzodiazepines, capsaicin, calcium channel blockers, clonidine hydrochloride, central nervous system stimulants, corticosteroids, local anesthetics, N-methyl-D-aspartate receptor antagonists, nonsteroidal antiinflammatory drugs, pentoxifylline, and scopolamine. Some adjuncts (eg, acetaminophen) are routinely used today, whereas others (eg, nifedipine [calcium channel blocker]) are used on a limited basis but have great potential for more widespread application. All professionals (eg, nurses, pharmacists, physicians, physicians' assistants, social workers, members of the clergy

  3. Presynaptic modulation of 5-HT release in the rat septal region.

    Science.gov (United States)

    Rutz, S; Riegert, C; Rothmaier, A K; Jackisch, R

    2007-05-11

    5-HT released from serotonergic axon terminals in the septal nuclei modulates the activity of septal output neurons (e.g. septohippocampal cholinergic neurons) bearing somatodendritic 5-HT receptors. Therefore, we studied the mechanisms involved in the presynaptic modulation of 5-HT release in the lateral (LS) and medial septum (MS), and the diagonal band of Broca (DB). HPLC analysis showed that tissue concentrations of noradrenaline, dopamine and 5-HT were highest in DB (DB>MS>LS). Slices prepared from LS, MS and DB regions were preincubated with [(3)H]5-HT, superfused in the presence of 6-nitro-2-(1-piperazinyl)-quinoline (6-nitroquipazine) and electrically stimulated up to three times (first electrical stimulation period (S(1)), S(2), S(3); 360 pulses, 3 Hz, 2 ms, 26-28 mA). In all septal regions the Ca(2+)-dependent and tetrodotoxin-sensitive electrically-evoked overflow of [(3)H] was inhibited by the 5-HT(1B) agonist CP-93,129 and the alpha(2)-adrenoceptor agonist 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline tartrate (UK-14,304). Also the mu- and kappa-opioid receptor agonists (d-Ala(2), N-Me-Phe(4), glycinol(5))-enkephalin (DAMGO) and [trans-(1S,2S(-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]-benzenacetamide hydro-chloride] (U-50,488H), respectively, acted inhibitory (although less potently), whereas the delta-opioid receptor agonist (d-Pen(2), d-Pen(5))-enkephalin (DPDPE), the dopamine D(2) receptor agonist quinpirole and the adenosine A(1) receptor agonist N(6)-cyclopentyladenosine were all ineffective; the GABA(B) receptor agonist baclofen had weak effects. All inhibitory effects of the agonists were antagonized by the corresponding antagonists (3-[3-(dimethylamino)propyl]-4-hydroxy-N-[4-(4-pyridinyl)phenyl]benzamide dihydrochloride (GR-55,562), idazoxan, naloxone, nor-binaltorphimine), which also significantly enhanced the evoked release of 5-HT at S(1). It is concluded that 5-HT release in septal nuclei of the rat is modulated by

  4. Early onset torsion dystonia (Oppenheim's dystonia

    Directory of Open Access Journals (Sweden)

    Kamm Christoph

    2006-11-01

    Full Text Available Abstract Early onset torsion dystonia (EOTD is a rare movement disorder characterized by involuntary, repetitive, sustained muscle contractions or postures involving one or more sites of the body. A US study estimated the prevalence at approximately 1 in 30,000. The estimated prevalence in the general population of Europe seems to be lower, ranging from 1 in 330,000 to 1 in 200,000, although precise numbers are currently not available. The estimated prevalence in the Ashkenazi Jewish population is approximately five to ten times higher, due to a founder mutation. Symptoms of EOTD typically develop first in an arm or leg in middle to late childhood and progress in approximately 30% of patients to other body regions (generalized dystonia within about five years. Distribution and severity of symptoms vary widely between affected individuals. The majority of cases from various ethnic groups are caused by an autosomal dominantly inherited deletion of 3 bp (GAG in the DYT1 gene on chromosome 9q34. This gene encodes a protein named torsinA, which is presumed to act as a chaperone protein associated with the endoplasmic reticulum and the nuclear envelope. It may interact with the dopamine transporter and participate in intracellular trafficking, although its precise function within the cell remains to be determined. Molecular genetic diagnostic and genetic counseling is recommended for individuals with age of onset below 26 years, and may also be considered in those with onset after 26 years having a relative with typical early onset dystonia. Treatment options include botulinum toxin injections for focal symptoms, pharmacological therapy such as anticholinergics (most commonly trihexiphenydil for generalized dystonia and surgical approaches such as deep brain stimulation of the internal globus pallidus or intrathecal baclofen application in severe cases. All patients have normal cognitive function, and despite a high rate of generalization of dystonia

  5. Effects of GABA Signal on Mouse Placenta Establishment in Early-Middle Phase%γ-氨基丁酸信号对小鼠胎盘早中期建立的影响

    Institute of Scientific and Technical Information of China (English)

    罗文萍; 谭冬梅; 杨根岭; 卢俊杰; 赵海; 谭毅

    2012-01-01

    为了观察γ-氨基丁酸B型受体R1亚基(GABAB1R,GB1)在妊娠小鼠第1天至第8天(D1~D8)子宫中的表达规律,探讨γ-氨基丁酸(GABA)信号是否参与了胎盘早中期建立.应用半定量RT-PCR、免疫组织化学及Western blotting检测GB1在妊娠小鼠D1~D8子宫中的表达情况,原代分离D8.5的绒毛膜锥(EPCs)及蜕膜细胞,检测GABA及GABA B型受体激动剂baclofen、拮抗剂2-hydroxysaclofen对EPCs黏附及外延生长以及对蜕膜细胞侵袭能力的影响.D8时体内注射0.05 g/kg、0.5 g/kg及5 g/kg的GABA,于D14收集胎盘,制作石蜡切片.结果显示,GB1 mRNA及蛋白动态表达于D1~D8子宫.100 μmol/L GABA及5μmol/L Baclofen促进EPCs的外延生长,抑制蜕膜细胞的侵袭,同时,20 μmol/L 2-hydroxysaclofen 成功逆转GABA对EPCs及蜕膜细胞的侵袭调节作用.5g/kg的GABA可导致D14小鼠胎盘的迷路层滋养层细胞增多,母鼠血窦及胎鼠血管减少或发育不良,海绵滋养层的细胞滋养层细胞变小,糖原细胞减少或消失.结果提示,在小鼠早中期胎盘建立过程中,GABA信号促进滋养层侵袭至母体蜕膜组织,而抑制蜕膜细胞积极主动的侵袭行为,并可损害胎盘的结构.%To explore the expression of GB1 in mouse uterus from day 1 to day 8 of pregnancy (D1~D8) and the role in placenta establishment, semi-quantitative reverse transcription polymerase chain reaction (semi-qRT-PCR), immunohistochemistry and Western blotting were applied to detect the expression levels of GB1 mRNA and protein respectively from D1 to D8. Besides, EPCs and decidual cell were dissected out from D8.5 uterus and then added different concentrations of GABA, GABA B receptor agonists baclofen and antagonists 2-hydroxysaclofen. In vitro attachment and outgrowth assays were performed in EPCs, and transwell chambeer was performed in decidual cells. In vivo, mouse from D8 to D13 were treated by intraperitoneal injection of different concentrations of GABA . On D14

  6. Effect of Baixiangdan Capsule on Expression of GABABR and Adenylate Cyclase of Frontal Cortex in Rats with Anxiety Emotion%白香丹胶囊对焦虑情绪模型大鼠额区皮层γ-氨基丁酸B受体和腺苷酸环化酶表达的影响

    Institute of Scientific and Technical Information of China (English)

    蔡洪信; 许莉莉; 殷慧敏; 张惠云

    2012-01-01

    目的:检测焦虑情绪模型大鼠额区皮层γ-氨基丁酸(GABA)B受体两个亚基GABABR1,GABABR2和腺苷酸环化酶(AC)表达的变化,初步探讨白香丹胶囊对焦虑情绪的干预机制.方法:白香丹胶囊由芍药苷、香附挥发油和丹皮酚配伍组成.大鼠随机分为正常组、模型组、白香丹胶囊组(200 mg·kg-1)、巴氯芬组(8 mg·kg-1),采用“孤养加异种大鼠入侵”方法,大鼠孤养2周,然后异种大鼠居住入侵刺激2周,制备焦虑情绪大鼠模型.从居住入侵第2周开始,药物组按相应剂量ig给药7d,每日1次.通过糖水偏好实验、旷场实验和高架十字迷宫实验进行模型评价,用免疫荧光技术检测各组大鼠额区皮层GABABR1,CABABR2和AC的表达变化.结果:与正常组比较,模型组糖水偏好系数降低,旷场实验得分增高(P<0.05),高架十字迷宫实验进入开放臂次数百分数(OE%)和开放臂停留时间的百分数(OT%)降低(P<0.05),额区皮层GABABR1,GABABR2,AC表达水平降低(P<0.05).与模型组比较,白香丹胶囊组和巴氯芬组旷场实验得分降低(P<0.05),OE%和OT%值升高(P<0.05),额区皮层GABABR1,GABABR2,AC表达水平升高(P<0.05).结论:大鼠额区皮层GABABR1,GABABR2,AC表达下凋可能与焦虑情绪的产生有关,白香丹胶囊抗焦虑作用的中枢机制可能与其恢复额区皮层的GABABR的表达和功能有关.%Objective: To detect the expression of γ-aminobutyric acid B receptor (GABABR) and adenylate cyclase ( AC) of forbral cortex in rats with anxiety emotion and to explore the antianxiety mechanism of baixiangdan capsule. Method; Paeoniflorin, cyperolone and paeonolum were main ingredients of baixiangdan capsule. Wistar rats were divided into normal group, model group, baixiangdan capsule group (200 mg·kg-1 ) and baclofen group (8 mg·kg-1 ). The rats were administrated with relevant drugs intragastrically once a day for 7 days. The anxiety emotion rat models were

  7. 白香丹胶囊对愤怒情绪模型大鼠海马GABABR和KIR表达的影响%Effect of Baixiangdan Capsule on Expression of GABABR and KIR in Hippocampus of Anger-out Rat Models

    Institute of Scientific and Technical Information of China (English)

    许莉莉; 蔡洪信; 高杰; 薄蔷; 张惠云

    2012-01-01

    Objective To detect the expression of two subunits of gamma arainobutyric acid B receptor, GABABR1 andGABABR2, as well as inwardly rectifying K+ channel (KIR) in hippocampus of anger-out rat models, and to explore the intervention mechanism of Baixiangdan Capsule in teating the syndrome of adverse flow of liver-Qi. Methods The Wistar rats were divided into normal group, modle group, Baixiangdan Capsule group(ig 0.2 g·kg-1, qd, for 7 d) and baclofen group (ig 0.008 g·kg-1, qd, for 7 d). The anger-out emotion rat models were established with social isolation plus resident intruder stress. The model was evaluated by sucrose intake test, open field test and elevated plus-maze test. The expression of GABABR 1, GABABR2 and KIR in hippocampus was detected by immunofloures-cence assay. Results Compared with the normal group, the modle group had lower sucrose intake, higher total score of open field test, lower open arm entry percent(OE %) and open arm time percent(OT %) of elevated plus-maze test, and lower expression of GABABR1, GABABR2 and KIR in hippocampus(P < 0.05). Compared with the model group, Baixiangdan capsule and baclofen decreased the total score of open field test, increased OE % and OT % of elevated plus-maze test, and promoted expression of GABABR1, GABABR2 and KIR in hippocampus(P < 0.05). Conclusion The lower expression of GABABR1, GABABR2 and KIR in hippocampus may have close relationship with anger-out emotion. Increasing the expression of GABABR and the function of G protein-coupled KIR in hippocampus maybe one of the mechanism of Baixiangdan capsule in soothing liver and regulating Qi flow.%目的 检测愤怒情绪模型大鼠海马γ-氨基丁酸B受体两个亚基GABABR1、GABABR2和内向整流型钾通道( KIR)表达的变化,初步探讨白香丹胶囊对肝气逆证的中枢干预机制.方法 大鼠随机分为正常对照组、模型组、白香丹胶囊组(0.2 g·kg-1)、巴氯芬组(0.008 g·kg-1),采用“社会隔离结合居住入侵

  8. Study on pathogenesis and treatment of belching syndrome by the combination of esophageal multichannel intralumminal impedance and pH monitoring%食管多通道腔内阻抗技术联合pH监测对嗳气症发病机制及治疗的研究

    Institute of Scientific and Technical Information of China (English)

    王捷鹏; 姚艳梅; 张寿山

    2012-01-01

    patients were treated with baclofen, the efficacy of each subtype was compared, and the collected data were statistically analyzed. Results ① The pathogenesis of aerophagia was different from that of non-specific belching syndrome.For belching of aerophagia, the symptoms were caused when the air was swallowed and did not enter into the stomach. While non-specific belching syndrome was caused by the air in the stomach without swallowing; ② Gastroesoph-ageal reflux was related to the onset time of belching. Aerophagia might be caused by the sudden loosing of lower esophageal sphincter (LES) and lead to the simultaneous occurrence of belching and reflux, while non-specific belching syndrome might be caused by the sudden loosing of LES after belching and lead to the occurrence of reflux; ③ The efficacy of baclofen on non-specific belching syndrome was found to be superior to that on aerophagia, with statistically significant difference (P>0.05). Conclusion The pathogenesis is different in each type of belching syndrome, which results in the difference of efficacy. And gastroesophageal reflux is related to the onset time of belching.

  9. 高压氧对脊髓损伤肌张力控制的队列研究%Cohort study of hyperbaric oxygention (HBO) in controlling hypermyotonia caused by spinal cord injury

    Institute of Scientific and Technical Information of China (English)

    卢爱兰; 张夏军; 许美飞

    2012-01-01

    目的:探讨高压氧(hyperbaric oxygenation,HBO)对脊髓损伤(spinal cord injury,SCI)肌张力增高患者的治疗效果.方法:选择2009年3月至2011年4月脊髓损伤肌张力增高患者80例作为研究对象,男49例,女31例;年龄17~60岁,平均(34.12±6.61)岁;病程14~30 d,平均(20.16±5.08)d.按就诊顺序、是否愿意同时进行高压氧治疗分成治疗组和对照组.其中治疗组40例,在运动康复训练和巴氯芬药物治疗的基础上,加用HBO治疗.治疗压力为2ATA;治疗方案为:面罩吸氧20 min,休息5 min,反复3个循环为1次,每日1次,10d为1个疗程,共治疗6个疗程.对照组40例,只进行运动康复训练和巴氯芬药物治疗,疗程同治疗组.两组均按国际通用修订的Ashworth评分(modifiedashworth scale,MAS)方法分别于治疗3个疗程和6个疗程时对肌张力进行评估.结果:治疗3个疗程时对肌张力的控制,治疗组有效5例,显效0例;对照组有效4例,显效0例.治疗6个疗程时对肌张力的控制,治疗组有效24例,显效5例;对照组有效14例,显效2例.3个疗程时,治疗组与对照组疗效差异无统计学意义(P=0.508);6个疗程时治疗组疗效优于对照组(P<0.05).结论:HBO对脊髓损伤肌张力增高患者有治疗作用,可作为一种常规辅助治疗方法,在临床上值得推广应用,但需要足够的疗程.%Objective:To evaluate the clinical effects of hyperbaric oxygention (HBO) in treating hypermyotonia caused by spinal cord injury (SCI). Methods: From March 2009 to April 2011,80 patients with hypermyotonia caused by SCI were divided into treatment group and control group,with 40 cases in each group. There were 49 males and 31 females with an average age of (34.12+6.61) years (ranged, 17 to 60) in the study. Course of disease was from 14 to 30 d with an average of (20.16± 5.08) d. The patients of the treatment group were treated with HBO,rehabilitation exercise and baclofen medication. With pressure of HBO was

  10. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?

    Science.gov (United States)

    Le Jeunne, Claire; Billon, Nathalie; Dandon, Anne; Berdaï, Driss; Adgibi, Yolande; Bergmann, Jean-François; Bordet, Régis; Carpentier, Anne; Cohn, Emmanuelle; Courcier, Soizic; Girault, Danièle; Goni, Sylvia; Jolliet, Pascale; Liard, François; Prot-Labarthe, Sonia; Simon, Tabassome; Vernotte, Christine; Westerloppe, Jérémie

    2013-01-01

    Following the Mediator crisis and the passage of the Health and Safety Law of December 2011, off-label prescriptions are a real concern shared by all those involved in healthcare system. Off-label, in the strictest sense of the term, is defined as all prescriptions that do not correspond to the summary of product characteristics (SPC), particularly those that fail to comply with the indications and dosage regimens defined by the marketing authorization (MA) for clear safety reasons. There are various rasons for off-label prescriptions, both conscious and unconscious. They are intended to respond to unmet medical needs, the needs of poorly studied populations or not studied at all in trials, but in relation to whom it is reasonable to extrapolate that MA would be given (common-sense prescriptions) and, additionally, to urgent public health needs (such as baclofen, pregnant women, and HIV drugs). All these prescriptions would deserve to be studied for a potential MA. However, there are off-label prescriptions that need to be restricted or even penalized in the case of compassionate prescriptions or unjustified prescriptions or prescriptions not based on any scientific grounds. Off-label prescriptions are not easy to track down because if the prescriber has to write "off-label" on his prescription, then clearly, in practice, he will only do so in exceptional cases. Neither the pharmacists who dispense the drug nor the Social Security that reimburses it, have access to the diagnosis (or targeted indication). Thus, in order to identify the off-label prescription, we must be able to cross reference the available databases (such as pharmacovigilance database, medicalized information system program [programme de médicalisation des systèmes d'information, PMSI], hospital drug formularies, general sample of beneficiaries [échantillon généraliste de bénéficiaires, EGB] or national inter-regional Health Insurance Information System [système national d

  11. 激活GABAB受体在针刺镇痛中的作用%The Important Role of Activation of GABAB Receptors in Acupuncture Analgesia

    Institute of Scientific and Technical Information of China (English)

    朱丽霞; 叶燕燕; 莫孝荣; 吉长福

    2002-01-01

    目的:脑室注射γ-氨基丁酸(GABA)A受体的拮抗剂荷包牡丹碱(Bic)未能阻断针刺镇痛效应,微电泳导入Bic部分阻断电针抑制脊髓背角伤害性反应,说明GABA可通过激活A受体参与针刺镇痛中脊髓节段性抑制.本文进一步探讨了激活GABAB受体在针刺镇痛中的作用.方法:以辐射热照射大鼠尾部引起甩尾反射潜伏期作为痛阈的指标,以针刺"次髎"穴后痛阈最大变化百分率判断镇痛效应,观察脑室注射(icv)5 μL或蛛网膜下腔(ith)注射10μL GABAB受体的拮抗剂CGP 55845对针刺镇痛效应的影响.每组6~8例.结果:icv GABA(125 μg、250 μg、500μg)或GABAB受体激动剂苯氯丁氨酸(Baclofen,25ng、250 ng、2500 ng)可产生剂量依赖的镇痛效应.icv CGP 55845(5 ng、50 ng)可大部分阻断GABA和Baclofen的镇痛效应.针刺双侧"次髎"穴(50 Hz,1~2 mA)10 min,痛阈提高到针前值的(142.5±2.1)%,镇痛效应显著.针前icv CGP55845针后痛阈分别提高到(111.2±1.2)%和(112.1±1.1)%,阻断率分别为73.7%和71.6%,和事先icv生理盐水(143.7±2.0)%相比,阻断效应明显.若针刺前ith CGP 55845(50 ng、500ng),也能明显阻断针刺镇痛效应.结论:脑内注射GABA或Baclofen可通过激活GABAB受体产生剂量依赖的镇痛效应.在针刺镇痛效应中脑内GABA主要通过激活B受体发挥作用,而在脊髓水平激活GABAA和B受体都参与针刺镇痛效应.对GABAB受体参与针刺镇痛作用的可能机制进行了讨论.